UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

x

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2015

OR

¨

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from              to             

Commission File Number 001-36415

 

QUOTIENT LIMITED

(Exact name of registrant as specified in its charter)

 

 

Jersey, Channel Islands

 

Not Applicable

(State or other jurisdiction of
incorporation or organization)

 

(I.R.S. Employer
Identification No.)

 

 

Pentlands Science Park

Bush Loan, Penicuik, Midlothian

EH26 0PZ, United Kingdom

 

Not Applicable

(Address of principal executive offices)

 

(Zip Code)

001-44-131-445-6159

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes   x     No   ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes   x     No   ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act (check one):

 

Large accelerated filer  ¨

 

Accelerated filer  ¨

  

Non-accelerated filer x

(Do not check if a smaller
reporting company)

 

Smaller reporting company ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes   ¨     No   x

As of October 29, 2015 there were 20,961,292 Ordinary Shares, nil par value, of Quotient Limited outstanding.

 

 

 

 

 


 

TABLE OF CONTENTS

 

 

  

Page

 

PART I – FINANCIAL INFORMATION

  

 

3

  

 

Item 1. Financial Statements

  

 

3

  

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

  

 

17

  

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

  

 

29

  

 

Item 4. Controls and Procedures

  

 

30

  

 

PART II – OTHER INFORMATION

  

 

30

  

 

Item 1. Legal Proceedings

  

 

30

  

 

Item 1A. Risk Factors

  

 

30

  

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

  

 

30

  

 

Item 3. Defaults Upon Senior Securities

  

 

31

  

 

Item 4. Mine Safety Disclosures

  

 

31

  

 

Item 5. Other Information

  

 

31

  

 

Item 6. Exhibits

  

 

31

  

 

Signatures

 

 

32

 

 

 

 

- i -


 

Cautionary note regarding forward-looking statements

This Quarterly Report on Form 10-Q, and exhibits thereto, contains estimates, predictions, opinions, projections and other statements that may be interpreted as “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that involve substantial risks and uncertainties. The forward-looking statements are contained principally in Part I, Item 2: “Management’s Discussion and Analysis of Final Condition and Results of Operations” and are also contained elsewhere in this Quarterly Report. Forward-looking statements can be identified by words such as “strategy,” “objective,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “contemplate,” “might,” “design” and other similar expressions, although not all forward-looking statements contain these identifying words. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain, and are subject to numerous known and unknown risks and uncertainties.

Forward-looking statements include statements about:

 

the development, regulatory approval and commercialization of MosaiQ T M ;

 

the design of blood grouping and disease screening capabilities of MosaiQ TM and the benefits of MosaiQ TM for both customers and patients;

 

future demand for and customer adoption of MosaiQ TM , the factors that we believe will drive such demand and our ability to address such demand;

 

our expected profit margins for MosaiQ TM ;

 

the size of the market for MosaiQ TM ;

 

the regulation of MosaiQ TM by the U.S. Food and Drug Administration, or the FDA, or other regulatory bodies, or any unanticipated regulatory changes or scrutiny by such regulators;

 

future plans for our conventional reagent products;

 

the status of our future relationships with customers, suppliers, and regulators relating to our conventional reagent products;

 

future demand for our conventional reagent products and our ability to meet such demand;

 

our ability to manage the risks associated with international operations;

 

anticipated changes, trends and challenges in our business and the transfusion diagnostics market;

 

the effects of competition;

 

the expected outcome or impact of litigation;

 

our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others;

 

our anticipated cash needs and our expected sources of funding, including the achievement of product development milestones, and our estimates regarding our capital requirements and capital expenditures; and

 

our plans for executive and director compensation for the future.

You should also refer to the various factors identified in this and other reports filed by us with the Securities and Exchange Commission, including but not limited to those discussed in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended March 31, 2015, for a discussion of other important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this Quarterly Report will prove to be accurate. Further, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this Quarterly Report represent our views only as of the date of this Quarterly Report. Subsequent events and developments may cause our views to change. While we may elect to update these forward-looking statements at some point in the future, we undertake no obligation to publicly update any forward-looking statements, except as required by law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Quarterly Report.

- 1 -


 

Where you can find more information

We file annual, quarterly and current reports, proxy statements and other information with the Securities and Exchange Commission. You can inspect, read and copy these reports, proxy statements and other information at the Securities and Exchange Commission’s Public Reference Room, which is located at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information regarding the operation of the Securities and Exchange Commission’s Public Reference Room by calling the Securities and Exchange Commission at 1-800-SEC-0330. The Securities and Exchange Commission also maintains a website at www.sec.gov that makes available reports, proxy statements and other information regarding issuers that file electronically.

We make available free of charge at www.quotientbd.com (in the “Investors” section) copies of materials we file with, or furnish to, the Securities and Exchange Commission. By referring to our corporate website, www.quotientbd.com , we do not incorporate any such website or its contents into this Quarterly Report on Form 10-Q.

 

 

 

- 2 -


 

PART I – FINANCIAL INFORMATION

 

Item 1. Financial Statements

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)

(Expressed in thousands of U.S. Dollars — except for share data and per share data)

 

 

 

September 30,

2015

 

 

March 31,

2015

 

ASSETS

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

25,656

 

 

$

37,525

 

Trade accounts receivable, net

 

 

2,123

 

 

 

1,808

 

Inventories

 

 

5,827

 

 

 

4,608

 

Prepaid expenses and other current assets

 

 

6,579

 

 

 

5,580

 

Total current assets

 

 

40,185

 

 

 

49,521

 

Property and equipment, net

 

 

43,305

 

 

 

29,733

 

Intangible assets, net

 

 

932

 

 

 

950

 

Total assets

 

$

84,422

 

 

$

80,204

 

LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

12,025

 

 

$

7,238

 

Accrued compensation and benefits

 

 

1,661

 

 

 

2,565

 

Accrued expenses and other current liabilities

 

 

4,410

 

 

 

8,787

 

Financial liability in respect of share warrants

 

 

9,880

 

 

 

31,011

 

Current portion of long-term debt

 

 

 

 

 

4,500

 

Current portion of lease incentive

 

 

434

 

 

 

435

 

Current portion of capital lease obligation

 

 

204

 

 

 

239

 

Total current liabilities

 

 

28,614

 

 

 

54,775

 

Long-term debt, less current portion

 

 

28,514

 

 

 

9,853

 

Lease incentive, less current portion

 

 

1,521

 

 

 

1,740

 

Capital lease obligation, less current portion

 

 

412

 

 

 

276

 

7% Cumulative redeemable preference shares

 

 

15,700

 

 

 

15,175

 

Total liabilities

 

 

74,761

 

 

 

81,819

 

Commitments and contingencies

 

 

 

 

 

 

Shareholders' equity (deficit)

 

 

 

 

 

 

 

 

Ordinary shares (nil par value) 18,551,947 and 17,020,574 issued and outstanding

   at September 30, 2015 and March 31, 2015 respectively;

 

 

97,876

 

 

 

84,525

 

Additional paid in (distribution in excess of) capital

 

 

4,425

 

 

 

(6,684

)

Accumulated other comprehensive loss

 

 

(3,699

)

 

 

(5,102

)

Accumulated deficit

 

 

(88,941

)

 

 

(74,354

)

Total shareholders' equity (deficit)

 

 

9,661

 

 

 

(1,615

)

Total liabilities and shareholders' equity (deficit)

 

$

84,422

 

 

$

80,204

 

The accompanying notes form an integral part of these consolidated financial statements.

 

 

 

- 3 -


 

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (unaudited)

(Expressed in thousands of U.S. Dollars — except for share data and per share data)

 

 

 

Quarter ended

 

 

Six months ended

 

 

 

September 30

 

 

September 30

 

 

 

2015

 

 

2014

 

 

2015

 

 

2014

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product sales

 

$

4,273

 

 

$

4,527

 

 

$

9,123

 

 

$

9,794

 

Other revenues

 

 

 

 

 

 

 

 

 

 

 

650

 

Total revenue

 

 

4,273

 

 

 

4,527

 

 

 

9,123

 

 

 

10,444

 

Cost of revenue

 

 

(2,124

)

 

 

(2,706

)

 

 

(4,875

)

 

 

(5,157

)

Gross profit

 

 

2,149

 

 

 

1,821

 

 

 

4,248

 

 

 

5,287

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

(774

)

 

 

(609

)

 

 

(1,432

)

 

 

(1,306

)

Research and development, net of government grants

 

 

(8,381

)

 

 

(5,435

)

 

 

(15,191

)

 

 

(9,120

)

General and administrative expense:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Compensation expense in respect of share options and

   management equity incentives

 

 

(477

)

 

 

(283

)

 

 

(814

)

 

 

(509

)

Other general and administrative expenses

 

 

(5,488

)

 

 

(3,715

)

 

 

(10,275

)

 

 

(6,979

)

Total general and administrative expense

 

 

(5,965

)

 

 

(3,998

)

 

 

(11,089

)

 

 

(7,488

)

Total operating expense

 

 

(15,120

)

 

 

(10,042

)

 

 

(27,712

)

 

 

(17,914

)

Operating loss

 

 

(12,971

)

 

 

(8,221

)

 

 

(23,464

)

 

 

(12,627

)

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense, net

 

 

(1,061

)

 

 

(538

)

 

 

(1,858

)

 

 

(1,072

)

Change in financial liability for share warrants

 

 

10,256

 

 

 

(2,595

)

 

 

12,027

 

 

 

984

 

Other, net

 

 

(657

)

 

 

(365

)

 

 

(1,292

)

 

 

(1,620

)

Other income, net

 

 

8,538

 

 

 

(3,498

)

 

 

8,877

 

 

 

(1,708

)

Loss before income taxes

 

 

(4,433

)

 

 

(11,719

)

 

 

(14,587

)

 

 

(14,335

)

Provision for income taxes

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(4,433

)

 

$

(11,719

)

 

$

(14,587

)

 

$

(14,335

)

Other comprehensive income (loss):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Change in fair value of effective portion of foreign currency

   cash flow hedges

 

$

(17

)

 

$

(159

)

 

$

209

 

 

$

(253

)

Foreign currency gain

 

 

(1,561

)

 

 

(1,865

)

 

 

1,194

 

 

 

(1,492

)

Other comprehensive income (loss), net

 

 

(1,578

)

 

 

(2,024

)

 

 

1,403

 

 

 

(1,745

)

Comprehensive loss

 

$

(6,011

)

 

$

(13,743

)

 

$

(13,184

)

 

$

(16,080

)

Net loss available to ordinary shareholders - basic and diluted

 

$

(4,433

)

 

$

(11,719

)

 

$

(14,587

)

 

$

(14,335

)

Loss per share - basic and diluted

 

$

(0.25

)

 

$

(0.82

)

 

$

(0.85

)

 

$

(1.06

)

Weighted-average shares outstanding - basic and diluted

 

 

17,416,674

 

 

 

14,376,547

 

 

 

17,222,221

 

 

 

13,584,197

 

The accompanying notes form an integral part of these consolidated financial statements.

 

 

 

- 4 -


 

CONDENSED CONSOLID ATED STATEMENT OF CHANGES IN SHAREHOLDERS’ EQUITY ( DEFICIT ) (unaudited)

(Expressed in thousands of U.S. Dollars — except for share data)

 

 

 

Ordinary shares

 

 

Additional paid in (Distribution

in excess

 

 

Accumulated

Other Comprehensive

 

 

Accumulated

 

 

Total Shareholders'

Equity

 

 

 

Shares

 

 

Amount

 

 

of) capital

 

 

Loss

 

 

Deficit

 

 

(Deficit)

 

Balances, March 31, 2015

 

 

17,020,574

 

 

$

84,525

 

 

$

(6,684

)

 

$

(5,102

)

 

$

(74,354

)

 

$

(1,615

)

Issue of shares upon exercise of incentive share

   options and vesting of RSUs

 

 

17,899

 

 

 

33

 

 

 

 

 

 

 

 

 

 

 

 

33

 

Issue of shares upon exercise of warrants

 

 

1,513,474

 

 

 

13,318

 

 

 

9,105

 

 

 

 

 

 

 

 

 

22,423

 

Issue of warrants

 

 

 

 

 

 

 

 

1,190

 

 

 

 

 

 

 

 

 

1,190

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(14,587

)

 

 

(14,587

)

Change in the fair value of the effective portion

   of foreign currency cash flow hedges

 

 

 

 

 

 

 

 

 

 

 

209

 

 

 

 

 

 

209

 

Foreign currency translation gain

 

 

 

 

 

 

 

 

 

 

 

1,194

 

 

 

 

 

 

1,194

 

Other comprehensive loss

 

 

 

 

 

 

 

 

 

 

 

1,403

 

 

 

 

 

 

1,403

 

Stock-based compensation

 

 

 

 

 

 

 

 

814

 

 

 

 

 

 

 

 

 

814

 

Balances, September 30, 2015

 

 

18,551,947

 

 

$

97,876

 

 

$

4,425

 

 

$

(3,699

)

 

$

(88,941

)

 

$

9,661

 

The accompanying notes form an integral part of these consolidated financial statements.

 

 

 

- 5 -


 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)

(Expressed in thousands of U.S. Dollars)

 

 

 

Six months ended

September 30,

 

 

 

2015

 

 

2014

 

OPERATING ACTIVITIES:

 

 

 

 

 

 

 

 

Net loss

 

$

(14,587

)

 

$

(14,335

)

Adjustments to reconcile net loss to net cash provided by operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

907

 

 

 

599

 

Share-based compensation

 

 

814

 

 

 

509

 

Amortization of lease incentive

 

 

(222

)

 

 

(235

)

Amortization of deferred debt issue costs

 

 

1,056

 

 

 

393

 

Accrued preference share dividends

 

 

525

 

 

 

 

Change in financial liability for share warrants

 

 

(12,027

)

 

 

(984

)

Net change in assets and liabilities:

 

 

 

 

 

 

 

 

Trade accounts receivable, net

 

 

(287

)

 

 

(372

)

Inventories

 

 

(1,125

)

 

 

(35

)

Accounts payable and accrued liabilities

 

 

233

 

 

 

1,496

 

Accrued compensation and benefits

 

 

(958

)

 

 

(162

)

Other assets

 

 

(832

)

 

 

58

 

Net cash used in operating activities

 

 

(26,503

)

 

 

(13,068

)

INVESTING ACTIVITIES:

 

 

 

 

 

 

 

 

Purchase of property and equipment

 

 

(14,063

)

 

 

(10,058

)

Purchase of intangible assets

 

 

 

 

 

(197

)

Net cash used in investing activities

 

 

(14,063

)

 

 

(10,255

)

FINANCING ACTIVITIES:

 

 

 

 

 

 

 

 

Proceeds from finance leases

 

 

126

 

 

 

338

 

Proceeds from drawdown of new debt, net of costs

 

 

14,297

 

 

 

 

Proceeds from issuance of ordinary shares

 

 

13,352

 

 

 

34,254

 

Net cash generated from financing activities

 

 

27,775

 

 

 

34,592

 

Effect of exchange rate fluctuations on cash and cash equivalents

 

 

922

 

 

 

(1,351

)

Change in cash and cash equivalents

 

 

(11,869

)

 

 

9,918

 

Beginning cash and cash equivalents

 

 

37,525

 

 

 

7,192

 

Ending cash and cash equivalents

 

$

25,656

 

 

$

17,110

 

Supplemental cash flow disclosures:

 

 

 

 

 

 

 

 

Income taxes paid

 

$

 

 

$

 

Interest paid

 

$

789

 

 

$

683

 

The accompanying notes form an integral part of these consolidated financial statements.

 

 

 

- 6 -


 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Expressed in thousands of U.S. Dollars — except for share data and per share data, unless otherwise stated)

 

Note 1. Description of Business and Basis of Presentation

Description of Business

The principal activity of Quotient Limited (the “Company”) and its subsidiaries (the “Group”) is the development, manufacture and sale of products for the global transfusion diagnostics market. Products manufactured by the Group are sold to hospitals, blood banking operations and other diagnostics companies worldwide.

Basis of Presentation

The condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and are unaudited. In accordance with those rules and regulations, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States (“GAAP”) for complete financial statements.

In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) considered necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented. The March 31, 2015 balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. However, the Company believes that the disclosures are adequate to make the information presented not misleading. The financial statements should be read in conjunction with the audited consolidated financial statements at and for the year ended March 31, 2015 included in the Company’s Annual Report on Form 10-K for the year then ended. The results of operations for the six month period ended September 30, 2015 are not necessarily indicative of the results of operations that may be expected for the year ending March 31, 2016 and any future period.

The Company has incurred net losses and negative cash flows from operations in each year since it commenced operations in 2007 and had an accumulated deficit of $88.9 million as of September 30, 2015. At September 30, 2015 the Company had cash holdings of $25.7 million and had covenants in place with lenders to maintain cash holdings above $10 million. Since September 30, 2015, the Company has received proceeds of $21.2 million on the exercise of its IPO warrants (see note 6), which expired on October 26, 2015.   The Company has expenditure plans over the next fifteen months that exceed its current cash holdings, raising substantial doubt about its ability to continue as a going concern. The Company expects to fund its operations from a combination of funding sources, including through the use of existing cash balances, product sales, asset sales, the achievement of product development milestones, the extension or expansion of its credit facilities and the issuance of new equity. The Company’s Directors are confident in the availability of these funding sources and accordingly have prepared the financial statements on the going concern basis. However, there can be no assurance that the Company will be able to obtain adequate financing when necessary and the terms of any financings may not be advantageous to the Company and may result in dilution to its shareholders.   

 

Note 2. Summary of Significant Accounting Policies

Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. As of September 30, 2015 and March 31, 2015, all cash and cash equivalents comprised readily accessible cash balances except for $314 at both September 30, 2015 and March 31, 2015 held in a restricted account as security for the property rental obligations of the Company’s Swiss subsidiary.

Trade Accounts Receivable

Trade accounts receivable are recorded at the invoiced amount and are not interest bearing. The Company maintains an allowance for doubtful accounts to reserve for potentially uncollectible trade receivables. Additions to the allowance for doubtful accounts are recorded as General and administrative expenses. The Company reviews its trade receivables to identify specific customers with known disputes or collectability issues. In addition, the Company maintains an allowance for all other receivables not included in the

- 7 -


 

specific reserve by applying specific rates of projected uncollectible receivables to the various aging categories. In determining these percentages, the Company analyzes its historical collection experience, customer credit-worthiness, current economic trends and changes in customer payment terms.

Concentration of Credit Risks and Other Uncertainties

The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Derivative instruments, consisting entirely of foreign exchange contracts, are stated at their estimated fair values, based on quoted market prices for the same or similar instruments. The counterparties to the agreements relating to the Company’s derivative instruments consist of large financial institutions of high credit standing.

The Company’s main financial institutions for banking operations hold all of the Company’s cash and cash equivalents as of September 30, 2015 and at March 31, 2015. The Company’s accounts receivable are derived from net revenue to customers and distributors located in the United States and other countries. The Company performs credit evaluations of its customers’ financial condition. The Company provides reserves for potential credit losses but has not experienced significant losses to date. There was one customer whose accounts receivable balance represented 10% or more of total accounts receivable, net, as of September 30, 2015 and March 31, 2015. This customer represented 46% and 47% of the accounts receivable balances as of September 30, 2015 and March 31, 2015, respectively.

The Company currently sells products through its direct sales force and through third-party distributors. There was one direct customer that accounted for 10% or more of total product sales for the six month periods ended September 30, 2015 and September 30, 2014. This customer represented 57% of total product sales for the the six month period ended September 30, 2015 and 54% for the six month period ended September 30, 2014.

Fair Value of Financial Instruments

The Company defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company’s valuation techniques used to measure fair value maximized the use of observable inputs and minimized the use of unobservable inputs. The fair value hierarchy is based on the following three levels of inputs:

Level 1—Quoted prices in active markets for identical assets or liabilities.

Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

See Note 6, “Commitment and Contingencies,” for information and related disclosures regarding the Company’s fair value measurements.

Inventory

Inventory is stated at the lower of standard cost (which approximates actual cost) or market, with cost determined on the first-in-first-out method. Accordingly, allocation of fixed production overheads to conversion costs is based on normal capacity of production. Abnormal amounts of idle facility expense, freight, handling costs and spoilage are expensed as incurred and not included in overhead. No stock-based compensation cost was included in inventory as of September 30, 2015 and March 31, 2015.

Property and Equipment

Property, equipment and leasehold improvements are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization are computed on a straight-line basis over the estimated useful lives of the related assets as follows:

Plant, machinery and equipment—4 to 25 years;

Leasehold improvements—the shorter of the lease term or the estimated useful life of the asset.

- 8 -


 

Repairs and maintenance expenditures, which are not considered improvements and do not extend the useful life of property and equipment, are expensed as incurred.

Intangible Assets and Goodwill

Intangible assets related to product licenses are recorded at cost, less accumulated amortization. Intangible assets related to technology and other intangible assets acquired in acquisitions are recorded at fair value at the date of acquisition, less accumulated amortization. Intangible assets are amortized over their estimated useful lives, on a straight-line basis as follows:

Customer relationships—5 years

Brands associated with acquired cell lines—40 years

Product licenses—10 years

Other intangibles assets—7 years

The Company reviews its intangible assets for impairment and conducts an impairment review when events or circumstances indicate the carrying value of a long-lived asset may be impaired by estimating the future undiscounted cash flows to be derived from an asset to assess whether or not a potential impairment exists. No impairment losses have been recorded in either of the six month periods ended September 30, 2015 or September 30, 2014.

Revenue Recognition

The Company recognizes revenue from product sales when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable and collectability is reasonably assured. Customers have no right of return except in the case of damaged goods. The Company has not experienced any significant returns of its products. Shipping and handling costs are expensed as incurred and included in cost of product sales. In those cases where the Company bills shipping and handling costs to customers, the amounts billed are classified as revenue.

The Company enters into revenue arrangements that may consist of multiple deliverables of its products and services. The terms of these arrangements may include non-refundable upfront payments, milestone payments, other contingent payments and royalties on any product sales derived on collaboration. Up-front fees received in connection with collaborative agreements are deferred upon receipts, are not considered a separate unit of accounting and are recognized as revenues over the relevant performance periods. Revenues related to research and development services included in a collaboration agreement are recognized as research and services are performed over the related performance periods for each contract. A payment that is contingent upon the achievement of a substantive milestone is recognized in its entirety in the period in which the milestone is achieved.

In June 2013, the Company entered into an agreement with Ortho-Clinical Diagnostics Inc. (“OCD”) to develop a range of rare antisera products. The Company had been working on this project for more than a year before the formal agreement was signed with OCD. Under the terms of the agreement, the Company is entitled to receive milestone payments of $1,400 upon the receipt of FDA approval of the rare antisera products and two further milestones of $500 each upon the updating of the CE-mark and FDA approvals to cover use of the products on OCD’s automation platform. The Company has concluded that as each of these milestones required significant levels of development work to be undertaken and there was no certainty at the start of the project that the development work would be successful, these milestones are substantive and will be accounted for under the milestone method of revenue recognition. The agreement also contains one further milestone of $650 payable upon fulfillment of $250 of cumulative orders of the rare antisera products covered by the agreement. This payment represents a royalty payment and was recognized in the quarter ended June 30, 2014 when the sales target was achieved.

Research and Development

Research and development expenses consist of costs incurred for company-sponsored and collaborative research and development activities. These costs include direct and research-related overhead expenses. The Company expenses research and development costs, including the expenses for research under collaborative agreements, as such costs are incurred. Where government grants are available for the sponsorship of such research, the grant receipt is included as a credit against the related expense.

- 9 -


 

Stock-Based Compensation

Stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company’s Condensed Consolidated Statements of Comprehensive Loss. Compensation cost related to restricted stock units with a market condition is recognized regardless of whether the market condition is satisfied, provided that the requisite service has been provided. Stock-based compensation cost for restricted stock units granted to non-employees is measured when the awards vest and the expense is recognized during the period the related services are rendered.

In determining the fair value of the stock-based compensation payments in respect of share options, the Company uses the Black–Scholes model and a single option award approach, which requires the input of subjective assumptions. These assumptions include: the fair value of the underlying share, estimating the length of time employees will retain their vested stock options before exercising them (expected term), the estimated volatility of the Company’s ordinary shares price over the expected term (expected volatility), risk-free interest rate (interest rate), expected dividends and the number of shares subject to options that will ultimately not complete their vesting requirements (forfeitures). The Company uses a barrier option pricing model to determine the grant date fair value of its multi-year performance related restricted stock unit awards. This requires the use of similar assumptions to the Black-Scholes model.

Debt Issuance Costs

On September 30, 2015, the Company elected to adopt early the requirements of Accounting Standards Update 2015-03, Interest — Imputation of Interest (Subtopic 835-30) — Simplifying the Presentation of Debt Issuance Costs, which requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the debt liability rather than as an asset.   In view of the refinancing of the Company’s secured credit facility on August 3, 2015 (see note 4), the Company believes that it is preferable to adopt this presentation in the year of refinancing in order to reflect more accurately the assets of the Company and the substance of the financing arrangements.  Comparative financial statements of prior years have been adjusted to apply the new presentation retrospectively.   This had the effect of reducing “Prepaid expenses and other current assets” and “Other non-current assets at March 31, 2015 by $549 and $366, respectively, with a consequential reduction in “Long term debt, less current portion” of $915.   There has been no impact on the comparative Statements of comprehensive loss, Statement of changes in shareholders’ deficit or Statements of cash flows.

 

Note 3. Intangible Assets

 

 

 

September 30, 2015

 

 

 

Gross

Carrying

Amount

 

 

Accumulated

Amortization

 

 

Net   Carrying

Amount

 

 

Weighted

Ave.

Remaining

Useful   Life

 

Customer relationships

 

$

2,986

 

 

$

(2,986

)

 

$

 

 

 

 

Brands associated with acquired cell lines

 

 

616

 

 

 

(125

)

 

 

491

 

 

31.9 years

 

Product licenses

 

 

723

 

 

 

(282

)

 

 

441

 

 

6.1 years

 

Other intangibles

 

 

194

 

 

 

(194

)

 

 

 

 

 

 

Total

 

$

4,519

 

 

$

(3,587

)

 

$

932

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

March 31, 2015

 

 

 

Gross

Carrying

Amount

 

 

Accumulated

Amortization

 

 

Net   Carrying

Amount

 

 

Weighted

Ave.

Remaining

Useful   Life

 

Customer relationships

 

$

2,923

 

 

$

(2,923

)

 

$

 

 

 

 

Brands associated with acquired cell lines

 

 

603

 

 

 

(115

)

 

 

488

 

 

32.4 years

 

Product licenses

 

 

703

 

 

 

(241

)

 

 

462

 

 

6.6 years

 

Other intangibles

 

 

190

 

 

 

(190

)

 

 

 

 

 

 

Total

 

$

4,419

 

 

$

(3,469

)

 

$

950

 

 

 

 

 

 

- 10 -


 

Note 4. Debt

Long-term debt comprises:

 

 

 

September 30,

2015

 

 

March 31,

2015

 

Total debt

 

$

30,000

 

 

$

15,000

 

Less current portion

 

 

 

 

 

(4,500

)

Long-term debt

 

$

30,000

 

 

$

10,500

 

Deferred debt costs, net of amortization

 

 

(367

)

 

 

(428

)

Fair value of associated share warrant, net of amortization

 

 

(1,119

)

 

 

(219

)

 

 

$

28,514

 

 

$

9,853

 

 

On August 3, 2015, the Company drew down $30,000 under a new secured credit facility agreement with MidCap Financial Trust. The facility is repayable over a four year period with no repayments until March 1, 2017 when the first of 30 equal monthly repayments is due. If the Company achieves CE Mark approvals for the MosaiQ TM instrument and blood grouping consumable, the facility is repayable over a four year period with no repayments until September 1, 2017 when the first of 24 equal monthly repayments is due. The facility bears interest at LIBOR plus 6.7%. The LIBOR rate applicable is the higher of the actual market rate from time to time or 2.0%. Other expense for the quarter ended September 30, 2015 included $0.6 million of previously deferred fees that were expensed as a result of the expansion of the credit facility.

At September 30, 2015, the outstanding debt is repayable as follows:

 

Within 1 year

 

$

 

Between 1 and 2 years

 

 

6,000

 

Between 2 and 3 years

 

 

12,000

 

Between 3 and 4 years

 

 

12,000

 

Total debt

 

$

30,000

 

 

 

Note 5. Consolidated Balance Sheet Detail

Inventory

The following table summarizes inventory by category for the dates presented:

 

 

 

September 30,

2015

 

 

March 31,

2015

 

Raw materials

 

$

1,974

 

 

$

1,180

 

Work in progress

 

 

2,078

 

 

 

2,071

 

Finished goods

 

 

1,775

 

 

 

1,357

 

Total inventories

 

$

5,827

 

 

$

4,608

 

Property and equipment

The following table summarizes property and equipment by categories for the dates presented:

 

 

 

September 30,

2015

 

 

March 31,

2015

 

 

 

 

 

 

 

 

 

 

Plant and Machinery

 

$

32,973

 

 

$

21,688

 

Leasehold improvements

 

 

14,605

 

 

 

11,412

 

Total property and equipment

 

 

47,578

 

 

 

33,100

 

Less: accumulated depreciation

 

 

(4,273

)

 

 

(3,367

)

Total property and equipment, net

 

$

43,305

 

 

$

29,733

 

 

Depreciation expenses were $491 and $290 in the quarters ended September 30, 2015 and September 30, 2014 respectively and $867 and $557 in the six month periods ended September 30, 2015 and September 30, 2014 respectively.

- 11 -


 

Accrued compensation and benefits

Accrued compensation and benefits consist of the following:

 

 

 

September 30,

2015

 

 

March 31,

2015

 

Salary and related benefits

 

$

489

 

 

$

300

 

Accrued vacation

 

 

187

 

 

 

165

 

Accrued payroll taxes

 

 

385

 

 

 

302

 

Accrued incentive payments

 

 

600

 

 

 

1,798

 

Total accrued compensation and benefits

 

$

1,661

 

 

$

2,565

 

 

Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consist of the following:

 

 

 

September 30,

2015

 

 

March 31,

2015

 

Accrued legal and professional fees

 

$

195

 

 

$

3,758

 

Accrued interest

 

 

217

 

 

 

112

 

Goods received not invoiced

 

 

684

 

 

 

787

 

Accrued capital expenditure

 

 

 

 

 

972

 

Accrued development expenditure

 

 

2,401

 

 

 

2,110

 

Other accrued expenses

 

 

913

 

 

 

1,048

 

Total accrued expenses and other current liabilities

 

$

4,410

 

 

$

8,787

 

 

 

Note 6. Commitments and Contingencies

Government Grant

In 2008, the Company was awarded research and development grant funding from Scottish Enterprise amounting to £1,791, for the development of MosaiQ TM . The total grant claimed to September 30, 2015 is £1,790. Regular meetings are held to update Scottish Enterprise with the status of the project and while the terms of the grant award provide for full repayment of the grant in certain circumstances, the Company does not consider that any repayment is likely.

Hedging arrangements

The Company’s subsidiary in the United Kingdom (“UK”) has entered into three forward exchange contracts to sell $300 and purchase pounds sterling at £1:$1.50 in each calendar month through December 2015 as a hedge of its U.S. dollar denominated revenues.

Share warrants

As part of its initial public offering in April 2014 the Company issued 5 million warrants each to acquire 0.8 of an ordinary share for a price of $8.80 per whole share (“IPO warrants”). During the period from the initial public offering to September 30, 2015, 1,969,479 of these warrants were exercised resulting in 3,030,521 warrants remaining at September 30, 2015. The financial statements include a financial liability in respect of these warrants which is equal to the market price of the warrants at the end of each financial period.

- 12 -


 

The following table summarizes the Company’s assets and liabilities that are measured at fair value on a recurring basis, by level, within the fair value hiera rchy:

 

 

 

September 30, 2015

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Foreign currency forward contracts

 

$

10

 

 

$

 

 

$

 

 

$

10

 

Total assets measured at fair value

 

$

10

 

 

$

 

 

$

 

 

$

10

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

September 30, 2015

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Foreign currency forward contracts

 

$

 

 

$

 

 

$

 

 

$

 

Fair value of share warrants

 

 

9,880

 

 

 

 

 

 

 

 

 

9,880

 

Total liabilities measured at fair value

 

$

9,880

 

 

$

 

 

$

 

 

$

9,880

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

March 31, 2015

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Foreign currency forward contracts

 

$

 

 

$

 

 

$

 

 

$

 

Total assets measured at fair value

 

$

 

 

$

 

 

$

 

 

$

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

March 31, 2015

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Foreign currency forward contracts

 

$

199

 

 

$

 

 

$

 

 

$

199

 

Fair value of share warrants

 

 

31,011

 

 

 

 

 

 

 

 

 

31,011

 

Total liabilities measured at fair value

 

$

31,210

 

 

$

 

 

$

 

 

$

31,210

 

  

The change in the estimated fair value of share warrant liabilities is summarized below:

 

 

March 31,2015

 

$

31,011

 

Change in fair value of ordinary share warrants

 

 

(12,027

)

Exercise of warrants

 

 

(9,104

)

September 30, 2015

 

$

9,880

 

 

Note 7. Ordinary Shares

Ordinary Shares

The Company’s issued and outstanding ordinary shares were as follows:

 

 

 

Shares Issued

and Outstanding

 

 

 

 

 

 

 

September 30,

2015

 

 

March 31,

2015

 

 

Par value

 

Ordinary shares

 

 

18,551,947

 

 

 

17,020,574

 

 

$

 

Total

 

 

18,551,947

 

 

 

17,020,574

 

 

$

 

 

- 13 -


 

Preference shares

The Company’s issued and outstanding preference shares consist of the following:

 

 

 

Shares Issued

and Outstanding

 

 

Liquidation

amount per share

 

 

 

September 30,

2015

 

 

March 31,

2015

 

 

September 30,

2015

 

 

March 31,

2015

 

7% Cumulative Redeemable Preference

   shares

 

 

666,665

 

 

 

666,665

 

 

$

23.55

 

 

$

22.76

 

Total

 

 

666,665

 

 

 

666,665

 

 

 

 

 

 

 

 

 

 

 

Note 8. Share-Based Compensation

The Company records share-based compensation expense in respect of options, multi-year performance based restricted stock units (“MRSUs”) and restricted stock units (“RSUs”) issued under its share incentive plans. Share-based compensation expense amounted to $814 and $509 in the six month periods ended September 30, 2015 and September 30, 2014, respectively.

Share option activity

The following table summarizes share option activity:

 

 

 

Number

of Share

Options

Outstanding

 

 

Weighted

Average

Exercise Price

 

 

Weighted

Average

Remaining Contractual   Life

(Months)

 

Outstanding — March 31, 2015

 

 

1,208,118

 

 

$

5.58

 

 

 

103

 

Granted

 

 

345,300

 

 

 

15.29

 

 

 

120

 

Exercised

 

 

(5,399

)

 

 

6.14

 

 

 

 

Forfeited

 

 

(3,795

)

 

 

10.64

 

 

 

 

Outstanding — September 30, 2015

 

 

1,544,224

 

 

$

7.73

 

 

 

101

 

Exercisable —September 30, 2015

 

 

613,813

 

 

$

3.91

 

 

 

94

 

The closing price of the Company’s Ordinary Shares on The NASDAQ Global Market on September 30, 2015 was $13.00.

The following table summarizes the options granted in the current financial year with their exercise prices, the fair value of ordinary shares as of the applicable grant date, and the intrinsic value:

 

Grant Date

 

Number of

Options Granted

 

 

Exercise Price

 

 

Ordinary

Shares

Fair Value Per

Share at Grant

Date

 

 

Per Share

Intrinsic

Value of

Options

 

May 20, 2015

 

 

312,300

 

 

$

15.17

 

 

$

15.17

 

 

$

6.08

 

August 5, 2015

 

 

8,000

 

 

$

16.70

 

 

$

16.70

 

 

$

6.54

 

September 2, 2015

 

 

25,000

 

 

$

16.34

 

 

$

16.34

 

 

$

6.52

 

 

Determining the fair value of share incentive awards

The fair value of each share incentive grant was determined by the Company using the Black-Scholes options pricing model.

Assumptions used in the option pricing models are discussed below. Each of these inputs is subjective and generally requires significant judgment to determine.

Expected volatility . The expected volatility was based on the historical share volatilities of a number of the Company’s publicly listed peers over a period equal to the expected terms of the options as the Company did not have a sufficient trading history to use the volatility of its own ordinary shares.

- 14 -


 

Fair value of ordinary shares.   The fair value of the ordinary shares is based upon the closing price of the Company’s shares on The NASDAQ Global Market on the last trading day prior to the date of grant.

Risk-Free Interest Rate.  The risk-free interest rate is based on the US Treasury 10-year bond yield in effect at the time of grant.

Expected term.  The expected term is determined after giving consideration to the contractual terms of the share-based awards, graded vesting schedules ranging from one to three years and expectations of future employee behavior as influenced by changes to the terms of its share-based awards.

Expected dividend.  According to the terms of the awards, the exercise price of the options is adjusted to take into account any dividends paid. As a result dividends are not required as an input to the model, as these reductions in the share price are offset by a corresponding reduction in exercise price.

A summary of the assumptions applicable to the share options issued in the current financial year is as follows:

 

 

 

May 20, 2015

 

 

August 5, 2015

 

 

September 2, 2015

 

Risk-free interest rate

 

 

2.29

%

 

 

2.27

%

 

 

2.18

%

Expected lives (years)

 

 

3

 

 

 

3

 

 

 

3

 

Volatility

 

 

57.14

%

 

 

55.67

%

 

 

57.01

%

Dividend yield

 

 

 

 

 

 

 

 

 

Grant date fair value (per share)

 

$

15.17

 

 

$

16.70

 

 

$

16.34

 

Number granted

 

 

312,300

 

 

 

8,000

 

 

 

25,000

 

 

The Company awarded 137,000 MRSUs on May 20, 2015. These MRSUs will vest if the volume weighted average price of the Company’s ordinary shares exceeds $60 for a continuous twenty day period between April 1, 2018 and December 31, 2018. The Company determined the grant date fair value of the MRSUs using a barrier option pricing model with the same grant date fair value per share, risk free interest rate, volatility and dividend yield assumptions as the options awarded on the same date. This resulted in a grant date fair value of $6.09 per MRSU on May 20, 2015.  On September 2, 2015 the Company issued 25,000 RSUs which will vest if specific sales performance targets are met prior to December 31, 2022.  The Company expects these performance targets to be met and share based compensation expense is being recognized on these awards over the period to the date when the sales performance targets are expected to be achieved.  The Company also issued 10,000 RSUs in the quarter ended May 20, 2015 and 9,867 RSUs on September 4, 2015, which vest over a two year period from the date of grant.  

During the quarter ended September 30, 2014, the Company awarded 50,000 RSUs to a non-executive director upon his appointment as a director of the Company.  These vest in equal annual installments over the four year period following the date of grant. During the quarter ended September 30, 2015, 12,500 of these RSUs vested resulting in the issuance of 12,500 ordinary shares and at September 30, 2015, 37,500 of these RSUs remained outstanding.

 

Note 9. Net Loss Per Share

In accordance with ASC 260 “Earnings Per Share”, basic earnings available to ordinary shareholders per share is computed based on the weighted average number of ordinary shares outstanding during each period. Diluted earnings available to ordinary shareholders per share is computed based on the weighted average number of ordinary shares outstanding during each period, plus potential ordinary shares considered outstanding during the period, as long as the inclusion of such shares is not anti-dilutive. Potential ordinary shares consist of the incremental ordinary shares issuable upon the exercise of share options (using the treasury shares method), the warrants to acquire ordinary shares and the ordinary shares issuable upon vesting of the MRSUs and RSUs.

- 15 -


 

The following table sets forth the computation of basic and diluted earnings per ordinary share.

 

 

 

Quarter ended

 

 

Six months ended

 

 

 

September 30

 

 

September 30

 

 

 

2015

 

 

2014

 

 

2015

 

 

2014

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(4,433

)

 

$

(11,719

)

 

$

(14,587

)

 

$

(14,335

)

Net loss available to ordinary shareholders - basic and diluted

 

$

(4,433

)

 

$

(11,719

)

 

$

(14,587

)

 

$

(14,335

)

Denominator:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average shares outstanding - basic and diluted

 

 

17,416,674

 

 

 

14,376,547

 

 

 

17,222,221

 

 

 

13,584,197

 

Loss per share - basic and diluted

 

$

(0.25

)

 

$

(0.82

)

 

$

(0.85

)

 

$

(1.06

)

 

The following table sets out the numbers of ordinary shares excluded from the above computation of earnings per share at September 30, 2015 and September 30, 2014 as their inclusion would have been anti-dilutive.

 

 

 

September 30,

2015

 

 

September 30,

2014

 

Ordinary shares issuable on exercise of options to purchase ordinary

   shares

 

 

1,544,224

 

 

 

1,320,482

 

Restricted stock units awarded, including the multi-year performance

   related restricted stock units

 

 

219,367

 

 

 

50,000

 

Ordinary shares issuable on exercise of warrants at $16.14 per share

 

 

111,525

 

 

 

 

Ordinary shares issuable on exercise of warrants at $9.37 per share

 

 

64,000

 

 

 

64,000

 

Ordinary shares issuable on exercise of warrants at $8.80 per share

 

 

2,424,416

 

 

 

4,000,000

 

Ordinary shares issuable on exercise of pre-funded warrants at $0.01 per

   share

 

 

850,000

 

 

 

 

 

 

 

5,213,532

 

 

 

5,434,482

 

 

 

Note 10. Subsequent Events

 

Exercise of IPO Warrants

Between September 30, 2015 and October 26, 2015, there were exercises of 3,011,573 of the IPO warrants. The remaining 18,948 warrants which had not been exercised expired on October 26, 2015.  This resulted in the issue of 2,409,245 ordinary shares, cash receipts of $21.2 million, a reduction in the financial liability in respect of the warrants in the balance sheet of $9.9 million and an increase in shareholders’ equity of $31.1 million subsequent to September 30, 2015.

 

 

 

 

- 16 -


 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with the corresponding section of our Annual Report on Form 10-K for the year ended March 31, 2015 filed with the Securities and Exchange Commission on June 1, 2015.

The information set forth and discussed below for the quarters and six month periods ended September 30, 2015 and September 30, 2014 is derived from the Condensed Consolidated Financial Statements included under Item 1 above. The financial information set forth and discussed below is unaudited but includes all adjustments (consisting of normal recurring adjustments) that our management considers necessary for a fair presentation of the financial position and the operating results and cash flows for those periods. Our results of operations for a particular quarter may not be indicative of the results that may be expected for other quarters or the entire year.

Overview

We were incorporated in Jersey, Channel Islands on January 28, 2012. On February 16, 2012, we acquired the entire issued share capital of Alba Bioscience Limited (or Alba), Quotient Biodiagnostics, Inc. (or QBDI) and QBD (QSIP) Limited (or QSIP) from Quotient Biodiagnostics Group Limited (or QBDG), our predecessor.

The acquisition of Alba, QBDI and QSIP by us is treated for accounting purposes as a combination of entities under common control as these entities were all controlled by QBDG prior to their acquisition by us. We recognized the assets and liabilities of Alba, QBDI and QSIP at their carrying amounts in the financial statements of those companies. We are a continuation of QBDG and its subsidiaries and, accordingly, our consolidated financial statements include the assets, liabilities and results of operations of the subsidiaries transferred since their inception.

Our Business

We are a commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the provision of innovative tests within established markets. Our initial focus is on blood grouping and serological disease screening, which is commonly referred to as transfusion diagnostics. Blood grouping involves specific procedures performed at donor or patient testing laboratories to characterize blood, which includes antigen typing and antibody identification. Serological disease screening involves the screening of donor blood for unwanted pathogens.

We have over 30 years of experience developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market. We are developing MosaiQ™, our proprietary technology platform, to better address the comprehensive needs of this large and established market. MosaiQ™ will initially comprise two separate consumables, one for blood grouping and one for serological disease screening, and a high-throughput instrument. We believe MosaiQ™ has the potential to transform transfusion diagnostics, significantly reducing the cost of blood grouping in the donor and patient testing environments, while improving patient outcomes.

We operate as one business segment with 298 employees in the United States, the United Kingdom and Switzerland as of September 30, 2015. Our principal markets are the United States, Europe and Japan. Based on the location of the customer, revenues outside the United States accounted for 54% and 56% of total revenue during the six month periods ended September 30, 2015 and September 30, 2014, respectively.

We have incurred net losses and negative cash flows from operations in each year since we commenced operations in 2007. As of September 30, 2015, we had an accumulated deficit of $88.9 million. We expect our operating losses will continue at least for the next two years as we continue our investment in the development and commercialization of MosaiQ™. For the six month period ended September 30, 2015, our total revenue was $9.1 million and our net loss was $14.6 million.

- 17 -


 

On April 29, 2014 we completed our initial public offering and issued 5,000,000 units at $8.00 per unit. Each unit comprised one ordinary share and one warrant to acquire 0.8 of an ordinary share at an exercise price of $8.80 per whole share. We raised $40.0 million of equity share capital before issuance costs of approximately $6.4 million. At the time of the offering, we recorded a financial liability in our financial statements amounting to $8.5 million, which represents the value ascribed to the warrants attributable to our initial public offering of units. On May 27, 2014, our ordinary shares an d warrants began trading separately on The NASDAQ Global Market and the units were delisted. During the period from our initial public offering to September 30, 2015, 1,969,479 of these warrants were exercised resulting in the issu ance of 1,575,578 ordinar y shares.  At September 30, 2015, 3,030,521 of these warrants remained outstanding and the market value of the warrants at September 30, 2015 was $9.9 million.  We have recorded the decrease in the market value of the warrants since March 31, 2015 as incom e of $12.0 million within net other income (expense) in our income statement for the six month period ended September 30, 2015.   Since September 30, 2015, an additional 3,011,573 of these warrants were exercised resulting in the issuance of an additional 2 ,409,245 ordinary shares , and the 18,948 remaining warrants that were not exercised expired on October 26, 2015 .

On November 25, 2014, we entered into subscription agreements with certain institutional and individual accredited investors for the private placement of 2,000,000 newly issued ordinary shares at a price of $9.50 per share and 850,000 newly issued pre-funded warrants at a price of $9.49 per warrant, amounting to an aggregate subscription price of approximately $27.1 million. Each pre-funded warrant permits the holder to subscribe for one new ordinary share at an exercise price of $0.01 per pre-funded warrant.

On January 29, 2015, we entered into a subscription agreement with Ortho-Clinical Diagnostics Finco S.Á.R.L., an affiliate of Ortho, for the private placement of 444,445 newly issued ordinary shares at a price of $22.50 per share and 666,665 newly issued 7% cumulative redeemable preference shares, of no par value, at a price of $22.50 per share, for an aggregate subscription price of approximately $25 million.

Revenue

We generate revenue from the sale of conventional reagent products directly to hospitals, donor collection agencies and independent testing laboratories in the United States, the United Kingdom and to distributors in Europe and the rest of the world, and indirectly through sales to our original equipment manufacturer (or OEM) customers. We recognize revenues in the form of product sales when the goods are shipped. Products sold by standing purchase orders as a percentage of product sales revenue were 73% and 71% for the six month periods ended September 30, 2015 and September 30, 2014, respectively. We also provide product development services to our OEM customers. We recognize revenue from these contractual relationships in the form of product development fees, which are included in other revenues. For a description of our revenue recognition policies, see “—Critical Accounting Policies and Significant Judgments and Estimates—Revenue Recognition and Accounts Receivable.”

Our revenue is denominated in multiple currencies. Sales in the United States and to certain of our OEM customers are denominated in U.S. Dollars. Sales in Europe and the rest of the world are denominated primarily in Pounds Sterling, Euros or Yen. Our expenses are generally denominated in the currencies in which our operations are located, which is primarily in the United Kingdom, United States and Switzerland. We operate globally and therefore changes in foreign currency exchange rates may become material to us in the future due to factors beyond our control. See Part I, Item 3: “Quantitative and Qualitative Disclosure About Market Risk—Foreign Currency Exchange Risk.”

Cost of revenue and operating expenses

Cost of revenue consists of direct labor expenses, including employee benefits, overhead expenses, material costs and freight costs, along with the depreciation of manufacturing equipment and leasehold improvements. Our gross profit represents total revenue less the cost of revenue and gross margin represents gross profit expressed as a percentage of total revenue. Our gross margin was 47% and 51% for the six month periods ended September 30, 2015 and September 30, 2014, respectively. Excluding other revenues, which consist of product development fees, our gross margin on product sales was 47% and 47% for the six month periods ended September 30, 2015 and September 30, 2014, respectively. We expect our overall cost of revenue to increase in absolute U.S. Dollars as we continue to increase our product sales volumes. However, we also believe that we can achieve efficiencies in our manufacturing operations, primarily through increasing production volumes.

Our sales and marketing expenses include costs associated with our sales organization, including our direct sales force, as well as our marketing and customer service personnel. These expenses consist principally of salaries, commissions, bonuses and employee benefits, as well as travel costs related to our sales activities. These expenses also include direct and indirect costs associated with our product marketing activities. We expense all sales and marketing costs as incurred. We expect sales and marketing expense to increase in absolute U.S. Dollars, primarily as a result of commissions on increased product sales in the United States.

- 18 -


 

Our research and development expenses include costs associated with performing research, development, field trials and our regulatory activities, as well as production costs incurred in advance of the commercial launch of MosaiQ TM . Research and development expenses include research personnel-related expenses, fees for contractual and consulti ng services, travel costs, laboratory supplies and depreciation of laboratory equipment.

We expense all research and development costs as incurred, net of government grants received and tax credits. In the year ended March 31, 2015 changes in UK tax legislation enabled our UK subsidiary to claim certain tax credits on its research and development expenditures. Previously, these tax credits increased the unutilized tax losses of our UK subsidiary, but are now being claimed and are included as an offset to our research and development expenses. Our research and development efforts are focused on developing new products and technologies for the global transfusion diagnostics market. We segregate research and development expenses for the MosaiQ™ project from expenses for other research and development projects. We do not maintain detailed records of these other costs by activity. We expect overall research and development expense to decrease in absolute U.S. Dollars following completion of the development of MosaiQ™.

Our general and administrative expenses include costs for our executive, accounting and finance, legal, corporate development, information technology and human resources functions. We expense all general and administrative expenses as incurred. These expenses consist principally of salaries, bonuses and employee benefits for the personnel performing these functions, including travel costs. These expenses also include share-based compensation, professional service fees (such as audit, tax and legal fees), costs related to our Board of Directors, and general corporate overhead costs, which includes depreciation and amortization. We expect our general and administrative expenses to increase as our business develops and also due to the costs of operating as a public company, such as additional legal, accounting and corporate governance expenses, including expenses related to compliance with the Sarbanes-Oxley Act, directors’ and officers’ insurance premiums and expenses for investor relations.

Net interest expense consists primarily of interest charges on our loan balances and the amortization of debt issuance costs, as well as accrued dividends on the 7% cumulative redeemable preference shares issued in January 2015. We amortize debt issuance costs over the life of the loan and report them as interest expense in our statements of operations.

Net other income (expense) consists primarily of realized and unrealized gains and losses on foreign exchange and income or expense arising on the change in the fair value of our warrants.  Realized exchange fluctuations result from the settlement of transactions in currencies other than the functional currencies of our businesses. Monetary assets and liabilities that are denominated in foreign currencies are measured at the period-end closing rate with resulting unrealized exchange fluctuations. The functional currencies of our businesses are Pounds Sterling, Swiss Francs and U.S. Dollars depending on the entity.

- 19 -


 

Results of Operations

Comparison of the Quarters ended September 30, 2015 and 2014

The following table sets forth, for the periods indicated, the amounts of certain components of our statements of operations and the percentage of total revenue represented by these items, showing period-to-period changes.

 

 

 

Quarter ended September 30,

 

 

 

 

 

 

 

 

 

 

 

2015

 

 

2014

 

 

Change

 

 

 

Amount

 

 

% of revenue

 

 

Amount

 

 

% of revenue

 

 

Amount

 

 

%

 

 

 

(in thousands, except percentages)

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product sales

 

$

4,273

 

 

 

100

%

 

$

4,527

 

 

 

100

%

 

$

(254

)

 

 

-6

%

Other revenues

 

 

 

 

 

0

%

 

 

 

 

 

0

%

 

 

 

 

 

0

%

Total revenue

 

 

4,273

 

 

 

100

%

 

 

4,527

 

 

 

100

%

 

 

(254

)

 

 

-6

%

Cost of revenue

 

 

2,124

 

 

 

50

%

 

 

2,706

 

 

 

60

%

 

 

(582

)

 

 

-22

%

Gross profit

 

 

2,149

 

 

 

50

%

 

 

1,821

 

 

 

40

%

 

 

328

 

 

 

18

%

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

774

 

 

 

18

%

 

 

609

 

 

 

13

%

 

 

165

 

 

 

27

%

Research and development

 

 

8,381

 

 

 

196

%

 

 

5,435

 

 

 

120

%

 

 

2,946

 

 

 

54

%

General and administrative

 

 

5,965

 

 

 

140

%

 

 

3,998

 

 

 

88

%

 

 

1,967

 

 

 

49

%

Total operating expenses

 

 

15,120

 

 

 

354

%

 

 

10,042

 

 

 

222

%

 

 

5,078

 

 

 

51

%

Operating loss

 

 

(12,971

)

 

 

-304

%

 

 

(8,221

)

 

 

-182

%

 

 

(4,750

)

 

 

58

%

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense, net

 

 

(1,061

)

 

 

-25

%

 

 

(538

)

 

 

-12

%

 

 

(523

)

 

 

97

%

Other, net

 

 

9,599

 

 

 

225

%

 

 

(2,960

)

 

 

-65

%

 

 

12,559

 

 

 

 

Total other income, net

 

 

8,538

 

 

 

200

%

 

 

(3,498

)

 

 

-77

%

 

 

12,036

 

 

 

 

Loss before income taxes

 

 

(4,433

)

 

 

-104

%

 

 

(11,719

)

 

 

-259

%

 

 

7,286

 

 

 

-62

%

Provision for income taxes

 

 

 

 

 

0

%

 

 

 

 

 

0

%

 

 

 

 

 

 

Net loss

 

$

(4,433

)

 

 

-104

%

 

$

(11,719

)

 

 

-259

%

 

$

7,286

 

 

 

-62

%

Revenue

Total revenue and product sales for the quarter ended September 30, 2015 decreased by 6% to $4.3 million, compared with $4.5 million for the quarter ended September 30, 2014. The decrease was mainly attributable to a $0.2 million negative impact of a stronger U.S. dollar relative to the British Pound and Euro and lower shipments of bulk antisera to OEM customers. Products sold by standing purchase order were 71% of product sales for the quarter ended September 30, 2015, compared with 70% for the quarter ended September 30, 2014.

The below table sets forth revenue by product group:

 

 

 

Quarter ended September 30,

 

 

 

 

 

 

 

 

 

 

 

2015

 

 

2014

 

 

Change

 

 

 

Amount

 

 

% of revenue

 

 

Amount

 

 

% of revenue

 

 

Amount

 

 

%

 

 

 

(in thousands, except percentages)

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product sales - OEM customers

 

$

2,784

 

 

 

65

%

 

$

3,116

 

 

 

69

%

 

$

(332

)

 

 

-11

%

Product sales - direct customers and

   distributors

 

 

1,489

 

 

 

35

%

 

 

1,411

 

 

 

31

%

 

 

78

 

 

 

6

%

Other revenues

 

 

 

 

 

0

%

 

 

 

 

 

0

%

 

 

 

 

 

0

%

Total revenue

 

$

4,273

 

 

 

100

%

 

$

4,527

 

 

 

100

%

 

$

(254

)

 

 

-6

%

OEM Sales. Product sales to OEM customers decreased 11% to $2.8 million for the quarter ended September 30, 2015, compared with $3.1 million for the quarter ended September 30, 2014. The decrease was attributable to the negative impact of a stronger U.S. dollar relative to the British Pound and Euro and lower shipments of bulk antisera to OEM customers.

Direct Sales to Customers and Distributors. Direct product sales of $1.5 million for the quarter ended September 30, 2015 increased by 6% compared to $1.4 million for the quarter ended September 30, 2014. Direct sales in the United States decreased by 1%, which

- 20 -


 

was primarily attributable to the timing of standing orders for our reage nt red blood cell products within the first two quarters of fiscal 2016 and 2015 . Direct sales outside the United States in creased by 26%, despite our decision to offer fewer products in Europe.

Other Revenues. Other revenues represent product development fees and there were no such revenues in the quarter ended September 30, 2015 or in the quarter ended September 30, 2014.

Cost of revenue and gross margin

Cost of revenue decreased by 22% to $2.1 million for the quarter ended September 30, 2015, compared with $2.7 million for the quarter ended September 30, 2014. The decrease was attributable to foreign exchange effects and efficiencies in our manufacturing operations, primarily achieved through increased production volumes.

Gross profit on total revenue for the quarter ended September 30, 2015 was $2.1 million, an increase of 18% when compared with $1.8 million in the quarter ended September 30, 2014. The increase was attributable to the lower cost of revenue in the quarter ended September 30, 2015. Gross margin, which represents gross profit expressed as a percentage of revenue, was 50 % for the quarter ended September 30, 2015, compared with 40% for the quarter ended September 30, 2014.

Sales and marketing expenses

Sales and marketing expense was $0.8 million for the quarter ended September 30, 2015, compared with $0.6 million for the quarter ended September 30, 2014. As a percentage of total product sales, sales and marketing expenses were 18% for the quarter ended September 30, 2015, compared with 13% for the quarter ended September 30, 2014.

Research and development expenses

 

 

 

Quarter ended September 30,

 

 

 

 

 

 

 

 

 

 

 

2015

 

 

2014

 

 

Change

 

 

 

Amount

 

 

% of revenue

 

 

Amount

 

 

% of revenue

 

 

Amount

 

 

%

 

 

 

(in thousands, except percentages)

 

Research and development expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

MosaiQ TM research and development

 

$

7,904

 

 

 

185

%

 

$

5,179

 

 

 

114

%

 

$

2,725

 

 

 

53

%

Other research and development

 

 

570

 

 

 

13

%

 

 

554

 

 

 

12

%

 

 

16

 

 

 

3

%

Tax credits and grants

 

 

(93

)

 

 

-2

%

 

 

(298

)

 

 

-7

%

 

 

205

 

 

 

 

Total research and development

   expenses

 

$

8,381

 

 

 

196

%

 

$

5,435

 

 

 

120

%

 

$

2,946

 

 

 

54

%

Research and development expenses increased by $2.9 million to $8.4 million for the quarter ended September 30, 2015, compared with $5.4 million for the quarter ended September 30, 2014. As a percentage of total revenue, research and development expenses increased to 196% for the quarter ended September 30, 2015, compared with 120% for the quarter ended September 30, 2014.  This reflects incremental costs associated with the commercial scale-up of MosaiQ™, including initial production costs, which are currently expensed as research and development.  Recent changes in UK tax legislation now enable our UK subsidiary to claim certain tax credits on its research and development expenditures.

General and administrative expenses

General and administrative expenses increased by 49% to $6.0 million for the quarter ended September 30, 2015, compared with $4.0 million for the quarter ended September 30, 2014, reflecting greater personnel-related costs, increased facility rental charges and increased corporate costs. We recognized $0.5 million of stock compensation expense in the quarter ended September 30, 2015 compared with $0.3 million in the quarter ended September 30, 2014. As a percentage of total revenue, general and administrative expenses increased to 140% for the quarter ended September 30, 2015, compared with 88% for the quarter ended September 30, 2014.

Other income (expense)

Net interest expense was $1.1 million for the quarter ended September 30, 2015, compared with $0.5 million for the quarter ended September 30, 2014. Interest expense in the quarters ended September 30, 2015 and September 30, 2014 included interest charges on our borrowings from MidCap Financial, which bore interest at LIBOR plus 6.7% (with a LIBOR floor of 2.00%). Borrowings from MidCap amounted to $15.0 million during the quarter ended September 30, 2014. Borrowings from July 1, 2015 to August 3, 2015

- 21 -


 

were $14.5 million and then increased to $30.0 million as a result of the increase in our secured credit facility . In the quarter ended Septem ber 30, 2015, net interest expense also included $0.3 million of dividends accrued on the 7% preference shares issued to OCD on January 29, 2015.

Other income for the quarter ended September 30, 2015 included income of $10.3 million related to the change in the fair value in the quarter of the warrants issued at the time of our initial public offering offset by $0.6 million of previously deferred fees that were expensed as a result of the expansion of our credit facility.

Other expense for the quarter ended September 30, 2014 included $2.6 million of expense related to the change in the fair value in the quarter of the warrants issued at the time of our initial public offering and $0.4 million of foreign exchange losses arising on monetary assets and liabilities denominated in foreign currencies.

Comparison of the six month periods ended September 30, 2015 and 2014

The following table sets forth, for the periods indicated, the amounts of certain components of our statements of operations and the percentage of total revenue represented by these items, showing period-to-period changes.

 

 

 

Six months ended September 30,

 

 

 

 

 

 

 

 

 

 

 

2015

 

 

2014

 

 

Change

 

 

 

Amount

 

 

% of revenue

 

 

Amount

 

 

% of revenue

 

 

Amount

 

 

%

 

 

 

(in thousands, except percentages)

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product sales

 

$

9,123

 

 

 

100

%

 

$

9,794

 

 

 

94

%

 

$

(671

)

 

 

-7

%

Other revenues

 

 

 

 

 

0

%

 

 

650

 

 

 

6

%

 

 

(650

)

 

 

-100

%

Total revenue

 

 

9,123

 

 

 

100

%

 

 

10,444

 

 

 

100

%

 

 

(1,321

)

 

 

-13

%

Cost of revenue

 

 

4,875

 

 

 

53

%

 

 

5,157

 

 

 

49

%

 

 

(282

)

 

 

-5

%

Gross profit

 

 

4,248

 

 

 

47

%

 

 

5,287

 

 

 

51

%

 

 

(1,039

)

 

 

-20

%

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales and marketing

 

 

1,432

 

 

 

16

%

 

 

1,306

 

 

 

13

%

 

 

126

 

 

 

10

%

Research and development

 

 

15,191

 

 

 

167

%

 

 

9,120

 

 

 

87

%

 

 

6,071

 

 

 

67

%

General and administrative

 

 

11,089

 

 

 

122

%

 

 

7,488

 

 

 

72

%

 

 

3,601

 

 

 

48

%

Total operating expenses

 

 

27,712

 

 

 

304

%

 

 

17,914

 

 

 

172

%

 

 

9,798

 

 

 

55

%

Operating (loss)

 

 

(23,464

)

 

 

-257

%

 

 

(12,627

)

 

 

-121

%

 

 

(10,837

)

 

 

86

%

Other expense:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense, net

 

 

(1,858

)

 

 

-20

%

 

 

(1,072

)

 

 

-10

%

 

 

(786

)

 

 

73

%

Other, net

 

 

10,735

 

 

 

118

%

 

 

(636

)

 

 

-6

%

 

 

11,371

 

 

 

 

Total other expense, net

 

 

8,877

 

 

 

97

%

 

 

(1,708

)

 

 

-16

%

 

 

10,585

 

 

 

-620

%

Loss before income taxes

 

 

(14,587

)

 

 

-160

%

 

 

(14,335

)

 

 

-137

%

 

 

(252

)

 

 

2

%

Provision for income taxes

 

 

 

 

 

0

%

 

 

 

 

 

0

%

 

 

 

 

 

 

Net loss

 

$

(14,587

)

 

 

-160

%

 

$

(14,335

)

 

 

-137

%

 

$

(252

)

 

 

2

%

Revenue

Total revenue for the six month period ended September 30, 2015 decreased by 13% to $9.1 million, compared with $10.4 million for the six month period ended September 30, 2014. Product sales revenue decreased 7% to $9.1 million for the six month period ended September 30, 2015, compared with $9.8 million for the six month period ended September 30, 2014.The decrease was attributable to a $0.7 million negative impact of a stronger U.S. dollar relative to the British Pound and Euro and lower shipments of bulk antisera to OEM customers. Products sold by standing purchase order were 73% of product sales for the six month period ended September 30, 2015, compared with 71% for the six month period ended September 30, 2014. Total revenue for the six month period ended September 30, 2014 also included revenue related to our product development services of $0.7 million.

- 22 -


 

The below table sets forth revenue by product group:

 

 

 

Six months ended September 30,

 

 

 

 

 

 

 

 

 

 

 

2015

 

 

2014

 

 

Change

 

 

 

Amount

 

 

% of revenue

 

 

Amount

 

 

% of revenue

 

 

Amount

 

 

%

 

 

 

(in thousands, except percentages)

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Product sales - OEM customers

 

$

6,214

 

 

 

68

%

 

$

6,922

 

 

 

66

%

 

$

(708

)

 

 

-10

%

Product sales - direct customers

    and distributors

 

 

2,909

 

 

 

32

%

 

 

2,872

 

 

 

27

%

 

 

37

 

 

 

1

%

Other revenues

 

 

 

 

 

0

%

 

 

650

 

 

 

6

%

 

 

(650

)

 

 

-100

%

Total revenue

 

$

9,123

 

 

 

100

%

 

$

10,444

 

 

 

100

%

 

$

(1,321

)

 

 

-13

%

OEM Sales. Product sales to OEM customers decreased 10% to $6.2 million for the six month period ended September 30, 2015, compared with $6.9 million for the six month period ended September 30, 2014. The decrease was attributable to the negative impact of a stronger U.S. dollar relative to the British Pound and Euro and lower shipments of bulk antisera to OEM customers.

Direct Sales to Customers and Distributors. Direct product sales of $2.9 million for the six month period ended September 30, 2015 increased by 1% compared to $2.9 million for the six month period ended September 30, 2014. Direct sales in the United States increased by 7%, which was primarily driven by sales of our reagent red blood cell products. Direct sales outside the United States decreased by 12% compared with the six months ended September 30, 2014, due to our decision to offer fewer products in Europe.

Other Revenues. Other revenues represent product development fees and there were no such revenues in the six month period ended September 30, 2015 compared with $0.7 million in the six month period ended September 30, 2014.

Cost of revenue and gross margin

Cost of revenue decreased by 5% to $4.9 million for the six month period ended September 30, 2015, compared with $5.3 million for the six month period ended September 30, 2014. The decrease was attributable to foreign exchange effects and efficiencies in our manufacturing operations, primarily achieved through increased production volumes.

Gross profit on total revenue for the six month period ended September 30, 2015 was $4.2 million, a decrease of 20% when compared with $5.3 million in the six month period ended September 30, 2014. The decrease was mainly attributable to a $0.7 million decrease in other revenues and lower product sales revenues, which more than offset the decrease in cost of revenue. Gross margin, which represents gross profit expressed as a percentage of total revenue, was 47 % for the six month period ended September 30, 2015, compared with 53% for the six month period ended September 30, 2014.   

Excluding other revenues, gross profit on product sales in the six month period ended September 30, 2015 was $4.2 million, a decrease of 8% when compared with $4.6 million in the six month period ended September 30, 2014. The decrease was attributable to lower product sales revenues, which more than offset the decrease in cost of revenue. Gross margin on product sales was 47% for the six month period ended September 30, 2015, which was in line with 47% for the six month period ended September 30, 2014.

Sales and marketing expenses

Sales and marketing expense was $1.4 million for the six month period ended September 30, 2015, compared with $1.3 million for the six month period ended September 30, 2014. As a percentage of total product sales, sales and marketing expenses were 16% for the six month period ended September 30, 2015, compared with 13% for the six month period ended September 30, 2014.

- 23 -


 

Research and development expenses

 

 

 

Six months ended September 30,

 

 

 

 

 

 

 

 

 

 

 

2015

 

 

2014

 

 

Change

 

 

 

Amount

 

 

% of revenue

 

 

Amount

 

 

% of revenue

 

 

Amount

 

 

%

 

 

 

(in thousands, except percentages)

 

Research and development expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

MosaiQ TM research and development

 

$

14,166

 

 

 

155

%

 

$

8,427

 

 

 

81

%

 

$

5,739

 

 

 

68

%

Other research and development

 

 

1,193

 

 

 

13

%

 

 

996

 

 

 

10

%

 

 

197

 

 

 

20

%

Tax credits and grants

 

 

(168

)

 

 

-2

%

 

 

(303

)

 

 

-3

%

 

 

135

 

 

 

-45

%

Total research and development

    expenses

 

$

15,191

 

 

 

167

%

 

$

9,120

 

 

 

87

%

 

$

6,071

 

 

 

67

%

Research and development expenses increased by $6.1 million to $15.2 million for the six month period ended September 30, 2015, compared with $9.1 million for the six month period ended September 30, 2014. As a percentage of total revenue, research and development expenses increased to 167% for the six month period ended September 30, 2015, compared with 87% for the six month period ended September 30, 2014. This reflects incremental costs associated with the commercial scale-up of MosaiQ™, including initial production costs, which are currently expensed as research and development.  Recent changes in UK tax legislation now enable our UK subsidiary to claim certain tax credits on its research and development expenditures.

General and administrative expenses

General and administrative expenses increased by 48% to $11.1million for the six month period ended September 30, 2015, compared with $7.5 million for the six month period ended September 30, 2014, reflecting greater personnel-related costs, increased facility rental charges and increased corporate costs. We recognized $0.8 million of stock compensation expense in the six month period ended September 30, 2015 compared with $0.5 million in the six month period ended September 30, 2014. As a percentage of total revenue, general and administrative expenses increased to 122% for the six month period ended September 30, 2015, compared with 72% for the six month period ended September 30, 2014.

Other income (expense)

Net interest expense was $1.9 million for the six month period ended September 30, 2015, compared with $1.1 million for the six month period ended September 30, 2014. Interest expense in the six month periods ended September 30, 2015 and September 30, 2014 included interest charges on our borrowings from MidCap Financial, which bore interest at LIBOR plus 6.7% (with a LIBOR floor of 2.00%). Borrowings from MidCap amounted to $15.0 million during the six months ended September 30, 2014. Borrowings from July 1, 2015 to August 3, 2015 were $14.5 million and then increased to $30.0 million as a result of the increase in our secured credit facility. In the six month period ended September 30, 2015, net interest expense also included $0.5 million of dividends accrued on the 7% preference shares issued to OCD on January 29, 2015.

Other income for the six month period ended September 30, 2015 included income of $12.0 million related to the change in the fair value in the six month period of the warrants issued at the time of our initial public offering offset by $0.7 million of foreign exchange losses arising on monetary assets and liabilities denominated in foreign currencies and $0.6 million of previously deferred fees that were expensed as a result of the expansion of our credit facility.

Other expense for the six month period ended September 30, 2014 included income of $1.0 million related to the change in the fair value of the warrants issued at the time of our initial public offering. It also included $0.6 million of fees related to our initial public offering that were attributable to the issuance of these warrants, an expense of $0.4 million related to the settlement of a legal dispute and $0.6 million of foreign exchange losses arising on monetary assets and liabilities denominated in foreign currencies.

Quarterly Results of Operations

Our quarterly product sales can fluctuate depending upon the shipment cycles for our red blood cell-based products, which account for approximately two-thirds of our current product sales. For these products, we typically experience 13 shipping cycles per year. This equates to three shipments of each product per quarter, except for one quarter per year when four shipments occur. In fiscal 2015, the greatest impact of extra product shipments occurred in our first quarter, while the greatest impact thus far in fiscal 2016 has also occurred in the first quarter. The timing of shipment of bulk antisera products to our OEM customers may also move revenues from quarter to quarter. We also experience some seasonality in demand around holiday periods in both Europe and the United States. As a

- 24 -


 

result of these factors, we expect to continue to see seasonality and quarter-to-quarter variations in our product sales. The timing of product development fees included in other revenues is most ly dependent upon the achievement of pre-negotiated project or revenue milestones.

Liquidity and Capital Resources

Since our commencement of operations in 2007, we have incurred net losses and negative cash flows from operations. During the six month period ended September 30, 2015, we had a net loss of $14.6 million and the cash used in our operating activities during this period was $26.5 million. During the six month period ended September 30, 2014, we incurred a net loss of $14.3 million and used $13.1 million of cash in our operating activities. During each period, this use of cash was primarily attributable to our investment in the development of MosaiQ™. As of September 30, 2015, we had an accumulated deficit of $89.1 million.

On April 30, 2014, we completed our initial public offering of 5,000,000 units at a price of $8.00 per unit, each unit consisting of one ordinary share and one warrant to purchase 0.8 of one ordinary share, and received net proceeds of $37.2 million after deducting underwriting discounts and commissions. Other costs of the offering, apart from underwriting discounts and commissions, were $3.6 million. The warrants were exercisable at a price of $8.80 per ordinary share until October 26, 2015. As of September 30, 2015, we had raised cash proceeds of $13.9 million from the exercise of these warrants. Since September 30, 2015 we have raised a further $21.2 million from exercises completed prior to the expiration of the warrants.

On November 25, 2014, we entered into subscription agreements with certain institutional and individual accredited investors for the private placement of 2,000,000 newly issued ordinary shares at a price of $9.50 per share and 850,000 newly issued pre-funded warrants at a price of $9.49 per warrant, amounting to an aggregate subscription price of approximately $27.1 million. Each pre-funded warrant permits the holder to subscribe for one new ordinary share at an exercise price of $0.01 per pre-funded warrant. The proceeds of this placement were $27.1 million before costs and $24.7 million net of costs.

On January 29, 2015, we entered into a subscription agreement with Ortho-Clinical Diagnostics Finco S.Á.R.L., an affiliate of Ortho, for the private placement of 444,445 newly issued ordinary shares at a price of $22.50 per share and 666,665 newly issued 7% cumulative redeemable preference shares, of no par value, at a price of $22.50 per share, for an aggregate subscription price of approximately $25 million.

On August 3, 2015, we entered into an amended agreement with MidCap Financial Trust to expand our existing secured term loan facility from $15.0 million to $30.0 million. MidCap Financial Trust also agreed to make available, subject to certain conditions, additional credit facilities totaling $20.0 million. The amended facility agreement with MidCap Financial Trust includes a covenant to maintain cash balances above $10 million. 

As of September 30, 2015, we had cash and cash equivalents of $25.7 million, which included $0.3 million of cash held in a restricted account as part of the arrangements relating to the lease of our property in Eysins, Switzerland. We expect to fund our operations from a combination of funding sources, including through the use of existing cash balances, product sales, asset sales, the achievement of product development milestones, the extension or expansion of credit facilities and the issuance of new equity. However, there can be no assurance that these funding sources will be available to us.

Cash Flows for the Six Month Periods Ended September 30, 2015 and 2014

Operating activities

Net cash used in operating activities was $26.5 million during the six month period ended September 30, 2015, which included net losses of $14.6 million and non-cash items of $8.9 million. Non-cash items were depreciation and amortization expense of $0.9 million, accrued preference share dividends of $0.5 million, share-based compensation expense of $0.8 million and amortization of deferred debt issue costs of $1.1 million, offset by a change in the fair value of the liability in respect of share warrants of $12.0 million and amortization of lease incentives of $0.2 million. We also experienced a net cash outflow of $3.0 million from changes in operating assets and liabilities during the period, consisting of a $0.3 million increase in accounts receivable, a $1.1 million increase in inventories, a $1.0 million reduction in accrued compensation and benefits and a $0.8 million increase in other assets, offset by a $0.2 million reduction in accounts payable and accrued liabilities,.

Net cash used in operating activities was $13.1 million during the six month period ended September 30, 2014, which included net losses of $14.3 million and non-cash items of $0.3 million. Non-cash items were depreciation and amortization expense of $0.6 million, amortization of deferred debt issue costs of $0.4 million, share-based compensation expense of $0.5 million, offset by amortization of lease incentives of $0.2 million and the change in the liability in respect of our ordinary share warrants of $1.0 million. We also experienced a net cash inflow of $1.0 million from changes in operating assets and liabilities during the period, consisting of

- 25 -


 

a $1.5 million increase in accounts payable and accrued liabilities and a $0.1 million decrease in other assets offset by a $0.4 million increase in accounts receivable and a $0.2 million reduction in accrued compensation and benefits.

Investing activities

Net cash used in investing activities was $14.1 million and $10.3 million for the six month periods ended September 30, 2015 and September 30, 2014, respectively. Purchases of property and equipment for the six month period ended September 30, 2015 were $14.1 million and included $12.5 million related to the MosaiQ TM project and $1.6 million related to our conventional reagent business. Purchases of property and equipment for the six month period ended September 30, 2014 were $10.1 million and included $9.8 million related to the MosaiQ TM project and $0.3 million related to our conventional reagent business. Purchases of intangible assets related to our conventional reagent business for the six month period ended September 30, 2014 were $0.2 million.

Financing activities

Net cash provided by financing activities was $27.8 million during the six month period ended September 30, 2015, consisting of $13.4 million of proceeds from the exercise of options and warrants, $14.3 million from an increase in our secured credit facility and $0.1 million of net capital lease receipts. Net cash provided by financing activities was $34.6 million during the six month period ended September 30, 2014, consisting of share issuance net proceeds of $34.3 million from our initial public offering and $0.3 million of net capital lease receipts.

Operating and Capital Expenditure Requirements

We have not achieved profitability on an annual basis since we commenced operations in 2007 and we expect to incur net losses for at least the next two years. We expect our operating expenses to increase during the year ended March 31, 2016, as we continue to invest in MosaiQ TM , grow our customer base, expand our marketing and distribution channels, hire additional employees and invest in other product development opportunities.

As of September 30, 2015, we had cash and cash equivalents of $25.7 million, including $0.3 million of cash held in a restricted account as part of the arrangements relating to the lease of our property in Eysins, Switzerland.

Our future capital requirements will depend on many factors, including:

 

our progress in developing and commercializing MosaiQ TM and the cost required to complete development, obtain regulatory approvals and complete our manufacturing scale up;

 

Ortho’s progress in commercializing MosaiQ™ for the patient testing market;

 

our ability to manufacture and sell our conventional reagent products, including the costs and timing of further expansion of our sales and marketing efforts;

 

our ability to collect our accounts receivable;

 

our ability to generate cash from operations;

 

any acquisition of businesses or technologies that we may undertake; and

 

our ability to penetrate our existing market and new markets.

Contractual Obligations

Our contractual obligations and commitments were summarized in our Annual Report on Form 10-K for the year ended March 31, 2015. On August 3, 2015, we entered into an amended agreement with MidCap Financial Trust to expand our existing secured term loan facility from $15.0 million to $30.0 million. Unless repaid sooner, as at September 30, 2015, the aggregate amount that will become due under the amended agreement with MidCap, inclusive of interest, is $38.2 million, with $2.6 million due in less than 1 year, $22.8 million due in 1to 3 years, $12.8 million due in 3 to 5 years and $0 due after 5 years. Other than the entry into this amended agreement, there were no major changes in the nature of our contractual obligations and commitments between March 31, 2015 and September 30, 2015.

Critical Accounting Policies and Significant Judgments and Estimates

We have prepared our condensed consolidated financial statements in accordance with U.S. GAAP. Our preparation of these consolidated financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets,

- 26 -


 

liabilities, expenses and related disclosures at the date of the consolidated financial statements, as well as revenue and expenses during the reporting periods. We evaluate o ur estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could therefore differ materially from these estimates under different assumptions or conditions.

While our significant accounting policies are described in more detail in Note 2 to our condensed consolidated financial statements included in this Quarterly Report, we believe the following accounting policies to be critical to the judgments and estimates used in the preparation of our financial statements.

Revenue recognition and accounts receivable

Revenue is recognized in accordance with Accounting Standards Codification, or ASC, Topic No. 605, “Revenue Recognition,” when the following four basic criteria have been met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services are rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. For product sales, the application of this policy results in sales revenue being recorded at the point of delivery of product to the customer.

We also earn revenue from the provision of development services to a small number of OEM customers. These development service contracts are reviewed individually to ensure that our revenue recognition is in accordance with applicable accounting standards, including ASC Topic No. 605. In recent years, our product development revenues have been commensurate with achieving milestones specified in the respective development agreements relating to those products. These milestones may include the approval of new products by the European or U.S. regulatory authorities, which are not within our control. While there can be no assurance that we will earn product development revenues when milestones are achieved, the nature of the milestones have been such that they effectively represent full completion of a particular part of a development program. As a result, we typically fully recognize milestone-related revenues as the milestones are achieved in accordance with applicable accounting standards.

Under certain development contracts, we also manufacture and supply the customer with finished products once it has been approved for use by relevant regulatory agencies. These agreements reflect both arrangements for product development and the sales prices and other contractual terms for subsequent supply of the product to the customer. Under these development contracts, we view the development service revenue as distinct from subsequent product sales revenue, and we recognize each separately as described above.

Accounts receivable consist primarily of amounts due from OEM customers, hospitals, donor testing laboratories, and distributors. Accounts receivable are reported net of an allowance for uncollectible accounts, which we also refer to as doubtful accounts. The allowance for doubtful accounts represents a reserve for estimated losses resulting from our inability to collect amounts due from our customers. Direct sales, where we may make many low value sales to a large number of customers, represents a larger risk of doubtful accounts, as opposed to OEM customer sales consisting primarily of a small number of well established businesses with whom we have a long trading history. The collectability of our trade receivables balances is regularly evaluated based on a combination of factors such as the ageing profile of our receivables, past history with our customers, changes in customer payment patterns, customer credit-worthiness and any other relevant factors. Based on these assessments, we adjust the reserve for doubtful accounts recorded in our financial statements.

Inventories

We record inventories at the lower of cost (first-in, first-out basis) or market (net realizable value), net of reserves. We record adjustments to inventory based upon historic usage, expected future demand and shelf life of the products held in inventory. We also calculate our inventory value based on the standard cost of each product. This approach requires us to analyze variances arising in the production process to determine whether they reflect part of the normal cost of production, and should therefore be reflected as inventory value, or whether they are a period cost and should thus not be included in inventory.

Intangible assets

The intangible assets included in our financial statements include intangible assets identified as at the time of the acquisition of the business of Alba Bioscience on August 31, 2007. At the time of this acquisition, we identified intangible assets related to customer relationships, master cell lines and certain other items, which include domain names and product trademarks. The customer relationships have been amortized over a five-year period, which resulted in them becoming fully amortized at August 31, 2012. The other items were amortized over a seven-year period from August 31, 2007, which resulted in them becoming fully amortized at August 31, 2014.

- 27 -


 

The intangible assets related to master cell lines reflect the know-how and market recognition associated with the cell lines, which are used as the sour ce material of certain of our products. These cell lines are maintained by us and have an indefinite life. We have nevertheless decided to amortize the intangible assets over a forty-year period to reflect the possibility of market changes or other events resulting in the lines becoming technically obsolete at some future date. In the event that any of the lines cease to be used, we would record additional amortization at that point.

We also include in intangible assets the costs of obtaining product licenses for our products. These include external costs such as regulatory agency fees associated with the approval and bringing to market of our products once the development is complete. We amortize these over an expected product life of eight years, although if any such product ceased to be produced, we would record additional amortization at that point.

Income taxes

We account for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax basis of our assets and liabilities and their financial statement reported amounts. In addition, deferred tax assets are recorded for the future benefit of utilizing NOLs and research and development credit carry forwards. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized.

We follow the accounting guidance for uncertainties in income taxes, which prescribes a recognition threshold and measurement process for recording uncertain tax positions taken, or expected to be taken, in a tax return in the financial statements. Additionally, the guidance also prescribes the de-recognition, classification, accounting in interim periods and disclosure requirements for uncertain tax positions. We accrue for the estimated amount of taxes for uncertain tax positions if it is more likely than not that we would be required to pay such additional taxes. An uncertain tax position will not be recognized if it has less than a 50% likelihood of being sustained. We did not have any accrued interest or penalties associated with any unrecognized tax positions, and there were no such interest or penalties recognized during the six month period ended September 30, 2015 or the years ended March 31, 2015, 2014 or 2013.

Stock compensation expense

Stock compensation expense is measured at the grant date based on the fair value of the award and is recognized as an expense in the income statement over the vesting period of the award. The calculation of the stock compensation expense is sensitive to the fair value of the underlying ordinary shares. Details of the assumptions used to value the various types of awards are set out in the notes to the condensed consolidated financial statements included in this Quarterly Report.

Off-Balance Sheet Arrangements

We do not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or for any other contractually narrow or limited purpose.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers.” The new guidance sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed in U.S. GAAP. The underlying principle of the new standard is that a business or other organization will recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects what it expects in exchange for the goods or services. The standard also requires more detailed disclosures and provides additional guidance for transactions that were not addressed completely in the prior accounting guidance. This ASU provides alternative methods of initial adoption and is effective for annual periods beginning after December 15, 2016 and interim periods within those annual periods. Early adoption is not permitted. We are currently evaluating the impact that this standard will have on our condensed consolidated financial statements.

We have considered other recent accounting pronouncements and determined that they are either not applicable to our business or that no material effect is expected on the consolidated financial statements as a result of future adoption.

- 28 -


 

JOBS Act

Under the Jumpstart Our Business Startups Act of 2012, emerging growth companies that become public can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are exposed to market risks in the ordinary course of our business. These market risks are principally limited to interest rate fluctuations and foreign currency exchange rate fluctuations.

Interest rate sensitivity

We are exposed to market risk related to changes in interest rates as it impacts our interest income and expense.

Cash and cash equivalents . At September 30, 2015, we had cash and cash equivalents of $25.7 million. Our exposure to market risk includes interest income sensitivity, which is impacted by changes in the general level of U.S. and European interest rates. Our cash and cash equivalents are held in interest-bearing savings accounts and bank accounts. We do not enter into investments for trading or speculative purposes. Due to the current levels of interest rates, we do not believe an immediate one percentage point change in interest rates would have a material effect on the fair market value of our holdings, and therefore we do not expect our operating results or cash flows to be significantly affected by changes in market interest rates.

Term loan facility . We currently have term debt of $30.0 million drawn under a term loan facility with MidCap Financial LLC. The term loan carries a variable interest rate of 6.7% above LIBOR, with a LIBOR floor of 2.00%. If there is a rise in LIBOR interest rates above 2.00%, our debt service obligation would increase even though the amount borrowed remained the same, which would affect our results of operations, financial condition and liquidity. Assuming no change in our debt obligations from the amount drawn down under the term loan, a hypothetical one percentage point change in underlying variable rates would not currently change our annual interest expense and cash flow from operations.

Foreign currency exchange risk

The main currencies that we use for our trading operations are the U.S. Dollar, the Pound Sterling, the Swiss Franc and to a lesser extent, the Euro. Our meaningful cash balances are held by entities outside the U.S. in a mixture of Euros, Pounds Sterling and Swiss Francs based upon the currency and amount of expected MosaiQ TM development and other corporate expenditures. These cash balances may not be the same as the functional currencies of the entities in which they are held and as a result, exchange rate fluctuations may result in foreign exchange gains and losses on our income statement until the planned MosaiQ TM development or other corporate expenditure has been incurred. However, as the cash balances are held in the same currencies as the planned MosaiQ TM development and other corporate expenditures, there is no overall impact on our ability to pay them.

We are subject to market risks arising from changes in foreign currency exchange rates between the U.S. Dollar and the Pound Sterling and the U.S. Dollar and the Swiss Franc. Accordingly, fluctuations in the U.S. Dollar versus Pounds Sterling and U.S. Dollar versus the Swiss Franc exchange rate give rise to exchange gains and losses. These gains and losses arise from the conversion of U.S. Dollars and Euros to Pounds Sterling and the retranslation of cash, accounts receivable, intercompany indebtedness and other asset and liability balances. Based on our assets and liabilities held in Pounds Sterling at September 30, 2015 we estimate that a 5% strengthening of the Pound Sterling against the U.S. Dollar would give rise to a gain of approximately $0.8 million and a 5% weakening of the Pound Sterling against the U.S. Dollar would give rise to loss of approximately $0.8 million. Based on our assets and liabilities held in Swiss Francs at September 30, 2015 we estimate that a 5% strengthening of the Swiss Franc against the U.S. Dollar would give rise to a gain of approximately $0.7 million and a 5% weakening of the Swiss Franc against the U.S. Dollar would give rise to loss of approximately $0.7 million.

A significant proportion of our revenues are earned in U.S. Dollars, but the costs of our conventional reagent manufacturing operations are payable mainly in Pounds Sterling. We therefore closely monitor the results of our UK operations to address this difference. During the year ended March 31, 2015, the net operating expenses arising in Pounds Sterling from our UK conventional reagent manufacturing operations amounted to $13.8 million. This expenditure is offset by revenues arising in U.S. Dollars and other currencies. We have entered into forward contracts to hedge against the effects of fluctuations in the U.S. Dollar versus the Pounds Sterling exchange rate. These contracts provide for the conversion of $300,000 per month at a rate of $1.50 to £1 each month from October 2015 through December 2015. Based on this, a hypothetical instantaneous 5% strengthening of the Pound Sterling against the U.S. Dollar would reduce our net income by $0.6 million in the year ending March 31, 2016, after taking account of the shelter

- 29 -


 

provided by our hedging arrangements through December 2015. Similarly, a hypothetical instantaneous 5% weakening of the Pound Sterling against the U.S. Dollar would increase group net income by $0.6 million over the same period. Our UK operations also have exposure to fluctuations in the Euro versus Pounds Sterling exchange rate, but to a lesser extent.

Financial liability related to warrants issued at the time of our initial public offering

We record a financial liability in our balance sheet relating to the warrants issued at the time of our initial public offering and we mark this liability to market based on the closing price of the warrants as quoted on The NASDAQ Global Market at the end of each financial period.  Based on the closing price of the warrants on September 30, 2015 a 5% increase in the market value of our warrants would result in an increase in the financial liability and a non-cash expense of $0.5 million and a 5% decrease in the market value of the warrants would result in a reduction of the liability and non-cash income of the same amount.

We do not use financial instruments for trading or other speculative purposes.

Our management does not believe that inflation in past years has had a significant impact on our results from operations. In the event inflation affects our costs in the future, we will offset the effect of inflation and maintain appropriate margins through increased selling prices.

 

 

 

Item 4. Controls and Procedures

Evaluation of disclosure controls and procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this Quarterly Report on Form 10-Q. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of September 30, 2015, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and is accumulated and communicated to our management, including our Chief Executive and Chief Financial Officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Changes in internal control over financial reporting

There have been no changes to our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings

We are not currently a party to any pending legal proceedings that we believe could have a material adverse effect on our business or financial condition. However, we may be subject to various claims and legal actions arising in the ordinary course of business from time to time.

 

Item 1A. Risk Factors

There have been no material changes in the risk factors described in Item 1A. “Risk Factors” of our Annual Report on Form 10-K for the year ended March 31, 2015.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

In connection with the expansion of our credit facility with MidCap, on August 3, 2015, we issued to MidCap, a warrant (“MidCap Warrant”) to purchase 111,525 new ordinary shares at an exercise price of $16.14 per ordinary share.  In connection with the subsequent syndication of the MidCap Facility, on September 25, 2015, MidCap transferred certain of the purchase rights represented by the MidCap Warrant to the other lenders under the facility. Our current report on Form 8-K regarding the expansion of the MidCap

- 30 -


 

Facility and the issuance of the MidCap Warrant filed with the SEC on August 7 , 201 5 and o ur current report on Form 8-K regarding the syndication of the MidCap Facility and the transfer of the MidCap Warrant filed with the SEC on October 1 , 201 5 are incorporated by reference herein in their entirety .

 

Item 3. Defaults Upon Senior Securities

None.

 

 

Item 4. Mine Safety Disclosures

Not applicable.

 

 

Item 5. Other Information

None.

 

 

Item 6. Exhibits

See the Exhibit Index on the page immediately preceding the exhibits for a list of exhibits filed as part of this Quarterly Report, which Exhibit Index is incorporated herein by this reference.

 

 

 

- 31 -


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

QUOTIENT LIMITED

 

Date: November 4, 2015

 

/s/ Paul Cowan

 

 

Paul Cowan

Chief Executive Officer and Chairman of the Board of Directors

 

 

 

- 32 -


 

EXHIBIT INDEX

 

Exhibit No.

 

Description

 

4.1

 

 

MidCap warrant to purchase 111,525 Ordinary Shares. (Filed as exhibit 4.1 of our Current Report on 8-K on August 7, 2015 and incorporated herein by reference).

 

4.2

 

 

Warrant in favor of MidCap to purchase 66,915 Ordinary Shares. (Filed as exhibit 4.1 of our Current Report on 8-K on October 1, 2015 and incorporated herein by reference).

 

4.3

 

 

Warrant in favor of Oxford to purchase 26,023 Ordinary Shares. (Filed as exhibit 4.2 of our Current Report on 8-K on October 1, 2015 and incorporated herein by reference).

 

4.4

 

 

Warrant in favor of Oxford to purchase 14,126 Ordinary Shares. (Filed as exhibit 4.3 of our Current Report on 8-K on October 1, 2015 and incorporated herein by reference).

 

4.5

 

 

Warrant in favor of Flexpoint to purchase 4,461 Ordinary Shares. (Filed as exhibit 4.4 of our Current Report on 8-K on October 1, 2015 and incorporated herein by reference).

 

10.1

 

 

Amended and Restated Credit, Security and Guaranty Agreement, dated August 3, 2015 among Quotient Biodiagnostics, Inc., MidCap Financial Trust, as administrative agent, the other Credit Parties party thereto, and the Lenders from time to time party thereto (the "MidCap 2015 Facility").

 

10.2

 

 

Amendment No.1 and Joinder to the MidCap 2015 Facility, dated September 10, 2015.

 

10.3

 

 

Amendment No.2 to the MidCap 2015 Facility, dated September 25, 2015.

 

10.4+

 

 

Second Amendment to the STRATEC Development Agreement, dated March 3, 2014 between STRATEC Biomedical AG and Quotient QS IP Ltd, dated August 25, 2015.

 

31.1

 

 

Certification of Paul Cowan, Chairman and Chief Executive pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

31.2

 

 

Certification of Stephen Unger, Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

32.1

 

 

Certification of Paul Cowan, Chairman and Chief Executive pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

32.2

 

 

Certification of Stephen Unger, Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

101*

 

 

The following financial statements from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets (unaudited), (ii) Condensed Consolidated Statements of Comprehensive Loss (unaudited), (iii) Condensed Consolidated Statements of Redeemable Convertible Preference Shares and Changes in Shareholders’ Deficit (unaudited), (iv) Condensed Consolidated Statements of Cash Flows (unaudited) and (v) Notes to Condensed Consolidated Financial Statements, tagged as blocks of text and including detailed tags.

 

* XBRL information is furnished and not filed for purposes of Section 11 and 12 of the Securities Act of 1933 and Section 18 of the Securities Exchange Act of 1934, and is not subject to liability under those sections, is not part of any registration statement, prospectus or other document to which it relates and is not incorporated or deemed to be incorporated by reference into any registration statement, prospectus or other document.

 

+ Registrant has omitted portions of the referenced exhibit pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

- 33 -

 

Exhibit 10.1

EXECUTION VERSION

 

 

AMENDED AND RESTATED

CREDIT, SECURITY AND GUARANTY AGREEMENT,

dated as of August 3, 2015,

by and among

 

Quotient Biodiagnostics, Inc.

as Borrower

 

the other Credit Parties party hereto,

 

MIDCAP FINANCIAL TRUST,

as Administrative Agent,

and

THE LENDERS

FROM TIME TO TIME PARTY HERETO

 

 

 

 

 

 

 


 

AMENDED AND RESTATED

CREDIT, GUARANTY AND SECURITY AGREEMENT

This AMENDED AND RESTATED CREDIT, GUARANTY AND SECURITY AGREEMENT (this “ Agreement ”), dated as of August 3, 2015 (the “ Closing Date ”), by and among MIDCAP FINANCIAL TRUST , a Delaware statutory trust (“ MidCap ”), as administrative agent (together with its successors and assigns, “ Agent ”), the Lenders listed on the Credit Facility Schedule attached hereto and otherwise party hereto from time to time (each a “ Lender ”, and collectively the “ Lenders ”), Quotient Biodiagnostics, Inc. , a Delaware corporation (“ Borrower ”), and the other Credit Parties listed on the signature pages hereof, provides the terms on which Lenders shall lend to Borrower and Borrower shall repay Lenders.  

RECITALS

WHEREAS , Borrower, the Credit Parties, Agent and certain Lenders are parties to that certain Credit, Guaranty and Security Agreement, dated as of December 6, 2013, as amended by that certain Amendment No. 1 and Joinder to Credit, Guaranty and Security Agreement, dated as of March 26, 2014, that certain Amendment No. 2 to Credit, Guaranty and Security Agreement, dated as of June 4, 2014 and that certain Amendment No. 3 to Credit, Guaranty and Security Agreement and Limited Waiver and Consent, dated as of January 26, 2015 (as so amended, and as otherwise amended, supplemented or otherwise modified prior to the date hereof, the “ Original Credit Agreement ”), pursuant to which Agent and certain Lenders agreed to make certain financing facilities available to Borrowers, including a term loan in the original principal amount of Fifteen Million Dollars ($15,000,000) , of which $14,500,000 remains outstanding as of the date hereof ;

WHEREAS , in connection with the continued working capital and other needs of Borrower and the other Credit Parties, Borrower and the other Credit Parties have requested, among other things, that Agent and Lenders (i) refinance the outstanding Term Credit Facility under the Original Credit Agreement and increase such Term Credit Facility by $15,500,000 to $30,000,000, (ii) make available to Borrower certain additional Term Credit Facilities in original principal amounts of Five Million Dollars ($5,000,000) and Fifteen Million Dollars ($15,000,000), respectively, and (iii) amend certain other covenants and provisions of the Original Credit Agreement; and

WHEREAS , Agent and Lenders have agreed to the requests of Borrower and the other Credit Parties on the terms and conditions set forth herein and in the other Financing Documents.

AGREEMENT

NOW, THEREFORE , in consideration of the premises and the agreements, provisions and covenants herein contained, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree to amend and restate the Original Credit Agreement in its entirety as follows:

 

1

ACCOUNTING AND OTHER TERMS

Accounting terms not defined in this Agreement shall be construed in accordance with GAAP.  Calculations and determinations must be made in accordance with GAAP.  Capitalized terms not otherwise defined in this Agreement shall have the meanings set forth in Section 16.  All other terms contained in this Agreement, unless otherwise indicated, shall have the meaning provided by the Code to the extent such terms are defined therein.  All headings numbered without a decimal point are herein referred to as “Articles,” and all paragraphs numbered with a decimal point (and all subparagraphs or subsections thereof) are herein referred to as “Sections.”

 

2

CREDIT FACILITIES AND TERMS

2.1 Promise to Pay .  Borrower hereby unconditionally promises to pay to each Lender in accordance with each Lender’s respective Pro Rata Share of each Credit Facility, the outstanding principal amount of all Credit Extensions made by the Lenders under such Credit Facility and accrued and unpaid interest thereon and any other amounts due hereunder as and when due in accordance with this Agreement.  

2.2 Credit Facilities .  Subject to the terms and conditions hereof, each Lender, severally, but not jointly, agrees to make available to Borrower Credit Extensions in respect of each Credit Facility set forth opposite such Lender’s name on the Credit Facility Schedule, in each case not to exceed such Lender’s commitment as identified on the Credit Facility Schedule (such commitment of each Lender, as it may be amended to reflect assignments made in accordance with this Agreement or terminated or reduced in accordance with this Agreement, its “ Applicable Commitment ”, and the aggregate of all such commitments, the “ Applicable Commitments ”).

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

1            

 

 


 

2.3 Term Credit Facilities .

(a) Nature of Credit Facility; Credit Extension Requests .  For any Credit Facility identified on the Credit Facility Schedule as a term facility (a “ Term Credit Facility ”), Credit Extensions in respect of a Term Credit Facility may be requested by Borrower during the Draw Period for such Term Credit Facility.  For any Credit Extension requested under a Term Credit Facility (other than a Credit Extension on the Closing Date), Agent must receive the completed Credit Extension Form by 12:00 noon (New York time) three (3) Business Days prior to the date of the Credit Extension is to be funded.   To the extent any Term Credit Facility proceeds are repaid for any reason, whether voluntarily or involuntarily (including repayments from insurance or condemnation proceeds), Agent and Lenders shall have no obligation to re-advance such sums to Borrower.  

(b) Principal Payments .  Principal payable on account of a Term Credit Facility shall be payable by Borrower to Agent immediately upon the earliest of (i) the date(s) set forth in the Amortization Schedule for such Term Credit Facility, or (ii) the Maturity Date. Except as this Agreement may specifically provide otherwise, all prepayments of Credit Extensions under Term Credit Facilities shall be applied by Agent to the applicable Term Credit Facility in inverse order of maturity.  The monthly payments required under the Amortization Schedule shall continue in the same amount (for so long as the applicable Term Credit Facility shall remain outstanding) notwithstanding any partial prepayment, whether mandatory or optional, of the applicable Term Credit Facility.

(c) Mandatory Prepayment .  If a Term Credit Facility is accelerated following the occurrence of an Event of Default, Borrower shall immediately pay to Agent, for payment to each Lender in accordance with its respective Pro Rata Share, an amount equal to the sum of: (i) all outstanding principal of the Term Credit Facility and all other Obligations, plus accrued and unpaid interest thereon, (ii) any fees payable under the Fee Letters by reason of such prepayment, (iii) the Applicable Prepayment Fee as specified in the Credit Facility Schedule for the Credit Facility being prepaid, and (iv) all other sums that shall have become due and payable, including Protective Advances.  Additionally, at the election of Agent, Borrower shall prepay the Term Credit Facilities (to be allocated pro rata among the outstanding Credit Extensions under all Term Credit Facilities) in the following amounts:  (A) on the date on which any Credit Party (or Agent as loss payee or assignee) receives any casualty proceeds in excess of One Hundred Thousand Dollars ($100,000) for personal property, or in excess of One Hundred Fifty Thousand Dollars ($150,000) for real property, in respect of assets upon which Agent maintained a Lien, an amount equal to one hundred percent (100%) of such proceeds (net of out-of-pocket expenses and, in the case of personal property, repayment of any permitted purchase money debt encumbering the personal property that suffered such casualty), or such lesser portion of such proceeds as Agent shall elect to apply to the Obligations; and (B) upon receipt by any Credit Party of the proceeds of any asset disposition of personal property not made in the Ordinary Course of Business (other than transfers permitted by Section 7.1) and resulting in net cash proceeds in excess of One Hundred Thousand Dollars ($100,000) an amount equal to one hundred percent (100%) of the net cash proceeds of such asset disposition (net of out-of-pocket expenses and repayment of any permitted purchase money debt encumbering such asset), or such lesser portion as Agent shall elect to apply to the Obligations .    Notwithstanding the foregoing, (a) so long as no Default or Event of Default has occurred and is continuing, Borrower shall have the option of applying the proceeds of any casualty policy up to $500,000 in the aggregate with respect to any property loss in any one year, toward the replacement or repair of destroyed or damaged property; provided that any such replaced or repaired property (x) shall be of equal or like value as the replaced or repaired Collateral and (y) shall be deemed Collateral in which Agent and Lenders have been granted a first priority security interest, and (b) after the occurrence and during the continuance of a Default or Event of Default, all proceeds payable under such casualty policy shall, at the option of Agent, be payable to Agent, for the ratable benefit of the Lenders, on account of the Obligations.

(d) Permitted Prepayment .   Except as provided below, Borrower shall have no right to prepay the Credit Extensions made in respect of a Term Credit Facility.  Borrower shall have the option to prepay the Prepayable Amount (as defined below) of a Term Credit Facility advanced by the Lenders under this Agreement, provided Borrower (i) provides written notice to Agent of its election to prepay the Prepayable Amount at least fifteen (15) days prior to such prepayment, and (ii) pays to Agent, for payment to each Lender in accordance with its respective Pro Rata Share, on the date of such prepayment, an amount equal to the sum of (A) the Prepayable Amount, plus accrued interest thereon, (B) any fees payable under the Fee Letters by reason of such prepayment, (C) the Applicable Prepayment Fee as specified in the Credit Facility Schedule for the Credit Facility being prepaid, and (D) all Protective Advances.  The term “Prepayable Amount” means all, but not less than all, of the Credit Extensions and all other Obligations under all Term Credit Facilities.

2.4 Reserved .  

2.5 Reserved .

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

2            

 

 


 

2.6 Interest and Payments; Administration .

(a) Interest; Computation of Interest .  Each Credit Extension shall bear interest on the outstanding principal amount thereof from the date when made until paid in full at a rate per annum equal to the Applicable Interest Rate.  Each Lender may, upon the failure of Borrower to pay any fees or interest as required herein, capitalize such interest and fees and begin to accrue interest thereon until paid in full, which such interest shall be at a rate per annum equal to the Applicable Interest Rate unless and until the Default Rate shall otherwise apply.  All other Obligations shall bear interest on the outstanding amount thereof from the date they first become payable by Borrower under the Financing Documents until paid in full at a rate per annum equal to the Applicable Interest Rate unless and until the Default Rate shall otherwise apply.  Interest on the Credit Extensions and all fees payable under the Financing Documents shall be computed on the basis of a 360-day year and the actual number of days elapsed in the period during which such interest accrues.  In computing interest on any Credit Extension or other advance, the date of the making of such Credit Extension or advance shall be included and the date of payment shall be excluded; provided, however, that if any Credit Extension or advance is repaid on the same day on which it is made, such day shall be included in computing interest on such Credit Extension or advance.  As of each Applicable Interest Rate Determination Date, Agent shall determine (which determination shall, absent manifest error in calculation, be final, conclusive and binding upon all parties) the interest rate that shall apply to the Credit Extensions.

(b) Default Rate . Upon the election of Agent following the occurrence and during the continuance of an Event of Default, Obligations shall bear interest at a rate per annum which is four hundred basis points (4.00%) above the rate that is otherwise applicable thereto (the “ Default Rate ”).  Payment or acceptance of the increased interest rate provided in this subsection is not a permitted alternative to timely payment and shall not constitute a waiver of any Event of Default or otherwise prejudice or limit any rights or remedies of Agent or Lenders.

(c) Payments Generally .  All payments in respect of the Obligations shall be made to Agent for the account of the applicable Lenders in accordance with their Pro Rata Share.  All Obligations are payable upon demand of Agent in the absence of any other due date specified herein.  All fees payable under the Financing Documents shall be deemed non-refundable as of the date paid.  Any payment required to be made to Agent or a Lender under this Agreement may be made by debit or automated clearing house payment initiated by Agent or such Lender from any of Borrower’s deposit accounts, including the Designated Funding Account, and Borrower hereby authorizes Agent and each Lender to debit any such accounts for any amounts Borrower owes hereunder when due.  Without limiting the foregoing, Borrower shall tender to Agent and Lenders any authorization forms as Agent or any Lender may require to implement such debit or automated clearing house payment.  These debits or automated clearing house payments shall not constitute a set-off. Payments of principal and/or interest received after 12:00 noon New York time are considered received at the opening of business on the next Business Day.  When a payment is due on a day that is not a Business Day, the payment is due the next Business Day and additional fees or interest, as applicable, shall continue to accrue until paid. All payments to be made by Borrower under any Financing Document shall be made without set-off, recoupment or counterclaim, in lawful money of the United States and in immediately available funds.  The balance of the Obligations, as recorded in Agent’s books and records at any time, shall be conclusive and binding evidence of the amounts due and owing to Agent and Lenders by Borrower absent manifest error; provided, however, that any failure to so record or any error in so recording shall not limit or otherwise affect Borrower’s duty to pay all amounts owing hereunder or under any Financing Document.  Agent shall endeavor to provide Borrower with a monthly statement regarding the Credit Extensions (but neither Agent nor any Lender shall have any liability if Agent shall fail to provide any such statement).  Unless Borrower notifies Agent of any objection to any such statement (specifically describing the basis for such objection) within ninety (90) days after the date of receipt thereof, it shall be deemed final, binding and conclusive upon Borrower in all respects as to all matters reflected therein.

(d) Interest Payments; Maturity Date .  Commencing on the first (1 st ) Payment Date following the funding of a Credit Extension, and continuing on the Payment Date of each successive month thereafter through and including the Maturity Date, Borrower shall make monthly payments of interest, in arrears, calculated as set forth in this Section 2.6.  All unpaid principal and accrued interest is due and payable in full on the Maturity Date or any earlier date specified herein.  If the Obligations are not paid in full on or before the Maturity Date, all interest thereafter accruing shall be payable immediately upon accrual.

(e) Fees .  Borrower shall pay, as and when due and payable under the terms of the Fee Letters, to Agent and each Lender, for their own accounts and not for the benefit of any other Lenders, the fees set forth in the Fee Letters.

(f) Protective Advances .  Borrower shall pay to Agent for the account of Lenders all Protective Advances (including reasonable attorneys’ fees and expenses for documentation and negotiation of this Agreement , the Warrants and the other Financing Documents) when due under any Financing Document (and in the absence of any other due date specified herein, such Protective Advances shall be due upon demand).

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

3            

 

 


 

(g) Maximum Lawful Rate .  In no event shall the interest charged hereunder with respect to the Obligations exceed the maximum amount permitted under the Laws of the State of Maryland.  Notwithstanding anything to the contrary in any Financing Document, if at any time the rate of interest payable hereunder (the “ Stated Rate ”) would exceed the highest rate of interest permitted under any applicable Law to be charged (the “ Maximum Lawful Rate ”), then for so long as the Maximum Lawful Rate would be so exceeded, the rate of interest payable shall be equal to the Maximum Lawful Rate; provided, however , that if at any time thereafter the Stated Rate is less than the Maximum Lawful Rate, Borrower shall, to the extent permitted by Law, continue to pay interest at the Maximum Lawful Rate until such time as the total interest received is equal to the total interest which would have been received had the Stated Rate been (but for the operation of this provision) the interest rate payable.  Thereafter, the interest rate payable shall be the Stated Rate unless and until the Stated Rate again would exceed the Maximum Lawful Rate, in which event this provision shall again apply.  In no event shall the total interest received by any Lender exceed the amount which it could lawfully have received, had the interest been calculated for the full term hereof at the Maximum Lawful Rate.  If, notwithstanding the prior sentence, any Lender has received interest hereunder in excess of the Maximum Lawful Rate, such excess amount shall be applied to the reduction of the principal balance of such Lender’s Credit Extensions or to other amounts (other than interest) payable hereunder, and if no such Credit Extensions or other amounts are then outstanding, such excess or part thereof remaining shall be paid to Borrower.  In computing interest payable with reference to the Maximum Lawful Rate applicable to any Lender, such interest shall be calculated at a daily rate equal to the Maximum Lawful Rate divided by the number of days in the year in which such calculation is made.

(h) Taxes; Additional Costs .

(i) All payments of principal and interest on the Obligations and all other amounts payable hereunder shall be made free and clear of and without deduction for any present or future income, excise, stamp, documentary, payroll, employment, property or franchise taxes and other taxes, fees, duties, levies, assessments, withholdings or other charges of any nature whatsoever (including interest and penalties thereon) imposed by any taxing authority, excluding taxes imposed on or measured by Agent's, any Lender's or any of their respective affiliates’ (including, without limitation, any direct or indirect holders of equity therein) net income by the jurisdictions under which Agent, such Lender, or any of their respective affiliates (including, without limitation, any direct or indirect holders of equity therein) is organized or conducts business (other than solely as the result of entering into any of the Financing Documents or taking any action thereunder) (all non-excluded items being called “ Taxes” ).  If any withholding or deduction from any payment to be made by any Credit Party hereunder is required in respect of any Taxes pursuant to any applicable Law, then such Credit Party will: (i) pay directly to the relevant authority the full amount required to be so withheld or deducted; (ii) promptly forward to Agent an official receipt or other documentation satisfactory to Agent evidencing such payment to such authority; and (iii) pay to Agent for the account of Agent and Lenders such additional amount or amounts as is necessary to ensure that the net amount actually received by Agent and each Lender will equal the full amount Agent and such Lender would have received had no such withholding or deduction been required.  If any Taxes are directly asserted against Agent, any Lender or any of their respective affiliates (including, without limitation, any direct or indirect holders of equity therein) with respect to any payment received by Agent or such Lender hereunder, Agent, such Lender or such affiliate may pay such Taxes and Borrower will promptly pay such additional amounts (including any penalty, interest or expense) as is necessary in order that the net amount received by such Person after the payment of such Taxes (including any Taxes on such additional amount) shall equal the amount such Person would have received had such Taxes not been asserted so long as such amounts have accrued on or after the day which is two hundred seventy (270) days prior to the date on which Agent or such Lender first made written demand therefor.

(ii) If any Borrower fails to pay any Taxes when due to the appropriate taxing authority or fails to remit to Agent, for the account of Agent and the respective Lenders, the required receipts or other required documentary evidence, Borrower shall indemnify Agent and Lenders for any incremental Taxes, interest or penalties that may become payable by Agent or any Lender as a result of any such failure.

(iii) Each Lender that (A) is organized under the laws of a jurisdiction other than the United States, and (B)(1) is a party hereto on the Closing Date or (2) purports to become an assignee of an interest as a Lender under this Agreement after the Closing Date (unless such Lender was already a Lender hereunder immediately prior to such assignment) (each such Lender a “ Foreign Lender ”) shall execute and deliver to each of Borrower and Agent one or more (as Borrower or Agent may reasonably request) United States Internal Revenue Service Forms W-8ECI, W-8BEN, W-8IMY (as applicable) and other applicable forms, certificates or documents prescribed by the United States Internal Revenue Service or reasonably requested by Agent certifying as to such Lender's entitlement to a complete exemption from withholding or deduction of Taxes.  Borrower shall not be required to pay additional amounts to any Lender pursuant to this subsection (h) with respect to United States withholding and income Taxes to the extent that the obligation to pay such additional amounts would not have arisen but for the failure of such Lender to comply with this paragraph other than as a result of a change in law.

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

4            

 

 


 

(iv) If any Lender shall determine in its commercially reasonable judgment that the adoption or taking effect of, or any change in, any applicable Law regarding capital adequacy, in each instance, after the Closing Date, or any change after the Closing Date in the interpretation, administration or application thereof by any Governmental Authority, central bank or comparable agency charged with the interpretation, administration or application thereof, or the compliance by any Lender or any Person controlling such Lender with any request, guideline or directive regarding capital adequacy (whether or not having the force of law) of any such Governmental Authority, central bank or comparable agency adopted or otherwise taking effect after the Closing Date, has or would have the effect of reducing the rate of return on such Lender's or such controlling Person's capital as a consequence of such Lender's obligations hereunder to a level below that which such Lender or such controlling Person could have achieved but for such adoption, taking effect, change, interpretation, administration, application or compliance (taking into consideration such Lender's or such controlling Person's policies with respect to capital adequacy) then from time to time, upon written demand by such Lender (which demand shall be accompanied by a statement setting forth the basis for such demand and a calculation of the amount thereof in reasonable detail, a copy of which shall be furnished to Agent), Borrower shall promptly pay to such Lender such additional amount as will compensate such Lender or such controlling Person for such reduction, so long as such amounts have accrued on or after the day which is two hundred seventy (270) days prior to the date on which such Lender first made demand therefor; provided, however, that notwithstanding anything in this Agreement to the contrary, (A) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives thereunder or issued in connection therewith and (B) all requests, rules, guidelines or directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities, in each case pursuant to Basel III, shall in each case be deemed to be a "change in applicable Law", regardless of the date enacted, adopted or issued.

(v)          (A) If any Lender requires compensation under this subsection (h), or requires Borrower to pay any additional amount to any Lender or any Governmental Authority for the account of any Lender pursuant to this subsection (h), then, upon the written request of Borrower, such Lender shall use reasonable efforts to designate a different lending office for funding or booking its Credit Extensions hereunder or to assign its rights and obligations hereunder (subject to the terms of this Agreement) to another of its offices, branches or affiliates, if, in the judgment of such Lender, such designation or assignment (x) would eliminate or materially reduce amounts payable pursuant to any such subsection, as the case may be, in the future, and (y) would not subject such Lender to any unreimbursed cost or expense and would not otherwise be disadvantageous to such Lender (as determined in its sole discretion).  Borrower hereby agrees to pay all reasonable costs and expenses incurred by any Lender in connection with any such designation or assignment.

(B) If any Lender (other than Midcap or its Affiliates) requires compensation under this subsection (h), or requires Borrower to pay any additional amount to any Lender or any Governmental Authority for the account of any Lender (other than Midcap or its Affiliates) pursuant to this subsection (h), and such Lender has declined or is unable to designate a different lending office in accordance with Section 2.6(h)(v)(A), then the Borrower may, at its sole expense and effort, upon notice to such Lender and the Agent, require such Lender to assign and delegate, without recourse (in accordance with and subject to the restrictions contained in, and consents required by, Section 13.1), all of its interests, rights (other than its existing rights to payments pursuant to this subsection (h)) and obligations under this Agreement and the related Financing Documents to an Eligible Assignee that shall assume such obligations; provided that: (x) such Lender shall have received payment of an amount equal to the outstanding principal of its Credit Extensions, accrued interest thereon, accrued fees and all other amounts payable to it hereunder and under the other Financing Documents from the assignee (to the extent of such outstanding principal and accrued interest and fees) or the Borrower (in the case of all other amounts), and (y) such assignment does not conflict with applicable law.  A Lender shall not be required to make any such assignment or delegation if, prior thereto, as a result of a waiver by such Lender or otherwise, the circumstances entitling the Borrower to require such assignment and delegation cease to apply.

(vi) If Borrower makes a Tax Payment and Lender determines:

(A) a Tax Credit is attributable to an increased payment of which that Tax Payment forms part, to that Tax Payment or to a Tax Deduction in consequence of which that Tax Payment was required; and

(B) Lender has obtained and utilized that Tax Credit.

Lender shall pay an amount to Borrower which Lender determines will leave it (after that payment) in the same after Tax position as it would have been in had the Tax Payment not been required to be made by Borrower.

(i) Administrative Fees and Charges .  

(i) Borrower shall pay to Agent, for its own account and not for the benefit of any other Lenders, all reasonable fees and expenses in connection with audits and inspections of the books and records of the Credit Parties, audits,

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

5            

 

 


 

valuations or appraisals of the Collateral, audits of Borrower’s compliance with applicable Laws and such other matters as Agent shall deem appropriate, which shall be due and payable on the first Business Day of the month following the date of issuance by Agent of a written request for payment thereof to any Borrower; provided, that, as long as no Default has occurred within the preceding twelve (12) months, Agent shall be entitled to such reimbursement for no more than one audit and inspection per calendar year .

(ii) If payments of principal or interest due on the Obligations, or any other amounts due hereunder or under the other Financing Documents, are not timely made and remain overdue for a period of five (5) days, Borrower, without notice or demand by Agent, promptly shall pay to Agent, for its own account and not for the benefit of any other Lenders, as additional compensation to Agent in administering the Obligations, an amount equal to five percent (5.0%) of each delinquent payment.  

2.7 Secured Promissory Notes .  At the election of any Lender made as to each Credit Facility for which it has made Credit Extensions, each Credit Facility shall be evidenced by one or more secured promissory notes in form and substance satisfactory to Agent and Lenders (each a “ Secured Promissory Note ”).  Upon receipt of an affidavit of an officer of a Lender as to the loss, theft, destruction, or mutilation of its Secured Promissory Note, Borrower shall issue, in lieu thereof, a replacement Secured Promissory Note in the same principal amount thereof and of like tenor.

2.8 Use of proceeds in Switzerland .  The Credit Parties shall ensure that no proceeds borrowed under any Credit Facility will be used in a manner which would constitute a "use of proceeds in Switzerland" as interpreted by Swiss tax authorities for the purposes of Swiss Withholding Tax (Verrechnungssteuer), except and to the extent that a written confirmation or tax ruling countersigned by the Swiss Federal Tax Administration (Eidgenössische Steuerverwaltung) has been obtained (in a form satisfactory to the Agent) confirming that the intended "use of proceeds in Switzerland" if guaranteed by a Swiss resident Guarantor does not result in a Credit Facility qualifying as a Swiss financing for Swiss Withholding Tax purposes.

 

3

CONDITIONS OF credit extensions

3.1 Conditions Precedent to Initial Credit Extension .  Each Lender’s obligation to make an advance in respect of a Credit Facility is subject to the condition precedent that Agent shall consent to or shall have received, in form and substance satisfactory to Agent, such documents, and completion of such other matters, as Agent may reasonably deem necessary or appropriate, including, without limitation, all items listed on the Closing Deliveries Schedule attached hereto.

3.2 Conditions Precedent to all Credit Extensions .  The obligation of each Lender to make each Credit Extension, including the initial Credit Extension, is subject to the following conditions precedent:

(a) satisfaction of all Applicable Funding Conditions for the applicable Credit Extension as set forth in the Credit Facility Schedule, each in form and substance satisfactory to Agent;

(b) timely receipt by the Agent of an executed Credit Extension Form in the form attached hereto;  

(c) the representations and warranties in Article 5 and elsewhere in the Financing Documents shall be true, correct and complete in all material respects on the date of the Credit Extension Form and on the Funding Date of each Credit Extension; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided, further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date.  Each Credit Extension is each Credit Party’s representation and warranty on that date that the representations and warranties in Article 5 and elsewhere in the Financing Documents remain true, accurate and complete in all material respects; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided, further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date;

(d) no Default or Event of Default shall have occurred and be continuing or result from the Credit Extension;

(e) Agent shall be satisfied with the results of any searches conducted under Section 3.5;

(f) receipt by Agent of such evidence as Agent shall request to confirm that the deliveries made in Section 3.1 remain current, accurate and in full force and effect, or if not, updates thereto, each in form and substance satisfactory to Agent; and

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

6            

 

 


 

(g) as determined in Agent ’s sole discretion, there has not been any Material Adverse Change or any material adverse deviation by Borrower or any Credit Party from the most recent business plan of the Credit Parties pre sented to and accepted by Agent .

3.3 Method of Borrowing .  Each Credit Extension in respect of each Credit Facility shall be in an amount at least equal to the applicable Minimum Credit Extension Amount for such Credit Facility as set forth in the Credit Facility Schedule or such lesser amount as shall remain undisbursed under the Applicable Commitments for such Credit Facility.  The date of funding for any requested Credit Extension shall be a Business Day.  To obtain a Credit Extension, Borrower shall deliver to Agent a completed Credit Extension Form executed by a Responsible Officer.  Agent may rely on any notice given by a person whom Agent reasonably believes is a Responsible Officer or designee thereof. Agent and Lenders shall have no duty to verify the authenticity of any such notice.

3.4 Funding of Credit Facilities .  Upon the terms and subject to the conditions set forth herein, each Lender, severally and not jointly, shall make available to Agent its Pro Rata Share of the requested Credit Extension, in lawful money of the United States of America in immediately available funds, prior to 11:00 a.m. (New York time) on the specified date for the Credit Extension.  Agent shall, unless it shall have determined that one of the conditions set forth in Section 3.1 or 3.2, as applicable, has not been satisfied, by 2:00 p.m. (New York time) on such day, credit the amounts received by it in like funds to Borrower by wire transfer to the Designated Funding Account (or to the account of Borrower in respect of the Obligations, if the Credit Extension is being made to pay an Obligation of Borrower). A Credit Extension made prior to the satisfaction of any conditions set forth in Section 3.1 or 3.2 shall not constitute a waiver by Agent or Lenders of Borrower’s obligation to satisfy such conditions, and any such Credit Extension made in the absence of such satisfaction shall be made in Agent’s discretion.

3.5 Searches .  Before the Closing Date, and thereafter (as and when determined by Agent in its discretion), Agent shall have the right to perform, all at the Credit Parties’ expense, the searches described in clauses (a), (b), and (c) below against Borrower and any other Credit Party, the results of which are to be consistent with the Credit Parties’ representations and warranties under this Agreement and the reasonably satisfactory results of which shall be a condition precedent to all Credit Extensions requested by Borrower:  (a) title investigations, UCC searches and fixture filings searches; (b) judgment, pending litigation, federal tax lien, personal property tax lien, and corporate and partnership tax lien searches, in each jurisdiction searched under clause (a) above; and (c) searches of applicable corporate, limited liability company, partnership and related records to confirm the continued existence, organization and good standing of the applicable Person and the exact legal name under which such Person is organized.

 

4

CREATION OF SECURITY INTEREST

4.1 Grant of Security Interest .  Each Credit Party hereby grants Agent, for the ratable benefit of the Lenders, to secure the payment and performance in full of all of the Obligations (subject, in the case of Quotient Suisse, to Section 15.11 of this Agreement) , a continuing security interest in, and pledges to Agent, for the ratable benefit of the Lenders, the Collateral (excluding that part of the Collateral which is otherwise subject to the security interest granted in the Foreign Security Documents), wherever located, whether now owned or hereafter acquired or arising, and all proceeds and products thereof.  Each Credit Party represents, warrants, and covenants that the security interest granted herein is and shall at all times continue to be a first priority perfected security interest in the Collateral, subject only to Permitted Liens that may have priority by operation of applicable Law or by the terms of a written intercreditor or subordination agreement entered into by Agent.  

4.2 Representations and Covenants .  

(a) As of the Closing Date, no Credit Party has ownership interest in any Chattel Paper, letter of credit rights, commercial tort claims, Instruments, documents or investment property (other than equity interests in any Subsidiaries of any Credit Party disclosed on the Disclosure Schedule attached hereto).

(b) Except for tangible Chattel Paper and Instruments in an aggregate amount of less than $50,000, each Credit Party shall deliver to Agent all tangible Chattel Paper and all Instruments and documents (other than tangible Chattel Paper and Instruments located in the United Kingdom, Jersey or Switzerland and subject to the Scottish Security Documents, the Jersey Security Documents or the Swiss Security Documents, as applicable, or located in another jurisdiction in which the Credit Parties have granted a perfected first priority Lien on such Collateral (subject only to Permitted Liens) in favor of the Agent) owned by such Credit Party and constituting part of the Collateral duly endorsed and accompanied by duly executed instruments of transfer or assignment, all in form and substance satisfactory to Agent.  Each Credit Party shall provide Agent with “control” (as in the Code) of all such electronic Chattel Paper owned by such Credit Party and constituting part of the Collateral by having Agent identified as the assignee on the records pertaining to the single authoritative copy thereof and otherwise complying with the applicable elements of control set forth in the Code.  Each Credit Party also shall deliver to Agent all security agreements securing any such Chattel Paper and securing any such Instruments.  Each Credit Party will mark conspicuously all such Chattel Paper and all such Instruments and Documents with a

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

7            

 

 


 

legend, in form and substance satisfactory to Agent, indicating that such Chattel Paper and such Instruments and Documents are subject to the security interests and Liens in favor of Agent created pursuant to this Agreement and the Financing Documents.  

(c) Except for letters of credit in an aggregate amount of less than $50,000, each Credit Party shall deliver to Agent all letters of credit (other than letters of credit located in the United Kingdom, Jersey or Switzerland and subject to the Scottish Security Documents, the Jersey Security Documents or the Swiss Security Documents, as applicable, or located in another jurisdiction in which the Credit Parties have granted a perfected first priority Lien on such Collateral (subject only to Permitted Liens) in favor of the Agent) on which such Credit Party is the beneficiary and which give rise to letter of credit rights owned by such Credit Party which constitute part of the Collateral in each case duly endorsed and accompanied by duly executed instruments of transfer or assignment, all in form and substance satisfactory to Agent.  Each Credit Party shall take any and all actions as may be necessary or desirable, or that Agent may request, from time to time, to cause Agent to obtain exclusive “control” (as defined in the Code) of any such letter of credit rights in a manner acceptable to Agent.

(d) Each Credit Party shall promptly advise Agent upon such Credit Party becoming aware that it has any interests in any commercial tort claim that constitutes part of the Collateral, which such notice shall include descriptions of the events and circumstances giving rise to such commercial tort claim and the dates such events and circumstances occurred, the potential defendants with respect such commercial tort claim and any court proceedings that have been instituted with respect to such commercial tort claims, and each Credit Party shall, to the extent permitted by applicable law, with respect to any such commercial tort claim, execute and deliver to Agent such documents as Agent shall request to perfect, preserve or protect the Liens, rights and remedies of Agent with respect to any such commercial tort claim.

(e) Except for Accounts and Inventory in an aggregate amount of no more than Fifty Thousand Dollars ($50,000) and Accounts and Inventory located in Switzerland or otherwise subject to the Scottish Security Documents, the Jersey Security Documents or the Swiss Security Documents, as applicable, no Accounts or Inventory or other Collateral shall at any time be in the possession or control of any warehouse, consignee, bailee or any of the Credit Parties’ agents or processors without prior written notice to Agent and the receipt by Agent, if Agent has so requested, of warehouse receipts, consignment agreements or bailee lien waivers (as applicable) satisfactory to Agent prior to the commencement of such possession or control.  Each Credit Party shall, upon the request of Agent, notify any such warehouse, consignee, bailee, agent or processor of the security interests and Liens in favor of Agent created pursuant to this Agreement and the Financing Documents, instruct such Person to hold all such Collateral for Agent’s account subject to Agent’s instructions and shall obtain an acknowledgement from such Person that such Person holds the Collateral for Agent’s benefit.

(f) Upon request of Agent, each Credit Party shall promptly deliver to Agent any and all certificates of title, applications for title or similar evidence of ownership of all such tangible personal property (other than tangible personal property located in Scotland, Jersey or Switzerland and subject to the Scottish Security Documents, the Jersey Security Documents or the Swiss Security Documents, as applicable, or located in another jurisdiction in which the Credit Parties have granted a perfected first priority Lien on such tangible personal property (subject only to Permitted Liens) in favor of the Agent) and shall cause Agent to be named as lienholder on any such certificate of title or other evidence of ownership.  Each Credit Party shall not permit any such tangible personal property to become fixtures to real estate unless such real estate is subject to a Lien in favor of Agent.

(g) Each Credit Party hereby authorizes Agent to file without the signature of such Credit Party one or more UCC financing statements (and shall comply with all equivalent requirements in jurisdictions outside the United States) relating to all or any part of the Collateral, which financing statements may list Agent as the “secured party” and such Credit Party as the “debtor” and which describe and indicate the collateral covered thereby as all or any part of the Collateral under the Financing Documents in such jurisdictions as Agent from time to time determines are appropriate, and to file without the signature of such Credit Party any continuations of or corrective amendments to any such financing statements, in any such case in order for Agent to perfect, preserve or protect the Liens, rights and remedies of Agent with respect to the Collateral.  Each Credit Party also ratifies its authorization for Agent to have filed in each relevant jurisdiction initial financing statements or amendments thereto if filed prior to the date hereof.  Any financing statement may include a notice that any disposition of the Collateral, by such Credit Party or any other Person, shall be deemed to violate the rights of Agent and the Lenders under the Code.

(h) As of the Closing Date, no Credit Party holds, and after the Closing Date each Credit Party shall promptly notify Agent in writing upon creation or acquisition by any Credit Party of, any Collateral which constitutes a claim against any Governmental Authority, including, without limitation, the federal government of the United States or any instrumentality or agency thereof, the assignment of which claim is restricted by any applicable Law, including, without limitation, the federal Assignment of Claims Act and any other comparable Law.  Upon the request of Agent, each Credit Party shall take such steps as may be necessary or desirable, or that Agent may request, to comply with any such applicable Law.

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

8            

 

 


 

(i) Each Credit Party shall furnish to Agent from time to time any statements and schedules further identifying or describing the Collateral and any other information, reports or evidence concerning the Collateral as Agent may reasonably request from time to time.

 

5

REPRESENTATIONS AND WARRANTIES

Each Credit Party (in respect of itself only), represents and warrants as follows on the Closing Date, the date of each Credit Extension , and on such other dates when such representations and warranties under this Agreement are made or deemed to be made (except to the extent that such representations and warranties expressly refer to a specific date, in which case as of such date) :

5.1 Due Organization, Authorization: Power and Authority .

(a) It is duly existing and in good standing, as a Registered Organization in its jurisdiction of formation or, in the case of any Credit Party formed outside the United States or any political subdivision thereof, incorporated, existing and in good standing as a limited company under the laws of its jurisdiction of incorporation.  It is qualified and licensed to do business and is in good standing in any jurisdiction in which the conduct of its business or its ownership of property requires that it be qualified except where the failure to do so could not reasonably be expected to result in a Material Adverse Change.  The Financing Documents to which it is a party have been duly authorized, executed and delivered by it and constitute legal, valid and binding agreements enforceable in accordance with their terms except as the enforceability thereof may be limited by bankruptcy, insolvency or other similar laws relating to the enforcement of creditors’ rights generally and by general equitable principles, and, for any Foreign Security Document, as the enforceability thereof may be limited by the Reservations.  The execution, delivery and performance by it of each Financing Document executed or to be executed by it is in each case within its powers.

(b) The execution, delivery and performance by it of the Financing Documents to which it is a party do not (i) conflict with any of its organizational documents; (ii) contravene, conflict with, constitute a default under or violate any Law applicable to it; (iii) contravene, conflict or violate any applicable order, writ, judgment, injunction, decree, determination or award of any Governmental Authority by which it or any of its property or assets may be bound or affected; (iv) require any action by, filing, registration, or qualification with, or Required Permit from, any Governmental Authority (except (i) such Required Permits which have already been obtained and are in full force and effect and (ii) in the case of the Scottish Security Documents, registration with the Registrar of Companies for Scotland and, where appropriate, with the Land Register for Scotland); or (v) constitute a default under or conflict with any Material Agreement to which it is a party.  It is not in default under any agreement to which it is a party or by which it is bound in which the default could reasonably be expected to result in a Material Adverse Change.

5.2 Litigation .  Except as disclosed on the Disclosure Schedule or, after the Closing Date, pursuant to Section 6.7, there are no actions, suits, proceedings or investigations pending or, to the knowledge of the Responsible Officers, threatened in writing by or against it which involves the possibility of any judgment or liability of more than One Hundred Fifty Thousand Dollars ($150,000.00) or that could result in a Material Adverse Change, or which questions the validity of the Financing Documents to which it is party, or the other documents required thereby or any action to be taken pursuant to any of the foregoing, nor does it have reason to believe that any such actions, suits, proceedings or investigations are threatened.

5.3 No Material Deterioration in Financial Condition; Financial Statements .  All financial statements for the Credit Parties delivered to Agent or any Lender fairly present, in conformity with GAAP, in all material respects the consolidated financial condition and consolidated results of operations of such Credit Party.  There has been no material deterioration in the consolidated financial condition of such Credit Party from the most recent financial statements and projections submitted to Agent or any Lender. There has been no adverse deviation from the most recent annual operating plan of Borrower delivered to Agent and Lenders that constitutes or that could result in a Material Adverse Change.

5.4 Solvency .  After giving effect to the transactions contemplated hereby, the fair salable value of such Credit Party’s assets (including goodwill minus disposition costs) exceeds the fair value of its liabilities.  After giving effect to the transactions described in this Agreement, (a) it is not left with unreasonably small capital in relation to its business as presently conducted, and (b) it is able to pay its debts (including trade debts) as they mature.

5.5 Subsidiaries; Investments .  It does not own any stock, partnership interest or other equity securities, except for Permitted Investments.

5.6 Tax Returns and Payments; Pension Contributions .  It has timely filed all required tax returns and reports, and has timely paid all foreign, federal, state and material local taxes, assessments, deposits and contributions owed by it.  It is not aware of any claims or adjustments proposed for any of its prior tax years which could result in additional taxes becoming due and payable by it.  It

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

9            

 

 


 

has paid all amounts necessary to fund all present pension, profit sharing and deferred compensation plans in accordance with their terms, and it has not withdrawn from participation in, or has permitted partial or complete termination of, or permitted the occurrence of any other event with respect to, any such plan which could reasonably be expected to result in any liability of it , including any liability to the Pension Benefit Guaranty Corporation or its successors or any other Governmental Authority .

5.7 Disclosure Schedule .  All information set forth in the Disclosure Schedule is true, accurate and complete as of the date hereof.  All information set forth in the Perfection Certificate is true, accurate and complete as of the date hereof.  

 

6

AFFIRMATIVE COVENANTS

Each Credit Party covenants and agrees as follows:

6.1 Organization and Existence; Government Compliance .

(a) Each Credit Party shall maintain its legal existence and good standing in its respective jurisdiction of formation and maintain qualification in each jurisdiction in which the failure to so qualify could reasonably be expected to result in a Material Adverse Change.  If a Credit Party is not now a Registered Organization but later becomes one, Borrower shall promptly notify Agent of such occurrence and provide Agent with such Credit Party’s organizational identification number.  

(b) Each Credit Party shall comply with all Laws, ordinances and regulations to which it or its business locations are subject, the noncompliance with which could reasonably be expected to result in a Material Adverse Change.  Each Credit Party shall obtain and keep in full force and effect and comply with all of the Required Permits, except where failure to have or maintain compliance with or effectiveness of such Required Permit could not reasonably be expected to result in a Material Adverse Change.  Each Credit Party shall promptly provide copies of any such obtained Required Permits to Agent. Borrower shall notify Agent within three (3) Business Days (but in any event prior to Borrower submitting any requests for Credit Extensions or release of any reserves) of the occurrence of any facts, events or circumstances known to any Credit Party, whether threatened, existing or pending, that could cause any Required Permit to become limited, suspended or revoked or that makes any Credit Party subject to or requires any Credit Party to file a plan of correction with respect to any accreditation survey.  

6.2 Financial Statements, Reports, Certificates .

(a) Borrower shall deliver, or shall cause Quotient Limited to deliver, to Agent and each Lender: (i) as soon as available, but no later than forty-five (45) days after the last day of each month, a company prepared consolidated and consolidating balance sheet, income statement and cash flow statement covering the Credit Parties’ consolidated operations for such month certified by a Responsible Officer and in a form acceptable to Agent; (ii) as soon as available, but no later than one hundred twenty (120) days after the last day of the Borrower’s fiscal year, audited consolidated and consolidating financial statements prepared under GAAP, consistently applied, together with an unqualified opinion on the financial statements from an independent certified public accounting firm acceptable to Agent in its reasonable discretion; (iii) as soon as available after approval thereof by such Credit Party’s governing board, but no later than sixty (60) days after the last day of such Credit Party’s fiscal year, and as amended and/or updated, such Credit Party’s financial projections for current fiscal year; (iv) within five (5) days of delivery, copies of all statements, reports and notices made available to all of such Credit Party’s security holders or to any holders of Subordinated Debt; (v) within five (5) days of filing, all reports on Form 10-K, 10-Q and 8‑K, filed with the Securities and Exchange Commission (“ SEC ”) or a link thereto on such Credit Party’s or another website on the Internet; (vi) budgets, sales projections, operating plans and other financial information reasonably requested by Agent or any Lender; (vii) as soon as available, but no later than forty-five (45) days after the last day of each month, copies of the month-end account statements for each Collateral Account maintained by a Credit Party, which statements may be provided to Agent by Borrower or directly from the applicable institution(s); and (viii) such additional information, reports or statements regarding the Credit Parties or their respective businesses, contractors and subcontractors as Agent or any Lender may from time to time reasonably request.

(b) Notwithstanding the foregoing, the obligations in Section 6.2(a)(i) and (ii) may be satisfied by furnishing: (i) the Borrower’s (or such direct or indirect parent thereof) Form 10-K or 10-Q, as applicable, filed with the SEC, in each case within the time frames specified in Section 6.2(a) above and (ii) as soon as available, but no later than forty-five (45) days after the last day of each month, a company prepared calculation of the consolidated cash and cash equivalents of the Credit Parties and a company prepared consolidated and consolidating income statement, provided that (x) to the extent such financial statements relate to a parent or indirect parent of Borrower, such financial statements will be accompanied by consolidating information that describes Borrower standing alone, certified by a Responsible Officer, and (y) to the extent such financial statements are provided in lieu of statements required by clause (a)(ii) above, such statements will be accompanied by a report and opinion of an independent registered public accounting firm and be in form and content acceptable to the Agent in its reasonable discretion.

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

10            

 

 


 

(c) Within forty-five ( 45 ) days after the last day of each month, Borrower shall deliver , or cause Quotient L imited to deliver, to Agent and each Lender, with the monthly financial statements described above, a duly completed Compliance Certificate signed by a Responsible Officer.

(d) Each Credit Party shall keep proper books of record and account in accordance with GAAP in which full, true and correct entries shall be made of all dealings and transactions in relation to its business and activities.  Upon prior written notice and during business hours (which such limitations shall not apply if a Default or Event of Default has occurred and is continuing), each Credit Party shall allow Agent and Lenders to visit and inspect any properties of such Credit Party, to examine and make abstracts or copies from such Credit Party’s books, to conduct a collateral audit and analysis of its operations and the Collateral to verify the amount and age of the accounts, the identity and credit of the respective account debtors, to review the billing practices of such Credit Party and to discuss its respective affairs, finances and accounts with their respective officers, employees and independent public accountants as often as may reasonably be desired.  The Credit Parties shall reimburse Agent and each Lender for all reasonable costs and expenses associated with such visits and inspections; provided, however, that the Credit Parties shall be required to reimburse Agent and each Lender for such costs and expenses for no more than two (2) such visits and inspections per twelve (12) month period unless a Default or Event of Default has occurred during such period.

(e) Each Credit Party shall deliver to Agent and each Lender, within five (5) days after the same are sent or received, copies of all material correspondence, reports, documents and other filings with any Governmental Authority that could reasonably be expected to have a material effect on any of the Required Permits material to the Credit Parties’ business or otherwise on the operations of the Credit Parties.

6.3 Maintenance of Property .  Each Credit Party shall cause all equipment and other tangible personal property other than Inventory to be maintained and preserved in the same condition, repair and in working order as of the date hereof, ordinary wear and tear excepted, and shall promptly make or cause to be made all repairs, replacements and other improvements in connection therewith that are necessary or desirable to such end.  Each Credit Party shall keep all Inventory in good and marketable condition, free from material defects.  Returns and allowances between any Credit Party and its Account Debtors shall follow such Credit Party’s customary practices as they exist at the Closing Date in all material respects.  Borrower shall promptly notify Agent of all returns, recoveries, disputes and claims that involve more than Two Hundred Thousand Dollars ($200,000) of Inventory collectively among all Credit Parties.

6.4 Taxes; Pensions .  Each Credit Party shall timely file all required tax returns and reports and timely pay all foreign, federal, state, and local taxes, assessments, deposits and contributions owed, and shall deliver to Agent, on demand, appropriate certificates attesting to such payments.  Each Credit Party shall pay all amounts necessary to fund all present pension, profit sharing and deferred compensation plans in accordance with their terms.  Notwithstanding the foregoing, any Credit Party may defer payment of any contested taxes, provided, however, that such Credit Party (a) in good faith contests its obligation to pay the taxes by appropriate proceedings promptly and diligently instituted and conducted, (b) notifies Agent in writing of the commencement of, and any material development in, the proceedings, and (c) posts bonds or takes any other steps required to prevent the governmental authority levying such contested taxes from obtaining a Lien upon any of the Collateral.

6.5 Insurance .  Each Credit Party shall keep its business and the Collateral insured for risks and in amounts standard for companies in such Credit Party’s industry and location and as Agent may reasonably request.  Insurance policies shall be in a form, with companies, and in amounts that are satisfactory to Agent.  All U.S. property policies shall have a lender’s loss payable endorsement showing Agent as sole lender’s loss payee and waive subrogation against Agent, all U.S. liability policies shall show, or have endorsements showing, Agent as an additional insured, and all non-U.S. property or liability policies shall have Agent’s interest noted in the manner customary in the relevant jurisdiction.  No other loss payees may be shown on the policies unless Agent shall otherwise consent in writing.  If required by Agent, all policies (or the loss payable and additional insured endorsements) shall provide that the insurer shall endeavor to give Agent at least thirty (30) days’ notice before canceling, amending, or declining to renew its policy.  At Agent’s request, each Credit Party shall deliver certified copies of all such Credit Party insurance policies and evidence of all premium payments.  If any Credit Party fails to obtain insurance as required under this Section 6.5 or to pay any amount or furnish any required proof of payment to third persons and Agent, Agent may make all or part of such payment or obtain such insurance policies required in this Section 6.5, and take any action under the policies Agent deems prudent.

6.6 Collateral Accounts .  Each Credit Party shall provide Agent five (5) days prior written notice before establishing any Collateral Account at or with any bank or financial institution.  In addition, for each Collateral Account that any Credit Party at any time maintains, each Credit Party shall, to the extent necessary and permitted under applicable Law to ensure the perfection and priority of Agent’s Lien in such Collateral Account in accordance with the terms hereunder, cause the applicable bank or financial institution at or with which any Collateral Account is maintained to execute and deliver a Control Agreement or other appropriate instrument with respect to such Collateral Account to perfect Agent’s Lien in such Collateral Account in accordance with the terms

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

11            

 

 


 

hereunder, which Control Agreement may not be terminated without prior written consent of Agent.    The provisions of the previous sentence shall not apply to deposit accounts exclusively used for payroll, payroll taxes and other employee wage and benefit payments to or for the benefit of a Credit Party’s employees and identified to Agent by such Credit Party as such; provided, however, that at all times Borrower shall maintain one or more separate Deposit Accounts to hold any and all amounts to be used for payroll, payroll taxes and other employee wage and benefit payments, and shall not commingle any monies allocated for such purposes with funds in any other Deposit Account.    Notwithstanding the foregoing, the Credit Parties may maintain the Citizens Account without such Collateral Account being subject to a Control Agreement provided that all funds on deposit in the Citizens Account shall be wired not later than three (3) Business Days after receipt thereof in such Citizens Account to a Collateral Account that is subject to a Control Agreement .

6.7 Notices of Material Agreements, Litigation and Defaults; Cooperation in Litigation .    Promptly (and in any event within three (3) Business Days), (a) upon any Credit Party becoming aware of the existence of any Event of Default or event which, with the giving of notice or passage of time, or both, would constitute an Event of Default or (b) upon the execution and delivery of any Material Agreement and each material amendment, consent, waiver or other modification, and each notice of termination or default or similar notice delivered to or by a Credit Party in connection with any Material Agreement , or (c) upon any Credit Party becoming aware of (or having reason to believe any of the following are pending or threatened in writing) any action, suit, proceeding or investigation by or against Borrower or any Credit Party which involves the possibility of any judgment or liability of more than One Hundred Fifty Thousand Dollars ($150,000) or that could result in a Material Adverse Change, or which questions the validity of any of the Financing Documents, or the other documents required thereby or any action to be taken pursuant to any of the foregoing, the Credit Parties shall give written notice to Agent of such occurrence, and such further information (including copies of such documentation) as Agent shall reasonably request. From the date hereof and continuing through the termination of this Agreement, each Credit Party shall make available to Agent and each Lender, without expense to Agent or any Lender, each Credit Party’s officers, employees and agents and books, to the extent that Agent or any Lender may deem them reasonably necessary to prosecute or defend any third-party suit or proceeding instituted by or against Agent or any Lender with respect to any Collateral or relating to any Credit Party.

6.8 Creation/Acquisition of Subsidiaries . In the event any Credit Party creates or, to the extent permitted hereunder, acquires any Subsidiary, such Credit Party shall promptly (and in any event within five (5) Business Days of such creation or acquisition) notify Agent of the creation or acquisition of such new Subsidiary and take all such action as may be reasonably required by Agent or the Required Lenders to cause each such Subsidiary to become a co-Borrower hereunder or to guarantee the Obligations of Borrower under the Financing Documents and, in each case, grant a continuing pledge and security interest in and to the assets of such Subsidiary (substantially as described on Exhibit A hereto or, in the case of a Subsidiary formed outside of the United States or any political subdivision thereof, in such form as reasonably acceptable to the Agent and as appropriate for the relevant jurisdiction in which the Subsidiary is formed); and such Credit Party shall grant and pledge to Agent, for the ratable benefit of the Lenders, a perfected security interest in the stock, units or other evidence of ownership of each Subsidiary (the foregoing collectively, the “ Joinder Requirements ”); provided, that the Credit Parties shall not be permitted to make any Investment (other than Permitted Investments described in clause (a) of the definition thereof) in such Subsidiary until such time as the Joinder Requirements of this Section 6.8 have been satisfied.

6.9 Use of Proceeds .  Borrower shall use the proceeds of the Credit Extensions solely for (a) transaction fees and other expenses incurred in connection with the Financing Documents, (b) subject the limitations set forth in Section 7.7 hereof with respect to Quotient Suisse, for working capital needs of Borrower and its Subsidiaries and the other Credit Parties, and (c) any other Permitted Purpose specified in the Credit Facility Schedule for such Credit Facility.  No portion of the proceeds of the Credit Extensions will be used for family, personal, agricultural or household use.

6.10 Hazardous Materials; Remediation.

(a) If any release or disposal of Hazardous Materials shall occur or shall have occurred on any real property or any other assets of any Credit Party, such Credit Party will cause the prompt containment and removal of such Hazardous Materials and the remediation of such real property or other assets as is necessary to comply with all Laws and to preserve the value of such real property or other assets.  Without limiting the generality of the foregoing, each Credit Party shall comply with each Law requiring the performance at any real property by such Credit Party of activities in response to the release or threatened release of a Hazardous Material.

(b) The Credit Parties will provide Agent within thirty (30) days after written demand therefor with a bond, letter of credit or similar financial assurance evidencing to the reasonable satisfaction of Agent that sufficient funds are available to pay the cost of removing, treating and disposing of any Hazardous Materials or Hazardous Materials Contamination and discharging any assessment which may be established on any property as a result thereof, such demand to be made, if at all, upon Agent’s

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

12            

 

 


 

determination that the failure to remove, treat or dispose of any Hazardous Materials or Hazardous Materials Contamination, or the failure to discharge any such assessment could reasonably be expected to have a Material Adverse Change.

(c) If there is any conflict between this Section 6.10 and any environmental indemnity agreement which is a Financing Document, the environmental indemnity agreement shall govern and control.

6.11 Power of Attorney .  Each of the officers of Agent is hereby irrevocably made, constituted and appointed the true and lawful attorney for each Credit Party (without requiring any of them to act as such) with full power of substitution to do the following:  (a) pay, contest or settle any Lien, charge, encumbrance, security interest, and adverse claim in or to the Collateral (in each case, so long as no Default or Event of Default has occurred, other than Permitted Liens), or any judgment based thereon, or otherwise take any action to terminate or discharge the same; (b) so long as Agent has provided not less than three (3) Business Days’ prior written notice to the Credit Parties to perform the same and the Credit Parties have failed to take such action, (i) execute in the name of any Person comprising any Credit Party any schedules, assignments, instruments, documents, and statements that such Credit Party is obligated to give Agent under this Agreement or that Agent or any Lender deems necessary to perfect or better perfect Agent’s security interest or Lien in any Collateral, (ii) do such other and further acts and deeds in the name of such Credit Party that Agent may deem necessary or desirable to enforce, protect or preserve any Collateral or its rights therein, including, but not limited to, to sign such Credit Party’s name on any invoice or bill of lading for any Account or drafts against Account Debtors; and (iii) after the occurrence and during the continuance of an Event of Default, (A) endorse the name of any Credit Party upon any and all checks, drafts, money orders, and other instruments for the payment of money that are payable to such Credit Party; (B) make, settle, and adjust all claims under the Credit Parties’ insurance policies; (C) take any action any Credit Party is required to take under this Agreement or any other Financing Document; (D) transfer the Collateral into the name of Agent or a third party as the Code permits; (E) exercise any rights and remedies described in this Agreement or the other Financing Documents; and (F) do such other and further acts and deeds in the name of any Credit Party that Agent may deem necessary or desirable to enforce its rights with regard to any Collateral.

6.12 Further Assurances .  Each Credit Party shall promptly execute any further instruments and take further action as Agent reasonably requests to perfect or better perfect or continue Agent’s Lien in the Collateral or to effect the purposes of this Agreement or any other Financing Document.

6.13 Post-Closing Obligations .  Each Credit Party shall complete each of the post-closing obligations and/or deliver to Agent each of the documents, instruments, agreements and information listed on the Post-Closing Obligations Schedule attached hereto, on or before the date set forth for each such item thereon (as the same may be extended by Agent in writing in its sole discretion), each of which shall be completed or provided in form and substance satisfactory to Agent and Lenders.

6.14 Disclosure Schedule .  Each Credit Party shall, on each date that it delivers a Compliance Certificate in accordance with Section 8.2(c), deliver to Agent a proposed update to the Disclosure Schedule correcting all outdated, inaccurate, incomplete or misleading information, to the extent any information is outdated, inaccurate, incomplete or misleading.  With respect to any proposed updates to the Disclosure Schedule involving Permitted Liens, Permitted Indebtedness or Permitted Investments, Agent will replace the Disclosure Schedule attached hereto with such proposed update only if such updated information is consistent with the definitions of and limitations herein pertaining to Permitted Liens, Permitted Indebtedness or Permitted Investments.  With respect to any proposed updates to the Disclosure Schedule involving other matters, Agent will replace the applicable portion of the Disclosure Schedule attached hereto with such proposed update upon Agent’s approval thereof.

6.15 Preference Shares .  From and after the third anniversary of the issuance of any Preference Shares and in each calendar year thereafter, Quotient Limited shall, pursuant to Section 2.3.2 of the Statement of Rights, extend the Redemption Date of such Preference Shares for a period of not less than one year (subject always to the limitations on the powers of the Company in respect of the same set out in such Section of the Statement of Rights).

6.16 Scottish Land Acquisition .  (a) Concurrently with the execution of the Scottish Lease Documents, Alba Bioscience Limited shall take all necessary action necessary or advisable to grant to Agent, on behalf of Lenders, a Lien on all of Alba Bioscience Limited’s right, title and interest in, to and under the Scottish Ground Lease (acceptable to Agent and otherwise subject only to Permitted Liens under clauses (e) or (l) of the definition thereof) and (b) concurrently with acquisition by Alba Bioscience Limited of title to the property defined as the “Subjects” in the Scottish Ground Lease pursuant to terms thereof or otherwise, Alba Bioscience Limited shall take all necessary action to grant to Agent, on behalf of Lenders, a Lien on such property under the laws of Scotland acceptable to Agent.

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

13            

 

 


 

 

7

NEGATIVE COVENANTS  

No Credit Party shall do any of the following without the prior written consent of Agent:

7.1 Dispositions .  Convey, sell, abandon, lease, license, transfer, assign or otherwise dispose of (collectively, “ Transfer ”) all or any part of its business or property, except for (a) sales, transfers or dispositions of Inventory in the Ordinary Course of Business; (b) sales or abandonment of worn‑out or obsolete Equipment; (c) Transfers of assets to another Credit Party in compliance with the covenants set forth in this Agreement, including without limitation, Sections 7.7 and 7.13 ; (d) Transfers of accounts receivable in connection with collection or compromise thereof, or (e) Transfers in the Ordinary Course of Business consisting of the abandonment of Intellectual Property rights which, in the reasonable good faith determination of such Credit Party, are uneconomical, negligible, obsolete or otherwise not useful in the conduct of its business.

7.2 Changes in Business, Management, Ownership or Business Locations .  (a) Engage in any business other than the businesses currently engaged in by such Credit Party, as applicable, or reasonably related thereto; (b) liquidate or dissolve; (c) (i) have a change in senior management where a suitable permanent replacement, as approved by such Credit Party’s board of directors, has not been named and hired by not later than sixty (60) days after such change, or (ii) enter into any transaction or series of related transactions which would result in a Change in Control; (d) add any new offices or business locations, or enter into any new leases with respect to existing offices or business locations (unless such new or existing offices or business locations contain less than Fifty Thousand Dollars ($50,000) of such Credit Party’s assets or property and do not contain any of such Credit Party’s Books) without first delivering (i) in the case of leased premises located in jurisdictions in which such documents are customary, including without limitation the United States, a fully-executed Access Agreement to Agent and (ii) any other documents which are necessary or advisable to maintain in favor of the Agent, Liens on the Collateral that are duly perfected in accordance with all applicable Law; (e) change its jurisdiction of organization; (f) change its organizational structure or type; (g) change its legal name; or (h) change any organizational number (if any) assigned by its jurisdiction of organization.

7.3 Mergers or Acquisitions .  Merge or consolidate with any other Person, or acquire all or substantially all of the capital stock or property of another Person; provided, however , that a Subsidiary of a Credit Party may merge or consolidate into another Subsidiary that is a Credit Party, so long as (a) Borrower has provided Agent with prior written notice of such transaction, (b) a Person already comprising a Credit Party shall be the surviving legal entity, (c) if the Borrower is a party thereto, the Borrower shall be the surviving legal entity, (d) the surviving Credit Party’s tangible net worth is not thereby reduced, (e) no Event of Default has occurred and is continuing prior thereto or arises as a result therefrom, and (f) the Credit Parties shall be in compliance with the covenants set forth in this Agreement, including without limitation Sections 7.7 and 7.13, both before and after giving effect to such transaction.

7.4 Indebtedness .  Create, incur, assume, or be liable for any Indebtedness other than Permitted Indebtedness.

7.5 Encumbrance .  (a) Create, incur, allow, or suffer any Lien on any of its property, except for Permitted Liens, (b) permit any Collateral to fail to be subject to the first priority security interest granted herein except for Permitted Liens that may have priority by operation of applicable Law or by the terms of a written intercreditor or subordination agreement entered into by Agent, or (c) enter into any agreement, document, instrument or other arrangement (except with or in favor of Agent) with any Person which directly or indirectly prohibits or has the effect of prohibiting any Credit Party or any Subsidiary from assigning, mortgaging, pledging, granting a security interest in or upon, or encumbering any Credit Party’s or any Subsidiary’s Collateral or Intellectual Property, except as is otherwise permitted in the definition of “Permitted Liens” herein.

7.6 Maintenance of Collateral Accounts .  Maintain any Collateral Account, except in compliance with the terms of Section 6.6 hereof.

7.7 Distributions; Investments .  (a) Pay any dividends or make any distribution or payment with respect to or redeem, retire or purchase or repurchase any of its equity interests (other than Permitted Distributions), or (b) directly or indirectly make any Investment (including, without limitation, any additional Investment in any Subsidiary) other than Permitted Investments.  

7.8 Transactions with Affiliates .  Directly or indirectly enter into or permit to exist any material transaction with any Affiliate of any Credit Party, except for (a) transactions that are upon fair and reasonable terms that are no less favorable to such Credit Party than would be obtained in an arm’s length transaction with a non-affiliated Person, (b) transactions with Credit Parties hereunder and that are not otherwise prohibited by Article 7 of this Agreement, and (c) transactions permitted by Section 7.7 of this Agreement;.

7.9 Subordinated Debt .  (a) Make or permit any payment on any Subordinated Debt, except to the extent expressly permitted to be made pursuant to the terms of the Subordination Agreement to which such Subordinated Debt is subject, or (b) amend any

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

14            

 

 


 

provision in any document relating to the Subordinated Debt other than as may be expressly permitted pursuant to the terms of any applicable Subordination Agreement to which such Subordinated Debt is subject.

7.10 Compliance .  Become an “investment company” or a company controlled by an “investment company”, under the Investment Company Act of 1940, as amended or undertake as one of its important activities extending credit to purchase or carry margin stock (as defined in Regulation U of the Board of Governors of the Federal Reserve System), or use the proceeds of any Credit Extension for that purpose; fail to meet the minimum funding requirements of ERISA, permit a Reportable Event or Prohibited Transaction, as defined in ERISA, to occur; fail to comply with the Federal Fair Labor Standards Act or violate any other Law or regulation, if the violation could reasonably be expected to result in a Material Adverse Change; withdraw from participation in, permit partial or complete termination of, or permit the occurrence of any other event with respect to, any present pension, profit sharing and deferred compensation plan which could reasonably be expected to result in any liability of such Credit Party, including any liability to the Pension Benefit Guaranty Corporation or its successors or any other governmental agency.

7.11 Amendments to Organization Documents and Material Agreements .  Subject to applicable requirements of law, amend, modify or waive any provision of (a) any Material Agreement in a manner that is materially adverse to any Credit Party, that is adverse to Agent or any Lender, that pertains to rights to assign or grant a security interest in such Material Agreement or that could or could reasonably be expected to result in a Material Adverse Change, or (b) any of its organizational documents (other than a change in registered agents, or a change that could not adversely affect the rights of Agent or Lenders hereunder, but, for the avoidance of doubt, under no circumstances a change of its name, type of organization or jurisdiction of organization), in each case, without the prior written consent of Agent, such consent not to be unreasonably withheld or delayed.  Each Credit Party shall provide to Agent copies of all amendments, waivers and modifications of any Material Agreement or organizational documents.

7.12 Compliance with Anti-Terrorism Laws .  Directly or indirectly, knowingly enter into any documents, instruments, agreements or contracts with any Person listed on the OFAC Lists.  Each Credit Party shall immediately notify Agent if such Credit Party has knowledge that any Credit Party or any Subsidiary or Affiliate is listed on the OFAC Lists or (a) is convicted on, (b) pleads nolo contendere to, (c) is indicted on, or (d) is arraigned and held over on charges involving money laundering or predicate crimes to money laundering.  No Credit Party will, nor will any Credit Party permit any Subsidiary or Affiliate to, directly or indirectly, (i) conduct any business or engage in any transaction or dealing with any Blocked Person, including, without limitation, the making or receiving of any contribution of funds, goods or services to or for the benefit of any Blocked Person, (ii) deal in, or otherwise engage in any transaction relating to, any property or interests in property blocked pursuant to Executive Order No. 13224, any similar executive order or other Anti-Terrorism Law, or (iii) engage in or conspire to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate, any of the prohibitions set forth in Executive Order No. 13224 or other Anti-Terrorism Law. Agent hereby notifies each Credit Party that pursuant to the requirements of Anti-Terrorism Laws, and Agent’s policies and practices, Agent is required to obtain, verify and record certain information and documentation that identifies such Credit Party and its principals, which information includes the name and address of such Credit Party and its principals and such other information that will allow Agent to identify such party in accordance with Anti-Terrorism Laws.  

7.13 Holdings .  (a)  Quotient Limited will not incur or permit to exist any Indebtedness (other than the Indebtedness incurred in connection with the Preference Shares) nor grant or permit to exist any Liens upon any of its properties or assets nor engage in any operations, business or activity other than (i) owning 100% of the Equity Interests of the Borrower and the other Credit Parties and all operations incidental thereto, (ii) granting a security interest in all its assets to the Agent, for the benefit of the Lenders, (iii) executing the Financing Documents to which it is a party, (iv) fulfilling its obligations under the Financing Documents to which it is a party, (v) performing administrative, governance and supervisory functions in connection with the operation of the business of its Subsidiaries, (vi) issuing equity interests, including without limitation pursuant to stock option plans and (vii) executing, delivering and performing the Scottish Lease Documents to which it is a party.

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

15            

 

 


 

(b) Following the creation of the Luxembourg Holding Company, the Luxembourg Holding Company will not incur or permit to exist any Indebtedness nor grant or permit to exist any Liens upon any of its properties or assets nor engage in any operations, business or activity other than ( i ) owning 100% of the Equity Interests of Quotient Suisse , Alba Bioscience Limited, and the Borrower and all operations incidental thereto, ( ii ) granting a security interest in all its assets to the Agent, for the benefit of the Lenders, ( iii ) executing the Financing Documents to which it is a party, ( iv ) fulfilling its obligations under the Financing Documents to which it is a party, ( v ) performing administrative, governance and supervisory functions in connection with the operation of the business of its Subsidiaries, and ( vi ) issuing equity interests, including without limitation pursuant to stock option plans.

 

8

ADDITIONAL COVENANTS

 

8.1

Life Sciences Covenants.

(a) As used in this Agreement, the following terms have the following meanings:

DEA ” means the Drug Enforcement Administration of the United States of America, and any successor agency thereof or any foreign equivalent thereof.

Drug Application ” means a new drug application, an abbreviated drug application, or a product license application for any Product, as appropriate, as those terms are defined in the FDCA.

FDA ” means the Food and Drug Administration of the United States of America, or any successor entity thereto or foreign equivalent thereof.

FDCA ” means the Federal Food, Drug and Cosmetic Act, as amended, 21 U.S.C. Section 301 et seq., and all regulations promulgated thereunder and any foreign equivalent of the Federal Food, Drug and Cosmetic Act and all regulations promulgated thereunder.

Material Intellectual Property ” means all of the Credit Parties’ Intellectual Property and license or sublicense agreements or other agreements with respect to rights in Intellectual Property that are material to the condition (financial or other), business or operations of the Credit Parties, as reasonably determined by Agent.

Permitted License ” means any non-exclusive license of patent rights of any Credit Party or its Subsidiaries granted to third parties in the Ordinary Course of Business and that does not result in a legal transfer of title to the licensed property.

Products ” means any products manufactured, sold, developed, tested or marketed by any Credit Party or any of its Subsidiaries, including without limitation, those products set forth on the Products Schedule (as updated from time to time in accordance with Section 8.1(d)); provided, however , that if Borrower shall fail to comply with the obligations under Section 8.1(d) to give notice to Agent and update the Products Schedule prior to manufacturing, selling, developing, testing or marketing any new Product, any such improperly undisclosed Product shall be deemed to be included in this definition.

Registered Intellectual Property ” means any patent, registered trademark or servicemark, registered copyright, registered mask work, or any pending application for any of the foregoing.

(a) Notwithstanding the terms of Section 7.1 of this Agreement to the contrary, the Credit Parties shall be permitted to make Transfers in the form of Permitted Licenses.  

(b) Each Credit Party represents and warrants as follows at all times unless expressly provided below:

(i) Intellectual Property and License Agreements .  A list of all Intellectual Property of the Credit Parties and all license agreements, sublicenses, or other rights of the Credit Parties to use Intellectual Property (including all in-bound license agreements, but excluding over-the-counter software that is commercially available to the public), as of the Closing Date and, as updated pursuant to Section 8.1(d), is set forth on the Intellectual Property Schedule , which indicates, for each item of property: (A) the name of the Credit Party owning such Intellectual Property or licensee to such license agreement; (B) whether such property is Intellectual Property (or application therefor) owned by a Credit Party or is property to which a Credit Party has rights pursuant to a license agreement, (C) the expiration date of such Intellectual Property or license agreement, and (D) whether such property constitutes Material Intellectual Property.  In the case of any Material Intellectual Property that is a license agreement, the Intellectual Property Schedule further indicates, for each: (1) the name and address of the licensor, (2) the name and date of the agreement pursuant to which such item of Material Intellectual Property is licensed, (3) whether or not such license agreement grants an

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

16            

 

 


 

exclusive license to such Credit Party, (4) whether there are any purported restrictions in such license agreement as to the ability of such Credit Party to grant a security interest in and/or to transfer any of its rights as a licensee under such license agreement, and (5) whether a default under or termination of such license agreement could interfere with Agent’s right to sell or assign such license or any other Collateral.  Except as noted on the Intellectual Property Schedule , each Credit Party is the sole owner of its Intellectual Property, except for licenses granted to its customers in the Ordinary Course of Business as identified on the Intellectual Property Schedule .  Each Patent is valid and enforceable and no part of the Material Intellectual Property has been judged invalid or unenforceable, in whole or in part, and to the best of the Credit Parties’ knowledge, no claim has been made that any part of the Intellectual Property violates the rights of any third party.  

(ii) Regulatory Status .

(A) All Products and all Required Permits are listed on the Products Schedule and Required Permits Schedule (as updated from time to time pursuant to Section 8.1(d)), and each Credit Party has delivered to Agent a copy of all Required Permits requested by Agent as of the date hereof or to the extent requested by Agent pursuant to Section 8.1(d).

(B) Without limiting the generality of Section 8.1 above, with respect to any Product being tested or manufactured, each Credit Party and its Subsidiaries have received, and such Product is the subject of, all Required Permits needed in connection with the testing or manufacture of such Product as such testing or manufacturing is currently being conducted by or on behalf of such Credit Party, and no Credit Party or its Subsidiaries have received any notice from any applicable Governmental Authority, specifically including the FDA, that such Governmental Authority is conducting an investigation or review of (1) such Credit Party’s or such Subsidiary’s manufacturing facilities and processes for such Product which have disclosed any material deficiencies or violations of Laws and/or the Required Permits related to the manufacture of such Product, or (2) any such Required Permit or that any such Required Permit has been revoked or withdrawn, nor has any such Governmental Authority issued any order or recommendation stating that the development, testing and/or manufacturing of such Product should cease.

(C) Without limiting the generality of Section 8.1 above, with respect to any Product marketed or sold by any Credit Party or its Subsidiaries, the Credit Parties and their Subsidiaries have received, and such Product is the subject of, all Required Permits needed in connection with the marketing and sales of such Product as currently being marketed or sold by the Credit Parties or their Subsidiaries, and the Credit Parties and their Subsidiaries have not received any notice from any applicable Governmental Authority, specifically including the FDA, that such Governmental Authority is conducting an investigation or review of any such Required Permit or approval or that any such Required Permit has been revoked or withdrawn, nor has any such Governmental Authority issued any order or recommendation stating that such marketing or sales of such Product cease or that such Product be withdrawn from the marketplace.

(D) Without limiting the generality of Section 8.1 above, (i) there have been no adverse clinical test results which have or could reasonably be expected to result in a Material Adverse Change, and (ii) there have been no Product recalls or voluntary Product withdrawals from any market, other than recalls or withdrawals that relate only to a specific lot or batch of a Product.

(E) The Credit Parties and their Subsidiaries have not experienced any significant failures in its manufacturing of any Product material to the business of the Credit Parties such that the amount of such Product successfully manufactured by any Credit Party or its Subsidiaries in accordance with all specifications thereof and the required payments related thereto shall decrease significantly.

(c) Each Credit Party covenants and agrees as follows:

(i) Reserved .

(ii) The Credit Parties shall own, or be licensed to use or otherwise have the right to use, all Material Intellectual Property.  All Material Intellectual Property of the Credit Parties is and shall be fully protected and/or duly and properly registered, filed or issued in the appropriate office and jurisdictions for such registrations, filings or issuances, except where the failure to do so would not reasonably be expected to result in a Material Adverse Change.  No Credit Party shall become a party to, nor become bound by, any material license or other agreement with respect to which such Credit Party is the licensee that prohibits or otherwise restricts such Credit Party from granting a security interest in such Credit Party’s interest in such license or agreement or other property.  Each Credit Party shall at all times conduct its business without infringing (knowingly or when Borrower should have known) any Intellectual Property rights of others.  Each Credit Party shall do the following, to the extent it determines, in the exercise of its reasonable business judgment, that it is prudent to do so: (A) protect, defend and maintain the validity and enforceability of its Material Intellectual Property; (B) promptly advise Agent in writing of material infringements of its Material Intellectual Property;

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

17            

 

 


 

and (C) not allow, without Agent’s prior written consent, any Material Intellectual Property to be abandoned, invalidated, forfeited or dedicated to the public or to become unenforceable.  If any Credit Party (1) obtains any patent, registered trademark or servicemark, registered copyright, registered mask work, or any pending application for any of the foregoing, whether as owner, licensee or otherwise, or (2) applies for any patent or the registration of any trademark or servicemark, then such Credit Party shall concurrently provide written notice thereof to Agent and shall execute such documents and take such other actions as Agent shall request in its good faith business judgment to perfect and maintain a first priority perfected security interest in favor of Agent, for the ratable benefit of Lenders, in the IP Proceeds (as defined in Exhibit A ) pertaining thereto .   Each Credit Party shall promptly provide to Agent copies of all applications that it files for patents or for the registration of trademarks, servicemarks, copyrights or mask works.

(iii) In connection with the development, testing, manufacture, marketing or sale of each and any Product by a Credit Party, such Credit Party shall comply fully and completely in all respects with all Required Permits at all times issued by any Governmental Authority the noncompliance with which could reasonably be expected to result in a Material Adverse Change, specifically including the FDA, with respect to such development, testing, manufacture, marketing or sales of such Product by such Credit Party as such activities are at any such time being conducted by such Credit Party.

(iv) Within ten (10) Business Days of (A) acquiring and/or developing any new Registered Intellectual Property, or (B) entering or becoming bound by any additional license or sublicense agreement or other agreement with respect to rights in Intellectual Property (other than over-the-counter software that is commercially available to the public), deliver to Agent an updated Intellectual Property Schedule reflecting same, and upon any other material change in any Credit Party ’s Material Intellectual Property from that listed on the Intellectual Property Schedule .  Each Credit Party shall take such steps as Agent requests to obtain the consent of, or waiver by, any person whose consent or waiver is necessary for (x) all licenses or agreements to be deemed “Collateral” and for Agent to have a security interest in it that might otherwise be restricted or prohibited by Law or by the terms of any such license or agreement, whether now existing or entered into in the future, and (y) Agent to have the ability in the event of a liquidation of any Collateral to dispose of such Collateral in accordance with Agent’s rights and remedies under this Agreement and the other Financing Documents.

(v) If, after the Closing Date, any Credit Party determines to manufacture, sell, develop, test or market any new Product, such Credit Party shall give prior written notice to Agent of such determination (which shall include a brief description of such Product, plus a list of all Required Permits relating to such new Product (and a copy of such Required Permits if requested by Agent) and/or such Credit Party’s manufacture, sale, development, testing or marketing thereof issued or outstanding as of the date of such notice), along with a copy of an updated Intellectual Property Schedule, Products Schedule and Required Permits Schedule ; provided, however, that if any Credit Party shall at any time obtain any new or additional Required Permits from the FDA, DEA, or parallel state or local authorities, or foreign counterparts of the FDA, DEA, or parallel state or local authorities, with respect to any Product which has previously been disclosed to Agent, such Credit Party shall promptly give written notice to Agent of such new or additional Required Permits (along with a copy thereof if requested by Agent).

(d) In addition to the events listed in Article 10, any one of the following shall also constitute an Event of Default under this Agreement, in each case, to the extent the following could reasonably be expected to result in a Material Adverse Change:  (i) the institution of any proceeding by FDA or similar Governmental Authority to order the withdrawal of any Product or Product category from the market or to enjoin any Credit Party, its Subsidiaries or any representative of such Credit Party or its Subsidiaries from manufacturing, marketing, selling or distributing any Product or Product category, (ii) the institution of any action or proceeding by any DEA, FDA, or any other Governmental Authority to revoke, suspend, reject, withdraw, limit, or restrict any Required Permit held by any Credit Party, its Subsidiaries or any representative of such Credit Party or its Subsidiaries, which, in each case, could result in Material Adverse Change,  (iii) the commencement of any enforcement action against any Credit Party, its Subsidiaries or any representative of such Credit Party or its Subsidiaries (with respect to the business of such Credit Party or its Subsidiaries) by DEA, FDA, or any other Governmental Authority, (iv) the recall of any Products from the market, the voluntary withdrawal of any Products from the market, or actions to discontinue the sale of any Products, or (v) the occurrence of adverse test results in connection with a Product.

8.2 Financial Covenants .

(a) As of each Testing Date, Credit Parties, taken as a whole, shall not permit their consolidated net product revenue for the applicable Calculation Period to be less than (i) for each Calculation Period ending on and including December 31, 2015, $16,500,000 and (ii) for each Calculation Period ending thereafter, $17,000,000.

(b) As of the last day of each calendar month, the Credit Parties shall maintain unrestricted cash and cash equivalents in an amount not less than $10,000,000 in the aggregate, which cash and cash equivalents shall (x) be subject to a first priority perfected lien (or equivalent thereof, as determined in Agent’s reasonable discretion, with respect to any applicable

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

18            

 

 


 

jurisdiction outside of the United States) in favor of Agent for the benefit of Lenders under the laws of the jurisdiction in which the Account is located, and (y) not include any drawn or committed but unpaid drafts, ACH or EFT transactions .

(c) Borrower shall furnish to Agent, together with the monthly financial reporting required of Borrower in this Agreement, a Compliance Certificate as evidence of Borrower’s compliance with the covenants in this Section.  The Compliance Certificate shall include, without limitation, (a) a statement and report, on a form approved by Agent, detailing Borrower’s calculations, (b) if requested by Agent, bank statements and (c) if requested by Agent, back-up documentation (including, without limitation, invoices, receipts and other evidence of costs incurred during such quarter as Agent shall reasonably require) evidencing the propriety of the calculations.

 

9

Reserved

 

10

EVENTS OF DEFAULT

10.1 Events of Default . The occurrence of any of the following conditions and/or events, whether voluntary or involuntary, by operation of law or otherwise, shall constitute an “ Event of Default ” and Credit Parties shall thereupon be in default under this Agreement and each of the other Financing Documents:

(a) Borrower fails to (i) make any payment of principal or interest on any Credit Extension on its due date, or (ii) pay any other Obligations within three (3) Business Days after such Obligations are due and payable (which three (3) Business Day grace period shall not apply to payments due on the Maturity Date or the date of acceleration pursuant to Section 10.2 hereof).

(b) Any Credit Party defaults in the performance of or compliance with any term contained in this Agreement or in any other Financing Document (other than occurrences described in other provisions of this Section 10.1 for which a different grace or cure period is specified or for which no grace or cure period is specified and thereby constitute immediate Events of Default) and such default is not remedied by the Credit Party or waived by Agent within fifteen (15) days after the earlier of (i) the date of receipt by any Borrower of notice from Agent or Required Lenders of such default, or (ii) the date a Responsible Officer of such Credit Party becomes aware, or through the exercise of reasonable diligence should have become aware, of such default; Any Credit Party defaults in the performance of or compliance with any term contained in Section 6.2, 6.4, 6.5, 6.6, 6.8 or 6.10 or Article 7 or Article 8.  

(c) Any representation, warranty, certification or statement made by any Credit Party or any other Person in any Financing Document or in any certificate, financial statement or other document delivered pursuant to any Financing Document is incorrect in any respect (or in any material respect if such representation, warranty, certification or statement is not by its terms already qualified as to materiality) when made (or deemed made);

(d) (i) any Credit Party defaults under or breaches any Material Agreement (after any applicable grace period contained therein), or a Material Agreement shall be terminated by a third party or parties party thereto prior to the expiration thereof, or there is a loss of a material right of a Credit Party under any Material Agreement to which it is a party, in each case, which could reasonably be expected to result in a Material Adverse Change, (ii) (A) any Credit Party fails to make (after any applicable grace period) any payment when due (whether due because of scheduled maturity, required prepayment provisions, acceleration, demand or otherwise) on any Indebtedness (other than the Obligations) of such Credit Party or such Subsidiary having an aggregate principal amount (including undrawn committed or available amounts and including amounts owing to all creditors under any combined or syndicated credit arrangement) of more than One Hundred Thousand Dollars ($100,000) (“ Material Indebtedness ”), (B) any other event shall occur or condition shall exist under any contractual obligation relating to any such Material Indebtedness, if the effect of such event or condition is to accelerate, or to permit the acceleration of (without regard to any subordination terms with respect thereto), the maturity of such Material Indebtedness or (C) any such Material Indebtedness shall become or be declared to be due and payable, or be required to be prepaid, redeemed, defeased or repurchased (other than by a regularly scheduled required prepayment), prior to the stated maturity thereof, (iii) any Credit Party defaults (beyond any applicable grace period) under any obligation for payments due or otherwise under any lease agreement for such Credit Party’s principal place of business or any place of business that meets the criteria for the requirement of an Access Agreement under Section 7.2 or for which an Access Agreement exists or was required to be delivered, (iv) the occurrence of any breach or default under any terms or provisions of any Subordinated Debt Document or under any agreement subordinating the Subordinated Debt to all or any portion of the Obligations, or the occurrence of any event requiring the prepayment of any Subordinated Debt, or the delivery of any notice with respect to any Subordinated Debt or pursuant to any Subordination Agreement that triggers the start of any standstill or similar period under any Subordination Agreement, or (v) any Borrower makes any payment on account of any Indebtedness that has been subordinated to any of the Obligations, other than payments specifically permitted by the terms of such subordination;

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

19            

 

 


 

(e) (i) any Credit Party shall generally not pay its debts as such debts become due, shall admit in writing its inability to pay its debts generally, shall make a general assignment for the benefit of creditors, or shall cease doing business as a going concern, (ii) any proceeding shall be instituted by or against any Credit Party seeking to adjudicate it a bankrupt or insolvent or seeking liquidation, winding up, reorganization, arrangement, adjustment, protection, relief, composition of it or its debts or any similar order (including any proceeding set out in Article 8 of the Interpretation (Jersey) Law 1954 or an application is made to declare the property of any Credit Party en desastre) , in each case under any law relating to bankruptcy, insolvency or reorganization or relief of debtors or seeking the entry of an order for relief or the appointment of a custodian, receiver, trustee, conservator, liquidating agent, liquidator, other similar official or other official with similar powers, in each case for it or for any substantial part of its property and, in the case of any such proceedings instituted against (but not by or with the consent of) such Credit Party, either such proceedings shall remain undismissed or unstayed for a period of forty-five ( 45 ) days or more or any action sought in such proceedings shall occur or (iii) any Credit Party shall take any corporate or similar action or any other action to authorize any action described in clause (i) or (ii) above;

(f) (i) The service of process seeking to attach, exercise diligence upon, execute or levy upon, seize or confiscate any Collateral Account, any Intellectual Property , or any funds of any Credit Party on deposit with Agent, any Lender or any Affiliate of Agent or any Lender, or (ii) a notice of lien, levy, or assessment is filed against any assets of a Credit Party by any government agency, and the same under subclauses (i) and (ii) hereof are not discharged or stayed (whether through the posting of a bond or otherwise) prior to the earlier to occur of ten (10) days after the occurrence thereof or such action becoming effective;  

(g) (i) any court order enjoins, restrains, or prevents Borrower from conducting any material part of its business, (ii) the institution by any Governmental Authority of criminal proceedings against any Credit Party, or (iii) one or more judgments or orders for the payment of money (not paid or fully covered by insurance and as to which the relevant insurance company has acknowledged coverage in writing) aggregating in excess of One Hundred Fifty Thousand Dollars $150,000 shall be rendered against any or all Credit Parties and either (A) enforcement proceedings shall have been commenced by any creditor upon any such judgments or orders, or (B) there shall be any period of ten (10) consecutive days during which a stay of enforcement of any such judgments or orders, by reason of a pending appeal, bond or otherwise, shall not be in effect,

(h) any Lien created by any of the Financing Documents shall at any time fail to constitute a valid and perfected Lien on all of the Collateral purported to be encumbered thereby, subject to no prior or equal Lien except Permitted Liens, or any Credit Party shall so assert; any provision of any Financing Document shall fail to be valid and binding on, or enforceable against, a Credit Party, or any Credit Party shall so assert;

(i) A Change in Control occurs or any Credit Party or direct or indirect equity owner in a Credit Party shall enter into agreement which contemplates a Change in Control;

(j) Any Required Permit shall have been (i) revoked, rescinded, suspended, modified in an adverse manner or not renewed in the Ordinary Course of Business for a full term, or (ii) subject to any decision by a Governmental Authority that designates a hearing with respect to any applications for renewal of any of such Required Permit or that could result in the Governmental Authority taking any of the actions described in clause (i) above, and such decision or such revocation, rescission, suspension, modification or non-renewal (A) results in, or could reasonably be expected to results in, a Material Adverse Change, or (B) adversely affects the legal qualifications of any Credit Party to hold such Required Permit in any applicable jurisdiction and such revocation, rescission, suspension, modification or non-renewal could reasonably be expected to affect the status of or legal qualifications of any Credit Party to hold any Required Permit in any other jurisdiction;

(k) If any Credit Party is or becomes an entity whose equity is registered with the SEC, and/or is publicly traded on and/or registered with a public securities exchange, such Credit Party’s equity fails to remain registered with the SEC in good standing, and/or such equity fails to remain publicly traded on and registered with a public securities exchange;

(l) Any Credit Party or any Person acting for any Credit Party makes any representation, warranty, or other statement now or later in this Agreement, any Financing Document or in any writing delivered to Agent and/or the Lenders or to induce Agent and/or the Lenders to enter this Agreement or any Financing Document, and such representation, warranty, or other statement is incorrect in any material respect when made;

(m) The occurrence of any fact, event or circumstance that could reasonably be expected to result in a Material Adverse Change, if such default shall have continued unremedied for a period of ten (10) days after written notice from Agent; or

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

20            

 

 


 

(n) Agent determines, based on information available to it and in its reasonable judgment, that there is a reasonable likelihood that Credit Parties shall fail to comply with one or more financial covenants in this Agreement during the next succeeding financial reporting period.

All cure periods provided for in this Section 10.1 shall run concurrently with any cure period provided for in any applicable Financing Documents under which the default occurred.

10.2 Rights and Remedies .

(a) Upon the occurrence and during the continuance of an Event of Default, Agent may, and at the written direction of any Lender shall , without notice or demand, do any or all of the following: (i) deliver notice of the Event of Default to Borrower, (ii) by notice to Borrower declare all Obligations immediately due and payable (but if an Event of Default described in Section 10.1(f) occurs all Obligations shall be immediately due and payable without any action by Agent or the Lenders), or (iii) by notice to any Borrower suspend or terminate the obligations, if  any, of the Lenders to advance money or extend credit for Borrower’s benefit under this Agreement or under any other agreement between any Credit Party and Agent and/or the Lenders (but if an Event of Default described in Section 10.1(f) occurs all obligations, if any, of the Lenders to  advance money or extend credit for Borrower’s benefit under this Agreement or under any other agreement between Borrower and Agent and/or the Lenders shall be immediately terminated without any action by Agent or the Lenders).

(b) Without limiting the rights of Agent and Lenders set forth in Section 10.2(a) above, upon the occurrence and during the continuance of an Event of Default, Agent shall have the right, without notice or demand, to do any or all of the following:  

(i) with or without legal process, enter any premises where the Collateral may be and take possession of and remove the Collateral from the premises or store it on the premises, and foreclose upon and/or sell, lease or liquidate, the Collateral, in whole or in part;

(ii) apply to the Obligations (A) any balances and deposits of any Credit Party that Agent or any Lender or any Affiliate of Agent or a Lender holds or controls, or (B) any amount held or controlled by Agent or any Lender or any Affiliate of Agent or a Lender owing to or for the credit or the account of any Credit Party;

(iii) settle, compromise or adjust and grant releases with respect to disputes and claims directly with Account Debtors for amounts on terms and in any order that Agent considers advisable, notify any Person owing any Credit Party money of Agent’s security interest in such funds, and verify the amount of such Account;  

(iv) make any payments and do any acts it considers necessary or reasonable to protect the Collateral and/or its security interest in the Collateral.  Borrower shall assemble the Collateral if Agent requests and make it available as Agent designates.  Agent may also, subject to applicable law, render any or all of the Collateral unusable at a Credit Party’s premises and may, subject to applicable law, dispose of such Collateral on such premises without liability for rent or costs. Each Credit Party, subject to applicable law, grants Agent a license to enter and occupy any of its premises, without charge, to exercise any of Agent’s rights or remedies;

(v) pay, purchase, contest, or compromise any Lien which appears to be prior or superior to its security interest and pay all expenses incurred;

(vi) subject to applicable law, ship, reclaim, recover, store, finish, maintain, repair, prepare for sale, and/or advertise for sale, the Collateral.  Agent is hereby granted a non-exclusive, royalty-free license or other right to use, without charge, each Credit Party’s labels, patents, copyrights, mask works, rights of use of any name, trade secrets, trade names, trademarks, service marks, and advertising matter, or any similar property as it pertains to the Collateral, in completing production of, advertising for sale, and selling any Collateral (and including in such license access to all media in which any of the licensed items may be recorded or stored and to all computer software and programs used for the compilation or printout thereof) and, in connection with Agent’s exercise of its rights under this Article 10, such Credit Party’s rights under all licenses and all franchise agreements shall be deemed to inure to Agent for the benefit of the Lenders;

(vii) place a “hold” on any account maintained with Agent or the Lenders or any Affiliate of Agent or a Lender and/or deliver a notice of exclusive control, any entitlement order, or other directions or instructions pursuant to any Control Agreement or similar agreements providing control of any Collateral;

(viii) demand and receive possession of the Books of Borrower and the other Credit Parties; and

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

21            

 

 


 

(ix) exercise all other rights and remedies available to Agent under the Financing Documents or at law or equity, including all remedies provided under the Code (including disposal of the Collateral pursuant to the terms thereof).

10.3 Notices .  Any notice that Agent is required to give to a Credit Party under the UCC of the time and place of any public sale or the time after which any private sale or other intended disposition of the Collateral is to be made shall be deemed to constitute reasonable notice if such notice is given in accordance with this Agreement at least five (5) days prior to such action.  

10.4 Protective Payments .  If any Credit Party fails to pay or perform any covenant or obligation under this Agreement or any other Financing Document, Agent may pay or perform such covenant or obligation, and all amounts so paid by Agent are Protective Advances and immediately due and payable, bearing interest at the then highest applicable rate for the Credit Facilities hereunder, and secured by the Collateral.  No such payments or performance by Agent shall be construed as an agreement to make similar payments or performance in the future or constitute Agent’s waiver of any Event of Default.

10.5 Liability for Collateral No Waiver; Remedies Cumulative .  So long as Agent and the Lenders comply with reasonable banking practices regarding the safekeeping of the Collateral in the possession or under the control of Agent and the Lenders, Agent and the Lenders shall not be liable or responsible for: (a) the safekeeping of the Collateral; (b) any loss or damage to the Collateral; (c) any diminution in the value of the Collateral; or (d) any act or default of any carrier, warehouseman, bailee, or other Person.  Borrower bears all risk of loss, damage or destruction of the Collateral.  Agent’s failure, at any time or times, to require strict performance by any Credit Party of any provision of this Agreement or any other Financing Document shall not waive, affect, or diminish any right of Agent thereafter to demand strict performance and compliance herewith or therewith.  No waiver hereunder shall be effective unless signed by Agent and then is only effective for the specific instance and purpose for which it is given.  Agent’s rights and remedies under this Agreement and the other Financing Documents are cumulative.  Agent has all rights and remedies provided under the Code, by Law, or in equity.  Agent’s exercise of one right or remedy is not an election, and Agent’s waiver of any Event of Default is not a continuing waiver.  Agent’s delay in exercising any remedy is not a waiver, election, or acquiescence.  

10.6 Application of Payments and Proceeds .  Notwithstanding anything to the contrary contained in this Agreement, upon the occurrence and during the continuance of an Event of Default, (i) Borrower, for itself and the other Credit Parties, irrevocably waives the right to direct the application of any and all payments at any time or times thereafter received by Agent from or on behalf of Borrower of all or any part of the Obligations, and, as between Borrower and the Credit Parties on the one hand and Agent and Lenders on the other, Agent shall have the continuing and exclusive right to apply and to reapply any and all payments received against the Obligations in such manner as Agent may deem advisable notwithstanding any previous application by Agent, and (ii) unless the Agent and the Lenders shall agree otherwise, the proceeds of any sale of, or other realization upon all or any part of the Collateral shall be applied: first , to the Protective Advances; second , to accrued and unpaid interest on the Obligations (including any interest which, but for the provisions of the United States Bankruptcy Code, would have accrued on such amounts); third , to the principal amount of the Obligations outstanding; and fourth , to any other indebtedness or obligations of the Credit Parties owing to Agent or any Lender under the Financing Documents.  Borrower shall remain fully liable for any deficiency.  Any balance remaining shall be delivered to Borrower or to whoever may be lawfully entitled to receive such balance or as a court of competent jurisdiction may direct.  Unless the Agent and the Lenders shall agree otherwise, in carrying out the foregoing, (x) amounts received shall be applied in the numerical order provided until exhausted prior to the application to the next succeeding category, and (y) each of the Persons entitled to receive a payment in any particular category shall receive an amount equal to its pro rata share of amounts available to be applied pursuant thereto for such category.  

10.7 Waivers .

(a) Except as otherwise provided for in this Agreement and to the fullest extent permitted by applicable law, Borrower waives:  (i) presentment, demand and protest, and notice of presentment, dishonor, intent to accelerate, acceleration, protest, default, nonpayment, maturity, release, compromise, settlement, extension or renewal of any or all Financing Documents and hereby ratifies and confirms whatever Agent or Lenders may do in this regard; (ii) all rights to notice and a hearing prior to Agent's or any Lender's entry upon the premises of Borrower, the taking possession or control of, or to Agent's or any Lender's replevy, attachment or levy upon, any Collateral or any bond or security which might be required by any court prior to allowing Agent or any Lender to exercise any of its remedies; and (iii) the benefit of all valuation, appraisal and exemption Laws.  Borrower acknowledges that it has been advised by counsel of its choice and decision with respect to this Agreement, the other Financing Documents and the transactions evidenced hereby and thereby.

(b) Borrower for itself and all its successors and assigns, (i) agrees that its liability shall not be in any manner affected by any indulgence, extension of time, renewal, waiver, or modification granted or consented to by Lender; (ii) consents to any indulgences and all extensions of time, renewals, waivers, or modifications that may be granted by Agent or any Lender with respect to the payment or other provisions of the Financing Documents, and to any substitution, exchange or release of the Collateral, or any

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

22            

 

 


 

part thereof, with or without substitution, and agrees to the addition or release of Borrower, endorsers, guarantors, or sureties, or whether primarily or secondarily liable, without notice to any other Borrower and without affecting its liability hereunder; (iii) agrees that its liability shall be unconditional and without regard to the liability of any other Credit Party , Agent or any Lender for any tax on the indebtedness; and (iv) to the fullest extent permitted by law, expressly waives the benefit of any statute or rule of law or equity now provided, or which may hereafter be provided, which would produce a result contrary to or in conflict with the foregoing.

(c) To the extent that Agent or any Lender may have acquiesced in any noncompliance with any requirements or conditions precedent to the closing of the Credit Facilities or to any subsequent disbursement of Credit Extensions, such acquiescence shall not be deemed to constitute a waiver by Agent or any Lender of such requirements with respect to any future Credit Extensions and Agent may at any time after such acquiescence require Borrower to comply with all such requirements.  Any forbearance by Agent or a Lender in exercising any right or remedy under any of the Financing Documents, or otherwise afforded by applicable law, including any failure to accelerate the maturity date of the Credit Facilities, shall not be a waiver of or preclude the exercise of any right or remedy nor shall it serve as a novation of the Financing Documents or as a reinstatement of the Obligations or a waiver of such right of acceleration or the right to insist upon strict compliance of the terms of the Financing Documents.  Agent's or any Lender's acceptance of payment of any sum secured by any of the Financing Documents after the due date of such payment shall not be a waiver of Agent's and such Lender's right to either require prompt payment when due of all other sums so secured or to declare a default for failure to make prompt payment.  The procurement of insurance or the payment of taxes or other Liens or charges by Agent as the result of an Event of Default shall not be a waiver of Agent's right to accelerate the maturity of the Obligations, nor shall Agent's receipt of any condemnation awards, insurance proceeds, or damages under this Agreement operate to cure or waive any Credit Party's default in payment of sums secured by any of the Financing Documents.

(d) Without limiting the generality of anything contained in this Agreement or the other Financing Documents, Borrower agrees that if an Event of Default is continuing (i) Agent and Lenders shall not be subject to any "one action" or "election of remedies" law or rule, and (ii) all Liens and other rights, remedies or privileges provided to Agent or Lenders shall remain in full force and effect until Agent or Lenders have exhausted all remedies against the Collateral and any other properties owned by Borrower and the Financing Documents and other security instruments or agreements securing the Obligations have been foreclosed, sold and/or otherwise realized upon in satisfaction of Borrower's obligations under the Financing Documents.

(e) Neither Agent nor any Lender shall be under any obligation to marshal any assets in payment of any or all of the Obligations.  Nothing contained herein or in any other Financing Document shall be construed as requiring Agent or any Lender to resort to any part of the Collateral for the satisfaction of any of Borrower's obligations under the Financing Documents in preference or priority to any other Collateral, and Agent may seek satisfaction out of all of the Collateral or any part thereof, in its absolute discretion in respect of Borrower's obligations under the Financing Documents.  To the fullest extent permitted by law, Borrower, for itself and its successors and assigns, waives in the event of foreclosure of any or all of the Collateral any equitable right otherwise available to any Credit Party which would require the separate sale of any of the Collateral or require Agent or Lenders to exhaust their remedies against any part of the Collateral before proceeding against any other part of the Collateral; and further in the event of such foreclosure Borrower does hereby expressly consent to and authorize, at the option of Agent, the foreclosure and sale either separately or together of each part of the Collateral.

10.8 Injunctive Relief .  The parties acknowledge and agree that, in the event of a breach or threatened breach of any Credit Party’s obligations under any Financing Documents, Agent and Lenders may have no adequate remedy in money damages and, accordingly, shall be entitled to an injunction (including, without limitation, a temporary restraining order, preliminary injunction, writ of attachment, or order compelling an audit) against such breach or threatened breach, including, without limitation, maintaining any cash management and collection procedure described herein.  However, no specification in this Agreement of a specific legal or equitable remedy shall be construed as a waiver or prohibition against any other legal or equitable remedies in the event of a breach or threatened breach of any provision of this Agreement.  Each Credit Party waives, to the fullest extent permitted by law, the requirement of the posting of any bond in connection with such injunctive relief.  By joining in the Financing Documents as a Credit Party, each Credit Party specifically joins in this Section 10.8 as if this Section 10.8 were a part of each Financing Document executed by such Credit Party.

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

23            

 

 


 

10.9 Other Currency .  Without limiting Section 2.6(c) or any other provision of this Agreement, to the extent permitted by applicable Law, the obligations of any of the Credit Parties in respect of any amount due under this Agreement shall, notwithstanding any payment in any other currency (the “ Other Currency ”) (whether pursuant to a judgment or otherwise), be discharged only to the extent of the amount in the currency in which it is due (the “ Agreed Currency ”) that the Agent or Lenders may, in accordance with normal banking procedures, purchase with the sum paid in the Other Currency (after any premium and costs of exchange) on the Business Day immediately after the day on which the Agent or Lender receives the payment.  If the amount of the Agreed Currency that may be so purchased for any reason falls short of the amount originally due, such Credit Party shall pay all additions amounts, in the Agreed Currency, as may be necessary to compensate for the shortfall.  Any obligation of a Credit Party not discharged by that payment shall, to the extent permitted by applicable law, be due as a separate and independent obligation and, until discharged as provided in this Section 10.9, continue in full force and effect.

 

11

NOTICES

All notices, consents, requests, approvals, demands, or other communication (collectively, “ Communication ”) by any party to this Agreement or any other Financing Document must be in writing and shall be deemed to have been validly served, given, or delivered: (a) if to Borrower or any other U.S. Credit Party or U.S. Subsidiary of a Credit Party, upon the earlier of actual receipt and three (3) Business Days after deposit in the U.S. mail, first class, registered or certified mail return receipt requested, with proper postage prepaid; (b) if to any non-U.S. Credit Party or non-U.S. Subsidiary of a Credit Party, upon the earlier or actual receipt and seven (7) Business Days after deposit in the U.S. mail, first class, registered or certified mail return receipt requested, with proper postage prepaid; (c) upon transmission, when sent by electronic mail (if an email address is specified herein) or facsimile transmission; (d) if to Borrower or any U.S. Credit Party or U.S. Subsidiary of a Credit Party, one (1) Business Day after deposit with a reputable overnight courier with all charges prepaid and if to any non-U.S. Credit Party or non-U.S. Subsidiary of a Credit Party, three (3) Business Days after deposit with a reputable overnight courier with all charges prepaid; or (e) when delivered, if hand-delivered by messenger, all of which shall be addressed to the party to be notified and sent to the address, facsimile number, or email address indicated below.  Any of Agent, Lender or Borrower may change its mailing or electronic mail address or facsimile number by giving the other party written notice thereof in accordance with the terms of this Article 11.

If to Borrower:

 

Quotient Biodiagnostics, Inc.

Pentlands Science Park, Bush Loan

Penicuik, Midlothian, EH26 0PL, United Kingdom

Attention: Roland Boyd

Fax: +44 131 445 6184

E-Mail: roland.boyd@quotientbd.com

If to Quotient Limited:

 

Quotient Limited

Pentlands Science Park, Bush Loan

Penicuik, Midlothian, EH26 0PL, United Kingdom

Attention: Roland Boyd

Fax: +44 131 445 6184

E-Mail: roland.boyd@quotientbd.com

If to Alba Bioscience Limited:

 

Alba Bioscience Limited

Pentlands Science Park, Bush Loan

Penicuik, Midlothian, EH26 0PL, United Kingdom

Attention: Roland Boyd

Fax: +44 131 445 6184

E-Mail: roland.boyd@quotientbd.com

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

24            

 

 


 

If to QBD (QSIP) Limited:

 

QBD (QSIP) Limited

Pentlands Science Park, Bush Loan

Penicuik, Midlothian, EH26 0PL, United Kingdom

Attention: Roland Boyd

Fax: +44 131 445 6184

E-Mail: roland.boyd@quotientbd.com

 

If to Agent or to MidCap (or any of its Affiliates or Approved Funds) as a Lender:

 

MidCap Financial Trust

c/o MidCap Financial Services, LLC, as servicer

7255 Woodmont Ave, Suite 200

Bethesda, MD 20814

Attn: Account Manager for Quotient transaction

Facsimile:  301-941-1450

Email:  notices@midcapfinancial.com

With a copy to:

MidCap Financial Trust

c/o MidCap Financial Services, LLC, as servicer

7255 Woodmont Ave, Suite 200

Bethesda, MD 20814

Attn: Legal

Facsimile:  301-941-1450

Email:  legalnotices@midcapfinancial.com

If to any Lender other than MidCap : at the address set forth in the signature pages to this Agreement or provided as a notice address for such in connection with any assignment hereunder.

 

12

CHOICE OF LAW, VENUE AND JURY TRIAL WAIVER

12.1 THIS AGREEMENT, EACH SECURED PROMISSORY NOTE AND EACH OTHER FINANCING DOCUMENT (EXCLUDING THOSE FINANCING DOCUMENTS THAT BY THEIR OWN TERMS ARE EXPRESSLY GOVERNED BY THE LAWS OF ANOTHER JURISDICTION), AND THE RIGHTS, REMEDIES AND OBLIGATIONS OF THE PARTIES HERETO AND THERETO, AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS AGREEMENT OR SUCH FINANCING DOCUMENT (EXCLUDING THOSE FINANCING DOCUMENTS THAT BY THEIR OWN TERMS ARE EXPRESSLY GOVERNED BY THE LAWS OF ANOTHER JURISDICTION), THE RELATIONSHIP OF THE PARTIES, AND/OR THE INTERPRETATION AND ENFORCEMENT OF THE RIGHTS AND DUTIES OF THE PARTIES AND ALL OTHER MATTERS RELATING HERETO, THERETO OR ARISING THEREFROM (WHETHER SOUNDING IN CONTRACT LAW, TORT LAW OR OTHERWISE), SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF MARYLAND, WITHOUT REFERENCE TO ITS CONFLICT OF LAW PROVISIONS.  NOTWITHSTANDING THE FOREGOING, AGENT AND LENDERS SHALL HAVE THE RIGHT TO BRING ANY ACTION OR PROCEEDING AGAINST EACH CREDIT PARTY OR ITS PROPERTY IN THE COURTS OF ANY OTHER JURISDICTION WHICH AGENT AND LENDERS (IN ACCORDANCE WITH THE PROVISIONS OF SECTION 12.1) DEEM NECESSARY OR APPROPRIATE TO REALIZE ON THE COLLATERAL OR TO OTHERWISE ENFORCE AGENT’S AND LENDERS’ RIGHTS AGAINST SUCH CREDIT PARTY OR ITS PROPERTY. EACH CREDIT PARTY EXPRESSLY SUBMITS AND CONSENTS IN ADVANCE TO SUCH JURISDICTION IN ANY ACTION OR SUIT COMMENCED IN ANY SUCH COURT, AND EACH CREDIT PARTY HEREBY WAIVES ANY OBJECTION THAT IT MAY HAVE BASED UPON LACK OF PERSONAL JURISDICTION, IMPROPER VENUE, OR FORUM NON CONVENIENS AND HEREBY CONSENTS TO THE GRANTING OF SUCH LEGAL OR EQUITABLE RELIEF AS IS DEEMED APPROPRIATE BY SUCH COURT.  EACH CREDIT PARTY HEREBY WAIVES PERSONAL SERVICE OF THE SUMMONS, COMPLAINTS, AND OTHER PROCESS ISSUED IN SUCH ACTION OR SUIT AND AGREES THAT SERVICE OF SUCH SUMMONS, COMPLAINTS, AND OTHER PROCESS MAY BE MADE BY REGISTERED OR CERTIFIED MAIL ADDRESSED TO THE APPLICABLE CREDIT PARTY AT THE ADDRESS SET FORTH IN ARTICLE 11 OF THIS AGREEMENT AND THAT SERVICE SO MADE SHALL BE DEEMED

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

25            

 

 


 

COMPLETED UPON THE EARLIER TO OCCUR OF SUCH CREDIT PARTY’S ACTUAL RECEIPT THEREOF OR THREE (3) DAYS AFTER DEPOSIT IN THE U.S. MAIL, PROPER POSTAGE PREPAID.

12.2 TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, EACH CREDIT PARTY, AGENT AND LENDERS EACH WAIVE THEIR RIGHT TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION ARISING OUT OF OR BASED UPON THIS AGREEMENT, THE FINANCING DOCUMENTS OR ANY CONTEMPLATED TRANSACTION, INCLUDING CONTRACT, TORT, BREACH OF DUTY AND ALL OTHER CLAIMS. THIS WAIVER IS A MATERIAL INDUCEMENT FOR BOTH PARTIES TO ENTER INTO THIS AGREEMENT.  EACH PARTY HAS REVIEWED THIS WAIVER WITH ITS COUNSEL.

12.3 Each Credit Party, Agent and each Lender agree that each Credit Extension (including those made on the Closing Date) shall be deemed to be made in, and the transactions contemplated hereunder and in any other Financing Document shall be deemed to have been performed in, the State of Maryland.

 

13

GENERAL PROVISIONS

13.1 Successors and Assigns .

(a) This Agreement binds and is for the benefit of the successors and permitted assigns of each party.  No Credit Party may assign this Agreement or any rights or obligations under it without Agent’s prior written consent (which may be granted or withheld in Agent’s discretion).  Any Lender may at any time assign to one or more Eligible Assignees all or any portion of such Lender’s Applicable Commitment and/or Credit Extensions, together with all related obligations of such Lender hereunder.  Borrower and Agent shall be entitled to continue to deal solely and directly with such Lender in connection with the interests so assigned until Agent shall have received and accepted an effective assignment agreement in substantially the form set forth in Exhibit I hereto or such other form as Agent may deem acceptable, executed, delivered and fully completed by the applicable parties thereto, and shall have received such other information regarding such Eligible Assignee as Agent reasonably shall require.  Notwithstanding anything set forth in this Agreement to the contrary, any Lender may at any time pledge or assign a security interest in all or any portion of its rights under this Agreement to secure obligations of such Lender, including any pledge or assignment to secure obligations to a Federal Reserve Bank; provided, however, that no such pledge or assignment shall release such Lender from any of its obligations hereunder or substitute any such pledgee or assignee for such Lender as a party hereto. If requested by Agent, each Credit Party agrees to (i) execute any documents reasonably required to effectuate and acknowledge each assignment of an Applicable Commitment or Credit Extension to an assignee hereunder, (ii) make such Credit Party’s management available to meet with Agent and prospective participants and assignees of Applicable Commitments or Credit Extensions and (iii) assist Agent or the Lenders in the preparation of information relating to the financial affairs of such Credit party as any prospective participant or assignee of an Applicable Commitment or Credit Extension reasonably may request.

(b) From and after the date on which the conditions described above have been met, (i) such Eligible Assignee shall be deemed automatically to have become a party hereto and, to the extent of the interests assigned to such Eligible Assignee pursuant to such assignment agreement, shall have the rights and obligations of a Lender hereunder, and (ii) the assigning Lender, to the extent that rights and obligations hereunder have been assigned by it pursuant to such assignment agreement, shall be released from its rights and obligations hereunder (other than those that survive termination).  Upon the request of the Eligible Assignee (and, as applicable, the assigning Lender) pursuant to an effective assignment agreement, each Borrower shall execute and deliver to Agent for delivery to the Eligible Assignee (and, as applicable, the assigning Lender) secured notes in the aggregate principal amount of the Eligible Assignee's Credit Extensions or Applicable Commitments (and, as applicable, secured promissory notes in the principal amount of that portion of the principal amount of the Credit Extensions or Applicable Commitments retained by the assigning Lender).  

(c) Agent, acting solely for this purpose as an agent of Borrower, shall maintain at its offices located in Bethesda, Maryland a copy of each assignment agreement delivered to it and a register for the recordation of the names and addresses of each Lender, and the commitments of, and principal amount of the Credit Extensions owing to, such Lender pursuant to the terms hereof.  The entries in such register shall be conclusive, and Borrower, Agent and Lenders may treat each Person whose name is recorded therein pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement, notwithstanding notice to the contrary.  Such register shall be available for inspection by Borrower and any Lender, at any reasonable time upon reasonable prior notice to Agent.

13.2 Indemnification .

(a) Borrower hereby agrees to promptly pay (i) all costs and expenses of Agent (including, without limitation, the fees, costs and expenses of counsel to, and independent appraisers and consultants retained by Agent) in connection with the

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

26            

 

 


 

examination, review, due diligence investigation, documentation, negotiation, closing and syndication of the transactions contemplated by the Financing Documents, in connection with the performance by Agent of its rights and remedies under the Financing Documents and in connection with the continued administration of the Financing Documents including (A) any amendments, modifications, consents and waivers to and/or under any and all Financing Documents, and (B) any periodic public record searches conducted by or at the request of Agent (including, without limitation, title investigations, UCC searches, fixture filing searches, judgment, pending litigation and tax lien searches and searches of applicable corporate, limited liability, partnership and related records concerning the continued existence, organization and good standing of certain Persons); (ii) without limitation of the preceding clause (i), all costs and expenses of Agent in connection with the creation, perfection and maintenance of Liens pursuant to the Financing Documents; (iii) without limitation of the preceding clause (i), all costs and expenses of Agent in connection with (A) protecting, storing, insuring, handling, maintaining or selling any Collateral, (B) any litigation, dispute, suit or proceeding relating to any Financing Document, and (C) any workout, collection, bankruptcy, insolvency and other enforcement proceedings under any and all of the Financing Documents; (iv) without limitation of the preceding clause (i), all costs and expenses of Agent in connection with Agent's reservation of funds in anticipation of the funding of the Credit Extensions to be made hereunder; and (v) all costs and expenses incurred by Agent or Lenders (including penalties and interest ) for which the Credit Parties are responsible under the Financing Documents (including, without limitation, section 2.6(h)) and in connection with any litigation, dispute, suit or proceeding relating to any Financing Document and in connection with any workout, collection, bankruptcy, insolvency and other enforcement proceedings under any and all Financing Documents, whether or not Agent or Lenders are a party thereto.  If Agent or any Lender uses in-house counsel for any of these purposes, Borrower further agrees that the Obligations include reasonable charges for such work commensurate with the fees that would otherwise be charged by outside legal counsel selected by Agent or such Lender for the work performed.

(b) Borrower hereby agrees to indemnify, pay and hold harmless Agent and Lenders and the officers, directors, employees, trustees, agents, investment advisors, collateral managers, servicers, and counsel of Agent and Lenders (collectively called the “ Indemnitees ”) from and against any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, claims, costs, expenses and disbursements of any kind or nature whatsoever (including the fees and disbursements of counsel for such Indemnitee) in connection with any investigative, response, remedial, administrative or judicial matter or proceeding, whether or not such Indemnitee shall be designated a party thereto and including any such proceeding initiated by or on behalf of a Credit Party, and the reasonable expenses of investigation by engineers, environmental consultants and similar technical personnel and any commission, fee or compensation claimed by any broker (other than any broker retained by Agent or Lenders) asserting any right to payment for the transactions contemplated hereby, which may be imposed on, incurred by or asserted against such Indemnitee as a result of or in connection with the transactions contemplated hereby and the use or intended use of the proceeds of the Credit Facilities, except that Borrower shall have no obligation hereunder to an Indemnitee with respect to any liability resulting from the gross negligence or willful misconduct of such Indemnitee, as determined by a final non-appealable judgment of a court of competent jurisdiction.  To the extent that the undertaking set forth in the immediately preceding sentence may be unenforceable, Borrower shall contribute the maximum portion which it is permitted to pay and satisfy under applicable Law to the payment and satisfaction of all such indemnified liabilities incurred by the Indemnitees or any of them. No Indemnitee shall be liable for any damages arising from the use by unintended recipients of any information or other materials distributed by it through telecommunications, electronic or other information transmission systems in connection with this Agreement or the other Financing Documents or the transactions contemplated hereby or thereby.

(c) Notwithstanding any contrary provision in this Agreement, the obligations of Borrower under this Section 13.2 shall survive the payment in full of the Obligations and the termination of this Agreement. NO INDEMNITEE SHALL BE RESPONSIBLE OR LIABLE TO ANY CREDIT PARTY OR TO ANY OTHER PARTY TO ANY FINANCING DOCUMENT, ANY SUCCESSOR, ASSIGNEE OR THIRD PARTY BENEFICIARY OR ANY OTHER PERSON ASSERTING CLAIMS DERIVATIVELY THROUGH SUCH PARTY, FOR INDIRECT, PUNITIVE, EXEMPLARY OR CONSEQUENTIAL DAMAGES WHICH MAY BE ALLEGED AS A RESULT OF CREDIT HAVING BEEN EXTENDED, SUSPENDED OR TERMINATED UNDER THIS AGREEMENT OR ANY OTHER FINANCING DOCUMENT OR AS A RESULT OF ANY OTHER TRANSACTION CONTEMPLATED HEREUNDER OR THEREUNDER.

13.3 Time of Essence .  Time is of the essence for the payment and performance of the Obligations in this Agreement.

13.4 Severability of Provisions .  Each provision of this Agreement is severable from every other provision in determining the enforceability of any provision.

13.5 Correction of Financing Documents .  Agent and the Lenders may correct patent errors and fill in any blanks in this Agreement and the other Financing Documents consistent with the agreement of the parties.

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

27            

 

 


 

13.6 Integration .  This Agreement and the Financing Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements.  All prior agreements, understandings, representations, warranties, and negotiations between the parties about the subject matter of this Agreement and the Financing Documents merge into this Agreement and the Financing Documents.

13.7 Counterparts .  This Agreement may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, is an original, and all taken together, constitute one Agreement. Delivery of an executed signature page of this Agreement by facsimile transmission or electronic transmission shall be as effective as delivery of a manually executed counterpart hereof.  

13.8 Survival .  All covenants, representations and warranties made in this Agreement continue in full force until this Agreement has terminated pursuant to its terms and all Obligations (other than inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of this Agreement) have been satisfied.  The obligation of Borrower in Section 13.2 to indemnify each Lender and Agent shall survive until the statute of limitations with respect to such claim or cause of action shall have run.  All powers of attorney and appointments of Agent or any Lender as Borrower’s attorney in fact hereunder, and all of Agent’s and Lenders’ rights and powers in respect thereof, are coupled with an interest, are irrevocable until all Obligations (other than inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of this Agreement) have been fully repaid and performed and Agent’s and the Lenders’ obligation to provide Credit Extensions terminates.

13.9 Confidentiality .  In handling any confidential information of Borrower, each of the Lenders and Agent shall use all reasonable efforts to maintain, in accordance with its customary practices, the confidentiality of information obtained by it pursuant to any Financing Document, but disclosure of information may be made: (a) to the Lenders’ and Agent’s Subsidiaries or Affiliates for purposes reasonably related to this Agreement; (b) to prospective transferees or purchasers of any interest in the Credit Extensions that are advised of the confidential nature of such information and are instructed to keep such information confidential; (c) as required by Law, regulation, subpoena, order or other legal, administrative, governmental or regulatory request; (d) to regulators or as otherwise required in connection with an examination or audit, or to any nationally recognized rating agency; (e) as Agent or any Lender considers appropriate in exercising remedies under the Financing Documents; (f) to financing sources that are advised of the confidential nature of such information and are instructed to keep such information confidential; (g) to third party service providers of the Lenders and/or Agent so long as such service providers are bound to such Lender or Agent by obligations of confidentiality; and (h) in connection with any litigation or other proceeding to which such Lender or Agent or any of their Affiliates is a party or bound.  Confidential information does not include information that either: (i) is in the public domain or in the Lenders’ and/or Agent’s possession when disclosed to the Lenders and/or Agent, or becomes part of the public domain after disclosure to the Lenders and/or Agent; or (ii) is disclosed to the Lenders and/or Agent by a third party, if the Lenders and/or Agent does not know that the third party is prohibited from disclosing the information.  The agreements provided under this Section 13.9 supersede all prior agreements, understanding, representations, warranties, and negotiations between the parties about the subject matter of this Section 13.9.

13.10 Right of Set-off .  Borrower hereby grants to Agent and to each Lender, a lien, security interest and right of set-off as security for all Obligations to Agent and each Lender hereunder, whether now existing or hereafter arising upon and against all deposits, credits, collateral and property, now or hereafter in the possession, custody, safekeeping or control of Agent or the Lenders or any entity under the control of Agent or the Lenders (including an Agent or Lender Affiliate) or in transit to any of them.  At any time after the occurrence and during the continuance of an Event of Default, without demand or notice, Agent or the Lenders may set-off the same or any part thereof and apply the same to any liability or obligation of Borrower even though unmatured and regardless of the adequacy of any other collateral securing the Obligations.  ANY AND ALL RIGHTS TO REQUIRE AGENT TO EXERCISE ITS RIGHTS OR REMEDIES WITH RESPECT TO ANY OTHER COLLATERAL WHICH SECURES THE OBLIGATIONS, PRIOR TO EXERCISING ITS RIGHT OF SET-OFF WITH RESPECT TO SUCH DEPOSITS, CREDITS OR OTHER PROPERTY OF BORROWER, ARE HEREBY KNOWINGLY, VOLUNTARILY AND IRREVOCABLY WAIVED.  

13.11 Publicity .  No Credit Party will directly or indirectly publish, disclose or otherwise use in any public disclosure, advertising material, promotional material, press release or interview, any reference to the name, logo or any trademark of Agent or any Lender or any of their Affiliates or any reference to this Agreement or the financing evidenced hereby, in any case except as required by applicable Law, subpoena or judicial or similar order, in which case Credit Parties shall endeavor to give Agent prior written notice of such publication or other disclosure.  Each Lender and each Credit Party hereby authorizes each Lender to publish the name of such Lender and such Credit Party, the existence of the financing arrangements referenced under this Agreement, the primary purpose and/or structure of those arrangements, the amount of credit extended under each facility, the title and role of each party to this Agreement, and the total amount of the financing evidenced hereby in any “tombstone”, comparable advertisement or press release which such Lender elects to submit for publication.  In addition, each Lender and each Credit Party agrees that each Lender may provide lending industry trade organizations with information necessary and customary for inclusion in league table measurements after the Closing Date.  With respect to any of the foregoing, such authorization shall be subject to such Lender

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

28            

 

 


 

providing Borrower and the other Lenders with an opportunity to review and confer with such Lender regarding, and approve, the contents of any such tombstone, advertisement or information, as applicable, prior to its initial submission for publication, but subsequent publications of the same tombstone, advertisement or information shall not require any Credit Party’s approval .

13.12 No Strict Construction . The parties hereto have participated jointly in the negotiation and drafting of this Agreement.  In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement.

13.13 Approvals .  Unless expressly provided herein to the contrary, any approval, consent, waiver or satisfaction of Agent or Lenders with respect to any matter that is the subject of this Agreement or the other Financing Documents may be granted or withheld by Agent and Lenders in their sole and absolute discretion and credit judgment.

13.14 Amendments; Required Lenders; Inter-Lender Matters .

(a) No amendment, modification, termination or waiver of any provision of this Agreement or any other Financing Document, no approval or consent thereunder, or any consent to any departure by any Credit Party therefrom (in each case, other than amendments, waivers, approvals or consents deemed ministerial by Agent), shall in any event be effective unless the same shall be in writing and signed by Borrower, the other Credit Parties if directly affected thereby, Agent and Required Lenders.  Except as set forth in clause (b) below, all such amendments, modifications, terminations or waivers requiring the consent of the “Lenders” shall require the written consent of Required Lenders.

(b) No amendment, modification, termination or waiver of any provision of this Agreement or any other Financing Document shall, unless in writing and signed by Agent and by each Lender directly affected thereby: (i) increase or decrease the Applicable Commitment of any Lender (which shall be deemed to affect all Lenders), (ii) reduce the principal of or rate of interest on any Obligation or the amount of any fees payable hereunder, (iii) postpone the date fixed for or waive any payment of principal of or interest on any Credit Extension, or any fees or reimbursement obligation hereunder, (iv) release all or substantially all of the Collateral, or consent to a transfer of any of the Intellectual Property, in each case, except as otherwise expressly permitted in the Financing Documents (which shall be deemed to affect all Lenders), (v) subordinate the lien granted in favor of Agent securing the Obligations (which shall be deemed to affect all Lenders, except as otherwise provided below), (vi) except as otherwise permitted under this Agreement release a Credit Party from, or consent to a Credit Party’s assignment or delegation of, such Credit Party’s obligations hereunder and under the other Financing Documents or any Guarantor from its guarantee of the Obligations (which shall be deemed to affect all Lenders); or (vii) amend, modify, terminate or waive this Section 13.14(b) or the definition of “Required Lenders” or “Pro Rata Share” or any other provision hereof specifying the number or percentage of Lenders required to amend, waive or otherwise modify any rights hereunder or make any determination or grant any consent hereunder, without the consent of each Lender.  For purposes of the foregoing, no Lender shall be deemed affected by (i) waiver of the imposition of the Default Rate or imposition of the Default Rate to only a portion of the Obligations, (ii) waiver of the accrual of late charges, (iii) waiver of any fee solely payable to Agent under the Financing Documents, (iv) subordination of a lien granted in favor of Agent provided such subordination is limited to equipment being financed by a third party providing Permitted Indebtedness. Notwithstanding any provision in this Section 13.14 to the contrary, no amendment, modification, termination or waiver affecting or modifying the rights or obligations of Agent hereunder shall be effective unless signed by Agent and Required Lenders.

(c) Agent shall not grant its written consent to any deviation or departure by Borrower or any Credit Party from the provisions of Article 7 without the prior written consent of the Required Lenders.  Required Lenders shall have the right to direct Agent to take any action described in Section 10.2(b). Upon the occurrence of any Event of Default, Agent shall have the right to exercise any and all remedies referenced in Section 10.2 without the written consent of Required Lenders following the occurrence of an “Exigent Circumstance” (as defined below).  All matters requiring the satisfaction or acceptance of Agent in the definition of Subordinated Debt shall further require the satisfaction and acceptance of each Required Lender.  Any reference in this Agreement to an allocation between or sharing by the Lenders of any right, interest or obligation “ratably,” “proportionally” or in similar terms shall refer to Pro Rata Share unless expressly provided otherwise.  As used in this Section, “ Exigent Circumstance ” means any event or circumstance that, in the reasonable judgment of Agent, imminently threatens the ability of Agent to realize upon all or any material portion of the Collateral, such as, without limitation, fraudulent removal, concealment, or abscondment thereof, destruction or material waste thereof, or failure of Borrower after reasonable demand to maintain or reinstate adequate casualty insurance coverage, or which, in the judgment of Agent, could result in a material diminution in value of the Collateral.  

13.15 Borrower Liability .  If there is more than one entity comprising Borrower, then (a) any Borrower may, acting singly, request Credit Extensions hereunder, (b) each Borrower hereby appoints the other as agent for the other for all purposes hereunder, including with respect to requesting Credit Extensions hereunder, (c) each Borrower shall be jointly and severally obligated to pay and

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

29            

 

 


 

perform all obligations under the Financing Documents, including, but not limited to, the obligation to repay all Credit Extensions made hereunder and all other Obligations, regardless of which Borrower actually receives said Credit Extensions, as if each Borrower directly received all Credit Extensions, and (d) each Borrower waives (1) any suretyship defenses available to it under the Code or any other applicable law, and (2) any right to require the Lenders or Agent to: (A) proceed against any Borrower or any other person; (B) proceed against or exhaust any security; or (C) pursue any other remedy.  The Lenders or Agent may exercise or not exercise any right or remedy they have against any Credit Party or any security (including the right to foreclose by judicial or non-judicial sale) without affecting any other Credit Party’s liability or any Lien against any other Credit Party’s assets.  Notwithstanding any other provision of this Agreement or other related document, until payment in full of the Obligations and termination of the Applicable Commitments, each Borrower irrevocably waives all rights that it may have at law or in equity (including, without limitation, any law subrogating Borrower to the rights of the Lenders and Agent under this Agreement) to seek contribution, indemnification or any other form of reimbursement from any other Credit Party, or any other Person now or hereafter primarily or secondarily liable for any of the Obligations, for any payment made by any Credit Party with respect to the Obligations in connection with this Agreement or otherwise and all rights that it might have to benefit from, or to participate in, any security for the Obligations as a result of any payment made by a Credit Party with respect to the Obligations in connection with this Agreement or otherwise.  Any agreement providing for indemnification, reimbursement or any other arrangement prohibited under this Section shall be null and void.  If any payment is made to a Credit Party in contravention of this Section, such Credit Party shall hold such payment in trust for the Lenders and Agent and such payment shall be promptly delivered to Agent for application to the Obligations, whether matured or unmatured.

13.16 Reinstatement .  This Agreement shall remain in full force and effect and continue to be effective should any petition or other proceeding be filed by or against any Credit Party for liquidation or reorganization, should any Credit Party become insolvent or make an assignment for the benefit of any creditor or creditors or should an interim receiver, receiver, receiver and manager or trustee be appointed for all or any significant part of any Credit Party’s assets, and shall continue to be effective or to be reinstated, as the case may be, if at any time payment and performance of the Obligations, or any part thereof, is, pursuant to applicable law, rescinded or reduced in amount, or must otherwise be restored or returned by any obligee of the Obligations, whether as a fraudulent preference reviewable transaction or otherwise, all as though such payment or performance had not been made.  In the event that any payment, or any part thereof, is rescinded, reduced, restored or returned, the Obligations shall be reinstated and deemed reduced only by such amount paid and not so rescinded, reduced, restored or returned.

13.17 USA PATRIOT Act Notification

.  Agent (for itself and not on behalf of any Lender) and each Lender hereby notifies each Credit Party that pursuant to the requirements of the USA PATRIOT Act, it is required to obtain, verify and record certain information and documentation that identifies such Credit party, which information includes the name and address of such Credit party and such other information that will allow Agent or such Lender, as applicable, to identify such Credit Party in accordance with the USA PATRIOT Act .

13.18 Warrants .  Notwithstanding anything to the contrary herein, any warrants issued to the Lenders by any Credit Party, the stock issuable thereunder, any equity securities purchased by Lenders, any amounts paid thereunder, any dividends, and any other rights in connection therewith shall not be subject to the terms and conditions of this Agreement.  Nothing herein shall affect any Lender’s rights under any such warrants, stock, or other equity securities to administer, manage, transfer, assign, or exercise such warrants, stock, or other equity securities for its own account.

13.19 Existing Agreements Superseded; Exhibits and Schedules.

(a) The Original Credit Agreement, including the schedules thereto, is superseded by this Agreement, including the schedules hereto, which has been executed in amendment, restatement and modification of, but not in novation or extinguishment of, the obligations under the Original Credit Agreement.  It is the express intention of the parties hereto to reaffirm the indebtedness created under the Original Credit Agreement which is evidenced by the notes provided for therein and secured by the Collateral.  Any and all outstanding amounts under the Original Credit Agreement including, but not limited to principal, accrued interest, fees (except as otherwise provided in the Fee Letter) and other charges, as of the Closing Date shall be carried over and deemed outstanding under this Agreement.  

(b) Each Credit Party reaffirms its obligations under each Financing Document to which it is a party, including but not limited to the Security Documents and the schedules thereto.  

(c) Each Credit Party acknowledges and confirms that (i) the Liens and security interests granted pursuant to the Financing Documents secure the indebtedness, liabilities and obligations of the Credit Parties to Agent and the Lenders under the Original Credit Agreement, as amended and restated hereby, and that the term “Obligations” as used in the Financing Documents (or any other term used therein to describe or refer to the indebtedness, liabilities and obligations of the Borrowers and the other Credit

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

30            

 

 


 

Parties to Agent and the Lenders) includes, without limitation, the indebtedness, liabilities and obligations of the Borrowers under this Agreement and the Secured Promissory Notes to be delivered hereunder, if any, and under the Original Credit Agreement, as amended and restated hereby, as the same further may be amended, restated, supplemented and/or modified from time to time, and (ii) the grants of Liens under and pursuant to the Financing Documents shall continue unaltered, and each other Financing Document shall continue in full force and effect in accordance with its terms unless otherwise amended by the parties thereto, and the parties hereto hereby ratify and confirm the terms thereof as being in full force and effect and unaltered by this Agreement and all references in the any of the Financing Documents to the “Credit Agreement” shall be deemed to refer to this Amended and Restated Credit Agreement .

 

14

AGENT

14.1 Appointment and Authorization of Agent .

(a) Each Lender hereby irrevocably appoints, designates and authorizes Agent to take such action on its behalf under the provisions of this Agreement and each other Financing Document and to exercise such powers and perform such duties as are expressly delegated to it by the terms of this Agreement or any other Financing Document, together with such powers as are reasonably incidental thereto. The provisions of this Article are solely for the benefit of Agent and Lenders and none of Credit Parties nor any other Person shall have any rights as a third party beneficiary of any of the provisions hereof.  The duties of Agent shall be mechanical and administrative in nature.  Notwithstanding any provision to the contrary contained elsewhere herein or in any other Financing Document, Agent shall not have any duties or responsibilities, except those expressly set forth herein, nor shall Agent have or be deemed to have any fiduciary relationship with any Lender or participant, and no implied covenants, functions, responsibilities, duties, obligations or liabilities shall be read into this Agreement or any other Financing Document or otherwise exist against Agent. Without limiting the generality of the foregoing sentence, the use of the term “agent” herein and in the other Financing Documents with reference to Agent is not intended to connote any fiduciary or other implied (or express) obligations arising under agency doctrine of any applicable Law. Instead, such term is used merely as a matter of market custom, and is intended to create or reflect only an administrative relationship between independent contracting parties.  Without limiting the generality of the foregoing, Agent shall have the sole and exclusive right and authority (to the exclusion of the Lenders), and is hereby authorized, to (a) act as collateral agent for Agent and each Lender for purposes of the perfection of all liens created by the Financing Documents and all other purposes stated therein, (b) manage, supervise and otherwise deal with the Collateral, (c) take such other action as is necessary or desirable to maintain the perfection and priority of the liens created or purported to be created by the Financing Documents, (d) except as may be otherwise specified in any Financing Document, exercise all remedies given to Agent and the other Lenders with respect to the Collateral, whether under the Financing Documents, applicable law or otherwise and (e) execute any amendment, consent or waiver under the Financing Documents on behalf of any Lender that has consented in writing to such amendment, consent or waiver; provided, however, that Agent hereby appoints, authorizes and directs each Lender to act as collateral sub-agent for Agent and the Lenders for purposes of the perfection of all liens with respect to the Collateral, including any deposit account maintained by a Credit Party with, and cash and cash equivalents held by, such Lender, and may further authorize and direct the Lenders to take further actions as collateral sub-agents for purposes of enforcing such liens or otherwise to transfer the Collateral subject thereto to Agent, and each Lender hereby agrees to take such further actions to the extent, and only to the extent, so authorized and directed.  

(b) In relation to the Swiss Security Documents the following additional provisions shall apply:

(i) The Agent holds:

(1) any security created or expressed to be created under or pursuant to the Swiss Security Documents by way of a security assignment ( Sicherungsabtretung ) or transfer for security purposes ( Sicherungsübereignung ) or any other non-accessory ( nicht akzessorische ) security;

(2) the benefit of this Section 14.1; and

(3) any proceeds and other benefits of such security as fiduciary ( treuhänderisch ) in its own name but for the account of all relevant Lenders which have the benefit of such security in accordance with this Agreement and the respective Swiss Security Documents;

(ii) Each Lender hereby authorizes the Agent:

(1) to (1) accept and execute as its direct representative ( direkter Stellvertreter ) any Swiss law pledge or any other Swiss law accessory ( akzessorische ) security created or expressed to be created under or pursuant to the Swiss Security Documents for the benefit of such Lender and (2) hold, administer and, if necessary, enforce any such security on behalf of each relevant Lender which has the benefit of such security;

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

31            

 

 


 

(2) to agree as its direct representative ( direkter Stellvertreter ) to amendments and alterations to any Swiss Security Documents which creates a pledge or any other Swiss law accessory ( akzessorische ) security;

(3) to effect as its direct representative ( direkter Stellvertreter ) any release of a security created under the Swiss Security Documents in accordance with this Agreement below; and

(4) to exercise as its direct representative ( direkter Stellvertreter ) such other rights granted to the Agent hereunder or under the relevant Swiss Security Documents; and

(iii) Each Credit Party hereby authorizes the Agent, when acting in its capacity as creditor of the Parallel Debt Claims as set forth in Section 14.13, to hold:

(1) any Swiss law pledge or any other Swiss law accessory ( akzessorische ) security;

(2) any proceeds of such security; and

(3) the benefit of this Section 14.1 and of the Parallel Debt claims, as creditor in its own right but for the benefit of the Lenders in accordance with this Agreement.

14.2 Successor Agent .

(a) Agent may at any time assign its rights, powers, privileges and duties hereunder to (i) another Lender or an Affiliate of Agent or any Lender or any Approved Fund, or (ii) any Person to whom Agent, in its capacity as a Lender, has assigned (or will assign, in conjunction with such assignment of agency rights hereunder) fifty percent (50%) or more of the Credit Extensions or Applicable Commitments then held by Agent (in its capacity as a Lender), in each case without the consent of the Lenders or Borrower.  Following any such assignment, Agent shall give notice to the Lenders and Borrower.  An assignment by Agent pursuant to this subsection (a) shall not be deemed a resignation by Agent for purposes of subsection (b) below.

(b) Without limiting the rights of Agent to designate an assignee pursuant to subsection (a) above, Agent may at any time give notice of its resignation to the Lenders and Borrower.  Upon receipt of any such notice of resignation, Required Lenders shall have the right to appoint a successor Agent.  If no such successor shall have been so appointed by Required Lenders and shall have accepted such appointment within ten (10) Business Days after the retiring Agent gives notice of its resignation, then the retiring Agent may, on behalf of the Lenders, appoint a successor Agent; provided, however, that if Agent shall notify Borrower and the Lenders that no Person has accepted such appointment, then such resignation shall nonetheless become effective in accordance with such notice from Agent that no Person has accepted such appointment and, from and following delivery of such notice, (i) the retiring Agent shall be discharged from its duties and obligations hereunder and under the other Financing Documents, and (ii) all payments, communications and determinations provided to be made by, to or through Agent shall instead be made by or to each Lender directly, until such time as Required Lenders appoint a successor Agent as provided for above in this subsection (b).  

(c) Upon (i) an assignment permitted by subsection (a) above, or (ii) the acceptance of a successor’s appointment as Agent pursuant to subsection (b) above, such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring (or retired) Agent, and the retiring Agent shall be discharged from all of its duties and obligations hereunder and under the other Financing Documents (if not already discharged therefrom as provided above in this subsection (c)).  The fees payable by Borrower to a successor Agent shall be the same as those payable to its predecessor unless otherwise agreed between Borrower and such successor.  After the retiring Agent’s resignation hereunder and under the other Financing Documents, the provisions of this Article shall continue in effect for the benefit of such retiring Agent and its sub-agents in respect of any actions taken or omitted to be taken by any of them while the retiring Agent was acting or was continuing to act as Agent.

14.3 Delegation of Duties . Agent may execute any of its duties under this Agreement or any other Financing Document by or through its, or its Affiliates’, agents, employees or attorneys-in-fact and shall be entitled to obtain and rely upon the advice of counsel and other consultants or experts concerning all matters pertaining to such duties. Agent shall not be responsible for the negligence or misconduct of any agent or attorney-in-fact that it selects in the absence of gross negligence or willful misconduct.  Any such Person to whom Agent delegates a duty shall benefit from this Article 14 to the extent provided by Agent.

14.4 Liability of Agent . Except as otherwise provided herein, no “Agent-Related Person” (as defined  below) shall (a) be liable for any action taken or omitted to be taken by any of them under or in connection with this Agreement or any other Financing Document or the transactions contemplated hereby (except for its own gross negligence or willful misconduct in connection with its duties expressly set forth herein), or (b) be responsible in any manner to any Lender or participant for any recital, statement,

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

32            

 

 


 

representation or warranty made by any Credit Party or any officer thereof, contained herein or in any other Financing Document, or in any certificate, report, statement or other document referred to or provided for in, or received by Agent under or in connection with, this Agreement or any other Financing Document, or the validity, effectiveness, genuineness, enforceability or sufficiency of this Agreement or any other Financing Document, or for any failure of any Credit Party or any other party to any Financing Document to perform its obligations hereunder or thereunder. No Agent-Related Person shall be under any obligation to any Lender or participant to ascertain or to inquire as to the observance or performance of any of the agreements contained in, or conditions of, this Agreement or any other Financing Document, or to inspect the Collateral, other properties or books or records of any Credit Party or any Affiliate thereof.  The term “ Agent-Related Person ” means the Agent, together with its Affiliates, and the officers, directors, employees, agents, advisors, auditors and attorneys-in-fact of such Persons; provided, however, that no Agent-Related Person shall be an Affiliate of Borrower.

14.5 Reliance by Agent . Agent shall be entitled to rely, and shall be fully protected in relying, upon any writing, communication, signature, resolution, representation, notice, consent, certificate, affidavit, letter, telegram, facsimile, telex or telephone message, electronic mail message, statement or other document or conversation believed by it to be genuine and correct and to have been signed, sent or made by the proper Person or Persons, and upon advice and statements of legal counsel (including counsel to Borrower), independent accountants and other experts selected by Agent. Agent shall be fully justified in failing or refusing to take any action under any Financing Document (a) if such action would, in the opinion of Agent, be contrary to law or any Financing Document, (b) if such action would, in the opinion of Agent, expose Agent to any potential liability under any law, statute or regulation or (c) if Agent shall not first have received such advice or concurrence of all Lenders as it deems appropriate and, if it so requests, it shall first be indemnified to its satisfaction by the Lenders against any and all liability and expense which may be incurred by it by reason of taking or continuing to take any such action. Agent shall in all cases be fully protected in acting, or in refraining from acting, under this Agreement or any other Financing Document in accordance with a request or consent of all Lenders (or Required Lenders where authorized herein) and such request and any action taken or failure to act pursuant thereto shall be binding upon all the Lenders.

14.6 Notice of Default . Agent shall not be deemed to have knowledge or notice of the occurrence of any Default and/or Event of Default, unless Agent shall have received written notice from a Lender or Borrower, describing such default or Event of Default. Agent will notify the Lenders of its receipt of any such notice. While an Event of Default has occurred and is continuing, Agent may (but shall not be obligated to) take such action, or refrain from taking such action, with respect to such Event of Default as Agent shall deem advisable or in the best interest of the Lenders, including without limitation,  satisfaction of other security interests, liens or encumbrances on the Collateral not permitted under the Financing Documents, payment of taxes on behalf of Borrower or any other Credit Party, payments to landlords, warehouseman, bailees and other Persons in possession of the Collateral and other actions to protect and safeguard the Collateral, and actions with respect to insurance claims for casualty events affecting a Credit Party and/or the Collateral.

14.7 Credit Decision; Disclosure of Information by Agent . Each Lender acknowledges that no Agent-Related Person has made any representation or warranty to it, and that no act by Agent hereafter taken, including any consent to and acceptance of any assignment or review of the affairs of Borrower or any Affiliate thereof, shall be deemed to constitute any representation or warranty by any Agent-Related Person to any Lender as to any matter, including whether Agent-Related Persons have disclosed material information in their possession. Each Lender represents to Agent that it has, independently and without reliance upon any Agent-Related Person and based on such documents and information as it has deemed appropriate, made its own appraisal of, and investigation into, the business, prospects, operations, property, financial and other condition and creditworthiness of the Credit Parties, and all applicable bank or other regulatory Laws relating to the transactions contemplated hereby, and made its own decision to enter into this Agreement and to extend credit to Borrower hereunder. Each Lender also represents that it will, independently and without reliance upon any Agent-Related Person and based on such documents and information as it shall deem appropriate at the time, continue to make its own credit analysis, appraisals and decisions in taking or not taking action under this Agreement and the other Financing Documents, and to make such investigations as it deems necessary to inform itself as to the business, prospects, operations, property, financial and other condition and creditworthiness of Borrower. Except for notices, reports and other documents expressly required to be furnished to the Lenders by Agent herein, Agent shall not have any duty or responsibility to provide any Lender with any credit or other information concerning the business, prospects, operations, property, financial and other condition or creditworthiness of any Credit Party which may come into the possession of any Agent-Related Person.

14.8 Indemnification of Agent . Whether or not the transactions contemplated hereby are consummated, each  Lender shall, severally and pro rata based on its respective Pro Rata Share, indemnify upon demand each Agent-Related Person (to the extent not reimbursed by or on behalf of Borrower and without limiting the obligation of Borrower to do so), and hold harmless each Agent-Related Person from and against any and all Indemnified Liabilities (which shall not include legal expenses of Agent incurred in connection with the closing of the transactions contemplated by this Agreement) incurred by it; provided, however , that no Lender shall be liable for the payment to any Agent-Related Person of any portion of such Indemnified Liabilities to the extent determined in

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

33            

 

 


 

a judgment by a court of competent jurisdiction to have resulted from such Agent-Related Person’s own gross negligence or willful misconduct; provided, however , that no action taken in accordance with the directions of the Required Lenders shall be deemed to constitute gross negligence or willful misconduct for purposes of this Section. Without limitation of the foregoing, each Lender shall , severally and pro rata based on its respective Pro Rata Share, reimburse Agent upon demand for its ratable share of any costs or out-of-pocket expenses (including Protective Advances incurred after the closing of the transactions contemplated by this Agreement) incurred by Agent (in its capacity as Agent, and not as a Lender) in connection with the preparation, execution, delivery, administration, modification, amendment or enforcement (whether through negotiations, legal proceedings or otherwise) of, or legal advice in respect of rights or responsibilities under, this Agreement, any other Financing Document, or any document contemplated by or referred to herein, to the extent that Agent is not reimbursed for such expenses by or on behalf of Borrower. The undertaking in this Section shall survive the payment in full of the Obligations, the termination of this Agreement and the resignation of Agent.   The term “Indemnified Liabilities” means those liabilities described in Section 13.2(a) and Section 13.2(b).

14.9 Agent in its Individual Capacity .  With respect to its Credit Extensions, MidCap shall have the same rights and powers under this Agreement as any other Lender and may exercise such rights and powers as though it were not Agent, and the terms “Lender” and “Lenders” include MidCap in its individual capacity. MidCap and its Affiliates may lend money to, invest in, and generally engage in any kind of business with, any Credit Party and any of their Affiliates and any person who may do business with or own securities of any Credit Party or any of their Affiliates, all as if MidCap were not Agent and without any duty to account therefor to Lenders.  MidCap and its Affiliates may accept fees and other consideration from a Credit Party for services in connection with this Agreement or otherwise without having to account for the same to Lenders.  Each Lender acknowledges the potential conflict of interest between MidCap as a Lender holding disproportionate interests in the Credit Extensions and MidCap as Agent, and expressly consents to, and waives, any claim based upon, such conflict of interest.

14.10 Agent May File Proofs of Claim . In case of the pendency of any receivership, insolvency, liquidation, bankruptcy, reorganization, arrangement, adjustment, composition or other judicial proceeding relative to any Credit Party, Agent (irrespective of whether the principal of any Credit Extension, shall then be due and payable as herein expressed or by declaration or otherwise and irrespective of whether Agent shall have made any demand on such Credit Party) shall be entitled and empowered, by intervention in such proceeding or otherwise:

(a) to file and prove a claim for the whole amount of the principal and interest owing and unpaid in respect of the Credit Extensions and all other Obligations that are owing and unpaid and to file such other documents as may be necessary or advisable in order to have the claims of the Lenders and Agent (including any claim for the reasonable compensation, expenses, disbursements and advances of the Lenders and Agent and their respective agents and counsel and all other amounts due the Lenders and Agent allowed in such judicial proceeding); and

(b) to collect and receive any monies or other property payable or deliverable on any such claims and to distribute the same;

and any custodian, receiver, assignee, trustee, liquidator, sequestrator or other similar official in any such judicial proceeding is hereby authorized by each Lender to make such payments to Agent and, in the event that Agent shall consent to the making of such payments directly to the Lenders, to pay to Agent any amount due for the reasonable compensation, expenses, disbursements and advances of Agent and its agents and counsel, including Protective Advances.  To the extent that Agent fails timely to do so, each Lender may file a claim relating to such Lender’s claim.

14.11 Collateral and Guaranty Matters . The Lenders irrevocably authorize Agent, at its option and in its discretion, to release (a) any Credit Party and any Lien on any Collateral granted to or held by Agent under any Financing Document upon the date that all Obligations due hereunder have been fully and indefeasibly paid in full and no Applicable Commitments or other obligations of any Lender to provide funds to Borrower under this Agreement remain outstanding, and (b) any Lien on any Collateral that is transferred or to be transferred as part of or in connection with any transfer permitted hereunder or under any other Financing Document. Upon request by Agent at any time, all Lenders will confirm in writing Agent’s authority to release its interest in particular types or items of Collateral pursuant to this Section 14.11.

14.12 Advances; Payments; Non-Funding Lenders .

(a) Advances; Payments .  If Agent receives any payment for the account of Lenders on or prior to 11:00 a.m. (New York time) on any Business Day, Agent shall pay to each applicable Lender such Lender’s Pro Rata Share of such payment on such Business Day. If Agent receives any payment for the account of Lenders after 11:00 a.m. (New York time) on any Business Day, Agent shall pay to each applicable Lender such Lender’s Pro Rata Share of such payment on the next Business Day. To the extent that

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

34            

 

 


 

any Lender has failed to fund any Credit Extension (a “ Non-Funding Lender ”), Agent shall be entitled to set-off the funding short-fall against that Non-Funding Lender’s Pro Rata Share of all payments received from Borrower.

(b) Return of Payments .

(i) If Agent pays an amount to a Lender under this Agreement in the belief or expectation that a related payment has been or will be received by Agent from a Credit Party and such related payment is not received by Agent, then Agent will be entitled to recover such amount (including interest accruing on such amount at the Federal Funds Rate for the first Business Day and thereafter, at the rate otherwise applicable to such Obligation) from such Lender on demand without set-off, counterclaim or deduction of any kind.  

(ii) If Agent determines at any time that any amount received by Agent under this Agreement must be returned to a Credit Party or paid to any other person pursuant to any insolvency law or otherwise, then, notwithstanding any other term or condition of this Agreement or any other Financing Document, Agent will not be required to distribute any portion thereof to any Lender.  In addition, each Lender will repay to Agent on demand any portion of such amount that Agent has distributed to such Lender, together with interest at such rate, if any, as Agent is required to pay to a Credit Party or such other person, without set-off, counterclaim or deduction of any kind.

14.13 Parallel Debt .

(a) Notwithstanding any other provision of this Agreement, and solely for the purpose of security granted under the Swiss Security Documents, Borrower and the other Credit Parties each hereby irrevocably and unconditionally undertakes (by way of an abstract acknowledgment of debt ( abstraktes Schuldanerkenntnis )) to pay to Agent as creditor in its own right and not as a representative of the Lenders amounts equal to any amounts owing from time to time by such Credit Party to any Lender under any Financing Documents as and when, and in the currency of, those amounts are due for payment under the applicable Financing Documents.

(b) Borrower and the other Credit Parties each acknowledge that the obligations of each Credit Party under Section 14.13(a) are several and are separate and independent from, and shall not in any way limit or affect, the corresponding obligations of such Credit Party to any Lender under any Financing Documents, as applicable (its “ Corresponding Debt ”), nor shall the amounts for which each Credit Party is liable under Section 14.13(a) (its “ Parallel Debt ”) be limited or affected in any way by its Corresponding Debt; provided , that , (i) the Parallel Debt of each Credit Party shall be decreased to the extent that its Corresponding Debt has been irrevocably paid or discharged; and (ii) the Corresponding Debt of each Credit Party shall be decreased to the extent that its Parallel Debt has been irrevocably paid or discharged, but further provided that the Corresponding Debt shall not be decreased, if it is effected by virtue of any set-off, counterclaim or similar defence invoked by a Credit Party vis-à-vis the Agent.

(c) Agent acts in its own name and not as a trustee, and its claims in respect of the Parallel Debt shall not be held in trust.  The Liens granted under the Financing Documents to Agent to secure the Parallel Debt is granted to Agent in its capacity as creditor of the Parallel Debt and shall not be held in trust.

(d) All monies received or recovered by Agent pursuant to this Section 14.13 , and all amounts received or recovered by Agent from or by the enforcement of any security interest granted to secure the Parallel Debt, shall be applied in accordance with this Agreement.

(e) Without limiting or affecting Agent’s rights against the Credit Parties (whether under this Section 14.13 or under any other provision of the Financing Documents, as applicable) each Credit Party acknowledges that (i) nothing in this Section 14.13 shall impose any obligation on Agent to advance any sum to any Credit Party or otherwise under any Financing Documents, except in its capacity as Lender; and (ii) for the purpose of any vote taken under any Financing Documents, Agent shall not be regarded as having any participation or commitment other than those which it has in its capacity as a Lender.

14.14 Miscellaneous .

(a) Neither Agent nor any Lender shall be responsible for the failure of any Non-Funding Lender to make a Credit Extension or make any other advance required hereunder.  The failure of any Non‑Funding Lender to make any Credit Extension or any payment required by it hereunder shall not relieve any other Lender (each such other Lender, an “ Other Lender ”) of its obligations to make the Credit Extension or payment required by it, but neither any Other Lender nor Agent shall be responsible for the failure of any Non-Funding Lender to make a Credit Extension or make any other payment required hereunder.  Notwithstanding anything set forth herein to the contrary, a Non-Funding Lender shall not have any voting or consent rights under or with respect to any Financing

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

35            

 

 


 

Document or constitute a “Lender” (or be included in the calculation of “Required Lender” hereunder) for any voting or consent rights under or with respect to any Financing Document.  At Borrower’s request, Agent or a person reasonably acceptable to Agent shall have the right with Agent’s consent and in Agent’s sole discretion (but shall have no obligation) to purchase from any Non-Funding Lender, and each Non-Funding Lender agrees that it shall, at Agent’s request, sell and assign to Agent or such person, all of the Applicable Commitments and all of the outstanding Credit Extensions of that Non-Funding Lender for an amount equal to the principal balance of the Credit Extensions held by such Non-Funding Lender and all accrued interest and fees with respect thereto through the date of sale, such purchase and sale to be consummated pursuant to an executed assignment agreement reasonably acceptable to Agent.

(b) Each Lender shall promptly remit to the other Lenders such sums as may be necessary to ensure the ratable repayment of each Lender’s portion of any Credit Extension and the ratable distribution of interest, fees and reimbursements paid or made by any Credit Party.  Notwithstanding the foregoing, if this Agreement requires payments of principal and interest to be made directly to the Lenders, a Lender receiving a scheduled payment shall not be responsible for determining whether the other Lenders also received their scheduled payment on such date; provided, however , if it is determined that a Lender received more than its ratable share of scheduled payments made on any date or dates, then such Lender shall remit to the Agent (for Agent to redistribute to itself and the Lenders in a manner to ensure the payment to Agent of any sums due Agent hereunder and the ratable repayment of each Lender’s portion of any Credit Extension and the ratable distribution of interest, fees and reimbursements) such sums as may be necessary to ensure the ratable payment of such scheduled payments, as instructed by Agent.  If any payment or distribution of any kind or character, whether in cash, properties or securities and whether voluntary, involuntary, through the exercise of any right of set-off, or otherwise, shall be received by a Lender in excess of its ratable share, then (i) the portion of such payment or distribution in excess of such Lender’s ratable share shall be received by such Lender in trust for application to the payments of amounts due on the other Lender’s claims, or, in the case of Collateral, shall hold such Collateral for itself and as agent and bailee for the Agent and other Lenders and (ii) such Lender shall promptly advise the Agent of the receipt of such payment, and, within five (5) Business Days of such receipt and, in the case of payments and distributions, such Lender shall purchase (for cash at face value) from the other Lenders (through the Agent), without recourse, such participations in the Credit Extension made by the other Lenders as shall be necessary to cause such purchasing Lender to share the excess payment ratably with each of them in accordance with the respective Pro Rata Shares of the Lenders; provided , however , that if all or any portion of such excess payment is thereafter recovered by or on behalf of a Credit Party from such purchasing Lender, the purchase shall be rescinded and the purchase price restored to the extent of such recovery, but without interest; provided , further , that the provisions of this Section shall not be construed to apply to (x) any payment made by a Credit Party pursuant to and in accordance with the express terms of this Agreement or the other Financing Documents, or (y) any payment obtained by a Lender as consideration for the assignment of or sale of a participation in any of its Applicable Commitment pursuant to Section 13.1.  Borrower agrees that any Lender so purchasing a participation from another Lender pursuant to this Section may exercise all its rights of payment (including the right of set-off) with respect to such participation as fully as if such Lender were the direct creditor of the Borrower in the amount of such participation.  No documentation other than notices and the like shall be required to implement the terms of this Section.  The Agent shall keep records (which shall be conclusive and binding in the absence of manifest error) of participations purchased pursuant to this Section and shall in each case notify the Lenders following any such purchases.

 

15

Guaranty

15.1 Guaranty .  Each Guarantor hereby unconditionally (a) guarantees, as a primary obligor and not merely as a surety, jointly and severally with each other Guarantor when and as due, whether at maturity, by acceleration, by notice of prepayment or otherwise, the due and punctual performance of all of the Obligations, including payment in full of the principal, accrued but unpaid interest and all other amounts due and owing to the Agent and Lenders under the Term Credit Facility and (b) indemnifies each Lender immediately on demand against any cost, loss or liability suffered by such Lender if any obligations guaranteed by it are or become unenforceable, invalid, voided, avoid or illegal, the amount of which such cost, loss or liability shall be equal to the amount which such Lender would otherwise be entitled to recover . Each payment made by any Guarantor pursuant to this Section 15 shall be made in lawful money of the United States in immediately available funds.

15.2 Payment of Amounts Owed .  The Guarantee hereunder is an absolute, unconditional and continuing guarantee of the full and punctual payment and performance of all of the Obligations and not of their collectability only and is in no way conditioned upon any requirement that the Agent or any Lender first attempt to collect any of the Obligations from Borrower or resort to any collateral security or other means of obtaining payment.  In the event of any default by Borrower in the payment of the Obligations, after the expiration of any applicable cure or grace period, each Guarantor agrees, on demand by Agent (which demand may be made concurrently with notice to Borrower that Borrower is in default of its obligations), to pay the Obligations, regardless of any defense, right of set-off or recoupment or claims which Borrower or Guarantor may have against Agent or Lenders or the holder of the Secured Promissory Notes.  All of the remedies set forth in this Agreement, in any other Financing Document or at law or equity shall be equally available to Agent and Lenders, and the choice by Agent or Lenders of one such alternative over another shall not be subject to question or challenge by any Guarantor or any other person, nor shall any such choice be asserted as a defense, setoff, recoupment

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

36            

 

 


 

or failure to mitigate damages in any action, proceeding, or counteraction by Agent or Lenders to recover or seeking any other remedy under this Guarantee, nor shall such choice preclude Agent or Lenders from subsequently electing t o exercise a different remedy.

15.3 Certain Waivers by Guarantor .  To the fullest extent permitted by law, each Guarantor does hereby:

(a) waive notice of acceptance of this Agreement by Agent and Lenders and any and all notices and demands of every kind which may be required to be given by any statute, rule or law;

(b) agree to refrain from asserting, until after repayment in full of the Obligations, any defense, right of set-off, right of recoupment or other claim which such Guarantor may have against Borrower;

(c) waive any defense, right of set-off, right of recoupment or other claim which such Guarantor may have against Agent, Lenders or the holder of the Secured Promissory Notes;

(d) waive any and all rights such Guarantor may have under any anti-deficiency statute or other similar protections;

(e) waive all rights at law or in equity to seek subrogation, contribution, indemnification or any other form of reimbursement or repayment from Borrower, any other Guarantor or any other person or entity now or hereafter primarily or secondarily liable for any of the Obligations until the Obligations have been paid in full;

(f) waive presentment for payment, demand for payment, notice of nonpayment or dishonor, protest and notice of protest, diligence in collection and any and all formalities which otherwise might be legally required to charge such Guarantor with liability;

(g) waive the benefit of all appraisement, valuation, marshalling, forbearance, stay, extension, redemption, homestead, exemption and moratorium laws now or hereafter in effect;

(h) waive any defense based on the incapacity, lack of authority, death or disability of any other person or entity or the failure of Agent or Lenders to file or enforce a claim against the estate of any other person or entity in any administrative, bankruptcy or other proceeding;

(i) waive any defense based on an election of remedies by Agent or Lenders, whether or not such election may affect in any way the recourse, subrogation or other rights of such Guarantor against Borrower, any other Guarantor or any other person in connection with the Obligations;

(j) waive any defense based on the failure of the Agent or Lenders to (i) provide notice to such Guarantor of a sale or other disposition of any of the security for any of the Obligations, or (ii) conduct such a sale or disposition in a commercially reasonable manner;

(k) waive any defense based on the negligence of Agent or Lenders in administering this Agreement or the other Financing Documents (including, but not limited to, the failure to perfect any security interest in any Collateral), or taking or failing to take any action in connection therewith, provided, however , that such waiver shall not apply to the gross negligence or willful misconduct of the Agent or Lenders, as determined by the final, non-appealable decision of a court having proper jurisdiction;

(l) waive the defense of expiration of any statute of limitations affecting the liability of such Guarantor hereunder or the enforcement hereof;

(m) waive any right to file any Claim (as defined below) as part of, and any right to request consolidation of any action or proceeding relating to a Claim with, any action or proceeding filed or maintained by Agent or Lenders to collect any Obligations of such Guarantor to Agent or Lenders hereunder or to exercise any rights or remedies available to Agent or Lenders under the Financing Documents, at law, in equity or otherwise;

(n) agree that neither Agent nor Lenders shall have any obligation to obtain, perfect or retain a security interest in any property to secure any of the Obligations (including any mortgage or security interest contemplated by the Financing Documents), or to protect or insure any such property;

(o) waive any obligation Agent or Lenders may have to disclose to such Guarantor any facts the Agent or Lenders now or hereafter may know or have reasonably available to it regarding Borrower or Borrower’s financial condition, whether or not

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

37            

 

 


 

the Agent or Lenders have a reasonable opportunity to communicate such facts or have reason to believe that any such facts are unknown to such Guarantor or materially increase the risk to such Guarantor beyond the risk such Guarantor intends to assume hereunder;

(p) agree that neither Agent nor Lenders shall be liable in any way for any decrease in the value or marketability of any property securing any of the Obligations which may result from any action or omission of the Agent or Lenders in enforcing any part of this Agreement;

(q) waive any defense based on any invalidity, irregularity or unenforceability, in whole or in part, of any one or more of the Financing Documents;

(r) waive any defense based on any change in the composition of Borrower, and

(s) waive any defense based on any representations and warranties made by such Guarantor herein or by Borrower herein or in any of the Financing Documents.  

Each Guarantor hereby abandons any right it may have under the existing or future laws of Jersey, whether by virtue of (a) the “droit de discussion” or otherwise to require that recourse be had to the assets of any other person before any claim is enforced against such Guarantor in respect of the obligations assumed by it under the guarantee; and (b) the “droit de division” or otherwise to require that any liability be apportioned or divided with any other person or be reduced in any manner whatsoever.

For purposes of this section, the term “ Claim ” shall mean any claim, action or cause of action, defense, counterclaim, retention, set-off or right of recoupment of any kind or nature against the Agent or Lenders, its officers, directors, employees, agents, members, actuaries, accountants, trustees or attorneys, or any affiliate of the Agent or Lenders in connection with the making, closing, administration, collection or enforcement by the Agent or Lenders of the Obligations.

15.4 Guarantor’s Obligations Not Affected by Modifications of Financing Documents .  Each Guarantor further agrees that such Guarantor’s liability as guarantor shall not be impaired or affected by any renewals or extensions which may be made from time to time, with or without the knowledge or consent of Guarantor for the time for payment of interest or principal or by any forbearance or delay in collecting interest or principal hereunder, or by any waiver by Agent or Lenders under this Agreement or any other Financing Documents, or by Agent’s or Lenders’ failure or election not to pursue any other remedies it may have against Borrower or Guarantor, or by any change or modification in the Secured Promissory Notes , this Agreement or any other Financing Document, or by the acceptance by Agent or Lenders of any additional security or any increase, substitution or change therein, or by the release by Agent or Lenders of any security or any withdrawal thereof or decrease therein, or by the application of payments received from any source to the payment of any obligation other than the Obligations even though Agent or Lenders might lawfully have elected to apply such payments to any part or all of the Obligations, it being the intent hereof that, subject to Agent’s or Lenders’ compliance with the terms of this Section 13 and the Financing Documents, each Guarantor shall remain liable for the payment of the Obligations, until the Obligations have been paid in full, notwithstanding any act or thing which might otherwise operate as a legal or equitable discharge of a surety.  Each Guarantor further understands and agrees that Agent or Lenders may at any time enter into agreements with Borrower to amend, modify and/or increase the principal amount of, interest rate applicable to or other economic and non-economic terms of this Agreement or the other Financing Documents, and may waive or release any provision or provisions of this Agreement or the other Financing Documents, and, with reference to such instruments, may make and enter into any such agreement or agreements as Agent, Lenders and Borrower may deem proper and desirable, without in any manner impairing this Guarantee or any of Agent’s or Lenders’ rights hereunder or each Guarantor’s obligations hereunder, and each Guarantor’s obligations hereunder shall apply to the this Agreement and other Financing Documents as so amended, modified, extended, renewed or increased.

15.5 Reinstatement; Deficiency .  This guaranty shall continue to be effective or be reinstated (as the case may be) if at any time payment of all or any part of any sum payable pursuant to this Agreement or any other Financing Document is rescinded or otherwise required to be returned by Agent or Lenders upon the insolvency, bankruptcy, dissolution, liquidation, or reorganization of Borrower, or upon or as a result of the appointment of a receiver, intervenor, custodian or conservator of or trustee or similar officer for, Borrower or any substantial part of its property, or otherwise, all as though such payment to Agent or Lenders had not been made, regardless of whether Agent or Lenders contested the order requiring the return of such payment.  In the event of the foreclosure of the Financing Documents and of a deficiency, each Guarantor hereby promises and agrees forthwith to pay the amount of such deficiency notwithstanding the fact that recovery of said deficiency against Borrower would not be allowed by applicable law; however, the foregoing shall not be deemed to require that Agent or Lenders institute foreclosure proceedings or otherwise resort to or exhaust any other collateral or security prior to or concurrently with enforcing this guaranty.

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

38            

 

 


 

15.6 Subordination of Borrower’s Obligations to Guarantors; Claims in Bankruptcy .  

(a) Any indebtedness of Borrower to any Guarantor (including, but not limited to, any right of such Guarantor to a return of any capital contributed to Borrower), whether now or hereafter existing, is hereby subordinated to the payment of the Obligations.  Each Guarantor agrees that, until the Obligations have been paid in full, such Guarantor will not seek, accept, or retain for its own account, any payment from Borrower on account of such subordinated debt.  Any payments to any Guarantor on account of such subordinated debt shall be collected and received by such Guarantor in trust for Agent and Lenders and shall be immediately paid over to Agent, for the benefit of Agent and Lenders, on account of the Obligations without impairing or releasing the obligations of such Guarantor hereunder.

(b) Each Guarantor shall promptly file in any bankruptcy or other proceeding in which the filing of claims is required by law, all claims and proofs of claims that such Guarantor may have against Borrower or any other Guarantor and does hereby assign to Agent or its nominee (and will, upon request of Agent, reconfirm in writing the assignment to Agent or its nominee of) all rights of such Guarantor under such claims.  If such Guarantor does not file any such claim, Agent, as attorney‑in ‑fact for such Guarantor, is hereby irrevocably authorized to do so in the name of such Guarantor, or in Agent’s discretion, to assign the claim to a designee and cause proof of claim to be filed in the name of Agent’s designee.  In all such cases, whether in administration, bankruptcy or otherwise, the person or persons authorized to pay such claim shall pay to Agent, for the benefit of Agent and Lenders, the full amount thereof and, to the full extent necessary for that purpose, each Guarantor hereby assigns to the Lenders all of such Guarantor’s rights to any such payments or distributions to which such Guarantor would otherwise be entitled, such assignment being a present and irrevocable assignment of all such rights.

15.7 Maximum Liability .  The provisions of this Section 15 are severable, and in any action or proceeding involving any state corporate law, or any state, federal or foreign bankruptcy, insolvency, reorganization or other law affecting the rights of creditors generally, if the obligations of any Guarantor under this Section 15 would otherwise be held or determined to be avoidable, invalid or unenforceable on account of the amount of such Guarantor’s liability under this Section 15, then, notwithstanding any other provision of this Section 15 to the contrary, the amount of such liability shall, without any further action by the Guarantors or the Agent or any Lender, be automatically limited and reduced to the highest amount that is valid and enforceable as determined in such action or proceeding (such highest amount determined hereunder being the relevant Guarantor’s “ Maximum Liability ”). This Section 15.7 with respect to the Maximum Liability of each Guarantor is intended solely to preserve the rights of the Agent and the Lenders to the maximum extent not subject to avoidance under applicable law, and no Guarantor nor any other Person shall have any right or claim under this Section 15.7 with respect to such Maximum Liability, except to the extent necessary so that the obligations of any Guarantor hereunder shall not be rendered voidable under applicable law. Each Guarantor agrees that the Obligations may at any time and from time to time exceed the Maximum Liability of each Guarantor without impairing this guaranty or affecting the rights and remedies of the Agent or the Lenders hereunder, provided that, nothing in this sentence shall be construed to increase any Guarantor’s obligations hereunder beyond its Maximum Liab ility.

15.8 Guarantor’s Investigation .  Each Guarantor acknowledges receipt of a copy of each of this Agreement and the other Financing Documents. Each Guarantor has made an independent investigation of the other Credit Parties and of the financial condition of the other Credit Parties. Neither Agent nor any Lender has made and neither Agent nor any Lender does make any representations or warranties as to the income, expense, operation, finances or any other matter or thing affecting any Credit Party nor has Agent or any Lender made any representations or warranties as to the amount or nature of the Obligations of any Credit Party to which this Section 15 applies as specifically herein set forth, nor has Agent or any Lender or any officer, agent or employee of Agent or any Lender or any representative thereof, made any other oral representations, agreements or commitments of any kind or nature, and each Guarantor hereby expressly acknowledges that no such representations or warranties have been made and such Guarantor expressly disclaims reliance on any such representations or warranties

15.9 Termination .  The provisions of this Section 15 shall remain in effect until this Agreement has terminated pursuant to its terms and all Obligations (other than inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of this Agreement) have been satisfied.

15.10 Representative .  Each Guarantor hereby designates Borrower and its representatives and agents on its behalf for the purpose of giving and receiving all notices and other consents hereunder or under any other Financing Document and taking all other actions on behalf of such Guarantor under the Financing Documents.  Borrower hereby accepts such appointment.

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

39            

 

 


 

15.11 S wiss Limit ations .  

(a) To the extent that Quotient Suisse grants its guaranty hereunder to secure obligations other than (x) its own Obligations or (y) Obligations of one of its subsidiaries, (i.e. to secure Obligations of its (direct or indirect) parent companies (up-stream security) or its sister companies (cross-stream security)), Quotient Suisse shall:

(i) only be liable for such payment obligation to the extent and in the maximum amount (the “ Swiss Available Amount ) of its profits and reserves available for distribution at the point in time Quotient Suisse's obligations become due ( in each case in accordance with art. 675(2) and art 671(1) , (2) and ( 3 ) Swiss Code of Obligations), provided that such limitation shall not free Quotient Suisse from its obligations in excess thereof, but merely postpone the performance date therefore until such times as performance is again permitted notwithstanding such limitation.  The Swiss Available Amount shall include the portion of equity capital surplus (including any unrestricted portion of legal general reserves, restricted reserves which may be converted into free reserves, other free reserves, retained earnings and current net profits) which is freely available (as the case may be after conversion) for distribution to shareholders under Swiss law. Quotient Suisse shall at the request of the Agent take all measures legally permissible required to ensure that the Swiss Available Amount is as high as possible under Swiss law, including, without limitation by converting restricted reserves into distributable reserves;

(ii) provide, within sixty (60) days from the request of the Agent, (a) an interim audited balance sheet, (b) a determination of the Swiss Available Amount based on such interim audited balance sheet and (c) a confirmation from the auditors of Quotient Suisse that the Swiss Available Amount complies with the provisions of Swiss corporate law which are aimed at protecting the share capital and legal reserves;

(iii) pay to the Agent the Swiss Available Amount and, if required under applicable law (including double-taxation treaties), deduct from any such payments Swiss anticipatory tax (withholding tax) at the rate of 35% (or such other rate as in force from time to time) and subject to any applicable double taxation treaty:

 

1.

pay such deduction to the Swiss Federal Tax Administration; and

 

2.

within 30 days of making either a tax deduction or any payment required in connection with that tax deduction, Quotient Suisse making that deduction shall deliver to the Agent evidence reasonably satisfactory to the Agent that the tax deduction has been made or (as applicable) any appropriate payment paid to the relevant taxing authority,

to the extent such a deduction is made, Quotient Suisse shall not be obliged to either gross up or indemnify the Lenders;

(iv) use its commercially reasonable efforts to ensure that any affiliate which is, as a result of a payment under the Financing Documents, entitled to a full or partial refund of the Swiss anticipatory tax, (i) requests a refund of the Swiss anticipatory tax under any applicable law (including double taxation treaties) and (ii) pays to the Agent upon receipt any amount so refunded to the extent required to settle the guaranteed Obligations;

(v) take and cause to be taken all and any other action, including, if required under Swiss practice or mandatory law at the time of payment, the passing of shareholder's resolutions for the distribution of profits and reserves available for distribution in accordance with the relevant provisions of the Swiss Code of Obligations being in force at that time

 

16

DEFINITIONS

In addition to any terms defined elsewhere in this Agreement, or in any schedule or exhibit attached hereto, as used in this Agreement, the following terms have the following meanings:

Access Agreement ” means a landlord consent, bailee letter or warehouseman’s letter, in form and substance reasonably satisfactory to Agent, in favor of Agent executed by such landlord, bailee or warehouseman, as applicable, for any third party location.

Account ” means any “account”, as defined in the Code, with such additions to such term as may hereafter be made, and includes, without limitation, all accounts receivable and other sums owing to Borrower.

Account Debtor ” means any “account debtor”, as defined in the Code, with such additions to such term as may hereafter be made.

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

40            

 

 


 

Affiliate ” means, with respect to any Person, a Person that owns or controls directly or indirectly the Person, any Person that controls or is controlled by or is under common control with the Person, and each of that Person’s senior executive officers, directors, partners and, for any Person that is a limited liability company, that Person’s managers and members.

Agent ” means, MidCap, not in its individual capacity, but solely in its capacity as agent on behalf of and for the benefit of the Lenders.

Agreement ” has the meaning given it in the preamble of this Agreement.

Alba Bioscience Limited ” means Alba Bioscience Limited, a company incorporated in Scotland with registration number SC310584.

Anti-Terrorism Laws ” means any Laws relating to terrorism or money laundering, including Executive Order No. 13224 (effective September 24, 2001), the USA PATRIOT Act, the Laws comprising or implementing the Bank Secrecy Act, and the Laws administered by OFAC.

Applicable Commitment ” has the meaning given it in Section 2.2

Applicable Floor ” means for each Credit Facility the per annum rate of interest specified on the Credit Facility Schedule; provided, however, that for the Applicable Prime Rate, the Applicable Floor is a per annum rate that is two hundred basis points above the Applicable Floor for the Applicable Libor Rate.  

Applicable Index Rate ” means, for any Applicable Interest Period, the rate per annum determined by Agent equal to the Applicable Libor Rate; provided, however, that in the event that any change in market conditions or any law, regulation, treaty, or directive, or any change therein or in the interpretation of application thereof, shall at any time after the date hereof, in the reasonable opinion of Agent or any Lender, make it unlawful or impractical for Agent or such Lender to fund or maintain Obligations bearing interest based upon the Applicable Libor Rate, Agent or such Lender shall give notice of such changed circumstances to Agent and Borrower and the Applicable Index Rate for Obligations outstanding or thereafter extended or made by Agent or such Lender shall thereafter be the Applicable Prime Rate until Agent or such Lender determines (as to the portion of the Credit Extensions or Obligations owed to it) that it would no longer be unlawful or impractical to fund or maintain such Obligations or Credit Extensions at the Applicable Libor Rate. In the event that Agent shall have determined (which determination shall be final and conclusive absent manifest error and binding upon all parties hereto), as of any Applicable Interest Rate Determination Date, that adequate and fair means do not exist for ascertaining the interest rate applicable to any Credit Facility on the basis provided for herein, then Agent may select a comparable replacement index and corresponding margin.  

Applicable Interest Period ” for each Credit Facility has the meaning specified for that Credit Facility in the Credit Facility Schedule; provided, however, that at any time that the Applicable Prime Rate is the Applicable Index Rate, Applicable Interest Period shall mean the period commencing as of the most recent Applicable Interest Rate Determination Date and continuing until the next Applicable Interest Rate Determination Date or such earlier date as the Applicable Prime Rate shall no longer be the Applicable Index Rate; and provided, further, that at any time the Libor Rate Index is adjusted as set forth in the definition thereof, or re-implemented following invocation of the Applicable Prime Rate as permitted herein, the Applicable Interest Period shall mean the period of as of such adjustment or re-implementation and continuing until the next Applicable Interest Rate Determination Date, if any.

“Applicable Interest Rate” means a per annum rate of interest equal to the Applicable Index Rate plus the Applicable Margin.

Applicable Interest Rate Determination Date ” means the second (2nd) Business Day prior to the first (1st) day of the related Applicable Interest Period; provided, however, that at any time that the Applicable Prime Rate is the Applicable Index Rate, Applicable Interest Rate Determination Date means the date of any change in the Base Rate Index; and provided, further, that at any time the Libor Rate Index is adjusted as set forth in the definition thereof, the Applicable Interest Rate Determination Date shall mean the date of such adjustment or the second (2nd) Business Day prior to the first (1st) day of the related Applicable Interest Period, as elected by Agent.

Applicable Libor Rate ” means, for any Applicable Interest Period, the rate per annum, determined by Agent (rounded upwards, if necessary, to the next 1/100th%), equal to the greater of (a) the Applicable Floor and (b) the Libor Rate Index.  

Applicable Margin ” for each Credit Facility has the meaning specified for that Credit Facility in the Credit Facility Schedule.  

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

41            

 

 


 

Applicable Prepayment Fee ”, for each Credit Facility , has the meaning given it in the Credit Facility Schedule for such Credit Facility.  

Applicable Prime Rate ” means, for any Applicable Interest Period, the rate per annum, determined by Agent (rounded upwards, if necessary, to the next 1/100th%), equal to the greater of (a) the Applicable Floor and (b) the Base Rate Index.  

Approved Fund ” means any (a) investment company, fund, trust, securitization vehicle or conduit that is (or will be) engaged in making, purchasing, holding or otherwise investing in commercial loans and similar extensions of credit in the Ordinary Course of Business, or (b) any Person (other than a natural person) which temporarily warehouses loans for any Lender or any entity described in the preceding clause (a) and that, with respect to each of the preceding clauses (a) and (b), is administered or managed by (i) a Lender, (ii) an Affiliate of a Lender or (iii) a Person (other than a natural person) or an Affiliate of a Person (other than a natural person) that administers or manages a Lender.

Base Rate Index ” means, for any Applicable Interest Period, the rate per annum, determined by Agent (rounded upwards, if necessary, to the next 1/100th%) as being the rate of interest announced, from time to time, within Wells Fargo Bank, N.A. (“ Wells Fargo ”) at its principal office in San Francisco as its “prime rate,” with the understanding that the “prime rate” is one of Wells Fargo’s base rates (not necessarily the lowest of such rates) and serves as the basis upon which effective rates of interest are calculated for those loans making reference thereto and is evidenced by the recording thereof after its announcement in such internal publications as Wells Fargo may designate; provided, however, that Agent may, upon prior written notice to any Borrower, choose a reasonably comparable index or source to use as the basis for the Base Rate Index.  

Blocked Person means: (a) any Person listed in the annex to, or is otherwise subject to the provisions of, Executive Order No. 13224, (b) a Person owned or controlled by, or acting for or on behalf of, any Person that is listed in the annex to, or is otherwise subject to the provisions of, Executive Order No. 13224, (c) a Person with which any Lender is prohibited from dealing or otherwise engaging in any transaction by any Anti-Terrorism Law, (d) a Person that commits, threatens or conspires to commit or supports “terrorism” as defined in Executive Order No. 13224, or (e) a Person that is named a “specially designated national” or “blocked person” on the most current list published by OFAC or other similar list.

Blood Grouping ” shall have the meaning set forth in the OCD Agreement on the date hereof.  

Borrower ” mean the entity(ies) described in the first paragraph of this Agreement and each of their successors and permitted assigns. The term “each Borrower” shall refer to each Person comprising the Borrower if there is more than one such Person, or the sole Borrower if there is only one such Person.  The term “any Borrower” shall refer to any Person comprising the Borrower if there is more than one such Person, or the sole Borrower if there is only one such Person.

Borrowing Resolutions ” means, with respect to any Person, those resolutions, in form and substance satisfactory to Agent, adopted by such Person’s Board of Directors or other appropriate governing body and delivered by such Person to Agent approving the Financing Documents to which such Person is a party and the transactions contemplated thereby, as well as any other approvals as may be necessary or desired to approve the entering into the Financing Documents or the consummation of the transactions contemplated thereby or in connection therewith.

Books ” means all of books and records of a Person, including ledgers, federal and state tax returns, records regarding the Person’s assets or liabilities, the Collateral, business operations or financial condition, and all computer programs or storage or any equipment containing such information.

Business Day ” means any day (other than Saturday or Sunday) on which banks are open for general business in Maryland.

Calculation Period ” means, for each Testing Date, the twelve month period ending on the last day of the month ending approximately 45 days prior to the applicable Testing Date.

Change in Control ” means any event, transaction, or occurrence as a result of which (a) Quotient Limited ceases to own and control, directly or indirectly, all of the economic and voting rights associated with the outstanding securities of each of its Subsidiaries; (b) the occurrence of any “change in control” or any term of similar effect under any Subordinated Debt Document; (c) Borrower ceases to own and control, directly or indirectly, all of the economic and voting rights associated with the outstanding voting capital stock (or other voting equity interest) of each of its Subsidiaries; (d) the chief executive officer of Borrower as of the date hereof shall cease to be involved in the day to day operations (including research and development) or management of the business of Borrower, and a successor of such officer reasonably acceptable to Agent is not appointed on terms reasonably acceptable to Agent within 90 days of such cessation or involvement, (e) a “person” or “group” (within the meaning of the Securities Exchange Act of

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

42            

 

 


 

1934 and the rules of the SEC thereunder as in effect on the date hereof) becomes, directly or indirectly, the beneficial owner of equity interests in Quotient Limited representing more than 35% of the aggregate ordinary voting power represented by the issued and outstanding equity interests of Quotient Limited or a majority of the seats (other than vacant seats) on the board of directors of Quotient Limited shall at any time be occupied by persons who were neither (x) nominated by the board of directors of Quotient Limited nor (y) appointed by directors so nominated or (f) a “Change of Control” under the Statement of Rights occurs.  

Closing Date ” has the meaning given it in the preamble of this Agreement.

Code ” means the Uniform Commercial Code in effect on the date hereof, as the same may, from time to time, be enacted and in effect in the State of Maryland; provided, however , that to the extent that the Code is used to define any term herein or in any Financing Document and such term is defined differently in different Articles or Divisions of the Code, the definition of such term contained in Article or Division 9 shall govern; and provided, further , that in the event that, by reason of mandatory provisions of Law, any or all of the attachment, perfection, or priority of, or remedies with respect to, Agent’s Lien on any Collateral is governed by the Uniform Commercial Code in effect in a jurisdiction other than the State of Maryland, the term “ Code ” shall mean the Uniform Commercial Code as enacted and in effect in such other jurisdiction solely for purposes of the provisions thereof relating to such attachment, perfection, priority, or remedies and for purposes of definitions relating to such provisions.

Collateral ” means all property, now existing or hereafter acquired, mortgaged or pledged to, or purported to be subjected to a Lien in favor of, Agent, for the benefit of Agent and Lenders, pursuant to this Agreement and the other Financing Documents, including, without limitation, all of the property described in Exhibit A hereto.

Collateral Account ” means any Deposit Account, Securities Account or Commodity Account.

Commitment Commencement Date ” has the meaning given it in the Credit Facility Schedule.

Commitment Termination Date ” has the meaning given it in the Credit Facility Schedule.

Commodity Account ” means any “commodity account”, as defined in the Code, with such additions to such term as may hereafter be made.

Communication ” has the meaning given it in Article 11.

Compliance Certificate ” means a certificate, duly executed by an authorized officer of Borrower, appropriately completed and substantially in the form of Exhibit B .

Contingent Obligation ” means, for any Person, any direct or indirect liability, contingent or not, of that Person for (a) any indebtedness, lease, dividend, letter of credit or other obligation of another such as an obligation directly or indirectly guaranteed, endorsed, co‑made, discounted or sold with recourse by that Person, or for which that Person is directly or indirectly liable; (b) any obligations for undrawn letters of credit for the account of that Person; and (c) all obligations from any interest rate, currency or commodity swap agreement, interest rate cap or collar agreement, or other agreement or arrangement designated to protect a Person against fluctuation in interest rates, currency exchange rates or commodity prices; but “Contingent Obligation” does not include endorsements in the Ordinary Course of Business.  The amount of a Contingent Obligation is the stated or determined amount of the primary obligation for which the Contingent Obligation is made or, if not determinable, the maximum reasonably anticipated liability for it determined by the Person in good faith; but the amount may not exceed the maximum of the obligations under any guarantee or other support arrangement.

Control Agreement ” means any control agreement entered into among the depository institution at which a Credit Party maintains a Deposit Account or the securities intermediary or commodity intermediary at which a Credit Party maintains a Securities Account or a Commodity Account, such Credit Party, and Agent pursuant to which Agent obtains control (within the meaning of the Code) for the benefit of the Lenders over such Deposit Account, Securities Account or Commodity Account.

Corresponding Debt ” has the meaning given it in Section 14.13.

Credit Extension ” means an advance or disbursement of proceeds to or for the account of Borrower in respect of a Credit Facility.

Credit Extension Form ” means that certain form attached hereto as Exhibit C , as the same may be from time to time revised by Agent.

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

43            

 

 


 

Credit Facility ” means a credit facility specified on the Credit Facility Schedule.

Credit Party ” means Borrower, any Guarantor under a guarantee of the Obligations or any part thereof, and any other Person (other than Agent, a Lender or a participant of a Lender), whether now existing or hereafter acquired or formed, that becomes obligated as a borrower, guarantor, surety, indemnitor, pledgor, assignor or other obligor under any Financing Document, and any Person whose equity interests or portion thereof have been pledged or hypothecated to Agent under any Financing Document; and “ Credit Parties ” means all such Persons, collectively.

Default ” means any fact, event or circumstance which with notice or passage of time or both, could constitute an Event of Default.

Default Rate ” has the meaning given it in Section 2.6(b).

Deposit Account ” means any “deposit account” as defined in the Code with such additions to such term as may hereafter be made.

Designated Funding Account ” is the Wells Account.

Dollars , dollars ” and “ $ ” each means lawful money of the United States.

Draw Period ” means, for each Credit Facility, the period commencing on the Commitment Commencement Date and ending on the Commitment Termination Date.

Eligible Assignee ” means (a) a Lender, (b) an Affiliate of a Lender, (c) an Approved Fund, and (d) any other Person (other than a natural person) approved by Agent; provided, however , that notwithstanding the foregoing, “Eligible Assignee” shall not include any Credit Party or any Subsidiary of a Credit Party.  Notwithstanding the foregoing, in connection with assignments by a Lender due to a forced divestiture at the request of any regulatory agency, the restrictions set forth herein shall not apply and Eligible Assignee shall mean any Person or party becoming an assignee incident to such forced divestiture.

Environmental Law ” means all present and future any law (statutory or common), ordinance, treaty, rule, regulation, order, policy, other legal requirement or determination of an arbitrator or of a Governmental Authority and/or Required Permits imposing liability or standards of conduct for or relating to the regulation and protection of human health, safety, the workplace, the environment and natural resources, and including public notification requirements and environmental transfer of ownership, notification or approval statutes.

Equipment ” means all “equipment”, as defined in the Code, with such additions to such term as may hereafter be made, and includes without limitation all machinery, fixtures, goods, vehicles (including motor vehicles and trailers), and any interest in any of the foregoing.

ERISA ” means the Employee Retirement Income Security Act of 1974, and all regulations promulgated thereunder.

Event of Default ” has the meaning given it in Section 10.1.

Exigent Circumstance ” has the meaning given it in Section 13.14.

Federal Funds Rate ” means, for any day, the rate per annum equal to the weighted average of the rates on overnight Federal funds transactions with members of the Federal Reserve System arranged by Federal funds brokers on such day, as published by the Federal Reserve Bank of New York on the Business Day next succeeding such day, provided that if no such rate is so published on such next succeeding Business Day, the Federal Funds Rate for such day shall be the average rate quoted to Agent on such day on such transactions as determined by Agent in a commercially reasonable manner.

Fee Letters ” means, collectively, the fee letter agreements among Borrower and Agent and Borrower and each Lender.

Financing Documents ” means, collectively, this Agreement, the Perfection Certificate, the Security Documents, the Fee Letter(s), each note and guarantee executed by one or more Credit Parties in connection with the indebtedness governed by this Agreement, and each other present or future agreement executed by one or more Credit Parties and, or for the benefit of, the Lenders and/or Agent in connection with this Agreement, all as amended, restated, or otherwise modified from time to time.

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

44            

 

 


 

Foreign Lender ” has the meaning given it in Section 2.6(h)(iii).

Foreign Security Documents ” means the Scottish Security Documents, the Jersey Security Documents and the Swiss Security Documents.

Funding Date means any date on which a Credit Extension is made to or on account of Borrower which shall be a Business Day.

GAAP means generally accepted accounting principles set forth in the opinions and pronouncements of the Accounting Principles Board of the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or in such other statements by such other Person as may be approved by a significant segment of the accounting profession in the United States, which are applicable to the circumstances as of the date of determination.

General Intangibles means all “general intangibles”, as defined in the Code, with such additions to such term as may hereafter be made, and includes without limitation, all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work, whether published or unpublished, any patents, trademarks, service marks and, to the extent permitted under applicable Law, any applications therefor, whether registered or not, any trade secret rights, including any rights to unpatented inventions, payment intangibles, royalties, contract rights, goodwill, franchise agreements, purchase orders, customer lists, route lists, telephone numbers, domain names, claims, income and other tax refunds, security and other deposits, options to purchase or sell real or personal property, rights in all litigation presently or hereafter pending (whether in contract, tort or otherwise), insurance policies (including, without limitation, key man, property damage, and business interruption insurance), payments of insurance and rights to payment of any kind.

Governmental Authority means any nation or government, any state or other political subdivision thereof, any agency, authority, instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative functions of or pertaining to government, any securities exchange and any self-regulatory organization.

Guarantor means each Person that is or hereafter becomes a party to this Agreement as a guarantor of the Obligations.  As of the Closing Date, the Guarantors are Quotient Limited, Alba Bioscience Limited, QBD (QSIP) Limited and Quotient Suisse SA.

Hazardous Materials ” means petroleum and petroleum products and compounds containing them, including gasoline, diesel fuel and oil; explosives, flammable materials; radioactive materials; polychlorinated biphenyls and compounds containing them; lead and lead-based paint; asbestos or asbestos-containing materials; underground or above-ground storage tanks, whether empty or containing any substance; any substance the presence of which is prohibited by any Laws; toxic mold, any substance that requires special handling; and any other material or substance now or in the future defined as a “hazardous substance,” “hazardous material,” “hazardous waste,” “toxic substance,” “toxic pollutant,” “contaminant,” “pollutant” or other words of similar import within the meaning of any Environmental Law, including:  (a) any “hazardous substance” defined as such in (or for purposes of) CERCLA, or any so-called “superfund” or “superlien” Law, including the judicial interpretation thereof; (b) any “pollutant or contaminant” as defined in 42 U.S.C.A. § 9601(33); (c) any material now defined as “hazardous waste” pursuant to 40 C.F.R. Part 260; (d) any petroleum or petroleum by-products, including crude oil or any fraction thereof; (e) natural gas, natural gas liquids, liquefied natural gas, or synthetic gas usable for fuel; (f) any “hazardous chemical” as defined pursuant to 29 C.F.R. Part 1910; (g) any toxic or harmful substances, wastes, materials, pollutants or contaminants (including, without limitation, asbestos, polychlorinated biphenyls (“PCB’s”), flammable explosives, radioactive materials, infectious substances, materials containing lead-based paint or raw materials which include hazardous constituents); and (h) any other toxic substance or contaminant that is subject to any Environmental Laws or other past or present requirement of any Governmental Authority.  

Hazardous Materials Contamination ” means contamination (whether now existing or hereafter occurring) of the improvements, buildings, facilities, personalty, soil, groundwater, air or other elements on or of the relevant property by Hazardous Materials, or any derivatives thereof, or on or of any other property as a result of Hazardous Materials, or any derivatives thereof, generated on, emanating from or disposed of in connection with the relevant property.

Indebtedness means, without duplication of amounts described by more than one of the following, (a) indebtedness for borrowed money (including the Obligations) or the deferred price of property or services, such as reimbursement and other obligations for surety bonds and letters of credit (other than trade accounts payable in the Ordinary Course of Business and liabilities associated with customer prepayments and deposits), (b) obligations evidenced by notes, bonds, debentures or similar instruments, (c) capital lease obligations, (d) non-contingent obligations of such Person to reimburse any bank or other Person in respect of amounts paid under a letter of credit, banker’s acceptance or similar instrument, (e) equity securities of such Person subject to repurchase or redemption other than at the sole option of such Person, (f) obligations secured by a Lien on any asset of such Person, whether or not

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

45            

 

 


 

such obligation is otherwise an obligation of such Person, (g) “earnouts”, purchase price adjustments, profit sharing arrangements, deferred purchase money amounts and similar payment obligations or continuing obligations of any nature of such Person arising out of purchase and sale contracts, (h) all Indebtedness of others guaranteed by such Person, (i) off-balance sheet liabilities and/or pension plan or multiemployer plan liabilities of such Person, (j) obligations arising under non-compete agreements, (k) obligations arising under bonus, deferred compensation, incentive compensation or similar arrangements, other than those arising in the Ordinary Course of Business, and (l) Contingent Obligations.

Indemnitee ” has the meaning given it in Section 13.2.

Initial Payment Date ” has the meaning given it in the Amortization Schedule .

Insolvency Proceeding means any proceeding by or against any Person under the United States Bankruptcy Code, or any other bankruptcy or insolvency Law, including (i) any procedures set out in Article 8 of the Interpretation (Jersey) Law 1954 or an application is made to declare that the property is en desastre, and (ii) assignments for the benefit of creditors, compositions, extensions generally with its creditors, or proceedings seeking reorganization, arrangement, or other relief.

Intellectual Property includes without limitation, all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work, whether published or unpublished, any patents, patent applications and like protections, including improvements, divisions, continuations, renewals, reissues, extensions, and continuations-in-part of the same, trademarks, trade names, service marks, mask works, rights of use of any name, domain names, or any other similar rights, any applications therefor, whether registered or not, know-how, operating manuals, trade secret rights, clinical and non-clinical data, rights to unpatented inventions, and any claims for damage by way of any past, present, or future infringement of any of the foregoing.

Intellectual Property Security Agreement” means that certain Intellectual Property Security Agreement, dated as of the date hereof, by and among Agent, Borrower, QBD (QSIP) Limited and Alba Bioscience Limited.

Inventory ” means all “inventory”, as defined in the Code, with such additions to such term as may hereafter be made, and includes without limitation all merchandise, raw materials, parts, supplies, packing and shipping materials, work in process and finished products, including without limitation such inventory as is temporarily out of Borrower’s custody or possession or in transit and including any returned goods and any documents of title representing any of the above.

Investment ” means, with respect to any Person, directly or indirectly, (a) to purchase or acquire any stock or stock equivalents, or any obligations or other securities of, or any interest in, any Person, including the establishment or creation of a Subsidiary, (b) to make or commit to make any acquisition (including through licensing) of (i) of all or substantially all of the assets of another Person, or (ii) any business, Products, business line or product line, division or other unit operation of any Person or (c) make or purchase any advance, loan, extension of credit or capital contribution to, or any other investment in, any Person.

Jersey Security Documents ” means the Jersey Security Interest Agreement in relation to the shares in QBD (QS IP) Limited and any other security document as may be executed from time to time in favor of the Agent which is governed by the laws of Jersey and grants a Lien to secure the Obligations, in each case, as amended, restated, supplemented or otherwise modified from time to time .

Joinder Requirements ” has the meaning set forth in Section 6.8.

Laws ” means any and all federal, state, provincial, territorial, local and foreign statutes, laws, judicial decisions, regulations, guidance, guidelines, ordinances, rules, judgments, orders, decrees, codes, plans, injunctions, permits, concessions, grants, franchises, governmental agreements and governmental restrictions, whether now or hereafter in effect, which are applicable to any Credit Party in any particular circumstance.

Lender ” means any one of the Lenders.

Lenders ” means the Persons identified on the Credit Facility Schedule as amended from time to time to reflect assignments made in accordance with this Agreement.

Libor Rate Index ” means, for any Applicable Interest Period, the rate per annum, determined by Agent (rounded upwards, if necessary, to the next 1/100th%) by dividing (a) the rate per annum, determined by Agent in accordance with its customary procedures, and utilizing such electronic or other quotation sources as it considers appropriate (rounded upwards, if necessary, to the next 1/100%), to be the rate at which Dollar deposits (for delivery on the first day of such Applicable Interest Period or, if such day is

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

46            

 

 


 

not a Business Day, on the preceding Business Day) in the amount of One Million Dollars ($1,000,000) are offered to major banks in the London interbank market on or about 11:00 a.m. (New York time) on the Applicable Interest Rate Determination Date, for a period of thirty (30) days, which determination shall be conclusive in the absence of manifest error, by (b) 100% minus the Reserve Percentage; provided, however, that Agent may, upon prior written notice to any Borrower, choose a reasonably comparable index or source to use as the basis for the Libor Rate Index . The Libor Rate Index may be adjusted by Agent with respect to any Lender on a prospective basis to take into account any additional or increased costs to such Lender of maintaining or obtaining any eurodollar deposits or increased costs, in each case, due to changes in applicable Law occurring subsequent to the commencement of the then Applicable Interest Period, including changes in tax laws (except changes of general applicability in corporate income tax laws) and changes in the reserve requirements imposed by the Board of Governors of the Federal Reserve System (or any successor), which additional or increased costs would increase the cost of funding loans bearing interest based upon the Libor Rate Index; provided, however, that notwithstanding anything in this Agreement to the contrary, (i) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives thereunder or issued in connection therewith and (ii) all requests, rules, guidelines or directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities, in each case pursuant to Basel III, shall in each case be deemed to be a “change in applicable Law”, regardless of the date enacted, adopted or issued.  In any such event, the affected Lender shall give Borrower and Agent notice of such a determination and adjustment and Agent promptly shall transmit the notice to each other Lender and, upon its receipt of the notice from the affected Lender, Borrower may, by notice to such affected Lender require such Lender to furnish to Borrower a statement setting forth the basis for adjusting such Libor Rate Index and the method for determining the amount of such adjustment.  

Lien ” means a claim, mortgage, deed of trust, lien, levy, charge, pledge, security interest or other encumbrance of any kind, whether voluntarily incurred or arising by operation of Law or otherwise against any property.

Luxembourg Holding Company ” means that certain company to be formed under the laws of Luxembourg for the purpose of owning 100% of the equity of Quotient Suisse, Alba Bioscience Limited, and the Borrower .

Material Adverse Change ” means (a) a material impairment in the perfection or priority of the Agent’s Lien (or any Lender’s Lien therein to the extent provided for in the Financing Documents) in the Collateral; (b) a material impairment in the value of the Collateral; (c) a material adverse change in the business, operations, or condition (financial or otherwise) of the Credit Parties, taken as a whole; or (d) a material impairment of the prospect of repayment of any portion of the Obligations.

Material Agreement ” means (a) the agreements listed in the Disclosure Schedule, (b) each agreement or contract to which a Credit Party is a party relating to licensure of Material Intellectual Property or development of Products which are material to the business of the Credit Parties or Material Intellectual Property, (c) the Scottish Lease Documents, and (d) any agreement or contract to which such Credit Party or its Subsidiaries is a party the termination of which could reasonably be expected to result in a Material Adverse Change.  

Material Indebtedness ” has the meaning given it in Section 10.1.

Maturity Date ” means August 3, 2019.

Maximum Lawful Rate ” has the meaning given it in Section 2.6(g).

MidCap ” has the meaning given it in the preamble of this Agreement.

MosaiQ CE Mark ” the signifier that the MosaiQ Device the MosaiQ Blood Grouping Consumable conform with all European Community directives that apply to such items, in accordance with Regulation (EC) No 765/2008, Decision No 768/2008/EC and any other applicable legislation of the European Union providing for its application.

MosaiQ CE Mark Approval Date ” means the date on which the MosaiQ CE Mark is obtained.

MosaiQ™ Blood Grouping Consumable ” means a consumable product designed for Blood Grouping when used in conjunction with the MosaiQ Device.

MosaiQ Consumables ” means the MosaiQ Blood Grouping Consumable.

MosaiQ Consumables Sale Date ” means the first day on which the MosaiQ Blood Grouping Consumable is sold in the European Union.

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

47            

 

 


 

MosaiQ Device ” means the instrument being developed by Quotient for use in Blood Grouping that is known as the MosaiQ™ instrument.

Obligations ” means all of Borrower’s obligations to pay when due any debts, principal, interest, Protective Advances, fees, indemnities and other amounts Borrower owes the Agent or Lenders now or later, under this Agreement or the other Financing Documents, including, without limitation, interest accruing after Insolvency Proceedings begin (whether or not allowed) and debts, liabilities, or obligations of Borrower assigned to the Lenders and/or Agent, and the payment and performance of each other Credit Party’s covenants and obligations under the Financing Documents.  “Obligations” does not include obligations under any warrants issued to Agent or a Lender.

OCD Agreement ” means that certain Distribution and Supply Agreement, dated as of January 29, 2015, by and among Quotient Suisse, QBD (QS IP) Limited and Ortho-Clinical Diagnostics, Inc., a New York corporation, as in effect on the date hereof.

OFAC ” means the U.S. Department of Treasury Office of Foreign Assets Control.

OFAC Lists ” means, collectively, the Specially Designated Nationals and Blocked Persons List maintained by OFAC pursuant to Executive Order No. 13224, 66 Fed. Reg. 49079 (Sept. 25, 2001) and/or any other list of terrorists or other restricted Persons maintained pursuant to any of the rules and regulations of OFAC or pursuant to any other applicable Executive Orders.

Operating Documents ” means, for any Person, such Person’s formation documents, and with respect to the Borrower, shall be certified with the Secretary of State of such Person’s state of formation on a date that is no earlier than thirty (30) days prior to the Closing Date, and (a) if such Person is a corporation, its bylaws in current form, (b) if such Person is a limited liability company, its limited liability company agreement (or similar agreement), and (c) if such Person is a partnership, its partnership agreement (or similar agreement), each of the foregoing with all current amendments or modifications thereto.

Ordinary Course of Business ” means, in respect of any transaction involving any Credit Party, the ordinary course of business of such Credit Party, as conducted by such Credit Party in accordance with past practices, which shall in any event be at arms-length.

Parallel Debt ” has the meaning given it in Section 14.13.

Payment Date ” means the first calendar day of each calendar month.

Perfection Certificate ” means the Perfection Certificate delivered to Agent as of the Closing Date, together with any amendments thereto required under this Agreement.

Permitted Contingent Obligations ” means (a) Contingent Obligations resulting from endorsements for collection or deposit in the Ordinary Course of Business; (b) Contingent Obligations incurred in the Ordinary Course of Business with respect to surety and appeal bonds, performance bonds and other similar obligations not to exceed One Hundred Thousand Dollars ($100,000) in the aggregate at any time outstanding; (c) Contingent Obligations arising under indemnity agreements with title insurers; (d) Contingent Obligations arising with respect to customary indemnification obligations in favor of purchasers in connection with dispositions of personal property assets permitted under Article 7; (e) so long as there exists no Event of Default both immediately before and immediately after giving effect to any such transaction, Contingent Obligations existing or arising under any swap contract, provided, however, that such obligations are (or were) entered into by Borrower or an Affiliate in the Ordinary Course of Business for the purpose of directly mitigating risks associated with liabilities, commitments, investments, assets, or property held or reasonably anticipated by such Person and not for purposes of speculation; (f) other Contingent Obligations not permitted by clauses (a) through (e) above, not to exceed One Hundred Thousand Dollars ($100,000) in the aggregate at any time outstanding and (g) Contingent Obligations arising under the Scottish Lease Guarantee.  

Permitted Distributions ” means the following distributions:  (a) dividends by any Credit Party or Subsidiary of any Credit Party to another Credit Party provided that the Agent, for the benefit of the Lenders under this Agreement and the other Financing Documents, has a first priority, perfected security interest in all or substantially all of the assets of the Credit Party to which such dividend is made; (b) dividends payable solely in common stock; (c) repurchases pursuant to the terms of employee stock purchase plans, employee restricted stock agreements or similar plans and (d) distributions consisting of the preferential dividend in connection with the Preference Shares, provided that any such dividend may not be paid in cash and the Preference Shares may not be redeemed until a date that is 91 days following the payment in full of the Obligations.

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

48            

 

 


 

Permitted Indebtedness ” means:  (a) Borrower’s Indebtedness to the Lenders and Agent under this Agreement and the other Financing Documents; (b) Indebtedness existing on the Closing Date and described on the Disclosure Schedule ; (c) Indebtedness secured by Permitted Liens; (d) Subordinated Debt; (e) unsecured Indebtedness to trade creditors incur red in the Ordinary Course of Business; (f) Permitted Contingent Obligations; (g) extensions, refinancings, modifications, amendments and restatements of any items of Permitted Indebtedness (b) and (c) above, provided, however , that the principal amount thereof is not increased or the terms thereof are not modified to impose more burdensome terms upon the obligors thereunder; (h) Indebtedness consisting of intercompany loans and advances made by any Credit Party to any other Credit Party, provided that (1) the obligations of the Credit Parties under such intercompany loan shall be subordinated at all times to the Obligations of the Credit Parties hereunder or under the other Financing Documents in a manner satisfactory to Agent and (2) to the extent that such Indebtedness is evidenced by a promissory note or other written instrument, Borrower shall pledge and deliver to Agent, for the benefit of itself and the Lenders, the original promissory note or instrument, as applicable, along with an endorsement in blank in form and substance satisfactory to Agent; (i) Indebtedness consisting of the preferential dividend in connection with the Preference Shares, provided that any such dividend may not be paid in cash and the Preference Shares may not be redeemed until a date that is 91 days following the payment in full of the Obligations; and (j) Indebtedness of Credit Parties arising under the Scottish Lease Documents.

Permitted Investments ” means:  (a) Investments existing on the Closing Date and described on the Disclosure Schedule ; (b) Investments consisting of cash equivalents; (c) any Investments in liquid assets permitted by Borrower’s investment policy, as amended from time to time, provided that such investment policy (and any such amendment thereto) has been approved in writing by Agent; (d) Investments consisting of the endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of any Credit Party’s business; (e) Investments consisting of deposit accounts or securities accounts in which the Agent has a first priority perfected security interest except as otherwise provided by Section 6.6; (f) Investments by any Credit Party in any other Credit Party (following compliance with Section 6.8 ); (g) Investments consisting of (i) travel advances and employee relocation loans and other employee loans and advances in the Ordinary Course of Business, and (ii) loans to employees, officers or directors relating to the purchase of equity securities of Borrower or its Subsidiaries pursuant to employee stock purchase plans or agreements approved by Borrower’s board of directors; (h) Investments (including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement of delinquent obligations of, and other disputes with, customers or suppliers arising in the Ordinary Course of Business, (i) Investments consisting of intercompany Indebtedness in accordance with and to the extent permitted by clause (h) of the definition of “Permitted Indebtedness” and (j) Investments made by Credit Parties pursuant to and in accordance with the terms of the Scottish Lease Documents.  

Permitted Liens ” means: (a) Liens existing on the Closing Date and shown on the Disclosure Schedule or arising under this Agreement and the other Financing Documents; (b) purchase money Liens (i) on Equipment acquired or held by a Credit Party incurred for financing the acquisition of the Equipment securing no more than Two Hundred Thousand Dollars ($200,000) in the aggregate amount outstanding, or (ii) existing on Equipment when acquired, if the Lien is confined to the property and improvements and the proceeds of the Equipment; (c) Liens for taxes, fees, assessments or other government charges or levies, either not delinquent or being contested in good faith and for which adequate reserves are maintained on the Books of the Credit Party against whose asset such Lien exists, provided that no notice of any such Lien has been filed or recorded under the Internal Revenue Code of 1986, as amended, and the treasury regulations adopted thereunder; (d) statutory Liens securing claims or demands of materialmen, mechanics, carriers, warehousemen, landlords and other Persons imposed without action of such parties, provided that they have no priority over any of Agent’s Lien and the aggregate amount of such Liens for all Credit Parties does not any time exceed Fifty Thousand Dollars ($50,000); (e) leases or subleases of real property granted in the Ordinary Course of Business, and leases, subleases, non-exclusive licenses or sublicenses of property (other than real property or Intellectual Property) granted in the Ordinary Course of Business, if the leases, subleases, licenses and sublicenses do not prohibit granting Agent a security interest; (f) banker’s liens, rights of set-off and Liens in favor of financial institutions incurred made in the Ordinary Course of Business arising in connection with a Credit Party’s Collateral Accounts provided that such Collateral Accounts are subject to a Control Agreement to the extent required hereunder; (g) Liens to secure payment of workers’ compensation, employment insurance, old-age pensions, social security and other like obligations incurred in the Ordinary Course of Business (other than Liens imposed by ERISA); (h) Liens arising from judgments, decrees or attachments in circumstances not constituting an Event of Default; (i) easements, reservations, rights-of-way, restrictions, minor defects or irregularities in title and similar charges or encumbrances affecting real property not constituting a Material Adverse Change; (j) Liens incurred in the extension, renewal or refinancing of the indebtedness secured by Liens described in (a) and (b) above, but any extension, renewal or replacement Lien must be limited to the property encumbered by the existing Lien and the principal amount of the Indebtedness may not increase; (k) liens on cash and cash equivalents held in deposit accounts or securities accounts to the extent they secure obligations in respect of corporate credit cards issued to officers or directors of Quotient Suisse in the ordinary course of business (which deposit accounts or securities accounts are maintained exclusively for such corporate credit cards); provided that the amount in such deposit accounts or securities accounts shall not exceed 25,000 Swiss Francs in the aggregate at any time and (l) liens granted in favor of Scottish Enterprise pursuant to and in accordance with the Scottish Lease Security Agreement.  

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

49            

 

 


 

Person ” means any individual, sole proprietorship, partnership, limited liability company, joint venture, company, trust, unincorporated organization, association, corporation, institution, public benefit corporation, firm, joint stock company, estate, entity or government agency.

“Preference Shares ” means those certain preference shares as further described on the Statement of Rights attached hereto as Exhibit D .

Pro Rata Share ” means, as determined by Agent, with respect to each Credit Facility and Lender holding an Applicable Commitment or Credit Extensions in respect of such Credit Facility, a percentage (expressed as a decimal, rounded to the ninth decimal place) determined by dividing (a) in the case of fully-funded Credit Facilities, the amount of Credit Extensions held by such Lender in such Credit Facility by the aggregate amount of all outstanding Credit Extensions for such Credit Facility, and (b) in the case of Credit Facilities that are not fully-funded, the amount of Credit Extensions and unfunded Applicable Commitments held by such Lender in such Credit Facility by the aggregate amount of all outstanding Credit Extensions and unfunded Applicable Commitments for such Credit Facility.

Protective Advances ” means all audit fees and expenses, costs, and expenses (including reasonable attorneys’ fees and expenses) of Agent and Lenders for preparing, amending, negotiating, administering, defending and enforcing the Financing Documents and the Warrants (including, without limitation, those incurred in connection with appeals or Insolvency Proceedings) or otherwise incurred by Agent or the Lenders in connection with the Financing Documents and the Warrants.

QBD (QS IP) Limited ” means QBD (QS-IP) Limited, a corporation incorporated under the laws of Jersey, Channel Islands, with registered number 109469.

Quotient Limited ” means Quotient Limited, a company incorporated under the laws of Jersey with registered number 109886.

Quotient Suisse ” means Quotient Suisse S.A., a company formed under the laws of Switzerland.

Redemption Date ” means the fourth anniversary of the issue date of the relevant Preference Shares, as may be extended pursuant to Section 2.3.2 of the Statement of Rights.

Registered Organization ” means any “registered organization” as defined in the Code, with such additions to such term as may hereafter be made.

Required Lenders ” means, unless all of the Lenders and Agent agree otherwise in writing, Lenders having (a) more than sixty percent (60%) of the Applicable Commitments of all Lenders, or (b) if such Applicable Commitments have expired or been terminated, more than sixty percent (60%) of the aggregate outstanding principal amount of the Credit Extensions.  

Required Permit ” means all licenses, certificates, accreditations, product clearances or approvals, provider numbers or provider authorizations, supplier numbers, provider numbers, marketing authorizations, other authorizations, registrations, permits, consents and approvals of a Credit Party (a) issued or required under Laws applicable to the business of Borrower or any of its Subsidiaries or necessary in the manufacturing, importing, exporting, possession, ownership, warehousing, marketing, promoting, sale, labeling, furnishing, distribution or delivery of goods or services under Laws applicable to the business of Borrower or any of its Subsidiaries, or (b) issued by any Person from which Borrower or any of its Subsidiaries have received an accreditation.  Without limiting the generality of the foregoing, “ Required Permits ” includes any Drug Application (including without limitation, at any point in time, all licenses, approvals and permits issued by the FDA or any other applicable Governmental Authority necessary for the testing, manufacture, marketing or sale of any Product by Borrower as such activities are being conducted by Borrower with respect to such Product at such time) and any drug listings and drug establishment registrations under 21 U.S.C. Section 510, registrations issued by DEA under 21 U.S.C. Section 823 (if applicable to any Product), and those issued by State governments for the conduct of Borrower’s or any Subsidiary’s business.

“Reservations” means:

 

(a)

the principle that equitable remedies may be granted or refused at the discretion of a court and the limitation of enforcement by laws relating to insolvency, reorganization and other laws generally affecting the rights of creditors;

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

50            

 

 


 

 

(b)

the time barring of claims under Laws relating to the limitation of claims, the possibility that an undertaking to assume liability for or indemnify a person against non-payment of UK stamp duty or other equivalent Taxes in any relevant jurisdiction may be void and defenses of set-off or counterclaim;  

 

(c)

similar principles, rights and defenses under the Laws of any relevant jurisdiction; and

 

(d)

any other matters which are set out as qualifications or reservations as to matters of law of general application in any legal opinions delivered to the Agent or the Lenders pursuant to the provisions of this Agreement.

Reserve Percentage ” means, on any day, for any Lender, the maximum percentage prescribed by the Board of Governors of the Federal Reserve System (or any successor Governmental Authority) for determining the reserve requirements (including any basic, supplemental, marginal, or emergency reserves) that are in effect on such date with respect to eurocurrency funding (currently referred to as “eurocurrency liabilities”) of that Lender, but so long as such Lender is not required or directed under applicable regulations to maintain such reserves, the Reserve Percentage shall be zero.

Responsible Officer ” means any of the President and Chief Executive Officer or Chief Financial Officer of Borrower or Quotient Limited, as the context may require.  

Scottish Lease Documents ” means (i) that certain Ground Lease to be entered into following the Closing Date between Scottish Enterprise and Alba Bioscience Limited, together with all annexes, schedules and exhibits thereto, all in a form substantially similar to, and with terms not materially less favorable to Credit Parties, Agent and Lenders than, the forms attached hereto as Exhibit D (the “ Scottish Ground Lease ”) (ii) that certain offer letter, to be issued following the Closing Date by Shepherd and Wedderburn LLP, as agents for Scottish Enterprise in favor of Alba Bioscience Limited, together with all annexes, schedules and exhibits thereto, all in a form substantially similar to, and with terms not materially less favorable to Credit Parties, Agent and Lenders than, the forms attached hereto as Exhibit E, (iii) that certain guarantee to be made following the Closing Date by Quotient Limited in favor of Scottish Enterprise, together with all annexes, schedules and exhibits thereto, all in a form substantially similar to, and with terms not materially less favorable to Credit Parties, Agent and Lenders than, the forms attached hereto as Exhibit (the “ Scottish Lease Guarantee ”), and (iv) that certain standard security to be made following the Closing Date by Alba Bioscience Limited in favor of Scottish Enterprise, together with all annexes, schedules and exhibits thereto, all in a form substantially similar to, and with terms not materially less favorable to Credit Parties, Agent and Lenders than, the forms attached hereto as Exhibit G (the “ Scottish Lease Security Agreement ”).

Scottish Security Documents ” means (i) the bond and floating charge dated on or about the Original Closing Date by Alba Bioscience Limited in favor of the Agent and (ii) the pledge of shares dated on or about the date hereof by Quotient Limited in favor of the Agent, in each case as amended, restated, supplemented or otherwise modified from time to time.

Secretary’s Certificate ” means, with respect to any Person, a certificate, in form and substance satisfactory to Agent, executed by such Person’s secretary on behalf of such Person certifying that (a) such Person has the authority to execute, deliver, and perform its obligations under each of the Financing Documents to which it is a party, (b) that attached as Exhibit A to such certificate is a true, correct, and complete copy of the Borrowing Resolutions then in full force and effect authorizing and ratifying the execution, delivery, and performance by such Person of the Financing Documents to which it is a party, (c) the name(s) of the Person(s) authorized to execute the Financing Documents on behalf of such Person, together with a sample of the true signature(s) of such Person(s), and (d) that Agent and the Lenders may conclusively rely on such certificate unless and until such Person shall have delivered to Agent a further certificate canceling or amending such prior certificate.

Secured Promissory Note ” has the meaning given it in Section 2.7.

Security Documents ” means the Foreign Security Documents and each other agreement, document or instrument executed concurrently herewith or at any time hereafter pursuant to which one or more Credit Parties or any other Person provides, as security for all or any portion of the Obligations, a Lien on any of its assets in favor of Agent for its own benefit and the benefit of the Lenders, as any or all of the same may be amended, supplemented, restated or otherwise modified from time to time.

Securities Account ” means any “securities account”, as defined in the Code, with such additions to such term as may hereafter be made.

Stated Rate ” has the meaning given it in Section 2.6(g).

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

51            

 

 


 

Statement of Rights ” means that certain Statement of Rights in relation to Preference Shares in the capital of the Company, made by Quotient Limited on or about January 26, 2015.

Subordinated Debt ” means indebtedness incurred by any Credit Party which shall be (a) in an amount satisfactory to Agent, (b) made pursuant to documents in form and substance satisfactory to Agent (the “ Subordinated Debt Documents ”), and (c) subordinated to all of such Credit Party’s now or hereafter indebtedness to the Agent and Lenders pursuant to a Subordination Agreement.

Subordination Agreement ” means a subordination, intercreditor, or other similar agreement in form and substance, and on terms, approved by Agent in writing.

Subsidiary ” means, with respect to any Person, any Person of which more than fifty percent (50.0%) of the voting stock or other equity interests (in the case of Persons other than corporations) is owned or controlled, directly or indirectly, by such Person.

Swiss Assignment Agreement ” means that certain Assignment Agreement, dated as of the Closing Date, by Quotient Limited and Quotient Suisse in favor of Agent, as amended, restated, supplemented or otherwise modified from time to time.

Swiss Security Documents ” means the Swiss Share Pledge and the Swiss Assignment Agreement.

Swiss Share Pledge ” means, collectively, that certain Restated and Amended Share Pledge Agreement and that certain Restatement Amendment Agreement Relating to the Share Pledge Agreement, pursuant to which Quotient Limited granted a continuing pledge and security interest in the equity interest of Quotient Suisse, as amended, restated, supplemented or otherwise modified from time to time.

“Swiss Withholding Tax” means taxes imposed under the Swiss Withholding Tax Act.

“Swiss Withholding Tax Act” means the Swiss Federal Act on the Withholding Tax of 13 October 1965 (Bundesgesetz über die Verrechnungssteuer), together with the related ordinances, regulations and guidelines, all as amended and applicable from time to time.

Tax Credit ” means a credit against, relief or remission for, or repayment of, any Tax.

Tax Payment ” means either the increase in a payment made by a Credit Party to the Agent or a Lender under Section 2.6(h)(i) or a payment under Section 2.6(h)(ii).

Taxes ” has the meaning given it in Section 2.6(h).

Testing Date ” means the 15 th day of each calendar month.

Transfer ” has the meaning given it in Section 7.1.

Warrants ” means the First Tranche Warrants, the Second Tranche Warrants and the Third Tranche Warrants.  

Wells Account ” has the meaning given it in Section 6.6.

[SIGNATURES APPEAR ON FOLLOWING PAGE(S)]

 

 

 

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

52            

 

 


 

IN WITNESS WHEREOF , intending that this instrument constitute an instrument executed and delivered under seal, the parties hereto have caused this Agreement to be executed as of the Closing Date.

 

BORROWER:

 

Quotient Biodiagnostics, Inc.

 

 

 

By:

 

/s/Paul Cowan _________________(SEAL)

Name:

 

Paul Cowan

Title:

 

Chairman and Chief Executive Officer

 

GUARANTORS:

 

Quotient Limited

 

 

 

By:

 

/s/Paul Cowan _________________(SEAL)

Name:

 

Paul Cowan

Title:

 

Chairman and Chief Executive Officer

 

Alba Bioscience Limited

 

 

 

By:

 

/s/Paul Cowan _________________(SEAL)

Name:

 

Paul Cowan

Title:

 

Chairman and Chief Executive Officer

 

QBD (QSIP) Limited

 

 

 

By:

 

/s/Paul Cowan _________________(SEAL)

Name:

 

Paul Cowan

Title:

 

Chairman and Chief Executive Officer

 

Quotient Suisse SA

 

 

 

By:

 

/s/Paul Cowan _________________(SEAL)

Name:

 

Paul Cowan

Title:

 

Chairman and Chief Executive Officer

 

AGENT:

 

 

 

MIDCAP FINANCIAL TRUST

 

By:

 

Apollo Capital Management, L.P.,

its investment manager

 

 

 

By:

 

Apollo Capital Management GP, LLC,

its general partner

 

 

 

By:

 

/s/Maurice Amsellem_____________(SEAL)

Name:

 

Maurice Amsellem

Title:

 

Authorized Signatory

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

1            

 

 


 

 

LENDERS:

 

 

 

MIDCAP FUNDING V TRUST

 

By:

 

Apollo Capital Management, L.P.,

its investment manager

 

 

 

By:

 

Apollo Capital Management GP, LLC,

its general partner

 

 

 

By:

 

/s/Maurice Amsellem_____________(SEAL)

Name:

 

Maurice Amsellem

Title:

 

Authorized Signatory

 

MIDCAP FUNDING XIII TRUST

 

By:

 

Apollo Capital Management, L.P.,

its investment manager

 

 

 

By:

 

Apollo Capital Management GP, LLC,

its general partner

 

 

 

By:

 

/s/Maurice Amsellem_____________(SEAL)

Name:

 

Maurice Amsellem

Title:

 

Authorized Signatory

 

 

 

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

2            

 

 


 

Exhibit 10.1

EXECUTION VERSION

EXHIBITS AND SCHEDULES

 

EXHIBITS 

 

 

 

Exhibit A

 

Collateral

Exhibit B

 

Form of Compliance Certificate

Exhibit C

 

Credit Extension Form

Exhibit D

 

Statement of Rights

Exhibit E

 

Scottish Ground Lease

Exhibit F

 

Offer Letter

Exhibit G

 

Scottish Lease Guaranty

Exhibit H

 

Scottish Lease Security Agreement

Exhibit I

 

Form of Assignment Agreement

 

SCHEDULES

Credit Facility Schedule

Amortization Schedule (for each Credit Facility)

Post-Closing Obligations Schedule

Closing Deliveries Schedule

Disclosure Schedule

Intellectual Property Schedule

Products Schedule

Required Permits Schedule

Minimum Net Product Revenue Schedule

 

 

 

 


 

EXHIBIT A

COLLATERAL

The Collateral consists of all assets of each Credit Party, including all of such Credit Party’s right, title and interest in and to the following personal property:

all goods, Accounts (including health-care insurance receivables), Equipment, Inventory, contract rights or rights to payment of money, leases, license agreements, franchise agreements, General Intangibles, commercial tort claims, documents, instruments (including any promissory notes), chattel paper (whether tangible or electronic), cash, deposit accounts, investment accounts, commodity accounts and other Collateral Accounts, all certificates of deposit, fixtures, letters of credit rights (whether or not the letter of credit is evidenced by a writing), securities, and all other investment property, supporting obligations, and financial assets, whether now owned or hereafter acquired, wherever located; and

all of such Credit Party’s Books relating to the foregoing, and any and all claims, rights and interests in any of the above and all substitutions for, additions, attachments, accessories, accessions and improvements to and replacements, products, proceeds and insurance proceeds of any or all of the foregoing.

Midcap / Quotient / Amended and Restated Credit Agreement


 

EXHIBIT B

COMPLIANCE CERTIFICATE

 

TO:

 

MidCap Financial Trust, as Agent

FROM:

 

__________________________________

DATE:

 

________________, 201__

The undersigned authorized officer of Quotient Biodiagnostics, Inc. (“ Borrower ”) certifies that under the terms and conditions of the Credit, Guaranty and Security Agreement between Borrower, Agent and the Lenders (as amended, restated, supplemented, replaced or otherwise modified from time to time, the “ Agreement ”):

(1) Borrower is in complete compliance with all required covenants for the month ending _______________, 201__, except as noted below;

(2) there are no Events of Default;

(3) all representations and warranties in the Agreement are true and correct in all material respects on this date except as noted below; provided, however , that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided, further, that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date ;

(4) Each of Borrower and the other Credit Parties has timely filed all required tax returns and reports, and has timely paid all foreign, federal, state and local taxes, assessments, deposits and contributions owed except as otherwise permitted pursuant to the terms of the Agreement; and

(5) no Liens have been levied or claims made against Borrower or any of its Subsidiaries relating to unpaid employee payroll or benefits of which Borrower has not previously provided written notification to Agent.  

Attached are the required documents supporting the certifications set forth in this Compliance Certificate.  The undersigned certifies, in his/her capacity as an officer of the Borrower, that these are prepared in accordance with GAAP consistently applied from one period to the next except as explained in an accompanying letter or footnotes.  The undersigned acknowledges, in his/her capacity as an officer of Borrower, that no borrowings may be requested at any time or date of determination that Borrower is not in compliance with any of the terms of the Agreement, and that compliance is determined not just at the date this certificate is delivered.  Capitalized terms used but not otherwise defined herein shall have the meanings given them in the Agreement.

 

Please indicate compliance status by circling Yes/No under “Complies” column.

 

Reporting Covenant

Required

Complies

Monthly Financial Statements

Monthly within 45 days

Yes          No

Audited Financial Statements

Annually within 120 days after FYE

Yes          No

Board Approved Projections

Annually within 60 days after FYE

Yes          No

Compliance Certificate

Monthly within 45 days

Yes          No

Financial Covenant

Required

Actual

Complies

Pursuant to Section 8.2(a), maintain at all times (tested monthly, unless otherwise noted) Minimum Net Product Revenue for the trailing twelve month period of:

$_________

$_________

Yes          No

Pursuant to Section 8.2(b), maintain as of the last day of each calendar month unrestricted cash and cash equivalents of:

$10,000,000.00

$_________

Yes          No

 

The following are the exceptions with respect to the certification above:  (If no exceptions exist, state “No exceptions to note.”)

 

------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Midcap / Quotient / Amended and Restated Credit Agreement


 

 

Quotient Biodiagnostics, Inc.

 

AGENT USE ONLY

 

 

 

 

 

 

 

 

 

 

 

 

 

Received by:

 

 

By:

 

__________________________

 

authorized signer

 

 

Name:

 

__________________________

 

Date:

 

 

Title:

 

__________________________

 

 

 

 

 

 

 

 

Verified:

 

 

 

 

 

 

authorized signer

 

 

 

 

 

 

Date:

 

 

 

 

 

 

 

 

 

 

 

 

 

Compliance Status:

 

Yes        No

Midcap / Quotient / Amended and Restated Credit Agreement


 

EXHIBIT C

CREDIT EXTENSION Form

Deadline is Noon E.S.T.

Date: __________________, 201__

 

Loan Advance:

 

Complete Outgoing Wire Request section below if all or a portion of the funds from this loan advance are for an outgoing wire.

 

From Account #  _____________________________          To Account # ______________________________

(Loan Account #)                                                           (Deposit Account #)

 

Amount of Advance $

 

All Borrower’s representations and warranties in the Credit, Guaranty and Security Agreement are true, correct and complete in all material respects on the date of the request for an advance; provided, however , that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided, further , that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date:

 

Authorized Signature:                                                            Phone Number: _______________________                

Print Name/Title: ____________________________  

 

 

Outgoing Wire Request:

 

Complete only if all or a portion of funds from the loan advance above is to be wired.

 

Beneficiary Name: ____________________________________________________________________________

                       Amount of Wire: $_____________________________

Beneficiary Lender: _________________________________

                       Account Number: _____________________________  

City and State: _______________________________

 

Beneficiary Lender Transit (ABA) #: _____________         Beneficiary Lender Code (Swift, Sort, Chip, etc.): ____

(For International Wires Only)

Intermediary Lender: __________________________        Transit (ABA) #: ______________________________

 

For Further Credit to: __________________________________________________________________________

Special Instruction: ___________________________________________________________________________  

 

By signing below, I (we) acknowledge and agree that my (our) funds transfer request shall be processed in accordance with and subject to the terms and conditions set forth in the agreements(s) covering funds transfer service(s), which agreements(s) were previously received and executed by me.

 

Authorized Signature: ________________________    2 nd Signature (if required): __________________________

Print Name/Title: ___________________________       Print Name/Title: _________________________________  

Telephone #: _______________________________      Telephone #:______________________________________

 

Midcap / Quotient / Amended and Restated Credit Agreement


 

EXHIBIT D

PREFERENCE SHARES

QUOTIENT LIMITED

(the " Company ")

Statement of Rights

in relation to Preference Shares in the capital of the Company

This statement of rights sets out the rights, obligations and restrictions applicable to preference shares of no par value in the capital of the Company (" Preference Shares ").

Capitalised terms used in this statement of rights and not defined herein shall, unless the context requires otherwise, have the meanings given to them in the articles of association of the Company (the " Articles "). The provisions of regulations 2.2 to 2.17 (inclusive) of the Articles shall apply to the interpretation of this statement of rights as if set out in full herein.

In addition, the following terms shall have the following meanings when used in this statement of rights:

(a)

" Accrual Date " means 31 March, 30 June, 30 September and 31 December in each calendar year;

(b)

" Accrual Period " means the period from 1 January to 31 March, 1 April to 30 June, 1 July to 30 September or 1 October to 31 December, as applicable;

(c)

" Affiliate " means, in relation to a holder of Preference Shares (the " Original Member "):

(i) where the Original Member is a body corporate, any holding body of the Original Member and any other body corporate which is a subsidiary of the Original Member or any holding body of the Original Member;

(ii) in any case, any person acting as nominee or custodian of or for the Original Member where beneficial title to the relevant Preference Shares remains vested in the Original Member; and

(iii) where the Original Member is Ortho-Clinical Diagnostics Finco S.à r.l., any direct or indirect subsidiary of OCD Bermuda;

(d)

" Change of Control " means any change in the ownership of the Company which confers Control on any "person" or "group" (as such terms are used in Sections 13(d) and 14(d) of the Exchange Act) who does/do not immediately prior to such change exercise Control;

(e)

" Control " means:

(i) the ownership, directly or indirectly, of shares in the capital of the Company which together confer more than 50% of the voting rights attaching to all issued shares in the capital of the Company;

(ii) the ownership, directly or indirectly, of shares in the capital of the Company and having the right to appoint or remove a majority of the board of directors of the Company; or

(iii) the ownership, directly or indirectly, of shares in the capital of the Company and controlling alone, pursuant to an agreement with other shareholders or members, a majority of the voting rights in the Company;

(f)

" Exchange Act " means the U.S. Securities Exchange Act of 1934, as amended;

(g)

" Holder Redemption Trigger Date " means the fourth anniversary of the issue date of the relevant Preference Share, as may be extended pursuant to paragraph 2.3.2 below;

Midcap / Quotient / Amended and Restated Credit Agreement


 

(h)

" Insolvency Event " means any one of the following:  

(i) a notice having been issued to convene a meeting for the purpose of passing a resolution to wind up the Company, or such a resolution having been passed other than a resolution for the solvent reconstruction or reorganization of the Company or for the purpose of inclusion of any part of the share capital of the Company in the Official List of the London Stock Exchange or in the list of the New York Stock Exchange or quotation of the same on the National Association of Securities Dealers Automated Quotation System or any other international stock exchange;

(ii) a resolution having been passed by the Company's directors or shareholders to seek a winding up order or a petition for a winding up order (in each case within the meanings given to those terms under the laws of England and Wales) or application for a declaration of désastre having been presented against the Company which has not been dismissed or withdrawn within 30 days of its presentation, or any analogous action is taken in a jurisdiction other than England and Wales;

(iii) a resolution having been proposed by the Company to appoint an administrator, or to apply to court for an administration order, or an application for an administration order having been lodged with the court whether or not by the Company or any step is taken pursuant to the Insolvency Act 1986, Schedule B1 and/or the Insolvency Rules 1986 (in each case of the United Kingdom) to appoint an administrator out of court or the Company enters administration (in each case within the meanings given to those terms under the laws of England and Wales), or any analogous action that is taken in a jurisdiction other than England and Wales;

(iv) a receiver, administrative receiver, receiver and manager, court appointed receiver, interim receiver, custodian, sequestrator or similar officer (in each case within the meanings given to those terms under the laws of England and Wales) is appointed in respect of the Company or over any part of the Company's assets or any Third Party takes steps to appoint such an officer in respect of the Company or an encumbrancer takes steps to enforce or enforces its security over any part of the Company's assets, or any analogous action that is taken in a jurisdiction other than England and Wales including but not limited to the appointment or application to appoint a liquidator or the Viscount of the Royal Court of Jersey in respect of the Company or any of its assets;

(v) a moratorium comes into force in respect of the Company or the Company's directors resolve to make a proposal for a voluntary arrangement or meetings are convened for consideration of a proposal for a voluntary arrangement made in relation to the Company under Part I and/or Schedule A1 of the Insolvency Act 1986 of the United Kingdom, or any analogous action that is taken in a jurisdiction other than England and Wales;

(vi) an application or proposal in respect of the Company is made under Part 26 of the Companies Act 2006 of the United Kingdom (as amended), Article 125 of the Law or any analogous action that is taken in a jurisdiction other than England and Wales;

(vii) a step or event having been taken or arisen outside the United Kingdom which is similar or analogous to any of the steps or events listed above including under the United States Bankruptcy Code (including a filing under Chapter 11 proceedings) or other relevant laws of the United States of America which shall not have been appealed within seven days of having been lodged or such an order shall having been made and not dismissed within 30 days thereafter;

(viii) the Company takes any step, whether under the Insolvency Act 1986 of the United Kingdom or otherwise (including starting negotiations), with a view to readjustment, rescheduling or deferral of any part of the Company's indebtedness, or proposes or makes any general assignment, composition or arrangement with or for the benefit of all or some of the Company's creditors or makes or suspends or threatens to suspend making payments to all or some of the Company's creditors or the Company submits to any type of voluntary arrangement (in each case within the meanings given to those terms under the laws of England and Wales), or any analogous action that is taken in a jurisdiction other than England and Wales;

(ix) where the Company is unable to pay or has no reasonable prospect of being able to pay its debts within the meaning of Section 123 Insolvency Act 1986 of the United Kingdom, but disregarding references in the Insolvency Act 1986 of the United Kingdom to proving this inability to the court's satisfaction, or any analogous event that is taken in a jurisdiction other than England and Wales including but not limited to the Company being unable to discharge its liabilities as they fall due for the purposes of the Law or the Bankruptcy (Désastre) (Jersey) Law 1990; or

Midcap / Quotient / Amended and Restated Credit Agreement


 

(x) the Company is or becomes bankrupt within the meaning given to that term in the Interpretation (Jersey} Law 1954,

for which purpose:

(1) " Group Affiliate " means, with respect to any Person, any other Person which directly or indirectly controls, is controlled by, or is under common control with, the first Person, provided that, with respect to OCD, for so long as OCD is controlled by OCD Bermuda or one or more Subsidiaries of OCD Bermuda, "Group Affiliate" shall only mean OCD Bermuda and its Subsidiaries (including future Subsidiaries) (and for the purposes of this definition, a Person shall be regarded as in control of another Person if it owns, or directly or indirectly controls, at least 50 per cent of the voting stock or other ownership interest of the other Person, or if it directly or indirectly possesses the power to direct or cause the direction of the management and policies of the other Person by any means whatsoever);

(2) " OCD " means Ortho-Clinical Diagnostics, Inc., a corporation incorporated under the laws of New York having its principal place of business at 1001 US Highway Route 202, Raritan, New Jersey 08869;

(3) " Person " means any individual, corporation, partnership, trust, business trust, association, joint stock company, joint venture, pool, syndicate, sole proprietorship, unincorporated organization, governmental authority or other form of entity not specifically listed in the foregoing;

(4) " Subsidiary " means, with respect to any Person, any other Person which directly or indirectly is controlled by such Person (eg a direct or indirect subsidiary corporation) (and for the purposes of this definition, a Person shall be regarded as in control of another Person if it owns, or directly or indirectly controls, at 50 per cent of the voting stock or other ownership interest of the other Person, or if it directly or indirectly possesses the power to direct or cause the direction of the management and policies of the other Person by any means whatsoever); and

(5) " Third Party " means and Person other than the Company, OCD and any Group Affiliate of the Company or OCD;

(i) " OCD Bermuda " means Ortho-Clinical Diagnostics Bermuda Co. Ltd., a corporation incorporated under the laws of Bermuda with registered number 48588 having its registered office at Clarendon House, 2 Church Street, Hamilton, Bermuda HM11; and

(j) " Redemption Notice " means a notice served on the Company by a holder pursuant to paragraph 2.3.1 below or served on a holder by the Company pursuant to paragraph 2.3.3 or paragraph 2.3.4 below.

The rights, obligations and restrictions applicable to Preference Shares are as follows:

1. GENERAL

1.1 Extension of rights generally

Save as set out in paragraphs 1.2 to 1.5 below, Preference Shares shall confer on their holders all rights and be subject to all obligations and restrictions set out in the Articles which apply to shares and their holders.

1.2 Di stributio ns

Save as expressly provided in paragraph 2.1 below, Preference Shares shall not confer on their holders any right to participate in any distribution made by the company, whether of income, profits or otherwise.

1.3 C apit al

Save as expressly provided in paragraph 2.2.1 below, Preference Shares shall not confer on their holders any right to participate in the capital of the Company on a winding-up of the Company, a return of capital by the Company or otherwise.

Midcap / Quotient / Amended and Restated Credit Agreement


 

1.4 Voti ng

Preference Shares shall not confer on their holders any right to vote (either in person or by proxy and whether on a poll or on a show of hands) at any general meeting of the Company or be counted in determining the total number of votes which may be cast at any such meeting, or required for the purposes of an ordinary resolution or special resolution of any members or any class of members, or for the purposes of any other consent required under the Articles, save that the holders of Preference Shares shall be entitled to receive notice of, attend and vote at any meeting of the holders of Preference Shares as a class held pursuant to Article 10 of the Articles, and each Preference Share shall confer on its holder one vote at any such meeting on a poll.

1.5 As regards rights expressly applicable to Ordinary Shares only

Preference Shares shall not confer on their holders any rights, or subject their holders to any restrictions or obligations, set out in the Articles which expressly apply to Ordinary Shares and their holders only.

2. SP ECIFIC RIGHTS

The following provisions shall apply in relation to Preference Shares:

2.1 Incom e

 

2.1.1

Each Preference Share shall confer on its holder the right to a cumulative preferential dividend of 7% per annum of the amount paid up on that Preference Share on and from the date of issue of such Preference Share to (but excluding) the date of redemption of such Preference Share in accordance with paragraph 2.3 below or the capitalisation of the accrued but unpaid amount of such preferential dividend in accordance with paragraph 2.2.2 below (" Preferential Dividend ").

 

2.1.2

Preferential Dividend shall accrue quarterly in respect of each Accrual Period on each Accrual Date, provided that:

 

(a)

where a Preference Share is issued otherwise than on the first day of an Accrual Period, the amount of Preferential Dividend accruing on the first Accrual Date following the date of issue of such Preference Share shall be calculated pro rata on and from the date of issue to (and including) the first Accrual Date following the date of issue; and

 

(b)

where a Preference Share is redeemed otherwise than on an Accrual Date, the amount of Preferential Dividend accruing on the date of redemption of such Preference Share shall be calculated pro rata on and from the first day of the Accrual Period during which such redemption takes place to (but excluding including) the date of redemption,

in each case on the basis of a 90 day Accrual Period.

 

2.1.3

All accrued Preferential Dividend in respect of a Preference Share shall be paid in accordance with paragraphs 2.1.4, 2.1.5 and 2.3 below.

 

2.1.4

The Company shall have the right (but shall be under no obligation) to make payment from time to time of some or all of the then accrued but unpaid Preferential Dividend (in which case such payment shall be made in respect of all Preference Shares then in issue in proportion to the aggregate amount of Preferential Dividend then accrued and unpaid).

 

2.1.5

The Company shall pay all accrued but unpaid Preferential Dividend in respect of a Preference Share immediately before that Preference Share is redeemed in accordance with paragraph 2.3 below.

 

2.1.6

The Company shall not declare or pay any dividend or make any other distribution of income or profits to the holders of Ordinary Shares for so long as any accrued Preferential Dividend remains accrued but unpaid.

2.2 Liquidation

 

2.2.1

On a winding-up or liquidation of the Company, the Preference Shares then in issue shall rank pari passu with Ordinary Shares as regards the repayment of the amount paid up thereon.

Midcap / Quotient / Amended and Restated Credit Agreement


 

 

2.2.2

Immediately prior to a winding-up or liquidation of the Company, all accrued but unpaid Preferential Dividend in respect of Preference Shares then in issue shall (without the requirement for any further corporate action to be taken) be capitalised into new Preference Shares on the basis of one new Preference Share for each whole US$22.50 of Preferential Dividend accrued but unpaid in favour of a holder of Preference Shares (in fractions of shares if necessary).  

2.3 Redemption

Preference Shares which are fully paid up shall be redeemable in accordance with the following provisions:

 

2.3.1

The holder of a fully paid up Preference Share shall have the right to require the Company to redeem that Preference Share at any time on and from the Holder Redemption Trigger Date applicable to that Preference Share by notice to the Company (which notice may be served prior to the Holder Redemption Trigger Date but, if so served, shall not take effect until the Holder Redemption Trigger Date). Any Preference Shares subject to such a notice shall, subject to paragraph 2.3.6 below, be redeemed by the Company within 60 days of the date of service of such notice on the Company.

 

2.3.2

The Company shall have the right by notice to all the holders of Preference Shares to extend the Holder Redemption Trigger Date of all Preference Shares in one year increments, subject to a maximum extension of the Holder Redemption Trigger Date to the 10th anniversary of the issue date of a Preference Share. The Company shall have the right to extend the Holder Redemption Trigger Date once per calendar year, and for the avoidance of doubt such extension shall apply notwithstanding any Redemption Notice having been served. For the avoidance of doubt, the extension of the Holder Redemption Trigger Date shall not constitute a variation to the rights attaching to the Preference Shares which requires the sanction of the holders thereof in accordance with the Articles.

 

2.3.3

The Company shall have the right to redeem all or some only of the fully paid up Preference Shares at any time by notice to the holders thereof. Where some only of the Preference Shares are to be so redeemed, such redemption shall be effected as closely as possible amongst the holders of Preference Shares pro rata to the number of Preference Shares held by each such holder.

 

2.3.4

All of the fully paid up Preference Shares shall immediately be redeemed on a Change of Control. The Company shall give notice of such redemption to the holders of Preference Shares as soon as reasonably practicable following it becoming aware that such Change of Control is reasonably likely to take effect, and (unless the Company becomes aware that such Change of Control is reasonably likely to take effect after such time) such notice shall be served on the holders of the Preference Shares not less than 15 days before such Change of Control is anticipated to take effect. For the avoidance of doubt, notwithstanding such a notice having been served, no Preference Shares shall be required to be redeemed pursuant to this paragraph unless a Change of Control actually takes effect.

 

2.3.5

On the redemption of a Preference Share, the Company shall, within 30 days of the date of redemption thereof, pay to the holder of that Preference Share an amount equal to the amount paid up on that Preference Share. All redemption monies shall (unless the Company determines otherwise in its absolute discretion) be paid by cheque to the address of the relevant holder contained in the Register, provided that, in the case of joint holders, the redemption monies shall be paid to the holder whose name stands first in the Register.

 

2.3.6

If the Company is not permitted by law to redeem all of the Preference Shares due for redemption at the relevant time, the Company shall redeem the maximum number of Preference Shares it is lawfully able to redeem, and shall redeem the remaining Preference Shares due for redemption (whether by way of a single redemption or in tranches) as soon as reasonably practicable following it being lawfully able to do so (and where the Preference Shares due for redemption are held by more than one holder, such Preference Shares shall be redeemed pro rata to the aggregate number of Preference Shares held by each relevant holder thereof).

 

2.3.7

Each Redemption Notice shall specify the Preference Share(s) to be redeemed and, in the case of a Redemption Notice served by the Company:

 

(a)

may request that the relevant holder of Preference Shares provides to the Company bank account details for the purposes of making electronic payments of Preference Share redemption monies; and

 

(b)

may specify an address for service of documents pursuant to paragraph 2.3.8 below.

Midcap / Quotient / Amended and Restated Credit Agreement


 

 

2.3.8

As soon as possible following (and in any event within 10 days of) service of a Redemption Notice, each holder of Preference Shares to be redeemed shall deliver to the Company at its registered office (or such other the place as specified in the Redemption Notice pursuant to paragraph 2.3.7(b) above):  

 

(a)

the certificate(s) for the relevant Preference Shares; or

 

(b)

an indemnity in a form satisfactory to the board in respect of any lost or damaged certificate(s) for the relevant Preference Shares.

If a certificate so delivered includes Preference Shares not then redeemable, the Company shall following redemption of the Preference Shares then redeemable issue to the relevant holder a new certificate for the balance of Preference Shares not redeemed, without charge.

 

2.3.9

If a holder of a Preference Share to be redeemed fails to comply with its obligations pursuant to paragraph 2.3.8 above, the Company shall nevertheless be entitled to redeem the relevant Preference Shares but shall be entitled to retain the relevant redemption monies pending compliance by the relevant holder with its obligations pursuant to paragraph 2.3.8 above.

 

2.3.10

Upon the redemption of a Preference Share, the certificate in respect thereof shall be cancelled and the holder (or holders) thereof shall cease to be entitled to any rights in respect thereof and accordingly the name of such holder (or, in the case of joint holders, such holders) shall be removed from the Register with respect of such Preference Share.

2.4 Transfer restrictions

 

2.4.1

Subject to paragraph 2.4.2 below, no Preference Share shall be transferred without the prior written consent of the Board.

 

2.4.2

An Original Member or an Affiliate of an Original Member shall be entitled to transfer some or all of the Preference Shares of which it is a holder to:

 

(a)

any one of more Affiliates of the Original Member, provided that if any such transferee ceases to be an Affiliate of the Original Member such transferee shall immediately transfer the relevant Preference Shares to the Original Member. The Board shall not be obliged to register such a transfer unless, prior to registration thereof, the relevant holder has provided to the Board evidence reasonably satisfactory to the Board that the proposed transferee is an Affiliate of the Original Member;

 

(b)

any acquirer of all or substantially all of the non-cash assets of OCD Bermuda and its subsidiaries; or

 

(c)

any transferee chosen by the Original Member if an Insolvency Event occurs in relation to the Company.

2.5 Anti-dilution

The following provisions shall apply for so long as any Preference Shares are in issue:

 

2.5.1

Subject to paragraphs 2.5.2 and 2.5.3 below, and notwithstanding regulation 10.4 of the Articles, neither:

 

(a)

the creation, allotment and/or issue by the Company of any shares which confer on their holders any preferred, deferred or other special rights or restrictions, whether in regard to dividend, return of capital, transfer, voting, conversion or otherwise, as may be determined in accordance with regulation 4 of the Articles; or

 

(b)

the division of any shares in the capital of the Company (other than Preference Shares) into more shares (a stock split) or the consolidation of any shares in the capital of the Company (other than Preference Shares) into fewer shares (a reverse stock split),

shall constitute or be deemed to constitute a variation or abrogation of the rights attaching to the holders of the Preference Shares.

 

2.5.2

The Company shall not create, allot and/or issue any shares which confer on their holders any rights as regards participation in the income, profits, capital and/or assets of the Company, including without limitation by way of

Midcap / Quotient / Amended and Restated Credit Agreement


 

 

dividend, distribution or return of capital, which rank ahead of, in priority to or pari passu with the rights of the holders of Preference Shares pursuant to paragraphs 2.1.5 and/or 2.3 above (for this purpose, " relevant shares ") unless:  

 

(a)

the creation, allotment and issue of the relevant shares has been consented to or sanctioned (as applicable) by the holders of the requisite number or majority (as applicable) of Preference Shares in accordance with regulation 10.1 of the Articles (for which purpose the creation, allotment and/or issue of relevant shares shall be deemed to constitute a variation of the rights attaching to the Preference Shares); or

 

(b)

the rights attaching to the relevant shares are such that, on and from the applicable Holder Redemption Trigger Date (as it may be extended by the Company pursuant to paragraph 2.3.2 above but not in any event later than the 10th anniversary of the issue date of a Preference Share), the rights attaching to the relevant shares (i) shall as regards rights to participate in the income, profits, capital and/or assets of the Company rank pari passu with, or rank behind, the rights attaching to the Preference Shares and (ii) shall in no way prevent, restrict or impair the rights of the holder(s) of that Preference Shares pursuant to paragraphs 2.1.5 and 2.3 above to be redeemed and receive the payments described in paragraphs 2.1.5 and 2.3.5 above.

 

2.5.3

If:

 

(a)

any shares in the capital of the Company (other than Preference Shares) are divided into more shares or consolidated into fewer shares (whether by share division or consolidation, share dividend, recapitalization or other similar transaction) or the Company issues any bonus shares; and

 

(b)

such division or consolidation or issue of bonus shares (as applicable) would or could reduce the entitlement of the holders of Preference Shares to participate in the income, profits, capital and/or assets of the Company pursuant to paragraphs 2.1.5, 2.2 and/or 2.3 above,

the number of Preference Shares then in issue shall (automatically and without any further corporate action being required on the part of the Company) be divided or consolidated (as applicable) so that there is no proportionate dilution in the total number of Preference Shares then in issue as compared to the total number of issued shares in the capital of the Company (and the amount paid up on each Preference Share following such division or consolidation shall be adjusted accordingly), and any resolution of the Company passed pursuant to Article 38A of the Law or otherwise in connection with any such division or consolidation of shares in the capital of the Company (other than Preference Shares) shall (irrespective of the express wording of such resolution) be deemed, for the purposes of Article 38A of the Law and for all other purposes, to include a special resolution to divide or consolidate (as applicable) the number of Preference Shares then in issue and adjust the amount paid up on each Preference Share then in issue in accordance with the foregoing provisions.

Midcap / Quotient / Amended and Restated Credit Agreement


 

EXHIBIT E

SCOTTISH GROUND LEASE

(See attached)

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

GROUND LEASE

between

Scottish Enterprise

and

Alba Bioscience Limited

 

Subjects:  Site 3, Bio Campus, Roslin, Midlothian

 

 

 

 

Shepherd and Wedderburn LLP

191 West George Street

Glasgow

G2 2LB

DX GW409 Glasgow

T: +44 (0)141 566 9900

F: +44 (0)141 565 1222

www.shepwedd.co.uk

 


 

CONTENTS

 

Clause

 

 

 

Page No

 

 

 

 

 

1.

 

Definitions and Interpretations

 

2

 

 

 

 

 

2.

 

The Grant

 

4

 

 

 

 

 

3.

 

Rent/Interest/Payment of Net Premium

 

4

 

 

 

 

 

4.

 

Tenants' Monetary Obligations

 

4

 

 

 

 

 

5.

 

Tenants Non Monetary Obligations

 

5

 

 

 

 

 

6.

 

Landlords Warranty and Assurances

 

8

 

 

 

 

 

7.

 

Irritancy

 

8

 

 

 

 

 

8.

 

Acceptance of Rent/No Waiver/Rei Interitus

 

8

 

 

 

 

 

9.

 

Title Transfer

 

9

 

 

 

 

 

10.

 

Notices

 

9

 

 

 

 

 

11.

 

Registration

 

10

 

 

 

 

 

 

 

Schedule

 

11

 

 

 

 

 

 

 

Part 1 The Subjects

 

11

 

 

 

 

 

 

 

Part 2 Landlord's Reserved Rights

 

12

 

 

 

 

 

 

 

Part 3 Title Transfer Provisions

 

13

 

 

 

 

 

 

 

Part 4 Approved Plans and Specification

 

15

 

 

 

 

 

 

 

Part 5 Disposition

 

16

 

 

 

 

 

 

 

Part 6 Plan

 

17

(1)


 

LEASE

between

SCOTTISH ENTERPRISE , established under the Enterprise and New Towns (Scotland) Act 1990 and having their principal place of business at Atrium Court, 50 Waterloo Street, Glasgow (who and whose successors are hereinafter referred to as "the Landlords")

and

ALBA BIOSCIENCE LIMITED, company incorporated under the Companies Acts (Registered Number SC310584) and having their Registered Office at Douglas Building, Pentlands Science Park, Bush Loan, Penicuik, Midlothian, EH26 0PL (who and whose permitted successors and assignees are hereinafter referred to as "the Tenants").

Definitions and Interpretations

In this Lease (including this sub-clause and the Schedule) the following words and expressions shall have the following meanings:-

 

"Advance Notice"

 

an advance notice as defined in section 56 of the 2012 Act;

 

 

 

"Architect"

 

means such suitably qualified firm of architects as may be employed or instructed by the Tenants to be the architect in connection with the Development Works;

 

 

 

"Approved Plans"

 

the detailed plans and specifications relating to the Development Works approved by the Landlords and contained in Part 4 of the Schedule subject to any permitted variations in terms of Clauses 5.4 and 5.5 of this Lease;

 

 

 

"Base Rate"

 

the Base Rate of the Bank of Scotland from time to time or in the case of the said Base Rate ceasing to exist such other equivalent rate as the Landlords (acting reasonably) may determine;

 

 

 

"Building Contract"

 

means the building contract relative to the execution of the Development Works entered into by the Tenants;

 

 

 

"Condam Regulations"

 

the Construction (Design and Management) Regulations 2015;

 

 

 

"Construction Expert"

 

a building surveyor practising in Scotland having not less than 10 years’ experience of substantial property development projects such as the Development Works, such surveyor to be jointly appointed by the parties to this Lease, or in the event of failure to agree upon the surveyor by the date falling 10 Working Days after the date of intimation by either party to the other of a dispute to be determined in terms of Clause 5.27 to be nominated by the President of the Scottish Branch of the RICS upon request by either party;

 

 

 

"Date of Practical Completion"

 

the date that a Certificate of Practical Completion is issued in terms of this Lease;

 

 

 

"Delay Event"

 

(a) any event or circumstance which would entitle the contractor under the JCT suite of standard form of building contracts or other form of industry standard building contracts as amended an extension of time (but excluding delays attributable to an act, default, omission or the financial circumstances of the Developer);  and (b) any act, default or omission of the Landlords, the Landlord's Representative or the Landlord's  agents, employees or contractors;

 

 

 

“Development Works”

 

means [detail] as shown on the Approved Plans;

 

 

 

“Disposition”

 

means the disposition contained in Part 5 of the Schedule;

 

 

 

"Duration"

 

the period of 99 years from (and including) the [insert Date of Entry] to [          ] 2115;

 

 

 

"Lease"

 

this ground lease;

 

 

 

"Necessary Consents"

 

all planning consents required under the Planning Acts, building warrants and all other consents required from any statutory authority, person, property owner or body that are required to enable the Development Works to be commenced and completed;

(2)


 

 

 

 

"Net Premium"

 

the sum of NINE HUNDRED AND EIGHTY SIX THOUSAND, EIGHT HUNDRED POUNDS (£986,800) exclusive of VAT;

 

 

 

“Net Premium Interest Rate”

 

means 4%;

 

 

 

“Plan”

 

the plan of the Subjects contained in Part 6 of the Schedule;

 

 

 

“Planning Acts”

 

the Town & Country Planning (Scotland) Acts 1947 to 1997, the Planning (Listed Buildings and Conservation Areas) (Scotland) Act 1997, the Planning (Hazardous Substances) (Scotland) Act 1997, the Planning (Consequential Provisions) (Scotland) Act 1997, the Local Government and Planning (Scotland) Act 1982, the Town & Country Planning Act 1984, the Planning and Compensation Act 1991 and any other legislation from time to time in force relating to planning matters;

 

 

 

“Practical Completion”

 

means the date on which the Development Works are deemed practically complete in terms of the Ground Lease;

 

 

 

“Quarter Days”

 

means 28 February, 28 May, 28 August and 28 November in each year and the expressions “Quarter Day” and the relevant “Quarter Day” shall be construed accordingly;

 

 

 

"Reserved Rights"

 

the reserved rights in favour of the Landlords described in Part 2 of the Schedule;

 

 

 

"Schedule"

 

the schedule of six parts annexed and executed as relative hereto;

 

 

 

"SE Representative"

 

means [     ] or such other party appointed by the Landlords and notified to the Tenants in writing;

 

 

 

"Specified Rate"

 

the rate of 4 per centum per annum above the base rate of the Royal Bank of Scotland;

 

 

 

"Subjects"

 

the subjects described in Part 1 of the Schedule;

 

 

 

"Title Transfer Provisions"

 

the heritable title transfer provisions set out in Part 3 of the Schedule;

 

 

 

"Validly Executed"

 

executed in accordance with the requirements of Section 3 and 7 and Schedule 2 of the Requirements of Writing (Scotland) Act 1995;

 

 

 

"Working Day"

 

any day other than a Saturday, Sunday or Public Holiday in Glasgow, Edinburgh or London; and

 

 

 

"2012 Act"

 

the Land Registration etc (Scotland) Act 2012.

In this Lease:-

Words importing the singular shall include the plural and words importing the masculine gender shall include the feminine gender and vice versa .  Where there are two or more persons included in the expression "the Tenants", obligations expressed to be undertaken by the Tenants shall be deemed to be undertaken by such persons jointly and severally.  The word "person" shall mean an individual, partnership, company, public authority or any other body whatsoever.

If the Tenants consist of a firm or partnership the obligations of the Tenants shall be binding jointly and severally not only on all persons who are partners of the firm at the time that this Lease is executed but also on all persons who shall become partners of the firm at any time during the Duration and their respective executors and representatives whomsoever as well as on the firm and its whole assets and such obligations shall subsist notwithstanding any change or changes which may take place in the name of the firm or constitution of the partnership.  The retiral, death or outgoing of any individual partner shall not of itself discharge such a partner or his executors from such partner's joint and several liability in terms of this Lease but the Landlords’ consent will not be unreasonably withheld to the discharge of any retiring or outgoing partner or the estate of any deceased partner where the remaining partners are demonstrably capable of fulfilling the obligations of the Tenants under this Lease If the Tenants comprise more than one person the Landlords shall be entitled to discharge any of the persons so comprised without in any way discharging any of the remaining persons so comprised in terms of this Lease.

Any reference to a statute or subordinate legislation shall include any modification, extension or re-enactment thereof for the time being in force and shall include all instruments, orders and regulations for the time being made, issued or given thereunder or deriving validity therefrom.

(3)


 

Any obligation by the Tenants not to do an act or thing shall be deemed to include an obligation not to agree or suffer or permit such act or thing to be done by any agent, employee, invitee, contractor or other for whom the Tenants are responsible in law.

Any reference to any act, omission or default of the Tenants shall be deemed to include an act, omission or default of their sub-tenants, agents, employees, invitees, contractors, licensees and others for whom they are responsible in law and/or the Tenants or their sub-tenants' respective predecessors in title.

The clause, paragraph and schedule headings in this Lease are for reference only and shall not affect the construction or interpretation of this Lease.

The Grant

In consideration of the payment of the Rent plus Value Added Tax due thereon, the Landlords hereby let to the Tenants the Subjects, but under reservation of the Reserved Rights and that for the Duration and on the terms and conditions contained in this Ground Lease.

Rent/Interest/Payment of Net Premium

The Tenants shall pay to the Landlords rent at the rate of ONE POUND (£1) per annum (exclusive of VAT) payable annually in arrears on the 31 st day of January in each year throughout the Duration, only if asked;

The Tenants shall pay to the Landlords without deduction, retention or demand yearly interest on the Net Premium at the Net Premium Interest Rate by equal quarterly instalments in advance on the Quarter Days by Bankers Order or such other method as the Landlords may from time to time direct until the Net Premium is paid by the Tenants to the Landlords in accordance with Clause 3.3.  The first payment will fall due on the Date of Entry and being a proportionate payment calculated on a daily basis over a year for the period from (and including) the Date of Entry until (but excluding) the Quarter Day next following; and

The Tenants will pay to the Landlords without deduction, retention or demand the Net Premium on the earlier of (i) Practical Completion; or (ii) the date falling two years after the Date of Entry.

Tenants' Monetary Obligations

The Tenants bind and oblige themselves during the entire Duration:-

To pay the rent from time to time payable in terms of this Lease in accordance with the provisions of Clause 3.1;

To pay the interest payable on the Net Premium in accordance with the provisions of Clause 3.2;

To pay the Net Premium in accordance with the provisions of Clause 3.3;

To pay all existing and future rates, taxes, charges, assessments, impositions and outgoings whatsoever (whether payable by the owner or occupier) charged, assessed or imposed on or in respect of the Subjects;

To pay on demand all expenses, costs, charges and fees properly and reasonably incurred by the Landlords in connection with

the enforcement of or procuring the remedy of any breach of any obligation on the Tenants in terms of this Lease;

in relation to every application for consent and approval made in terms of this Lease, whether such consent or approval is granted or refused in terms of the Lease.

To pay to the Landlords or to such other party as the Landlords may direct on demand the proportion applicable to the Subjects in terms of the title deeds or by statute, common law or otherwise of the costs and expenses of repairing, maintaining, renewing, rebuilding, lighting and cleansing of all roads, pavements, sewers, drains, pipes, water courses, walls, fences and any other structure or facility owned or used in common by the Subjects and other adjoining, neighbouring or nearby properties;

(4)


 

To pay to the Landlords any Value Added Tax and/or any other tax or charge of a similar nature as shall be properly chargeable in respect of all monies (including rent) undertaken to be paid by the Tenants under this Lease all which monies are for the avoidance of doubt expressed exclusive of Value Added Tax or such other tax as aforesaid; and

To pay to the Landlords on demand all costs incurred by the Landlords in connection with the monitoring of the Development Works in terms of this Lease up to a maximum of £10,000 plus VAT; such costs are to be payable no later than (i) Practical Completion or (ii) the date falling two years after the Date of Entry;

Save as expressly otherwise specified in this Lease to pay to the Landlords on demand interest at the Specified Rate on all sums due to the Landlords under this Lease from the due date for payment thereof until the date of actual receipt of payment in full by the Landlords, such interest to be calculated on a daily basis on any balances outstanding.

Tenants Non Monetary Obligations

The Tenants bind and oblige themselves throughout the entire duration as follows:-

The Tenants will commence with and proceed diligently in a good and workmanlike manner with the Development Works in accordance with the Approved Plans and the Necessary Consents.  

The Tenants undertake to the Landlords to complete the Development Works within twenty four months of the Date of Entry.

The timescales specified in Clause 5.2 shall be extended in respect of the occurrence of any Delay Event by the period of time properly attributable to such Delay Event.

The Tenant shall not make any alterations to or deviations from the Approved Plans or use any materials in substitution for those specified therein without the prior written consent of the Landlords which consent shall not be unreasonably withheld or delayed for any internal or non-material external alterations or additions which do not materially alter the Development Works.  Upon such consent being given, all such amended drawings, specifications illustrating such alterations or deviations shall be deemed to be incorporated in the Approved Plans. For the avoidance of doubt, in the event of a dispute as to whether any such alteration to or deviation from the Approved Plans or use of materials in substitution as aforesaid materially alters the Development Works then either party may refer the matter to the Construction Expert for determination in terms of Clause 5.27.  

Notwithstanding the provisions of Clause 5.4 above, no consent shall be required in the case of the following alterations to the Approved Plans:-

minor changes or variations of the sort normally instructed on a day to day basis under a building contract for works equivalent or similar to the Development Works ; and

internal alterations (including fitting-out works), which are not fundamental to the structural integrity of the building to be constructed on the Subjects;

For the avoidance of doubt, in the event of a dispute as to whether consent is required or not as aforesaid then either party may refer the matter to the Construction Expert for determination in terms of Clause 5.27.  

The Tenants accept the Subjects as being in all respects fit for full occupation and use by the Tenants and to carry out any formal obligations otherwise incumbent upon the Landlords and/or the owner of the Subjects whether at common law or by statute or otherwise.

To comply at the Tenant's expense with the provisions and requirements of all European Union and United Kingdom statutes and subordinate legislation, regulations and directives and any notices and directions issued thereunder (including without prejudice to the foregoing generality, the Planning Acts, the Factories Act 1961, the Offices, Shops and Railway Premises Act 1963, the Fire (Scotland) Act 2005, the Health and Safety at Work Etc Act 1974, the Environmental Protection Act 1990, the Environment Act 1995, the Construction (Design and Management) Regulations 2015 and the Control of Asbestos Regulations 2012) and to comply likewise with all provisions contained in the title deeds relating to the Subjects and all requirements or regulations of any competent authority relating to the Subjects and their use and that whether the said provisions are imposed on the owner or occupier of the Subjects.

(5)


 

Not to use or permit or suffer the buildings constructed on the Subjects or any part thereof to be used otherwise than for a use falling within [Manufacture of biotechnology products and/or research into the production of biotechnology products and/or development of processes for the production of biotechnology products] and without prejudice to the foregoing, not to:-

use the Subjects for a noxious, noisy, offensive, dangerous or immoral trade or business or for any purpose which, in the reasonable opinion of the Landlords may be or may cause a nuisance, noise, disturbance or inconvenience to the Landlords or to any occupier of premises in the neighbourhood;

bring on to the Subjects any hazardous, explosive, dangerous or combustible goods or materials;

Not to pass or allow to pass into the pipes, drains, sewers or other serving the Subjects any polluting agent or noxious or deleterious effluvia or any substance that may cause any obstruction or injury to the said pipes and others or otherwise cause contamination but to employ such plant for treating such effluent before it enters the drains as may be required by any local or public authority and make good and remedy any injury or contamination which occurs to the reasonable satisfaction of the Landlords, and not to permit any smoke, effluvia, vapour or grit to be emitted from the Subjects.

Not to do or permit anything on or in connection with the Subjects or any adjoining subjects which is likely to be a nuisance, obstruction, annoyance or cause of damage to the Landlords or to the owner or occupier of any adjoining or neighbouring property.  Without prejudice to the generality not to permit motor or other vehicles to obstruct or be parked or otherwise kept in any roads leading to the Subjects.

Not to assign or sublet this Lease in whole or in part without the prior consent of the Landlords.

Not to grant any fixed security or floating charge over the Tenant's interest in this Lease without the consent of the Landlords which consent is not to be unreasonably withheld or delayed in respect of a bona fide security or floating charge granted to any established national or international financial institution.  For the avoidance of doubt Landlords’ consent shall be deemed granted for any security granted in favour of the Landlords over the Tenants’ interest in the Lease.

Following Practical Completion of the Development Works to keep all buildings and other structures on the Subjects fully insured against loss or damage by fire, lightening, flooding, explosion, storm and tempest, impact, aircraft and such other risks as the Tenants may consider appropriate with a reputable insurance company for the full reinstatement value of such buildings and others (including site clearance and professional fees) and to produce to the Landlords on reasonable request evidence that the foregoing obligations have been complied with.

To free, relieve and indemnify the Landlords from and against any liability in respect of any injury to or the death of any person, damage to any property, heritable or movable, any interdict or court action, the infringement, disturbance or destruction of any right, servitude or privilege or otherwise by reason of or arising directly or indirectly out of the repair, state of repair or condition of the Subjects or any buildings or other structures thereon or any alteration or addition or improvement to the same or the use of the Subjects or from any act, omission or default of the Tenants in the implementation and observance of the obligations contained in this Lease from all proper fees, penalties, charges proceedings costs, claims, expenses and demands of whatsoever nature in respect of any such liability or alleged liability or any such act, omission or default, provided the same does not arise through the fault of the Landlords.

The Tenants will procure the making good of any damage to footpaths, roads, pavements or adjoining property within the larger bio campus of which the subjects form part and any services therein to the extent that such damage arises directly out of or by reason of the carrying out of the Development Works or any part thereof, all to the reasonable satisfaction of the SE Representative.

The SE Representative shall be entitled at any reasonably time on reasonable prior notice to enter on to the Subjects (but without impeding the progress of the Development Works and without giving any instructions in respect of the Development Works or otherwise and subject to the Landlords making good any damage caused thereby) to inspect the progress of the Development Works, to inspect materials and workmanship and generally to ensure that the Tenants are complying with its obligations under this Clause 5.

The SE Representative shall also be entitled to attend (as an observer only) the monthly design team meetings, and the Developer shall ensure that the SE Representative is given at least five working days’ prior written notice of and receives copies of the minutes of all such meetings.

The Tenants shall have due regard to any comments or representations made by the SE Representative in relation to the implementation of the Development Works in accordance with the terms of this Lease.

(6)


 

The Tenants shall in relation to the Development Works insure or cause to be insured the Subjects together with the Development Works from time to time from the date of commencement of the Development Works until the Practical Completion against all risks usually covered by a contractor's comprehensive "All Risks" policy.  The Tenants will when reasonably required produce to the Landlords evidence of such insurances.

In the event that any of the Development Works are destroyed or damaged by fire or other insured risks at any time before Practical Completion, then and as often as the same may happen, the Tenants shall procure that the monies paid by virtue of any insurance policy are applied forthwith towards carrying out and completing the Development Works and/or rebuilding, repairing or otherwise reinstating all damage to the Development Works in accordance with the provisions of this Lease.

In questions between the Tenants and the Landlords, the Tenants shall be "the client" for the purposes of the Condam Regulations and shall prior to the commencement of the Development Works make a declaration in writing to the Health & Safety Executive to the effect that it is the only client for the purposes of the Condam Regulations.  Copies of the declaration and any acknowledgement from the Health & Safety Executive shall be supplied to the Landlords upon request.

The Tenants shall procure that there is given to the SE Representative at least 10 Working Days’ notice of the anticipated date of Practical Completion and be given the opportunity to inspect the Development Works at or prior to the anticipated date of Practical Completion.

The Tenants shall deliver to the Landlords a copy of the Certificate of Practical Completion when issued (which may include a schedule of any works of an unfinished nature which would normally be the subject of a contractor’s snagging list (not including any items other than minor snagging items (“the snagging list”)).  In the event that the Landlords consider that notwithstanding the issue of Practical Completion, the Development Works have not been properly completed, then within a further 21 days (counting from the date of delivery of the Certificate of Practical Completion to the Landlords with reference to this clause of the Lease), the Landlords may refer the matter to the Construction Expert for determination in terms of Clause 5.27.  In the event of such a referral, the Development Works shall not be deemed to be complete in terms of the Lease until the Construction Expert has issued his determination.  In the event the Construction Expert determines that the Development Works have not been properly completed, the Tenants shall be required to carry out all further works required to complete the Development Works as specified by the Construction Expert before the Development Works are deemed complete for the purposes of the Lease.  In the event of any dispute as to whether the further works have been completed, either party may refer the matter to the Construction Expert for determination in terms of Clause 5.27.  The provisions of this clause shall be repeated until the Development Works are deemed complete for the purposes of the Lease by the Expert (or agreed to be complete by the parties).

If the Landlords do not make a reference to the Construction Expert within the 21 day period, then the Landlords shall be deemed to agree that the Development Works have been properly completed in accordance with the provisions of the Lease.

For the avoidance of doubt the Landlords shall not be permitted to make a reference to the Construction Expert because of the existence of the snagging list.

The Tenants shall exhibit to the Landlords within two months after the date of issue of the Certificate of Practical Completion an acceptance by the local authority of the issue of a Completion Certificate in respect of the Development Works.

All disputes, differences and questions between the Landlords and the Tenants, concerning, arising out of or connected with the execution or completion of the Development Works or any Delay Event shall be referred to the Construction Expert.

Any reference made under the provisions of Clause 5.27 may be made by the Landlords or the Tenants provided that they shall first have given the other party not less than 5 Working Days' notice of their intention to make such reference.

The Construction Expert shall be entitled to call on the Landlords or the Tenants to provide such records or other information as they may consider necessary for the purposes of resolving the dispute in question and the Landlords and the Tenants undertake to provide all such information in their possession or under their control as quickly as reasonably practicable.

The Construction Expert appointed to resolve the dispute under this Agreement:-

shall fully consider all written representations made by or on behalf of the Landlords or the Tenants which are delivered to him within 10 Working Days of his appointment, and shall thereafter give each party a further period of 5 Working Days within which to make further written representations thereon;

(7)


 

may call for such written evidence from the parties and seek such additional legal or expert assistance as they may reasonably require;

shall not accept oral representations from any party without allowing the other party the opportunity to be present and to give evidence and cross-examine each other;

shall have regard to all representations and evidence submitted when making his decision (which shall be in writing) and shall give reason for his decision;

shall use all reasonable endeavours to issue his decision (with reasons) within 20 Working Days of his appointment (or within such a longer period as may be agreed by the parties at the time of such appointment);

The decision of the Construction Expert in connection with any dispute shall be final and binding on the Landlords and the Tenants.

The fees and expenses and of the Construction Expert (including the fees of any party as to nominate such Expert) shall be payable by the Landlords and the Tenants in such proportions as the Construction Expert shall determine, or in default of such determination such be borne equally.

Landlords Warranty and Assurances

The Landlords warrant that the Tenants may, subject to the Reserved Rights, quietly enjoy the Subjects during the Duration.  Nothing contained in this Lease shall however be deemed to constitute any warranty by the Landlords that the Subjects or any part thereof are authorised for use under the Planning Acts or otherwise for any specific purpose or that the Subjects are fit for any of the Tenant's purposes under this Lease.

The Landlords shall not sell or dispose of or otherwise alienate their interest in the Subjects during the Duration, other than such a sale, disposal or alienation as aforesaid to a statutory successor of the Landlords, whom the Landlords shall specifically take bound (in self proving form addressed to the Tenants) to fulfil the Landlords’ obligations herein, including Clause 9 hereof.  

Irritancy

If the Tenants shall fail to perform or observe any of the obligations undertaken by them in this Lease or if the Tenants (being a corporation) shall go into liquidation, (whether compulsory or voluntary), or have a winding up order made against them or have a receiver or administrator appointed or if the Tenants (being a company with unlimited liability) apply to limit their liability or in the event that the Tenants or any of them enter into a composition for the benefit of creditors or shall make any arrangement with their creditors, or shall become insolvent or apparently insolvent or have a curator or judicial factor appointed then and in any of these events it shall be in the power of the Landlords by notice to bring this Lease to an end forthwith without any declarator or process of law to that effect and to remove the Tenants from possession of the Subjects, and repossess and enjoy the same as if this Lease had not been granted and that without prejudice to any other remedy of the Landlords in respect of any antecedent breach of any of the Tenants obligations hereunder, and under reservation of all rights and claims competent to the Landlords in terms of this Lease which irritancy is hereby deemed to be pactional and not penal and should not be purgeable at the bar.

In the case of a breach, non-observance or non-performance by the Tenants which is capable of being remedied, the Landlords shall not exercise any such option of forfeiture unless and until they shall first have given written notice to the Tenants and any other Relevant Third Party, specifying the breach, non-observance or non-performance and requiring the same to be remedied and intimating their intention to exercise their option of forfeiture the event of the said breach, non-observance or non-performance not being remedied within such period as may be stated in the notice (being such reasonable period of time as the Landlord shall stipulate in the notice which in the case of failure to pay monies due in terms of the Lease shall be a period of not less than fourteen days and in the case of failure to comply with the Tenants’ development obligations under Clause 5.2 shall be a period of not less than six months from the date of service of the notice) and the Tenants shall fail to have remedied the same within the period specified in the notice.

(8)


 

Acceptance of Rent/No Waiver/Rei Interitus

The demand for or acceptance of rent (or other sums) by the Landlords or their agents at any time shall not in any circumstances constitute nor be construed to be a waiver of any of the Tenant's obligations under this Lease nor of the Landlords remedies for breach thereof.

Notwithstanding any rule of law to the contrary this Lease shall not come to an end and shall not be capable of being brought to an end by either the Landlords or the Tenants by reason of damage or destruction of the Subjects or the Development Works but shall continue in full force and effect accordingly to its terms.

Title Transfer

At any time following the date of completion of the Development Works in accordance with the terms of this Lease and provided all payments due under Clause 3.2 and Clause 3.3 of this Ground Lease have been made by the Tenants to the Landlords the Tenants may serve written notice on the Landlords requiring the Landlords to grant a disposition of the Subjects in accordance with the Title Transfer Provisions.

Notwithstanding the foregoing, the Landlords may at any time serve written notice on the Tenants requiring the Tenants to accept a disposition of the Subjects in accordance with the Title Transfer Provisions.

Notices

All notices which require to be given in terms of this Lease shall be in writing and shall be deemed to be sufficiently given if sent by recorded delivery post addressed to :

in the case of the Tenants, to the Tenants (if a body corporate) at their Registered or Head Office and (if an individual) at his last known address in the United Kingdom and (if a partnership) to the partnership or any one or more of the partners thereof or at such other address as the Tenants may have notified in writing to the Landlords with reference to this Clause and to [                 ];

in the case of the Landlords, to the Head of Property, Scottish Enterprise, Atrium Court, 50 Waterloo Street, Glasgow, G2 6HQ and to Shepherd and Wedderburn LLP, 191 West George Street, Glasgow, G2 2LB (for the attention of GLM) or to such other address as the Landlords may have notified in writing to the Tenants with reference to this Clause.

Any such notice shall be deemed to be to have been served on the first Working Day after the date on which the same was posted.  In proving service, it shall be sufficient to prove that the envelope containing the notice was duly addressed to the Landlords or the Tenants, as the case may be, in accordance with this Clause and posted to the place to which it was so addressed.

(9)


 

Registration

The Landlords and Tenants consent to registration hereof for preservation and execution:-

IN WITNESS WHEREOF

 

Executed on behalf of Scottish Enterprise by

 

............................................................................. (signature)

Full Name:............................................................................

Director/Company Secretary/Authorised Signatory*

at..........................................................................................

on ........................................................................................

* Please delete as applicable

 

In the presence of this witness:

Witness' Signature:

 

............................................................................................

Full name of witness:

 

…………….........................................................................

 

Address of witness:

…………….........................................................................

............................................................................................

............................................................................................

 

 

 

Executed on behalf of Alba Bioscience Limited by

 

............................................................................ (signature)

Full Name:...........................................................................

Director/Company Secretary/Authorised Signatory*

at.........................................................................................

on .......................................................................................

* Please delete as applicable

 

In the presence of this witness:

Witness' Signature:

 

...........................................................................................

Full name of witness:

 

……………........................................................................

 

Address of witness:

……………........................................................................

...........................................................................................

............................................................................................

 

(10)


 

This is Schedule referred to in the foregoing Lease between Scottish Enterprise and Alba Bioscience Limited relative to Site 3, Bio Campus, Roslin, Midlothian

Schedule

Part 1

The Subjects

ALL and WHOLE the subjects at Site 3, Bio Campus, Roslin, Midlothian, extending to 3.18 hectares or thereby as shown delineated in red on the Plan which subjects form part and portion of the subjects at Gowkley Moss Farm, Bush Loan, Milton Bridge, Penicuil, EH26 0NX, registered in the Land Register of Scotland under Title Number MID4540.

(11)


 

Part 2

Landlord's Reserved Rights

1.

There is reserved to the Landlords, their successors and to any persons to whom the Landlords may grant such rights (a) all necessary rights of access over the Subjects for the purposes of inspecting and monitoring the progress of the Development Works but only in accordance with the terms of this Lease; and (b) a servitude right of wayleave in respect of all existing and future service pipes, cables, wires and others (including without prejudice to the foregoing generality all electricity wires and cables) which now or in the future serve the Development or any part thereof and are situated within, over, through or under the Subjects by way of an existing route or routes or such other route or routes as the Landlords or their successors may reasonably require, such other route or routes to be subject to the prior written approval of the Tenants which approval shall not be unreasonably withheld or decision thereon unreasonably delayed (for the avoidance of doubt,  the Tenants shall not be unreasonably withholding  consent to any route or routes running through the buildings on the Subjects), together with all such necessary rights to lay, maintain, remove, repair or replace or renew the same  subject to the Landlords or their successors making good all damage caused by the exercise of such rights and exercising the rights in such a way to cause as little inconvenience as reasonably practicable to the occupiers of the Subjects.

[Do SE require any more rights?]

(12)


 

Part 3

Title Transfer Provisions

1.

The Landlords shall grant the Validly Executed Disposition of the Subjects in favour of the Tenants.

2.

The consideration for the grant of the Disposition shall be the sum of £1 only (exclusive of VAT).

3.

The date of entry in the disposition shall be the twentieth Working Day after notice by either the Landlords or the Tenants in accordance with Clause 10 or such earlier date as may be agreed in writing

4.

The Landlords will apply to the Keeper for an Advance Notice for the Disposition, in the form adjusted with the Tenants, to be entered on the application record for the Subjects no earlier than 5 Working Days prior to the date of entry.  The cost of the Advance Notice for the disposition will be met by the Landlords.

5.

The Landlords consent to the Tenants applying to the Keeper for Advance Notices for any deeds which the Tenants intend to grant in relation to the Subjects.  The cost of any Advance Notices which the Tenants apply for will be met by the Tenants.

6.

At the date of entry, the Landlord shall deliver to the Tenants a Legal Report showing no entry adverse to the interest of the Landlords.

7.

The disposition will contain the rights (if any) granted in favour of the Tenants in this Lease and the Reserved Rights in favour of the Landlords and the Landlords will deliver to the Tenants  a Land Register application form in respect of the same, as is necessary.

8.

The Tenants undertake to pay all Land and Buildings Transaction Tax payable on the disposition and register the disposition in the Land Register of Scotland within 21 days of the Date of Entry.

9.

The Land Certificate to be issued to the Tenants or the updated or created Title Sheet for the Tenants’ interest in the Subjects will disclose no deed, decree or diligence prejudicial to the interest of the Tenants other than such as are created by or against the Tenants or have been disclosed to and accepted by the Tenants prior to the date of entry in the disposition.

10.

The Landlords will deliver to the Tenants, on demand from time to time and at the Landlords' expense such documents and evidence as the Keeper may require to enable the Keeper to update or create (as the case may be) the Title Sheet of the Subjects to disclose the Tenants as the registered proprietors of the whole Subjects.

11.

The Landlords shall cooperate fully with the Tenants to procure that the Tenants’ applications for registration are dealt with by the Keeper as quickly as practicable.

12.

 

12.1

Definitions

In Clause 13:

"Environment" means any and all organisms (including humans), ecosystems, natural or man-made buildings or structures, and the following media:

 

(a)

air (including air within buildings or structures, whether above or below ground)

 

(b)

water (including surface and ground water and water in wells, boreholes, pipes, sewers and drains); and

 

(c)

land (including surface land and sub-surface strata and any land under seabeds or rivers, wetlands or flood plains);

"Environmental Authority" means any person or legal entity (whether statutory or non-statutory or governmental or non-governmental) having regulatory authority under Environmental Law and/or any court of law or tribunal or any other judicial or quasi-judicial body;

(13)


 

"Environmental Law" means all laws, regulations, directives, statutes, subordinate legislation, rules of common law and generally all international, EU, national and local laws and all judgments, orders, instructions, decisions, guidance awards, codes of practice and other lawful statements of any Environmental Authority applying from time to time in relation to the Protective Strip in respect of pollution of or protection of the Environment or the production, processing, treatment, storage, transport or disposal of Hazardous Substances, in each case insofar as having the force of law;

"Hazardous Substances" means any natural or artificial substance (whether in solid or liquid form or in the form of a gas or vapour and whether alone or in combination with any other substance) capable of causing harm to the Environment and/or harm to the health of living organisms or other interference with the ecological systems of which they form part and/or harm to property and/or in the case of humans, offence caused to any sense;

 

12.2

Agreement as to Environmental Liabilities

The Landlords and the Tenants agree that:

 

13.2.1.

if any notice or requirement of any Environmental Authority made pursuant to Environmental Law is served on or made of either of them in respect of the Subjects or any Hazardous Substances attributable to the Subjects, then, as between the Landlords and the Tenants, the sole responsibility for complying with such notice or requirement is to rest with the Tenants to the exclusion of the Landlords; and

 

13.2.2

if any Environmental Authority wishes to recover costs incurred by it in carrying out any investigation, assessment, monitoring, removal, remedial or risk mitigation works under Environmental Law in respect of the Subjects or any Hazardous Substances attributable to the Subjects from either or both of the Landlords and the Tenants then, as between Landlords and the Tenants, the sole responsibility for the payment of such costs is to rest with the Tenants to the exclusion of the Landlords.

The agreements outlined under Clauses 13.2.1 and 13.2.2 are made with the intention that any Environmental Authority serving any notice or seeking to recover any costs should give effect to the agreements pursuant to the statutory guidance issued under Part IIA of the Environmental Protection Act 1990.  

The Landlords and the Tenants agree that the appropriate Environmental Authority may be notified in writing of the provisions of Clause 13 if required to give effect to the agreements outlined under Clauses 13.2.1 and 13.2.2.

 

12.3

The Tenants will indemnify the Landlords in respect of all and any actions, losses, damages, liabilities, charges, claims, costs and expenses which may be paid, incurred, suffered or sustained by Landlords arising (directly or indirectly) out of or in connection with the presence of any Hazardous Substances in, on or under the Subjects or migrating to or from the Subjects.

(14)


 

Part 4

Approved Plans and Specification

[insert approved Development Works plans and specifications]

(15)


 

Part 5

Disposition

[insert agreed Disposition]

(16)


 

Part 6

Plan

[insert lease plan]

(See attached)

 

 

 

(17)


 

EXHIBIT F

OFFER LETTER

(See attached)

 


 

OUR REF   S2742.1572/GLM/MGH

YOUR REF  

[Date]

DWF LLP

Dalmore House

310 St Vincent Street

Glasgow

G2 5QR

Dear Sirs

Site 3, Bio Campus, Roslin, Midlothian

On behalf of and as instructed by our clients, the Landlords, we offer to lease to your clients, the Tenants, the Premises, and that on the following terms and conditions:

Definitions and interpretation

In this Offer (including the foregoing preamble):

 

"2012 Act"

 

means the Land Registration etc (Scotland) Act 2012;

 

 

 

"Advance Notice"

 

means an advance notice as defined in Section 56 of the 2012 Act;

 

 

 

"Date of Entry"

 

means the date of conclusion of Missives or such other date as may be agreed in writing;

 

 

 

“Deposit”

 

means the sum of TWENTY THOUSAND POUNDS (£20,000) STERLING, exclusive of VAT which shall be payable in addition;

 

 

 

"duly executed"

 

means executed in accordance with the requirements of Sections 3 and 7 and Schedule 2 or sections 9(B) and 9(C) of the Requirements of Writing (Scotland) Act 1995, or in such other manner as is acceptable to the Landlords;

 

 

 

“Guarantee”

 

means the guarantee to be granted by the Guarantor in favour of the Landlords of the Tenants’ obligations under the Lease in terms of the draft Guarantee contained in Part 3 of the Schedule;

 

 

 

“Guarantor”

 

means [Quotient Limited/Quotient Inc] ;

 

 

 

"HMRC"

 

means HM Revenue & Customs;

 

 

 

"Interest"

 

means interest on the sum in question at 4% per annum above the base rate from time to time of the Royal Bank of Scotland plc from the date that such sum is due for payment or, if there is no such date specified, the date of demand for such sum until such sum is paid;

 

 

 

"Landlords"

 

means Scottish Enterprise established under the Enterprise and New Towns (Scotland) Act 1990 and having their principal place of business at Atrium Court, 50 Waterloo Street, Glasgow;

 

 

 

"Landlords' Solicitors"

 

means Shepherd and Wedderburn LLP, 191 West George Street, Glasgow, G2 2LB (Ref S2742.1572/MGH/GLM);

 

 

 

"LBTT"

 

means Land and Buildings Transaction Tax under the Land and Buildings Transaction Tax (Scotland) Act 2013;

 

 

 

"Lease"

 

means the lease referred to in clause 4 of this Offer and set out in Part 1 of the Schedule;

 

 

 

"Missives"

 

means the binding contract constituted by this Offer and all formal letters following on it (subject always to clause 13.1 of this Offer);

 

 

 

"Offer"

 

means this offer;

 

 

 

" Premises "

 

means the subjects known as Site 3, Bio Campus, Midlothian all as more particularly described in the Lease;

 


 

 

 

 

"Premium"

 

means the sum of NINE HUNDRED AND EIGHTY SIX THOUSAND EIGHT HUNDRED POUNDS (£986,800) STERLING, exclusive of all, if any, VAT paid and less the Deposit in so far as already paid to the Landlords;

 

 

 

"Schedule"

 

means the schedule of four parts annexed to this Offer;

 

 

 

“Standard Security”

 

means the standard security by the Tenants in favour of the Landlords over the Tenants’ interest in the Ground Lease in terms of the draft Standard Security contained in Part 2 of the Schedule;

 

 

 

"Tenants"

 

means Alba Bioscience Limited, incorporated under the Companies Acts (Company Number SC310584) and having their Registered Office at Douglas Building, Pentlands Science Park, Bush Loan, Penicuik, Midlothian, EH26 0PL;

 

 

 

"Tenants' Solicitors"

 

means DWF LLP, Dalmore House, 310 St Vincent Street, Glasgow, G2 5QR (Ref [          ]);

 

 

 

“Undertaking”

 

means the undertaking to be granted by the Tenants’ Solicitors to the Landlords undertaking to register the Standard Security simultaneously with the Ground Lease, in terms of the draft undertaking contained in Part 4 of the Schedule;

 

 

 

"Working Day"

 

means any day on which clearing banks in Edinburgh, Glasgow and London are open for normal business.

Price

Payment

The Landlords and the Tenants agree that the Premium (but not any VAT payable thereon) shall be paid in terms of the Ground Lease.

The Deposit will be paid by the Tenants on the Date of Entry by instantaneous bank transfer of cleared funds to the Landlords’ Solicitors’ client account, failing which the Landlords shall be entitled to resile from the Missives, by written notice to that effect to the Tenants, provided the said notice is received prior to any subsequent payment of the Deposit. For the avoidance of doubt the Deposit shall be non-returnable.

Notwithstanding the foregoing the VAT due on the Premium and the Deposit will be paid by the Tenants on the Date of Entry by instantaneous bank transfer of cleared funds to the Landlords’ Solicitors’ client account in exchange for a valid VAT invoice addressed to the Tenants.

A payment not made in accordance with Clause 2.1.1 may be refused.

Interest

If the VAT or any part of it is not paid to the Landlords on the Date of Entry then notwithstanding consignation or that the Tenants have not taken entry, the Tenants will pay to the Landlords Interest on the outstanding money.

Cancellation of Sale

If the Tenants fail to pay the VAT payable on the Premium with Interest as set out in Clause 2.2 within 10 Working Days after the Date of Entry the Landlords will be entitled (but not bound) to rescind the Missives.

Duration/Rent

The Lease will endure for the period from and including the Date of Entry until the date falling 99 years after the Date of Entry.

The annual rent payable under the Lease will be ONE POUND (£1) STERLING (exclusive of Value Added Tax) payable as provided for in the Lease.  

 


 

The Lease

The Lease to be entered into between the Landlords and the Tenants will be in the form of the draft lease contained in Part 1 of the Schedule, which draft sets out the whole remaining terms and conditions of the Lease and will be deemed incorporated into this Offer mutatis mutandis , but incorporating such other additions and modifications as may be necessary to reflect the terms of this Offer and the Missives.

Advance Notice

The Landlords will apply to the Keeper for an Advance Notice for the Lease, in the form adjusted with the Tenants, to be either (i) entered on the application record for the larger subjects of which the Premises form a part or (ii) recorded in the Register of Sasines, no earlier than 5 Working Days prior to the Date of Entry.  The cost of the Advance Notice for the Lease will be met by the Landlords.

The Landlords consent to the Tenants applying to the Keeper for Advance Notices for any deeds which the Tenants intend to grant in relation to the Premises.  The cost of any Advance Notices which the Tenants apply for will be met by the Tenants.

If the Landlords rescind the Missives in the circumstances set out in clause 2.3 the Tenants consent to the discharge of the Advance Notice for the Lease and the Tenants confirm that they will immediately discharge at their own cost any Advance Notice submitted by them if requested to do so by the Landlords.

If settlement is likely to occur after the Date of Entry, the Landlords, if requested to do so by the Tenants, will apply for a further Advance Notice for the Lease, in the form adjusted with the Tenants, and the cost of any additional Advance Notices will be met:

by the Landlords, if the delay in settlement is due to any failure or breach by or on behalf of the Landlords to implement their obligations under the Missives on time; or

by the Tenants, if the delay in settlement is due to any failure or breach by or on behalf of the Tenants to implement their obligations under the Missives on time.

The Landlords' Solicitors will not provide any letter of obligation or undertaking to clear the records of any deed, decree or diligence.

Completion of Lease

The Tenants will ensure that the Lease is duly executed by the Tenants, and that a certified copy of the executed Lease is returned to the Landlords' Solicitors within 21 days after the date of delivery of the engrossment of the Lease, duly executed by the Landlords, to the Tenants' Solicitors, together with evidence of the valid execution of the Lease by the Tenants.

If the transaction contemplated by the Missives is notifiable for LBTT purposes, the Tenants will submit to Revenue Scotland an LBTT Return.

Within 7 days after receipt by the Tenants of the electronic submission receipt issued by Revenue Scotland, the Tenants will

submit the Lease to the Books of Council and Session for registration for preservation and execution and will obtain 3 extracts of it, and will deliver 2 of the extracts to the Landlords' Solicitor for the use of the Landlords within 7 days of receipt of the extracts; and

be responsible for dealing with registration of the Lease in the Land Register and will deliver to the Landlords (i) a copy of the Keeper's acknowledgement of receipt showing the Title Number to be allocated to the Title Sheet for the Tenants' interest within 14 days of receipt of the same and (ii) within 7 days after receipt by the Tenants of a pdf of the Title Sheet in respect of that interest, a copy of the pdf of the Title Sheet, with a colour copy of the Title Plan(s).

The Tenants acknowledge that if they breach the terms of their obligations in clauses 6.2 and 6.3 inclusive, they will indemnify the Landlords in respect of loss suffered by the Landlords by virtue of such delay.  

Tenants' obligations

Subject to the foregoing provisions of this Offer, if for any reason the Lease is not executed by the Date of Entry, the Landlords and the Tenants agree to be bound by the whole obligations and provisions specified in the Lease during the period from and after the Date of Entry.

 


 

Title

By acceptance of this Offer, the Tenants are deemed to have satisfied themselves in all respects with the Landlords' title to the Premises both as to the extent and description of the Premises and the burdens and conditions affecting the Premises, and the Tenants will be bound to accept the title as it stands subject to Clause 10 and the exhibition of a legal report in terms of Clause 9.2.

Settlement

On the Date of Entry the Landlords will deliver to the Tenants:

the Lease, duly executed by the Landlords;

a legal report brought down to a date as near as practicable to the Date of Entry which report will show:

no entries adverse to the Landlords’ interest in the Premises;

the Advance Notice for the Lease; and

no other Advance Notices other than those submitted by the Tenants and those disclosed to and accepted by the Tenants in writing prior to the Date of Entry;

a letter of consent to the grant of the Lease from any heritable creditor of the Landlords holding a heritable security over the Premises and/or if applicable, a letter of non-crystallisation from the holder of any floating charge affecting the Premises;

a valid VAT invoice addressed to the Tenants in respect of the VAT due on the Premium;

all necessary signed Land Registration Forms for the registration of the Standard Security in the Land Register;

Simultaneously and in exchange for the above items the Tenants will deliver to the Landlords on the Date of Entry:-

the Guarantee, duly executed by the Guarantors [plus US legal opinion of Quotient Inc] ;

a certified true copy of the Standard Security, duly executed by the Tenants.

Post completion

Provided that the Lease is presented for registration prior to the date of expiry of the Advance Notice registered in relation to the Lease, the updated or newly created Title Sheet for the Lease will contain no exclusion or limitation of warranty in terms of Section 75 of the 2012 Act and will disclose no entry, deed or diligence (including any charging order under the Buildings (Recovery of Expenses) (Scotland) Act 2014 or any notice of potential liability for costs registered under the Tenements (Scotland) Act 2004 or the Title Conditions (Scotland) Act 2003) prejudicial to the interest of the Tenants other than such as are created by or against the Tenants or have been disclosed to, and accepted in writing by, the Tenants prior to the Date of Entry except for the Standard Security.

The Landlords will register the Guarantee in the Books of Council and Session and provide one extract to the Tenants, subject to the Tenants paying to the Landlords the costs of registration and obtaining two extracts.

Frustration

Unless the parties otherwise agree in writing the Missives will remain in full force and effect notwithstanding any damage to or destruction of the Premises which may occur prior to the Date of Entry.

Missives Personal

Alba Bioscience Limited will not be entitled to assign, absolutely or in security, or otherwise part with or deal in any way with the rights conferred on them by the Missives other than as permitted in terms of the Lease.

 


 

Prior communings

Any letter forming part of the Missives and any amendment to or variation of the Missives will require to be duly executed.

The Missives set out the entire agreement and understanding between the Landlords and the Tenants in relation to the Lease of the Premises and will supersede all previous proposals, agreements and other communications whether written, oral or otherwise relating to it.

Time limit for acceptance

This Offer, unless previously withdrawn or amended, is open for written acceptance reaching us here not later than [          ].

Yours faithfully

 

……………………………………………....., a Member

For and on behalf of Shepherd and Wedderburn LLP,

as agents for Scottish Enterprise

 

……………………………………………………….. (Witness)

of 191 West George Street, Glasgow

 


 

schedule

Part 1

The Lease

 


 

Part 2

Standard Security

 


 

Part 3

Guarantee

 


 

Part 4

Undertaking

 


 

EXHIBIT G

SCOTTISH LEASE GUARANTEE

(See attached)

 

 

 

 


 

 

 

 

 

 

GUARANTEE

by

Quotient Limited

in favour of

Scottish Enterprise

Property: Site 3, Biocampus, Penicuik, Midlothian

 

 

 

Shepherd and Wedderburn LLP

191 West George Street

Glasgow

G2 2LB

DX GW409 Glasgow

T: +44 (0)141 566 9900

F: +44 (0)141 565 1222

www.shepwedd.co.uk

 


 

GUARANTEE

by

QUOTIENT LIMITED , [        ] (" Guarantors ");

in favour of

SCOTTISH ENTERPRISE , established under the Enterprise and New Towns (Scotland) Act 1990 and having their principal place of business at Atrium Court, 50 Waterloo Street, Glasgow, and includes where the context so requires their successors as landlords under the Lease (" Landlords ");

WHEREAS:

(A)

The Landlords are in right of the landlord's part of the Lease.

(B)

The Tenants are in right of the tenant's part of the Lease.

(C)

The Guarantors have agreed to guarantee the obligations of the Tenants under the Lease;

IT IS AGREED as follows:

Definitions and Interpretation

In this Guarantee:

 

" Guaranteed Obligations "

 

means all past, present, future and contingent obligations of the Tenants:

(a)     to pay all rents and other sums; and

(b)     to perform and fulfil all other obligations

which are now or may at any time in the future become due by the Tenants to the Landlords in terms of the Lease;

 

 

 

" Interest "

 

means interest on the sum in question at four per cent per annum above the base rate from time to time of the Royal Bank of Scotland plc from the date that such sum is due for payment or, if there is no such date specified, the date of demand for such sum until such sum is paid;

 

 

 

" Lease "

 

means the lease between the Landlords and the Tenants dated [        ] and [       ] and about to be registered in the Books of Council and Session on [      ];

 

 

 

" Property "

 

means Site 3, Biocampus, Roslin, Midlothian being the subjects more particularly described in the Lease;

 

 

 

" Relevant Event "

 

means any of the following events or circumstances:

 

 

 

(i)

The Tenants going into liquidation including provisional liquidation or a petition being presented or resolution proposed or passed for their liquidation;  

 

 

 

(ii)

The Tenants having a receiver appointed in respect of any part of their undertaking or assets;

 

 

 

(iii)

The Tenants being dissolved, struck off or otherwise ceasing to exist;

 

 

 

(iv)

The Landlords serving notice on the Tenants that an event has occurred which entitles the Landlords to irritate the Lease;

 

 

 

(v)

The Lease being terminated by reason of irritancy;

 

 

 

(vi)

The Tenants having an administrator appointed or a petition being presented for the appointment of an administrator or notice of intention to appoint an administrator being given;

 

 

 

(vii)

The Tenants instituting or giving notice of or indicating an intention to institute a voluntary arrangement or composition in respect of their debts or affairs; or

 

 

 

(viii)

The Tenants becoming unable to pay their debts within the meaning of section 123 of the Insolvency Act 1986;

 


 

 

 

 

 

 

" Tenants "

 

means Alba Bioscience Limited, incorporated under the Companies Acts (Registered Number SC310584) and having their Registered Office at Douglas Building, Pentlands Science Park, Bush Loan, Penicuik, Midlothian, EH26 0PL;

 

 

 

" Working Day "

 

means a day on which clearing banks in Edinburgh and Glasgow are open for normal business.

In this Guarantee, unless otherwise specified or the context otherwise requires:

any reference to one gender includes all other genders;

words in the singular only include the plural and vice versa;

any reference to the whole is to be treated as including reference to any part of the whole;

any reference to a person includes a natural person, corporate or unincorporated body (whether or not having separate legal personality); words importing individuals include corporations and vice versa;

any references to this Guarantee or to the Lease or to any other document are references to this Guarantee, the Lease or to that other document as varied, supplemented, assigned, novated or replaced from time to time;

any reference to a Clause is to the relevant Clause of this Guarantee;

any reference to a statute or statutory provision includes any subordinate legislation which is in force from time to time under that statute or statutory provision;

any reference to any statute, statutory provision or subordinate legislation is a reference to it as it is in force from time to time taking account of any amendment or re-enactment;

any phrase introduced by the words "including", "include", "in particular" or any similar expression is to be construed as illustrative only and is not to be construed as limiting the generality of any preceding words;

references to writing or written do not include faxes or e-mail;

where at any one time there are two or more persons included in the expression "Guarantors" obligations contained in this Guarantee which are expressed to be made by the Guarantors are binding jointly and severally on them and their respective executors and representatives whomsoever without the necessity of discussing them in their order;

1.3

The headings in this Guarantee are included for convenience only and are to be ignored in construing this Guarantee.

1.4

Unless the context otherwise requires, words and expressions which are defined in the Lease will bear the same meanings for the purposes of this Guarantee.

Guarantee

The Guarantors irrevocably and unconditionally guarantee to the Landlords full and punctual payment or performance by the Tenants of the Guaranteed Obligations as and when they fall due for payment or performance and failing such payment or performance by the Tenants the Guarantors will on demand by the Landlords make payment or effect performance of the Guaranteed Obligations in question together with:

all liabilities, losses, costs, damages and expenses incurred by the Landlords by reason of or in connection with any such failure together with Interest; and

all costs and expenses properly and reasonably incurred by the Landlords in connection with the enforcement of this Guarantee together with Interest.

 


 

Primary Obligation

The obligations of the Guarantors under this Guarantee will be independent primary obligations and not merely those of guarantor or cautioner and if any of the Guaranteed Obligations are not, or cease to be, valid and enforceable for any reason whatever (whether or not known to the Landlords) or for any reason are not recoverable from or capable of performance by the Guarantors under Clause 2 the Guarantors will still be liable to the Landlords in respect of such Guaranteed Obligations as if they were fully valid and enforceable and/or recoverable or capable of performance and the Guarantors were principal debtor in place of the Tenants.

Indemnity

The Guarantors undertake to indemnify the Landlords on demand against all liabilities, losses, costs, damages and expenses which the Landlords may incur by reason of or in connection with any failure by the Tenants to make payment of or perform any of the Guaranteed Obligations as and when they fall due or as a result of any of the Guaranteed Obligations being or becoming void or unenforceable for any reason or the Guaranteed Obligations for any reason not being recoverable or capable of performance under Clause 2, together with Interest.

The Guarantors undertake to indemnify the Landlords on demand against all liabilities, losses, costs, damages and expenses which the Landlords may incur by reason of or in connection with the Tenants proposing or entering into any company voluntary arrangement or other scheme or arrangement having or purporting to have the effect of impairing, compromising or releasing any or all of the Guarantors' obligations under this Guarantee.

Guarantors to take new lease

Without prejudice to any other provision of this Guarantee if a Relevant Event occurs, the Landlords may serve notice on the Guarantors within six months after the Relevant Event requiring the Guarantors to accept, as required by the Landlords, either:

a new lease of the Property for a period equal to the residue of the term of the Lease which would have remained if the Relevant Event had not occurred, at the same rent and on the same terms as the Lease commencing on the date of the Relevant Event, except that any works carried out by or on behalf of the Tenants (or their predecessors as tenants under the Lease) shall be treated by reference to the date of entry under the Lease and not the date of the Relevant Event; or

an assignation to the Guarantors of the Tenants' interest under the Lease, effective from the date of the Relevant Event.

Duration

This Guarantee will be a continuing security notwithstanding any intermediate payment or performance and will remain in force so long as any liability (including any future or contingent liability):

on the part of the Tenants under the Lease, or

on the part of the Guarantors under this Guarantee

remains unfulfilled unless discharged by the Landlords in accordance with Clause 8.

Non-impairment

This Guarantee will not be discharged or prejudiced by:

the Landlords holding, acquiring, failing to perfect, releasing or giving up any obligation, security or remedy (present or future) for the obligations of the Tenants under the Lease or any neglect, delay or forbearance on the part of the Landlords in enforcing such obligation, security or remedy;

the Landlords giving time or any other indulgence to the Tenants;

any variation, amendment, supplement or extension whether formal or informal, of the terms of the Lease or the implementation of any rent review provisions in the Lease;

the Landlords irritating the Lease;

 


 

the Landlords releasing any person(s) comprised in the Tenants from liability under the Lease, or

any other act, omission or event whereby (but for this Clause) the Guarantors would be discharged in whole or in part from this Guarantee.

Discharge

If the Tenants assign their interest under the Lease in accordance with the terms of the Lease, or the Landlords accept a renunciation of the Tenants' interest under the Lease, the Landlords will at the request and cost of the Guarantors grant a valid discharge of this Guarantee as at the date of valid intimation of such assignation or the effective date of such renunciation (as the case may be) provided that there are no outstanding claims under the Guarantee, or if there are any such claims, upon such claims being satisfied in full.

Assignation

The Landlords have the right to assign or transfer this Guarantee to their successors as landlords under the Lease without the consent of the Guarantors.  

The Guarantors do not have the right to assign or transfer their rights or obligations under this Guarantee.

Postponement of Claims by Guarantors

Until the Guaranteed Obligations have been fully and unconditionally paid or performed, the Guarantors will not be entitled to share any security held or money received by the Landlords on account of the Guaranteed Obligations.

Until the Guaranteed Obligations have been fully and unconditionally paid or performed, the Guarantors waive their rights of subrogation, reimbursement and indemnity against the Tenants and any other person and any other right they may have to stand in the place of the Landlords in respect of any security from or money payable by the Tenants or any other person.

Until the Guaranteed Obligations have been fully and unconditionally paid or performed, the Guarantors will have no recourse, nor be entitled to pursue any right or remedy, against the Tenants arising from the performance of any of the Guarantors’ obligations under this Guarantee.

In the event of the liquidation, receivership, administration, sequestration or other insolvency or dissolution of the Tenants the Guaranteed Obligations will be deemed to continue to be due and outstanding until fully and unconditionally paid or performed.  The Landlords will be entitled to claim in the liquidation, receivership, administration, sequestration or other insolvency of the Tenants for the full amount of the Guaranteed Obligations and to retain the whole of the dividends from such claim to the exclusion of any rights of the Guarantors as guarantor in competition with the Landlords until the Landlords' claim is satisfied in full.

Exclusion of Set Off

All payments due by the Guarantors under this Guarantee will be made without any retention, deduction, set-off or counterclaim and free from any deduction or withholding for or on account of any taxes or other charges in the nature of taxes imposed by any competent authority.  If any such deduction or withholding shall be required by law the Guarantors will pay the Landlords such additional amount as may be necessary to ensure that the Landlords receive the full amount of the relevant payment as if such deduction or withholding had not been made.

The Guarantors will not be entitled to withhold or restrict performance of any obligation by them  under this Guarantee by reason of any purported right or claim of retention, set off or counterclaim or for any other reason.

Certificate

A certificate signed by any authorised signatory on behalf of the Landlords will, except in the case of manifest error, conclusively constitute the amount of the Guaranteed Obligations or any sum due by the Guarantors under Clause 13 or any other provision of this Guarantee at the relevant time for all purposes of this Guarantee.

 


 

Costs

The Guarantors will pay to the Landlords within five Working Days after written demand:

the legal fees and expenses reasonably and properly incurred by the Landlords in connection with the preparation and execution of this Guarantee;

the costs of registering this Guarantee in the Books of Council and Session and of obtaining three extracts (one) of which will be delivered to the Guarantors' solicitors);

the legal fees and expenses reasonably and properly incurred by the Landlords in connection with the preparation and completion of any new lease or assignation entered into under the terms of Clause 5 including the registration dues on such new lease or assignation and of obtaining three extracts (one of which will be delivered to the Guarantors' solicitors);

all Value Added Tax on any of the fees, costs and expenses set out above.

13.2

If any amount specified in Clause 13.1 is not paid within 14 days of demand the Guarantors will pay Interest on such amounts.

13.3

The Guarantors will be responsible for any Land and Buildings Transaction Tax chargeable on any such new lease or assignation.

Notices

Any notice, demand, request or certificate required by this Guarantee will be in writing and may be delivered personally or sent by post to the relevant party using the relevant details specified in Clause 14.3.

Any notice, demand, request or certificate will be deemed to be received:

if delivered personally, (with proof of delivery) at the time of delivery;

if sent by recorded delivery post, 48 hours after the date of posting; and

in the case of fax, at the time when the sender's fax machine confirms transmission;

Provided that if, in the case of personal delivery or transmission by fax, such delivery or transmission occurs outwith normal business hours on a Working Day or on a day which is not a Working Day, delivery will be deemed to occur on the next Working Day.

The details referred to in Clause 14.1 are:

Guarantors

 

Address:

              [       ]

For the attention of:  [       ]

Landlords

Address:              [       ]

For the attention of: [       ];

or such other address or person as may be notified in writing from time to time by the relevant party to the other party for the purposes of this Clause.

 


 

Applicable Law and Jurisdiction

This Guarantee is governed by and is to be construed in accordance with the law of Scotland and in so far as not already subject to it, the parties irrevocably submit to the non-exclusive jurisdiction of the Scottish Courts.

Registration

The Guarantors consent to the registration of this Guarantee and any certificate pursuant to this Guarantee for preservation and execution: IN WITNESS WHEREOF

 

Executed on behalf of Scottish Enterprise by

 

............................................................................ (signature)

Full Name:...........................................................................

Director/Company Secretary/Authorised Signatory*

at.........................................................................................

on .......................................................................................

* Please delete as applicable

 

In the presence of this witness:

Witness' Signature:

 

.............................................................................................

Full name of witness:

 

……………..........................................................................

 

Address of witness:

……………..........................................................................

.............................................................................................

.............................................................................................

 

 

 

Executed on behalf of Quotient Limited by

 

........................................................................... (signature)

Full Name:..........................................................................

Director/Company Secretary/Authorised Signatory*

at........................................................................................

on ......................................................................................

* Please delete as applicable

 

In the presence of this witness:

Witness' Signature:

 

……………..........................................................................

Full name of witness:

 

……………..........................................................................

 

Address of witness:

……………..........................................................................

.............................................................................................

..............................................................................................

 

 


 

EXHIBIT H

SCOTTISH LEASE SECURITY AGREEMENT

(See attached)

 

 

 

 


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

STANDARD SECURITY

by

Alba Bioscience Limited

in favour of

Scottish Enterprise

 

 

Property:      Site 3, Biocampus, Roslin, Midlothian

 

 

 

 

 

Shepherd and Wedderburn LLP

191 West George Street

Glasgow

G2 2LB

DX GW409 Glasgow

T: +44 (0)141 566 9900

F: +44 (0)141 565 1222

www.shepwedd.co.uk

 


 

WE , ALBA BIOSCIENCE LIMITED , incorporated under the Companies Acts in Scotland (Company Number SC310584) and having its Registered Office at Douglas Building, Pentlands Science Park, Bush Loan, Penicuik, Midlothian, EH26 0PL (hereinafter referred to as "the Proprietor") hereby IN SECURITY of all sums and obligations due and that may become due to SCOTTISH ENTERPRISE , established under the Enterprise and New Towns (Scotland) Act 1990 and having their principal place of business at Atrium Court, 50 Waterloo Street, Glasgow, and their successors and assignees (hereinafter referred to as "the Creditor") in terms of the Lease between the Creditor and the Proprietor dated [insert date] (the “Lease”) (hereinafter referred to as "the Borrower") or any variation or alteration thereof GRANT a Standard Security in favour of the Creditor over the tenants’ interest in the Lease of ALL and WHOLE [insert description and plan from Lease] ;   The Standard Conditions specified in Schedule 3 to the Conveyancing and Feudal Reform (Scotland) Act 1970, as amended, and any lawful variation thereof operative for the time being shall apply and we , the Borrower and the Proprietor, agree that Standard Condition 5(a) shall be varied to the effect that the sum for which the security subjects shall be insured in terms of said Condition 5(a) shall be reinstatement value and not market value;

 

 

1


 

And we grant warrandice:  IN WITNESS WHEREOF

 

Executed on behalf of Scottish Enterprise by

 

........................................................ (signature)

Full Name:........................................................

Director/Company Secretary/Authorised Signatory*

at......................................................................

on ....................................................................

* Please delete as applicable

 

In the presence of this witness:

Witness' Signature:

 

........................................................................

Full name of witness:

 

........................................................................

 

Address of witness:

........................................................................

........................................................................

........................................................................

 

 

 

Executed on behalf of Alba Bioscience Limited by

 

........................................................ (signature)

Full Name:........................................................

Director/Company Secretary/Authorised Signatory*

at......................................................................

on ....................................................................

* Please delete as applicable

 

In the presence of this witness:

Witness' Signature:

 

........................................................................

Full name of witness:

 

........................................................................

 

Address of witness:

........................................................................

........................................................................

........................................................................

 

 

 

 

2


 

EXHIBIT I

FORM OF ASSIGNMENT AND TRANSFER AGREEMENT

This Assignment and Transfer Agreement (this “ Assignment Agreement ”) is entered into as of [________] by and between the Assignor named on the signature page hereto (“ Assignor ”) and the Assignee named on the signature page hereto (“ Assignee ”).  Reference is made to that certain Amended and Restated Credit, Security and Guaranty Agreement, dated as of August ___, 2015 (as amended, restated, supplemented or otherwise modified from time to time, the “ Credit Agreement ”), among Quotient Biodiagnostics, Inc., and any additional Borrower that may hereafter be added thereto (collectively, “ Borrowers ”), certain affiliates of Borrowers from time to time party thereto as guarantors,  MidCap Financial Trust, as Agent (in such capacity, together with its successors and assigns, “ Agent ”), and the financial institutions or other entities from time to time parties thereto, each as a Lender.  Capitalized terms used herein and not otherwise defined shall have the meanings assigned to them in the Credit Agreement.

Assignor and Assignee hereby agree as follows:

1. Assignor hereby sells and assigns to Assignee, and Assignee hereby purchases and assumes from Assignor, the interests set forth on the schedule attached hereto (the “ Schedule ”), in and to Assignor’s rights and obligations under the Credit Agreement as of the effective date set forth on the Schedule (the “ Effective Date ”).  Such purchase and sale is made without recourse, representation or warranty except as expressly set forth herein.  On the Effective Date, Assignee shall pay to Assignor an amount equal to the aggregate amounts assigned pursuant to the Schedule (exclusive of unfunded portions of the Revolving Loan Commitment).

2. It is the intention of the Assignor and the Assignee that the assignment contemplated hereunder by the Assignor to the Assignee shall constitute a sale and assignment and not a loan or participation.

3. Assignor (i) represents that as of the Effective Date, that it is the legal and beneficial owner of the interests assigned hereunder free and clear of any adverse claim, (ii) makes no other representation or warranty and assumes no responsibility with respect to any statement, warranties or representations made in or in connection with the Credit Agreement or the execution, legality, validity, enforceability, genuineness, sufficiency or value of the Credit Agreement, any other Financing Documents or any other instrument or document furnished pursuant thereto, and (iii) makes no representation or warranty and assumes no responsibility with respect to the financial condition of any other Credit Party or any other Person or the performance or observance by any Credit Party of its Obligations under the Credit Agreement or any other Financing Documents or any other instrument or document furnished pursuant thereto.

4. Assignee (i) confirms that it has received a copy of the Credit Agreement and the other Financing Documents, together with copies of the most recent financial statements delivered pursuant thereto and such other documents and information as it has deemed appropriate to make its own credit analysis and decision to enter into this Assignment Agreement, (ii) agrees that it will, independently and without reliance upon Agent, Assignor or any other Lender and based on such documents and information as it shall deem appropriate at the time, continue to make its own credit decisions in taking or not taking action under the Credit Agreement, (iii) appoints and authorizes Agent to take such action as Agent on its behalf and to exercise such powers under the Credit Agreement and the other Financing Documents as are delegated to Agent by the terms thereof, together with such powers as are reasonably incidental thereto, (iv) agrees that it will perform in accordance with their terms all obligations which by the terms of the Credit Agreement are required to be performed by it as a Lender, (v) represents that on the date of this Assignment Agreement it is not presently aware of any facts that would cause it to make a claim under the Credit Agreement, (vi) represents and warrants that Assignee is not a Foreign Lender or, if it is a Foreign Lender, that it has delivered to Agent the documentation required to be delivered to Agent by Section 14 below, (vii) represents and warrants that Assignee is (or, upon receipt of the required consents hereto by Agent, will become) an Eligible Assignee and (viii) represents and warrants that it has experience and expertise in the making or the purchasing of loans such as the Loans, and that it has acquired the interests described herein for its own account and without any present intention of selling all or any portion of such interests.

5. Each of Assignor and Assignee represents and warrants to the other party hereto that it has full power and authority to enter into this Assignment Agreement and to perform its obligations hereunder in accordance with the provisions hereof, that this Assignment Agreement has been duly authorized, executed and delivered by such party and that this Assignment Agreement constitutes a legal, valid and binding obligation of such party, enforceable against such party in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting creditors’ rights generally and by general principles of equity.

6. Upon the effectiveness of this Assignment Agreement pursuant to Section 14 below, (i) Agent shall register Assignee as a Lender, pursuant to the terms of the Credit Agreement, (ii) Assignee shall be a party to the Credit Agreement and, to the extent

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

1            

 

 


 

provided in this Assignment Agreement, have the rights and obligations of a Lender thereunder, (iii) Assignor shall, to the extent provided in this Assignment Agreement, relinquish its rights and be released from its obligations under the Credit Agreement and (iv) Agent shall thereafter make all payments in respect of the interest assigned hereby (including payments of principal, interest, fees and other amounts) to Assignee.  Assignor and Assignee shall make all appropriate adjustments in payments for periods prior to the Effective Date by Agent or with respect to the making of this assignment directly between themselves.

7. The Agent for itself and on behalf of each of the Lenders (by virtue of the authorization contained in Section 14.1 (Appointment and Authorization of Agent) of the Credit Agreement), the Assignor and the Assignee agree that with effect from the Effective Date the Assignee, pro rata to its participation (i) becomes a party as a pledgee to the Share Pledge Agreement over the shares in Quotient Suisse SA (the "Swiss Pledge Agreement") and is bound by all the terms and conditions thereof, (ii) assumes all rights and obligations of the Assignor under the Swiss Pledge Agreement and (iii) participates in the security granted pursuant to the Swiss Pledge Agreement.

8. Each of Assignor and Assignee hereby agrees from time to time, upon request of the other such party hereto, to take such additional actions and to execute and deliver such additional documents and instruments as such other party may reasonably request to effect the transactions contemplated by, and to carry out the intent of, this Assignment Agreement, including, but not limited to, notifying the Borrower of the execution of this Assignment Agreement and the sale and assignment contemplated hereby.

9. Neither this Assignment Agreement nor any term hereof may be changed, waived, discharged or terminated, except by an instrument in writing signed by the party (including, if applicable, any party required to evidence its consent to or acceptance of this Assignment Agreement) against whom enforcement of such change, waiver, discharge or termination is sought.  

10. For the purposes hereof and for purposes of the Credit Agreement, the notice address of Assignee shall be as set forth on the Schedule.  Any notice or other communication herein required or permitted to be given shall be in writing and delivered in accordance with the notice provisions of the Credit Agreement.

11. In case any provision in or obligation under this Assignment Agreement shall be invalid, illegal or unenforceable in any jurisdiction, the validity, legality and enforceability of the remaining provisions or obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or impaired thereby.  

12. THIS ASSIGNMENT AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF MARYLAND, WITHOUT REFERENCE TO ITS CONFLICT OF LAW PROVISIONS.  

13. This Assignment Agreement shall be binding upon, and shall inure to the benefit of, the parties hereto and their respective successors and assigns.  

14. This Assignment Agreement may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the signatures hereto were upon the same agreement.

15. This Assignment Agreement shall become effective as of the Effective Date upon the satisfaction of each of the following conditions:  (i) the execution of a counterpart hereof by each of Assignor and Assignee, (ii) the execution of a counterpart hereof by Agent as evidence of its consent hereto to the extent required pursuant to Section 11.17(a) of the Credit Agreement, (iii) in the event Assignee is a Foreign Lender, the receipt by Agent of United States Internal Revenue Service Forms W-8ECI, W-8EXP, W-8BEN or W-8IMY (as applicable), and such other forms, certificates or documents, including those prescribed by the United States Internal Revenue Service, properly completed and executed by Assignee, certifying as to Assignee’s entitlement to exemption from withholding or deduction of Taxes, and (iv) the receipt by Agent of originals or telecopies of the counterparts described above.  Agent hereby waives the requirement that Assignor pay the $3,500 processing fee as required under Section 11.17(a) of the Credit Agreement.

 

( Signature Pages Follow )

 

 

 

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement

2            

 

 


 

The parties hereto have duly executed and delivered this Assignment Agreement as of the date first written above.

 

ASSIGNOR:

[_____________________]

 

By:                                                                                         

 

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement


 

ASSIGNEE:

[________________________[

 

By:                                                                                         

 

 

 

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement


 

CONSENTED TO BY:

MIDCAP FINANCIAL TRUST , a Delaware statutory trust, as Agent

By:        Apollo Capital Management, L.P.,

its investment manager

By:        Apollo Capital Management GP, LLC,

its general partner

By:  ___________________________________

Name:

Title: Authorized Signatory

 

 

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement


 

Schedule to Assignment Agreement

 

Assignor:

[___________________]

Assignee:

[___________________]

Effective Date:

[___________________]

 

Amended and Restated Credit, Security and Guaranty Agreement, dated as of August ___, 2015 (as amended, restated, supplemented or otherwise modified from time to time), among Quotient Biodiagnostics, Inc., and any additional Borrower that may hereafter be added thereto (collectively, “ Borrowers ”), certain affiliates of Borrowers from time to time party thereto as guarantors,  MidCap Financial Trust, as Agent (in such capacity, together with its successors and assigns, “ Agent ”), and the financial institutions or other entities from time to time parties thereto, each as a Lender.

Interests Assigned:

 

 

Term Loan Amount

Term Loan Commitment Amount

 Assignor Amounts

$[_________]

$[_________]

 Amounts Assigned

$[_________]

$[_________]

 Assignor Amounts
 (post-assignment)

$[_________]

$[_________]

 Assignee Amounts

 (post-assignment)

$[_________]

$[_________]

 

Assignee Information:

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement


 

CREDIT FACILITY SCHEDULE

The following Credit Facilities are specified on this Credit Facility Schedule:

Credit Facility #1 :

Credit Facility and Type:      Term

Lenders for and their respective Applicable Commitments to this Credit Facility:

 

Lender

Applicable Commitment

Midcap Funding V Trust

$15,000,000

MidCap Funding XIII Trust

$15,000,000

Total

$30,000,000

The following defined terms apply to this Credit Facility:

Applicable Interest Period:   means the one-month period starting on the first (1st) day of each month and ending on the last day of such month; provided, however , that the first (1st) Applicable Interest Period for each Credit Extension under this Credit Facility shall commence on the date that the applicable Credit Extension is made and end on the last day of such month.  

Applicable Floor:   means two percent (2.0%) per annum for the Applicable Libor Rate.

Applicable Margin:   a rate of interest equal to six and seven one-tenths percent (6.7%) per annum.

Applicable Prepayment Fee:   means the following amount, calculated as of the date (the “ Accrual Date ”) that the Applicable Prepayment Fee becomes payable in the case of prepayments required under the Financing Documents or the date any voluntary prepayment is made:  (a) for an Accrual Date on or after the Closing Date through and including the date which is twelve (12) months after the Closing Date, five percent (5.0%) multiplied by the aggregate amount of the Credit Extensions made under this Agreement (or, in the case of a partial prepayment, multiplied by the product of the aggregate amount of the Credit Extensions made under this Agreement and a fraction equal to the principal amount of Credit Extensions being prepaid or required to be prepaid  (whichever is greater) divided by the aggregate amount of the Credit Extensions made under this Agreement); (b) for an Accrual Date on or after the date which is twelve (12) months after the Closing Date through and including the date which is twenty-four (24) months after the Closing Date, three percent (3.0%) multiplied by the aggregate amount of the Credit Extensions made under this Agreement (or, in the case of a partial prepayment, multiplied by the product of the aggregate amount of the Credit Extensions made under this Agreement and a fraction equal to the principal amount of Credit Extensions being prepaid or required to be prepaid  (whichever is greater) divided by the aggregate amount of the Credit Extensions made under this Agreement); and (c) for an Accrual Date on or after the date which is twenty-four (24) months after the Closing Date through and including the date immediately preceding the Maturity Date one percent (1.0%) multiplied by the aggregate amount of the Credit Extensions made under this Agreement (or, in the case of a partial prepayment, multiplied by the product of the aggregate amount of the Credit Extensions made under this Agreement and a fraction equal to the principal amount of Credit Extensions being prepaid or required to be prepaid  (whichever is greater) divided by the aggregate amount of the Credit Extensions made under this Agreement).

Commitment Commencement Date:   Closing Date.

Commitment Termination Date:          the close of the Business Day following the Closing Date.

Minimum Credit Extension Amount: $30,000,000

Permitted Purpose: means general working capital needs of the Borrower and to finance the repayment of existing inter-company loans made by the other Credit Parties to the Borrower and the making of inter-company loans by Borrower to the other Credit Parties to fund the general working capital needs of the other Credit Parties.

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement


 

Credit Facility #2 :

Credit Facility and Type:      Term

Lenders for and their respective Applicable Commitments to this Credit Facility:

 

Lender

Applicable Commitment

Midcap Funding V Trust

$2,500,000

MidCap Funding XIII Trust

$2,500,000

Total

$5,000,000

 

The following defined terms apply to this Credit Facility:

Applicable Interest Period:   means the one-month period starting on the first (1st) day of each month and ending on the last day of such month; provided, however , that the first (1st) Applicable Interest Period for each Credit Extension under this Credit Facility shall commence on the date that the applicable Credit Extension is made and end on the last day of such month.  

Applicable Floor:   means two percent (2.0%) per annum for the Applicable Libor Rate.

Applicable Margin:   a rate of interest equal to six and seven one-tenths percent (6.7%) per annum.

Applicable Prepayment Fee:   means the following amount, calculated as of the date (the “ Accrual Date ”) that the Applicable Prepayment Fee becomes payable in the case of prepayments required under the Financing Documents or the date any voluntary prepayment is made:  (a) for an Accrual Date on or after the Closing Date through and including the date which is twelve (12) months after the Closing Date, five percent (5.0%) multiplied by the aggregate amount of the Credit Extensions made under this Agreement (or, in the case of a partial prepayment, multiplied by the product of the aggregate amount of the Credit Extensions made under this Agreement and a fraction equal to the principal amount of Credit Extensions being prepaid or required to be prepaid  (whichever is greater) divided by the aggregate amount of the Credit Extensions made under this Agreement) ; (b) for an Accrual Date on or after the date which is twelve (12) months after the Closing Date through and including the date which is twenty-four (24) months after the Closing Date, three percent (3.0%) multiplied by the aggregate amount of the Credit Extensions made under this Agreement (or, in the case of a partial prepayment, multiplied by the product of the aggregate amount of the Credit Extensions made under this Agreement and a fraction equal to the principal amount of Credit Extensions being prepaid or required to be prepaid  (whichever is greater) divided by the aggregate amount of the Credit Extensions made under this Agreement); and (c) for an Accrual Date on or after the date which is twenty-four (24) months after the Closing Date through and including the date immediately preceding the Maturity Date one percent (1.0%) multiplied by the aggregate amount of the Credit Extensions made under this Agreement (or, in the case of a partial prepayment, multiplied by the product of the aggregate amount of the Credit Extensions made under this Agreement and a fraction equal to the principal amount of Credit Extensions being prepaid or required to be prepaid  (whichever is greater) divided by the aggregate amount of the Credit Extensions made under this Agreement).

Commitment Commencement Date:   MosaiQ CE Mark Approval Date.

Commitment Termination Date:        January 31, 2017.

Minimum Credit Extension Amount: $5,000,000

Permitted Purpose: means general working capital needs of the Borrower and to finance the repayment of existing inter-company loans made by the other credit parties to the Borrower and the making of inter-company loans by Borrower to the other Credit Parties to fund the general working capital needs of the other Credit Parties

Applicable Funding Conditions:

(a) Lenders shall have received warrants to purchase shares of Quotient Limited’s fully registered common stock equal to $300,000 divided by the “exercise price”, each in form and substance substantially similar to the First Tranche Warrants, or otherwise reasonably satisfactory to Agent and Lenders (the “ Second Tranche Warrants ”), with the “exercise price” set at the Fair Market Value (as defined in the First Tranche Warrant) as of the issue date based on a valuation period of the ten Trading Days (as defined in the First Tranche Warrant) immediately prior to such issue date; and

(b) MosaiQ CE Mark Approval Date shall have occurred.

 

 

Midcap / Quotient / Amended and Restated Credit Agreement


 

Credit Facility #3 :

Credit Facility and Type:      Term

Lenders for and their respective Applicable Commitments to this Credit Facility:

 

Midcap Funding V Trust

$7,500,000

MidCap Funding XIII Trust

$7,500,000

Total

$15,000,000

The following defined terms apply to this Credit Facility:

Applicable Interest Period:   means the one-month period starting on the first (1st) day of each month and ending on the last day of such month; provided, however , that the first (1st) Applicable Interest Period for each Credit Extension under this Credit Facility shall commence on the date that the applicable Credit Extension is made and end on the last day of such month.  

Applicable Floor:   means two percent (2.00%) per annum for the Applicable Libor Rate.

Applicable Margin:   a rate of interest equal to six and seven one-tenths percent (6.70%) per annum.

Applicable Prepayment Fee:   means the following amount, calculated as of the date (the “ Accrual Date ”) that the Applicable Prepayment Fee becomes payable in the case of prepayments required under the Financing Documents or the date any voluntary prepayment is made:  (a) for an Accrual Date on or after the Closing Date through and including the date which is twelve (12) months after the Closing Date, five percent (5.0%) multiplied by the aggregate amount of the Credit Extensions made under this Agreement (or, in the case of a partial prepayment, multiplied by the product of the aggregate amount of the Credit Extensions made under this Agreement and a fraction equal to the principal amount of Credit Extensions being prepaid or required to be prepaid  (whichever is greater) divided by the aggregate amount of the Credit Extensions made under this Agreement); (b) for an Accrual Date on or after the date which is twelve (12) months after the Closing Date through and including the date which is twenty-four (24) months after the Closing Date, three percent (3.0%) multiplied by the aggregate amount of the Credit Extensions made under this Agreement (or, in the case of a partial prepayment, multiplied by the product of the aggregate amount of the Credit Extensions made under this Agreement and a fraction equal to the principal amount of Credit Extensions being prepaid or required to be prepaid  (whichever is greater) divided by the aggregate amount of the Credit Extensions made under this Agreement); and (c) for an Accrual Date on or after the date which is twenty-four (24) months after the Closing Date through and including the date immediately preceding the Maturity Date one percent (1.0%) multiplied by the aggregate amount of the Credit Extensions made under this Agreement (or, in the case of a partial prepayment, multiplied by the product of the aggregate amount of the Credit Extensions made under this Agreement and a fraction equal to the principal amount of Credit Extensions being prepaid or required to be prepaid  (whichever is greater) divided by the aggregate amount of the Credit Extensions made under this Agreement).

Commitment Commencement Date:   MosaiQ Consumables Sale Date.

Commitment Termination Date:        June 30, 2017.

Minimum Credit Extension Amount: $15,000,000.

Permitted Purpose: means general working capital needs of the Borrower and to finance the repayment of existing inter-company loans made by the other credit parties to the Borrower and the making of inter-company loans by Borrower to the other Credit Parties to fund the general working capital needs of the other Credit Parties

Midcap / Quotient / Amended and Restated Credit Agreement


 

Applicable Funding Conditions:

(a) Lenders shall have received warrants to purchase shares of Quotient Limited’s fully registered common stock equal to $900,000 divided by the “exercise price”, each in form and substance substantially similar to the First Tranche Warrants or otherwise reasonably satisfactory to Agent and Lenders (the “ Third Tranche Warrants ”), with the “exercise price” set at the Fair Market Value (as defined in the First Tranche Warrant) as of the issue date based on a valuation period of the ten Trading Days (as defined in the First Tranche Warrant) immediately prior to such issue date;

(b) MosaiQ Consumables Sale Date shall have occurred; and

(c) Credit Facility #2 shall have been fully funded.

 

 

Midcap / Quotient / Amended and Restated Credit Agreement


 

AMORTIZATION SCHEDULE (FOR EACH CREDIT FACILITY)

Term Credit Facility #1

Commencing on the Initial Payment Date (as defined below), and continuing on each Payment Date thereafter, in an amount equal to (i) the original principal amount of such Term Credit Facility divided by (ii) the number of remaining Payment Dates.

Term Credit Facility #2

Commencing on the Initial Payment Date and continuing on each Payment Date thereafter, in an amount equal to (i) the original principal amount of such Term Credit Facility divided by (ii) the number of remaining Payment Dates.

Term Credit Facility #3

Commencing on the Initial Payment Date (or if the Initial Payment Date commenced on or prior to the funding of Term Credit Facility #3, on the first day of the first calendar month following such funding) and continuing on each Payment Date thereafter, in an amount equal to (i) the original principal amount of such Term Credit Facility divided by (ii) the number of remaining Payment Dates.

Initial Payment Date ” means the first day of the nineteenth full calendar month following the Closing Date provided , however , if Agent has received satisfactory evidence that the MosaiQ CE Mark Approval Date has occurred prior to the first day of the nineteenth full calendar month following the Closing Date, then the “Initial Payment Date” shall be extended to the first day of the twenty-fifth full calendar month following the Closing Date.

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement


 

POST CLOSING OBLIGATIONS SCHEDULE

Credit Parties shall satisfy and complete each of the following obligations, or provide Agent each of the items listed below, as applicable, on or before the date indicated below, all to the satisfaction of Agent in its sole and absolute discretion:

(1) Credit Parties shall, by the date that is thirty (30) days following the Closing Date (or such later date as Agent may agree in its sole discretion), provide an Access Agreement in respect of  Borrower’s facility located at 2240 Outer Loop, Louisville, KY 40219, USA.

Credit Parties’ failure to complete and satisfy any of the above obligations on or before the date indicated above, or Credit Parties failure to deliver any of the above listed items on or before the date indicated above, shall constitute an immediate and automatic Event of Default.

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement


 

CLOSING DELIVERIES SCHEDULE

1.

duly executed original signatures to the Financing Documents to which Borrower is a party;

2.

duly executed original Secured Promissory Notes in favor of each Lender with a face amount equal to the portion of such Lender’s Applicable Commitment under each Credit Facility to be funded on such date ;

3.

the Operating Documents of each Credit Party and good standing certificates (or, to the extent applicable, the equivalent in the relevant jurisdiction of organization of such Credit Party) of each Credit Party certified by the Secretary of State of the state(s) of organization of such Credit Party or another applicable government official, if customary, as of a date no earlier than thirty (30) days prior to the Closing Date;

4.

good standing certificates dated as of a date no earlier than thirty (30) days prior to the Closing Date to the effect that each Credit Party is qualified to transact business in all states in which the nature of such Credit Party’s business so requires;

5.

duly executed original signatures to the completed Borrowing Resolutions for each Credit Party;

6.

certified copies, dated as of a recent date, of financing statement searches, as Agent shall request, accompanied by written evidence (including any UCC termination statements) that the Liens indicated in any such financing statements either constitute Permitted Liens or have been or, in connection with the initial Credit Extension, will be terminated or released;

7.

the Perfection Certificate executed by Borrower;

8.

a legal opinion of Borrower’s U.S. counsel dated as of the Closing Date together with the duly executed original signatures thereto;

9.

legal opinions of Agent’s counsel in Scotland, Jersey and Switzerland dated as of the Closing Date together with the duly executed original signatures thereto;

10.

evidence satisfactory to Agent that the insurance policies required by Article 6 are in full force and effect, together with appropriate evidence showing loss payable and/or additional insured clauses or endorsements in favor of Agent, for the ratable benefit of the Lenders;

11.

payment of the fees and expenses of Agent and Lenders then accrued, including pursuant to the Fee Letters;

12.

a duly executed original Secretary's Certificate for each Credit Party dated as of the Closing Date which includes copies of the completed Borrowing Resolutions for such Credit Party;

13.

timely receipt by the Agent of an executed disbursement letter;

14.

a certificate executed by a Responsible Officer of Borrower, in form and substance satisfactory to Agent, which shall certify as to certain conditions to the funding of the Credit Extensions on the Closing Date;

15.

Lenders (or their Affiliates) shall have received warrants to purchase shares of Quotient Limited’s fully registered common stock equal to $1,800,000 divided by the exercise price, which shall be US$16.14 per share, each in form and substance satisfactory to Agent and Lenders (the “ First Tranche Warrants ”);  

16.

all notices and acknowledgements required under the Jersey Security Document being a notice to QBD (QS IP) Limited substantially in the relevant form set out in the Jersey Security Document;

17.

a signed and dated directors' certificate to be given by two directors of each of Quotient Limited and QBD (QS IP) Limited to accompany the legal opinion of Bedell Cristin Jersey Partnership;

18.

a search by Bedell Cristin Jersey Partnership, at the Jersey Financial Services Commission and the Viscount's Department in relation to each of Quotient Limited and QBD (QS IP) Limited.

19.

the minutes of a meeting of the shareholders of Quotient Suisse unanimously approving and authorizing the execution, delivery and performance of the Amended and Restated Credit Agreement and the other Financing Documents and that the Swiss Security Documents shall continue to be in full force and effect;

Midcap / Quotient / Amended and Restated Credit Agreement


 

20.

a resolution passed by the board of directors of Quotient Suisse approving and authorizing the execution, delivery and performance of the Amended and Restated Credit Agreement and the other Financing Documents and that the Swiss Security Documents shall continue to be in full force and effect;  

21.

a certified extract from the register of commerce of Quotient Suisse and a certified copy of the articles of association ( Statuten ) of Quotient Suisse; and

22.

a certificate of the secretary or other officer of Quotient Suisse in charge of maintaining books and records of Quotient Suisse certifying as to (A) the articles of association of Quotient Suisse attached to such certificate are complete and correct copies of such articles of association as in effect on the date of such certification, (B) the resolutions of Quotient Suisse's board of directors and the minutes of Quotient Suisse's extraordinary shareholder's meeting approving and authorizing the execution, delivery and performance of the Amended and Restated Credit Agreement and the other Financing Documents and that the Swiss Share Pledge shall continue to be in full force and effect and (C) a certified extract from the register of commerce with respect to Quotient Suisse.

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement


 

DISCLOSURE SCHEDULE

Scheduled Permitted Liens

 

Debtor

Secured Party

Collateral

State and Jurisdiction

Filing Date and Number (include original file date and continuations, amendments, etc.)

Fid Fund Management SA

Quotient Suisse SA

CHF 305,000 rent deposit in blocked Credit Suisse account.

Switzerland

IBAN CH54 0483 5164 3084 5000 O

 

 

 

 

 

 

 

 

 

 

 

Scheduled Permitted Indebtedness

 

Debtor

Creditor

Amount of Indebtedness outstanding as of June 30, 2015

Maturity Date

Alba Bioscience Limited

Lombard, 3 Princess Way, Redhill, Surrey RH1 1NP

Hire purchase facility amounting to £700,000 (Seven hundred thousand pounds sterling).  Amounts outstanding at June 30, 2015 are:

Agreement number P001325225 - £31,890

Agreement number P001411643 - £29,052

Agreement number

P001648291 - £153,407

Agreement number P001648292 - £151,173

Agreement number P001325225 – 30 November 2015

Agreement number P001411643 – 31 March 2016

Agreement number

P001648291 – 31 July 2019

Agreement number

P001648292 – 31 May 2020

Alba Bioscience Limited

IBM Financial Services Limited, PO Box 41, North Harbour, Portsmouth PO6 3AU

Hire purchase agreement number GBEJ-9GEKSA-7 - £44,567

Agreement number GBEJ-9GEKSA-7 31 January 2017

Alba Bioscience Limited

Royal Bank of Scotland, St Andrew Square, Edinburgh

Corporate credit card facility of £90,000.  Balance utilized at June 30, 2015 was £25,463

Indefinite facility

Alba Bioscience Limited

Scottish Enterprise

Atrium Court

50 Waterloo Street

Glasgow G2 6HQ

Contingent liability relating to grants of £1,791,000 from Scottish Enterprise for the development of the MosaiQ project (formerly known as Q Screen).  The terms of the grant provide for the full amount received to be repayable in the event that Scottish Enterprise are not satisfied with the progress of the project.  Alba considers it unlikely that any amounts will be repayable.

 

Quotient Biodiagnostics Inc

American Express

PO Box 1270

Newark NJ

07101-1270

Corporate credit card facility. Account : 3767 4110 0035 2009.  No formal credit limit.

Indefinite facility

Quotient Suisse SA

Jungheinrich AG, Holzikerstrasse 5, 5042 Hirschthal, Switzerland

Hire purchase agreement no 5024016127 Amount outstanding at June 30, 2015 was CHF39,318

September 30, 2018

Quotient Suisse SA

Credit Suisse, Rue Pichard 22, PO Box 5722, 1002 Lausanne, Switzerland

Corporate credit card facility with a credit limit of CHF25,000.

Indefinite facility

Midcap / Quotient / Amended and Restated Credit Agreement


 

 

Schedule Permitted Investments

 

Debtor

Type of Investment

Date

Amount Outstanding as of _______

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Scheduled Material Agreements

1. Master Development Agreement between the Technology Partnership PLC and Alba Bioscience Limited dated 4 January 2010.

2. Umbrella Supply Agreement between Ortho Clinical Diagnostics and Alba Bioscience Limited dated 1 December 2004 as amended and updated.

3. Intellectual Property Rights Agreement between The Technology Partnership PLC and QBD (QS IP) Limited dated March 4, 2014.

4. Instrument Development Agreement between STRATEC Biomedical AG and QBD (QS IP) Ltd dated January 7, 2014.

5. Supply and Manufacturing Agreement between STRATEC Biomedical AG and QBD (QS-IP) Limited dated April 1, 2014.

6. Construction Contract Agreement between MW High Tech Projects UK Limited and Quotient Suisse SA dated October 27, 2014.

7. Distribution and Supply Agreement by and between Ortho Clinical Diagnostics, QBD (QS-IP) Limited and Quotient Suisse SA dated January 29, 2015.

Scheduled Litigation

None.

Scheduled ownership interest in any Chattel Paper, letter of credit rights, commercial tort claims, Instruments, documents or investment property

1. None

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement


 

INTELLECTUAL PROPERTY SCHEDULE

Please note that the applicable Credit Party owner/licensee of all the Intellectual Property mentioned in this Intellectual Property Schedule is Alba Bioscience Limited, unless otherwise stated.

All Intellectual Property referenced below is owned, not licensed, unless otherwise noted below.

Licenses & Registrations - USA

US Establishment Registration

 

Registered

Number

Jurisdiction

Market

Owner Name

Scope

US FDA

FEI 3003580203

Regulatory Authority

USA

Alba Bioscience Limited

21 CFR, Part 600, Biological products general

21 CFR, Part 800, Medical devices

21 CFR, Part 820, Quality system regulations - Facility and red cell manufacturing processes last inspected February 2011

 

US Agent

 

Contact Name

Company

Address

Tel.

Email Address

Jeremy Stackawitz

Quotient Biodiagnostics Inc.

301 South State Street, Suite S-204 Newtown, PA 18940

1-888-284-1901

jeremy.stackawitz@quotientbd.com

 

US Licensed Products

 

License Number

Products

License

Applicant

Intended Use

Contract Type

Approval Date

1807

Monoclonal blood grouping reagents, Anti-A Z001U, Anti-B Z015U, Anti-A,B Z023U, Anti-D alpha Z031U, Anti-D beta Z036U, Anti-D delta Z039U, Anti-D blend Z041U, Anti-E Z073U, Anti-c Z083U, Anti-k Z137U, Anti-M Z171U, Anti-N Z176U, Anti-Le a Z212U, Anti-Le b Z217U, Anti-Lu b Z223U

Alba Bioscience Limited

Detection and identification of human group A, B, AB, RhD, c, E, k, Lea, Leb, Lub, M, N red blood cells by direct agglutination

Alba Manufacturer / QBD Distributor

16 October 2009

2-3% Reagent Red Blood Cells, A 1 Z401U, A 2 Z406U, B Z411U and Orr Z421U for Reverse Grouping, Antibody Screen (untreated) Z451U, Antibody Identification Panels (papain-treated and untreated) Z471U and Z472U

Alba Bioscience Limited

Reverse grouping, detection/identification of unexpected antibodies

Alba Manufacturer / QBD Distributor

13 January 2012

Polyclonal blood grouping reagents, Anti-K Z131, Anti-Fy a Z151, Anti-Fy b Z153, Anti-s Z186, Anti-Wr a Z231

Alba Bioscience Limited

blood grouping reagents for the in vitro detection and identification of human group K, Fya, Fyb, Wra and s positive red blood cells by the indirect antiglobulin test

Alba Manufacturer / QBD Distributor

27 September 2012

 

Midcap / Quotient / Amended and Restated Credit Agreement


 

US Licensed Products – OEM

 

License Number

Products

License Applicant

Contract Type

1798

Anti-k finished bulk, product code Z649, Anti-Le a finished bulk, product code Z680

Biotest Medical Diagnostics GmbH (now BioRad)

Contract Manufacturing Agreement

 

510(k) Clearances

 

510(k) Number

Products

Intended Use

Contract Type

510(k) Clearance Date

BK050005

Quant-Rho ® FITC Anti-D,product code Z499

For the estimation of FMH by in vitro labelling of RhD positive cells for analysis by flow cytometry.

Alba Manufacturer / QBD Distributor

27 September 2005

BK070033

AlbaQ-Chek ® Kit (whole blood controls), product code Z49 8

For use as controls of  blood grouping reagents in column agglutination techniques.

Alba Manufacturer / OCD Distributor

18 June 2007

 

510(k) Number

Products

Intended Use

Contract Type

510(k) Clearance Date

BK080027

Anti-D Control, product code Z271

For use as a negative control in conjunction with Alba Bioscience monoclonal Anti-D reagents.

Alba Manufacturer / QBD Distributor

29 July 2008

BK080051

Fetalscreen II, product code Z488

Qualitative Screening Test for RhD (Rh o ) positive fetal red blood cells in the maternal circulation.

Alba Manufacturer / OCD Distributor

8 April 2009

BK090030

ALBAcheck ® Simulated Whole Blood Control, product code Z489

For ABO, Rh and Kell and antibody screening controls on the Immucor Galileo and Echo blood typing systems.

Alba Manufacturer / QBD Distributor

14 June 2010

BK100005

ALBAcyte ® IgG Sensitized Red Blood Cells, product code Z441U

For the control of the Indirect Antiglobulin Test (IAT) and Direct Antiglobulin Test (DAT).

Alba Manufacturer / QBD Distributor

26 August 2010

 

 

Midcap / Quotient / Amended and Restated Credit Agreement


 

510(k) Exempt/RUO/Non-IVD Products

 

Category

Products

Intended Use

Contract Type

Marketing Date (First Shipment to US)

Non-IVD

Competency Training Kit, product code Z275U

For use as an internal, self assessment of both individual operators and of antibody screening testing platforms.

Alba Manufacturer / QBD Distributor

October 2008

RUO

ALBAclone ® Advanced Partial RhD Typing Kit, product code Z293U

For the in vitro classification of human partial RhD and weak D types 1 and 2 by indirect agglutination.  The product is not suitable for routine RhD typing.

Alba Manufacturer / QBD Distributor

October 2004

510(k) Exempt

ALBAlect Anti-A1 Lectin, product code Z241U

For the in vitro detection and identification of human A 1 red blood cells by direct agglutination.

Alba Manufacturer / QBD Distributor

December 2007

510(k) Exempt

BSA 22%, product code Z305U

For the potentiation of agglutination reactions in blood group serology tests.

Alba Manufacturer / QBD Distributor

October 2009

510(k) Exempt

ALBAhance PEG 4000, product code Z312U

Potentiating reagent for the detection of red cell antibodies in human serum or plasma.

Alba Manufacturer / QBD Distributor

June 2010

510(k) Exempt

LISS Additive Reagent, product code Z333U

For use as a potentiator in antibody detection, antibody identification and compatibility test procedures.

Alba Manufacturer / QBD Distributor

June 2010

Evaluation Kit

QBD Evaluation Kit (A,B,AB,D), product code ZEVL1

Detection and identification of human group A, B, AB, RhD red blood cells by direct agglutination

Alba Manufacturer / QBD Distributor

October 2009

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement


 

Licenses - Canada

Health Canada Licences – Class III

 

Classification

Products

License Number

Applicant

Approval Date


III

Monoclonal ABO Typing Serums Z001, Z011, Z015, Z021, Z023

 

Licence 74799

Alba Bioscience Limited

29 August 2007

III

Monoclonal Rhesus Antisera Z031, Z036, Z039, Z041, Z063, Z073, Z083, Z113

 

Licence 76758

Alba Bioscience Limited

04 April 2008

III

Rare Monoclonal Antisera Z137, Z171, Z176, Z212, Z217, Z223, Z244

 

Licence 77736

Alba Bioscience Limited

06 August 2008

III

Rare Polyclonal Antisera Z103, Z131, Z139, Z151, Z153, Z186, Z191, Z221, Z231, Z248

 

 

Licence 77539

Alba Bioscience Limited

09 July 2008

III

Anti-Human Globulin Reagents Z350, Z356

Licence 76757

Alba Bioscience Limited

04 April 2008

III

A1 and B (Reverse Grouping) Red Cells (3%) Z401/Z411

Licence 75911

Alba Bioscience Limited

17 December 2007

III

Anti-Human Globulin Control Serums Z251, Z261, Z262, Z263, Z264, Z265, Z271

Licence 75975

Alba Bioscience Limited

31 December 2007

III

ALBAclone® Advanced Partial RhD Typing Kit Z293

Licence 77927

Alba Bioscience Limited

10 June 2008

III

Anti-A 1 Lectin Dolichos biflorus blood grouping serum Z241

Licence 76468

Alba Bioscience Limited

04 March 2008

III

O Adult I Cells

(2-3%) Z431

Licence 76469

Alba Bioscience Limited

04 March 2008

 

III

IgG Sensitised Cells (5%) Z441

Licence 76470

Alba Bioscience Limited

04 March 2008

 

III

3 Cell Antibody Screening Z451/Z452

Licence 76471

Alba Bioscience Limited

04 March 2008

 

III

10 Cell Antibody Identification Z471/Z472

Licence 76472

Alba Bioscience Limited

04 March 2008

III

Red Cells used for Controls of Serological Testing – Not Rhesus grouping Z406, Z413, Z414, Z415, Z435

Licence 77363

Alba Bioscience Limited

13 June 2008

III

Red Cells for Control of Rhesus Grouping Procedures Z416, Z417,

Z421, Z427

Licence 77364

Alba Bioscience Limited

13 June 2008

III

AlbaQ-Chek Simulated Whole Blood Controls Z489

Licence 76004

Alba Bioscience Limited

10 January 2008


III

Fetalscreen II Z488

Licence 82903

Alba Bioscience Limited

10 January 2008

 

Midcap / Quotient / Amended and Restated Credit Agreement


 

Health Canada Licences Class II

 

Classification

Products

License Number

Applicant

Approval Date

II

PBS Concentrate Z332

Licence 73171

Alba Bioscience Limited

23 January 2007

II

ALBAcheck ® - BGS AB Serum Z281

Licence 73172

Alba Bioscience Limited

23 January 2007

II

ALBAcheck ® - BGS Proficiency Test Z275

Licence 73173

Alba Bioscience Limited

23 January 2007

II

Quant-Rho™ FITC Anti-D Z499

Licence 73175

Alba Bioscience Limited

23 January 2007

II

Anti-Human C3 Z360

Licence 73609

Alba Bioscience Limited

20 March 2007

II

Enzyme Control Glycine soja Z256

Licence 73610

Alba Bioscience Limited

20 March 2007

II

0.5% Bromelin Z311

Licence 73611

Alba Bioscience Limited

20 March 2007

II

1% Papain Z316

Licence 73612

Alba Bioscience Limited

20 March 2007

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement


 

 

 

 

 

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement


 

Trademarks and Servicemarks

 

Mark/Status

App and Reg Dates

App. No./Reg. No.

Owner/Company

ALBA BIOSCIENCE


Registered

Filed: July 19, 2005

Registered

December 7, 2010

App. No.:79015047

Reg. No.:3885465

 

International Registration Number:0861345

ALBA BIOSCIENCE LIMITED

ALBA BIOSCIENCE and Design

 

Registered

Filed: April 25, 2006

Registered

June 1, 2010

App. No.:79027504

Reg. No.:3795828

 

International Registration Number: 894982

ALBA BIOSCIENCE LIMITED

ALBA Q-CHEK

 

Registered

Filed:  November 1, 2006

Registered

August 1, 2014

App. No.:76668476

Reg. No.:3376763

ALBA BIOSCIENCE LIMITED

ALBACHECK (Stylized)

 

Registered

Filed: September 5, 2005

Registered

June 17, 2014

App. No.:79020026

Reg. No.:3344383

 

International Registration Number: 0874434

ALBA BIOSCIENCE LIMITED

ALBACLONE (Stylized)

 

Registered

Filed September 5, 2005

Registered

July 31, 2014

App. No.:79023951

Reg. No.:3382053

 

International Registration Number: 0885135

ALBA BIOSCIENCE LIMITED

ALBAHANCE

 

Published

Filed: May 7, 2014

Published: December 2, 2014

App. No.:86274373

ALBA BIOSCIENCE LIMITED

ALBALECT

 

Registered

Filed: May 7, 2014

Registered

June 30, 2015

App. No.:86274393

Reg. No.:4763117

ALBA BIOSCIENCE LIMITED

ALBASERA

 

Registered

Filed: April 5, 2007

Registered

January 29, 2015

App. No.:79038484

Reg. No.:3462524

 

International Registration Number: 0924187

ALBA BIOSCIENCE LIMITED

ALBASURE

 

Published

Filed: May 7, 2014

Published

December 2, 2014

App. No.:86274360

ALBA BIOSCIENCE LIMITED

Midcap / Quotient / Amended and Restated Credit Agreement


 

Trademarks and Servicemarks

 

Mark/Status

App and Reg Dates

App. No./Reg. No.

Owner/Company

ALBAZYME

 

Published

Filed: May 7, 2014

Published

December 2, 2014

App. No.:86274409

ALBA BIOSCIENCE LIMITED

QUANT-RHO (Stylized)

 

Registered

Filed:  May 14, 2003

Registered

August 29, 2011

App. No.:76514111

Reg. No.:2980428

ALBA BIOSCIENCE LIMITED

Midcap / Quotient / Amended and Restated Credit Agreement


 

 

Material License AgreementS

Name and Address of Licensor

Name and Date of License Agreement

Exclusive License? (Yes/No)

Restrictions to grant a lien?

(Yes/No)

Default or Termination affect Agent’s ability to sell or assign?

(Yes/No)

The Technology Partnership PLC (“TTP”) located at Melbourn Science Park, Melbourn, Hertfordshire, SG8 6EE

 

*Please note that all Intellectual Property arising out of this TTP Master Development Agreement is licensed Intellectual Property.

Master Development Agreement dated January 4, 2010

Partially exclusive.

 

 

N

No, so long as the license was granted prior to default or termination.

QBD (QS-IP) Limited

PO Box 1075, Elizabeth House, 9 Castle Street, Jersey, JE4 2PQ, Channel Islands

Intellectual Property Rights Agreement dated March 4, 2014

No.

No

No.

TTP located at Melbourn Science Park, Melbourn, Hertfordshire, SG8 6EE

Intellectual Property Rights Agreement dated March 4, 2014

No for two licenses and yes for one license.

No.

Yes.

QBD (QS-IP) Limited and Quotient Suisse SA

PO Box 1075, Elizabeth House, 9 Castle Street, Jersey, JE4 2PQ, Channel Islands

 

 

Distribution and Supply Agreement dated January 29, 2015

Yes (for a certain territory).

Yes.

Yes.

STRATEC Biomedical AG located at Gewerbestrasse 37, D-75217 Birkenfeld-Graefenhausen, Germany

Supply and Manufacturing Agreement dated April 1, 2014

Yes for one license and no for the other license.

No.

Yes.

STRATEC Biomedical AG located at Gewerbestrasse 37, D-75217 Birkenfeld-Graefenhausen, Germany

Instrument Development Agreement dated January 7, 2014

No for one license and partially exclusive for one license. (Note that the licenses granted pursuant to this Instrument Development Agreement are for IP that may be developed under this Instrument Development Agreement.)

No.

Yes.

QBD (QS IP) Ltd located at PO Box 1075, Elizabeth House, 9 Castle Street, Jersey, JE4 2PQ, Channel Islands

Instrument Development Agreement dated January 7, 2014

No.

No.

Yes.

Midcap / Quotient / Amended and Restated Credit Agreement


 

 

PATENT APPLICATION IN THE UNITED KINGDOM

Applicant

Application Number

Product

Application Date

QBD (QS-IP) Limited

1402174.5

Cross matching in relation to the MosaiQ project.

07 February 2014

QBD (QS-IP) Limited

1403115.7

Red cell addition control

21 February 2014

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement


 

PRODUCTS SCHEDULE

See the products in the above Intellectual Property Schedule, all of which are incorporated by reference herein.

Marked Products

 

Product

Code

Product Description

Classification

FD039B

ORTHO TM Sera Anti D (DVI)

Annex II - List A

FD041B

ORTHO TM Sera Anti-D (IAT)

Annex II - List A

FD132B

ORTHO TM Sera Anti-K

Annex II - List A

Z001

ALBAclone® Anti-A (LA2) 10ml

Annex II - List A

Z011

ALBAclone® Anti-B (LB2) 10ml

Annex II - List A

Z021

ALBAclone® Anti A,B (LA2, LB2, ES15) 10ml

Annex II - List A

Z031

ALBAclone® Anti-D alpha IgM (LDM1) 10ml

Annex II - List A

Z036

ALBAclone® Anti-D beta (LDM3) 10ml

Annex II - List A

Z039

ALBAclone® Anti-D (ESD1-M) optimum 10ml

Annex II - List A

Z041

ALBAclone® Anti-D (LDM3/ESD1) blend 10ml

Annex II - List A

Z063

ALBAclone® Anti-C (P3X25513G8) 5ml

Annex II - List A

Z073

ALBAclone® Anti-E (DEM1) 5ml

Annex II - List A

Z083

ALBAclone® Anti-c (H48) 5ml

Annex II - List A

Z094A

ALBAclone® Anti-e (P3GD512,MS63) 5ml

Annex II - List A

Z131

ALBAsera® Anti-K Indirect (polyclonal) 5ml

Annex II - List A

Z401

ALBAcyte® Reagent Red Cells A1 10ml

Annex II - List A

Z411

ALBAcyte® Reagent Red Cells B 10ml

Annex II - List A

FD151B

ORTHO TM Sera Anti-Fy a

Annex II - List B

FD153B

ORTHO TM Sera Anti-Fy b

Annex II - List B

FD162B

ORTHO TM Sera Anti-Jk a

Annex II - List B

FD166B

ORTHO TM Sera Anti-Jk b

Annex II - List B

Z151

ALBAsera® Anti-Fy a Indirect 5ml

Annex II - List B

Z153

ALBAsera® Anti-Fy b Indirect 2ml

Annex II - List B

Z162

ALBAclone® Anti-Jk a (P3HT7) 2ml

Annex II - List B

Z166

ALBAclone® Anti- Jk b (P3.143) 2ml

Annex II - List B

Z350

Polyspecific AHG 10x10ml

Annex II - List B

Z356

Monospecific Anti-IgG 3x10ml

Annex II - List B

Z451

ALBAcyte® Antibody Screening Cells 3 x 10ml

Annex II - List B

Z455

ALBAcyte® Reagent Red Cells for Antibody Screening (0.8%) 3x10ml

Annex II - List B

Z458

ALBAcyte® Reagent Red Cells for Antibody Identification Native (0.8%) 11x4ml

Annex II - List B

Z459

ALBAcyte® Reagent Red Cells for Antibody Identification Papainised (0.8%) 11x4ml

Annex II - List B

Z466

ALBAcyte® RhD Negative Reagent Red Cells for Antibody Screening (0.8%) 3x5ml

Annex II - List B

Z471

ALBAcyte® Antibody Identification Panels 10 x 10ml

Annex II - List B

Z472

ALBAcyte® Antibody Identification Panels 10 x 10ml

Annex II - List B

FD171B

ORTHOTM Sera Anti-M

Annex III (self declaration)

FD176B

ORTHOTM Sera Anti-N

Annex III (self declaration)

FD182B

ORTHOTM Sera Anti-S

Annex III (self declaration)

FD186B

ORTHOTM Sera Anti-s

Annex III (self declaration)

FD202B

ORTHOTM Sera Anti-P1

Annex III (self declaration)

FD212B

ORTHOTM Sera Anti-Lea

Annex III (self declaration)

FD217B

ORTHOTM Sera Anti-Leb

Annex III (self declaration)

Midcap / Quotient / Amended and Restated Credit Agreement


 

Product

Code

Product Description

Classification

FD483G

Grifols DG Gel DUO QC Kit

Annex III (self

declaration)

Z102

ALBAsera® Anti-Cw Indirect (polyclonal) 5ml

Annex III (self declaration)

Z137

ALBAclone® Anti-k (Lk1/LKL1) 2ml

Annex III (self declaration)

Z139

ALBAsera® Anti-Kpa Indirect 2ml

Annex III (self declaration)

Z171

ALBAclone® Anti-M (LM1) 5ml

Annex III (self declaration)

Z176

ALBAclone® Anti-N (LN3) 5ml

Annex III (self declaration)

Z182

ALBAclone® Anti-S (P3S13JS123) 2ml

Annex III (self declaration)

Z186

ALBAsera® Anti-s Indirect 2ml

Annex III (self declaration)

Z191

ALBAsera® Anti-Vw Indirect 2ml

Annex III (self declaration)

Z202

ALBAclone® Anti-P1 (650) 5ml

Annex III (self declaration)

Z212

ALBAclone® Anti-Lea (LEA2) 5ml

Annex III (self declaration)

Z217

ALBAclone® Anti Leb (LEB2) 5ml

Annex III (self declaration)

Z221

ALBAsera® Anti-Lua Indirect 2ml

Annex III (self declaration)

Z223

ALBAclone® Anti-Lub (LU2) 2ml

Annex III (self declaration)

Z231

ALBAsera® Anti-Wra Indirect 2ml

Annex III (self declaration)

Z241

Anti-A1 Lectin (Dolichos biflorus) 3x5mL

Annex III (self declaration)

Z244

ALBAclone® Anti-H (LH1) 2ml

Annex III (self declaration)

Z250

DiaSure Sensitivity Control Kit 4x5mL

Annex III (self declaration)

Z251

ALBAcheck® - BGS Anti-D 0.3 iu/ml 10x10mL

Annex III (self declaration)

Z252

ALBAcheck® - BGS Anti-c (weak) 3x5mL

Annex III (self declaration)

Z253

ALBAcheck® - BGS Anti-Fya (weak) 3x5mL

Annex III (self declaration)

Z256

ALBAcheck® - BGS Enzyme Control (Glycine soja) 10x10mL

Annex III (self declaration)

Z257

ALBAcheck® - BGS High Titre Controls 4x6mL

Annex III (self declaration)

Z262

ALBAcheck® - BGS Anti-D <0.1 iu/ml 3x5mL

Annex III (self declaration)

Z263

ALBAcheck® - BGS Anti-D 0.05 iu/ml 3x5mL

Annex III (self declaration)

Z271

ALBAcheck® - BGS Anti-D Reagent Control 10x10ml

Annex III (self declaration)

Z281

ALBAcheck® - BGS AB Serum (human) 5ml

Annex III (self declaration)

Z293

ALBAclone® Advanced Partial RhD Kit 12x2mL

Annex III (self declaration)

Midcap / Quotient / Amended and Restated Credit Agreement


 

Product

Code

Product Description

Classification

Z311

Bromelin (0.5%) 10x5ml

Annex III (self

declaration)

Z316

Papain (1%) 10x5ml

Annex III (self declaration)

Z332

Phosphate Buffer Concentrate 10x25mL

Annex III (self declaration)

Z360

Anti-Human C3 (Monoclonal) 1x3ml

Annex III (self declaration)

Z406

ALBAcyte® Reagent Red Cells A2 10ml

Annex III (self declaration)

Z416

ALBAcyte® Reagent Red Cells OR1r 5ml

Annex III (self declaration)

Z421

ALBAcyte® Reagent Red Cells Orr 10ml

Annex III (self declaration)

Z427

ALBAcyte® Reagent Red Cells DVI 5ml

Annex III (self declaration)

Z441

ALBAcyte® Reagent Red Cells IgG Sensitised Cells 10ml

Annex III (self declaration)

Z483

ALBAcheck®-BGS DUO 2x6mL

Annex III (self declaration)

Z484

Ortho Confidence WB

Annex III (self declaration)

Z487

Bio Test Whole Blood Control Z487

Annex III (self declaration)

Z489

Simulated Whole Blood Controls Product No: Z489

Annex III (self declaration)

Z489

ALBAcheck-BGS Simulated WBC

Annex III (self declaration)

Z489M

ALBAcheck-BGS Simulated WBC

Annex III (self declaration)

Z494

IHQC Whole Blood Control

Annex III (self declaration)

Z497

AlbaQ-Chek J Simulated Whole Blood Controls Product Number

Annex III (self declaration)

Z499

Quant-RhoTM Anti-D FITC 5mL

Annex III (self declaration)

NB. Various products listed above also sold as bulk or FFMU under separate product codes but not classified as CE marked products.

Other Non-CE Marked Products

 

Product Code

Product Name

Product Use

Reason for Non-CE Marking

Z275

Proficiency Test Kit, 20x2mL

Internal, self-assessment

Non-IVD

Z335

LISS (Low Ionic Strength Solution) 1 Litre

Suspension of red cells

Bulk Product

Z337

Modified Alsevers Solution 2 Litres

Preservation of red cells

Bulk Product

Z338

Modified Alsevers Solution + ATP 1 Litre

Preservation of red cells

Bulk Product

Z339

Modified Alsevers Solution + ATP 5 Litres

Preservation of red cells

Bulk Product

Midcap / Quotient / Amended and Restated Credit Agreement


 

Withdrawn Products (Pending)

 

Product Code

Product Name

Assessment

Route

NB/NCA Notifications

Z093

ALBAclone ® Anti-e (monoclonal) 5ml

Annex II, List A

In progress

Z094

ALBAclone ® Anti-e (monoclonal) 5ml

Annex II, List A

In progress

Z004

ALBAclone ® Anti-A (LA2) (microplate) 30ml

Annex II, List A

In progress

Z014

ALBAclone ® Anti-B (LB2) (microplate) 30ml

Annex II, List A

In progress

Z024

ALBAclone ® Anti A,B (LA2, LB2, ES15) (microplate) 30ml

Annex II, List A

In progress

Z034

ALBAclone ® Anti-D alpha (LDM1) (microplate) 30ml

Annex II, List A

In progress

Z037

ALBAclone ® Anti-D beta (LDM3) (microplate) 30ml

Annex II, List A

In progress

Key:

(SC) = Self certified

2. List of products that are U.S. Licensed/510(k) Cleared and/or distributed in the U.S.A.

 

Product Code

Product Description

Classification

STN/PSN

Z001U

Blood Grouping Reagent, Anti-A (Murine Monoclonal) LA2

Biological Product

125301

Z015U

Blood Grouping Reagent, Anti-B (Murine Monoclonal) LB3

Biological Product

125302

Z023U

Blood Grouping Reagent, Anti-A,B (Murine Monoclonal) LA2/LB3/ES1

Biological Product

125303

Z031U

Blood Grouping Reagent, Anti-D (Monoclonal) (IgM) LDM1

Biological Product

125304

Z036U

Blood Grouping Reagent, Anti-D (Monoclonal) (IgM) LDM3

Biological Product

125304

Z039U

Blood Grouping Reagent, Anti-D (Monoclonal) (IgM Blend) ( Delta) LDM1/ESD1-M

Biological Product

125313

Z041U

Blood Grouping Reagent, Anti-D (Monoclonal Blend) LDM3/ESD1

Biological Product

125314

Z073U

Blood Grouping Reagent, Anti-E (Monoclonal) DEM1

Biological Product

125305

Z083U

Blood Grouping Reagent, Anti-c (Monoclonal) H48

Biological Product

125306

Z131U

Blood Grouping Reagent, Anti-K (Polyclonal)

Biological Product

125340

Z137U

Blood Grouping Reagent, Anti-k (Murine Monoclonal) Lk1/LKL1

Biological Product

125307

Z151U

Blood Grouping Reagent, Anti-Fy a (Polyclonal)

Biological Product

125341

Z153U

Blood Grouping Reagent, Anti-Fy b (Polyclonal)

Biological Product

125342

Z171U

Blood Grouping Reagent, Anti-M (Murine Monoclonal) LM1

Biological Product

125308

Z176U

Blood Grouping Reagent, Anti-N (Murine Monoclonal) LN3

Biological Product

125309

Z186U

Blood Grouping Reagent, Anti-s (Polyclonal)

Biological Product

125345

Z212U

Blood Grouping Reagent, Anti-Le a (Murine Monoclonal) LEA2

Biological Product

125310

Z217U

Blood Grouping Reagent, Anti-Le b (Murine Monoclonal) LEB2

Biological Product

125311

Z223U

Blood Grouping Reagent, Anti-Lu b (Murine Monoclonal) LU2

Biological Product

125312

Z231U

Blood Grouping Reagent, Anti-Wr a (Polyclonal)

Biological Product

125343

Z241U

ALBAlect Anti-A1 Lectin

Class 2 Medical Device

N/A

Z271U

Anti-D Control

Class 2 Medical Device

BK080027

Z275U

Competency Training Kit

Non In Vitro Diagnostic

N/A

Z293U

ALBAclone® Advanced Partial RhD Typing Kit

Research Use Only

N/A

Z305U

Bovine Serum Albumin 22%

Class 2 Medical Device

N/A

Z312U

ALBAhance PEG 4000

Class 2 Medical Device

N/A

Z317U

ALBAzyme TM Papain Solution Kit

Class 2 Medical Device

BK140144

Z333U

LISS Additive Reagent

Class 2 Medical Device

N/A

Z401U

2-3% Reagent Red Blood Cells A1 Cells

Biological Product

125337

Z406U

2-3% Reagent Red Blood Cells A2 Cells

Biological Product

125337

Z411U

2-3% Reagent Red Blood Cells B Cells

Biological Product

125337

Z421U

2-3% Reagent Red Blood Cells Orr Cells

Biological Product

125337

Z441U

ALBAcyte ® IgG Sensitized Red Blood Cells

Class 2 Medical Device

BK100005

Z451U

2-3% Reagent Red Blood Cells for Reverse Grouping, Antibody Screen (untreated)

Biological Product

125337

Z454U

ALBAcyte® Antibody Screen (2-Cell)

Biological Product

125337

Midcap / Quotient / Amended and Restated Credit Agreement


 

Z464U

ALBAcyte® Expanded Rh Negative Antibody Screen

Biological Product

125337

Z471U

2-3% Reagent Red Blood Cells for Antibody Identification Panels (untreated)

Biological Product

125337

Z472U

2-3% Reagent Red Blood Cells for Antibody Identification Panels (papain-treated)

Biological Product

125337

Z473U

ALBAcyte® Antibody Identification (16-Cell)

Biological Product

125337

Z481U

ALBAsure® QC Kit

Class 2 Medical Device

BK890021

Z482U

ALBAcyte® C3 Coated Red Blood Cells

Class 2 Medical Device

BK110050

Z488

Fetalscreen II

Class 2 Medical Device

BK080051

Z489U

ALBAcheck® Simulated Whole Blood Control

Class 2 Medical Device

BK090030

Z498

AlbaQ-Chek® Kit (whole blood controls)

Class 2 Medical Device

BK070033

Z499U

Quant-Rho® FITC Anti-D

Class 2 Medical Device

BK050005

Z649

Blood Grouping Reagent (Finished Bulk) Anti-k (Lk1/LKL1) Murine Monoclonal

Biological Product (Finished Bulk)

N/A

Z680

Blood Grouping Reagent (Finished Bulk) Anti-Lea (LEA2) Murine Monoclonal

Biological Product (Finished Bulk)

N/A

Z701U

Blood Grouping Reagent (For Further Manufacturing Use) Anti-A (LA2) Murine Monoclonal IgM

Biological Product (FFMU)

125438

Z704U

Blood Grouping Reagent (For Further Manufacturing Use) Anti-A (DAM1) Murine Monoclonal IgM

Biological Product (FFMU)

125438

Z735U

Blood Grouping Reagent (For Further Manufacturing Use), Anti-c (H48) Human/Murine Monoclonal IgM

Biological Product (FFMU)

125440

ZEVL1

QBD Evaluation Kit (A,B,AB,D)

Evaluation Kit

N/A

3. List of products that are Licensed in Canada

 

Product Code

Product/License Description

Classification

License Number

Z332

PBS Concentrate

II

73171

Z281

ALBAcheck®- BGS AB Serum

II

73172

Z275

ALBAcheck®- BGS Proficiency Test

II

73173

Z499

Quant-Rho TM FITC Anti-D

II

73175

Z360

Anti-Human C3

II

73609

Z256

Enzyme Control Glycine soja

II

73610

Z311

0.5% Bromelin

II

73611

Z316

1% Papain

II

73612

Z001

Monoclonal ABO Typing Serums

III

74799

Z011

Monoclonal ABO Typing Serums

III

74799

Z015

Monoclonal ABO Typing Serums

III

74799

Z021

Monoclonal ABO Typing Serums

III

74799

Z023

Monoclonal ABO Typing Serums

III

74799

Z031

Monoclonal Rhesus Antisera

III

76758

Z036

Monoclonal Rhesus Antisera

III

76758

Z039

Monoclonal Rhesus Antisera

III

76758

Z041

Monoclonal Rhesus Antisera

III

76758

Z063

Monoclonal Rhesus Antisera

III

76758

Z073

Monoclonal Rhesus Antisera

III

76758

Z083

Monoclonal Rhesus Antisera

III

76758

Z113

Monoclonal Rhesus Antisera

III

76758

Z137

Rare Monoclonal Antisera

III

77736

Z171

Rare Monoclonal Antisera

III

77736

Z176

Rare Monoclonal Antisera

III

77736

Z212

Rare Monoclonal Antisera

III

77736

Z217

Rare Monoclonal Antisera

III

77736

Z223

Rare Monoclonal Antisera

III

77736

Z244

Rare Monoclonal Antisera

III

77736

Z131

Rare Polyclonal Antisera

III

77539

Midcap / Quotient / Amended and Restated Credit Agreement


 

Z139

Rare Polyclonal Antisera

III

77539

Z151

Rare Polyclonal Antisera

III

77539

Z153

Rare Polyclonal Antisera

III

77539

Z186

Rare Polyclonal Antisera

III

77539

Z191

Rare Polyclonal Antisera

III

77539

Z221

Rare Polyclonal Antisera

III

77539

Z231

Rare Polyclonal Antisera

III

77539

Z248

Rare Polyclonal Antisera

III

77539

Z350

Anti-Human Globulin Reagents

III

76757

Z356

Anti-Human Globulin Reagents

III

76757

Z401

A1 and B (Reverse Grouping) Red Cells (3%)

III

75911

Z411

A1 and B (Reverse Grouping) Red Cells (3%)

III

75911

Z251

Anti-Human Globulin Control Serums

III

75975

Z262

Anti-Human Globulin Control Serums

III

75975

Z263

Anti-Human Globulin Control Serums

III

75975

Z271

Anti-Human Globulin Control Serums

III

75975

Z293

ALBAclone® Advanced Partial RhD Typing Kit

III

77927

Z241

Anti-A1 Lectin Dolichos biflorus blood grouping serum

III

76468

Z431

O Adult I Cells (2-3%)

III

76469

Z441

IgG Sensitised Cells (5%)

III

76470

Z451

3 Cell Antibody Screening

III

76471

Z471

10 Cell Antibody Identification

III

76472

Z472

10 Cell Antibody Identification

III

76472

Z406

Red Cells used for Controls of Serological Testing – Not Rhesus grouping

III

77363

Z413

Red Cells used for Controls of Serological Testing – Not Rhesus grouping

III

77363

Z414

Red Cells used for Controls of Serological Testing – Not Rhesus grouping

III

77363

Z415

Red Cells used for Controls of Serological Testing – Not Rhesus grouping

III

77363

Z435

Red Cells used for Controls of Serological Testing – Not Rhesus grouping

III

77363

Z416

Red Cells for Control of Rhesus Grouping Procedure

III

77364

Z417

Red Cells for Control of Rhesus Grouping Procedure

III

77364

Z421

Red Cells for Control of Rhesus Grouping Procedure

III

77364

Z427

Red Cells for Control of Rhesus Grouping Procedure

III

77364

Z489

AlbaQ-Chek Simulated Whole Blood Controls

III

76004

Z488

Fetalscreen II

III

82903

4. List of products that are Registered in Australia

 

Product Code

Product Description

Classification

Z171

ALBAclone® Anti-M Blood Grouping Reagent

Class 3

Z176

ALBAclone® Anti-N Blood Grouping Reagent

Class 3

Z182

ALBAclone® Anti-S Blood Grouping Reagent

Class 3

Z186

ALBAsera® Anti-s Blood Grouping Reagent

Class 3

Z191

ALBAsera® Anti-V w Blood Grouping Reagent

Class 3

Z202

ALBAclone® Anti-P1 Blood Grouping Reagent

Class 3

Z212

ALBAclone® Anti-Le a Blood Grouping Reagent

Class 3

Z217

ALBAclone® Anti Le b Blood Grouping Reagent

Class 3

Z221

ALBAsera® Anti-Lu a Blood Grouping Reagent

Class 3

Z223

ALBAclone® Anti-Lu b Blood Grouping Reagent

Class 3

Z231

ALBAsera® Anti-Wr a Blood Grouping Reagent

Class 3

Z241

Anti-A1 Lectin (Dolichos biflorus) Blood Grouping Reagent

Class 3

Z244

ALBAclone® Anti-H Blood Grouping Reagent

Class 3

Z250

ALBAsure Sensitivity Control Kit

Class 2

Z252

ALBAcheck® - BGS Anti-c (weak)

Class 2

Z253

ALBAcheck® - BGS Anti-Fy a (weak)

Class 2

Z293

ALBAclone® Advanced Partial RhD Kit

Class 3

Midcap / Quotient / Amended and Restated Credit Agreement


 

Z311

0.5% Bromelin

Class 2

Z316

1% Papain

Class 2

Z332

Phosphate Buffer (2.632M Concentrate)

Class 2

Z350

Polyspecific Anti-Human Globulin Reagent

Class 3

Z356

Monospecific Anti-Human IgG Blood Grouping Reagent

Class 3

Z360

Anti-Human C3 Blood Grouping Reagent

Class 2

Z441

ALBAcyte® IgG Sensitized Reagent Red Cells

Class 3

Z483

ALBAcheck® DUO Simulated Whole Blood Controls

Class 2

Z484

Ortho Confidence WB

Class 2

Z489

ALBAcheck® Simulated Whole Blood Controls

Class 2

5. List of products that are Registered in Brazil

 

Product Code

Product Description

Classification

Registration
Expiry Date

FD039B

ORTHO TM Sera Anti D (DVI)

III

June 2019

FD041B

ORTHO TM Sera Anti-D (IAT)

III

June 2019

FD132B

ORTHO TM Sera Anti-K

III

June 2019

FD151B

ORTHO TM Sera Anti-Fy a

III

June 2019

FD153B

ORTHO TM Sera Anti-Fy b

III

June 2019

FD162B

ORTHO TM Sera Anti-Jk a

III

June 2019

FD166B

ORTHO TM Sera Anti-Jk b

III

June 2019

FD171B

ORTHO TM Sera Anti-M

III

June 2019

FD176B

ORTHO TM Sera Anti-N

III

June 2019

FD182B

ORTHO TM Sera Anti-S

III

June 2019

FD186B

ORTHO TM Sera Anti-s

III

June 2019

FD202B

ORTHO TM Sera Anti-P1

III

June 2019

FD212B

ORTHO TM Sera Anti-Le a

III

June 2019

FD217B

ORTHO TM Sera Anti-Le b

III

June 2019

Z484

Ortho Confidence WB

IV

July 2018

 

 

 

Midcap / Quotient / Amended and Restated Credit Agreement


 

REQUIRED PERMITS SCHEDULE

See the following sections of the Intellectual Property Schedule: US Establishment Registration, US Agent, 510(k) Clearances, 510(k) Exempt/RUO/Non-IVD Products, Health Canada Licenses – Class III, and Health Canada Licenses Class II; all of which are incorporated by reference herein.

 

Midcap / Quotient / Amended and Restated Credit Agreement

 

Exhibit 10.2

Execution Version

AMENDMENT NO. 1 AND JOINDER TO CREDIT, SECURITY AND GUARANTY AGREEMENT

This AMENDMENT NO. 1 AND JOINDER TO CREDIT, SECURITY AND GUARANTY AGREEMENT (this “ Agreement ”) is made as of this 10th day of September, 2015 (the “ Effective Date ”), by and among quotient biodiagnostics, inc. , a Delaware corporation (the “ Borrower ”), the other Credit Parties listed on the signature pages hereof, MIDCAP FINANCIAL TRUST , a Delaware statutory trust, as administrative agent (together with its successors and assigns, the “ Agent ”), and the other financial institutions or other entities from time to time parties to the Credit Agreement referenced below, each as a Lender.

RECITALS

A. Pursuant to that certain Amended and Restated Credit, Security and Guaranty Agreement, dated as of August 3, 2015 (the “ Original Credit Agreement ” and as the same is amended hereby and as it may be hereafter amended, restated, supplemented or otherwise modified from time to time, the “ Credit Agreement ”), by and among the Borrower, Quotient Limited, a company incorporated under the laws of Jersey (“ Quotient Limited ”), Alba Bioscience Limited, a company incorporated in Scotland (“ Alba ”), QBD (QS IP) Limited, a company incorporated under the laws of Jersey (“ QBD ”), Quotient Suisse SA, a company formed under the laws of Switzerland (“ Quotient Suisse ” and together with Quotient Limited, Alba and QBD, the “ Existing Guarantors ”), the Agent and the Lenders, the Lenders agreed to make available to Borrower term loans in an aggregate amount of $50,000,000.  Capitalized terms used but not otherwise defined in this Agreement, including in these Recitals, shall have the meanings set forth in the Credit Agreement.

B. Pursuant to Section 6.8 of the Credit Agreement, subject to the conditions set forth therein, the Credit Parties are required to cause certain subsidiaries to become Credit Parties under the Credit Agreement upon the formation, incorporation or acquisition of any such subsidiaries.

C. Borrower desires to join Quotient Biocampus Limited, a company incorporated in Scotland (“ New Guarantor ” and together with the Existing Guarantors, the “ Guarantors ” and each a “ Guarantor ”), as a Guarantor in accordance with Section 6.8 of the Credit Agreement and subject to and in accordance with the terms and conditions of this Agreement and the applicable requirements of the Credit Agreement, and the Agent and Lenders constituting at least Required Lenders are willing to enter into this Agreement to join New Guarantor as a Guarantor under the Credit Agreement and the other Financing Documents.

D. Borrower has requested that Agent and Lenders agree to amend certain provisions of the Original Credit Agreement to, among other things, (i) permit the creation and continued operation of the New Guarantor, (ii) allow the New Guarantor to enter into certain Scottish Lease Documents and enter into an intercompany lease agreement with Alba with respect to the Scottish Real Property (as defined below) and (iii) permit the acquisition by the New Guarantor of certain real property more particularly described in the Scottish Ground Lease (the “ Scottish Real Property ”).

E. Agent and Lenders, subject to and in accordance with the terms and conditions of this Agreement and the applicable requirements of the Credit Agreement, are willing to agree to such request.

AGREEMENT

NOW, THEREFORE, in consideration of the foregoing, the terms and conditions set forth in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

1. Recitals.   This Agreement shall constitute a Financing Document and the Recitals set forth above shall be construed as part of this Agreement as if set forth fully in the body of this Agreement.

2. Joinder of New Guarantor .  By executing and delivering this Agreement, New Guarantor hereby becomes a party to the Credit Agreement and such other Financing Documents applicable to it as a Guarantor and expressly assumes all of the Obligations of a Guarantor under and agrees to be bound by the terms and conditions of the Credit Agreement and the other Financing Documents in the same manner as and to the same extent of any other Guarantor as if it had been an original signatory thereto (the “ Joinder ”).

 

Mid-Cap / Quotient – Amendment No. 1 and Joinder to Credit, Guaranty and Security Agreement


 

3. Amendments to Credit Agreement .

(a) Section 6.16 of the Original Credit Agreement is hereby amended by replacing such Section in its entirety with the following:

“6.16 Scottish Land Acquisition .  (a) Concurrently with the execution of the Scottish Lease Documents, Quotient Biocampus shall take all necessary action necessary or advisable to grant to Agent, on behalf of Lenders, a Lien on all of New Guarantor’s right, title and interest in, to and under the Scottish Ground Lease (acceptable to Agent and otherwise subject only to Permitted Liens under clauses (e) or (l) of the definition thereof) and (b) concurrently with acquisition by Quotient Biocampus of title to the property defined as the “Subjects” in the Scottish Ground Lease pursuant to terms thereof or otherwise, Quotient Biocampus shall take all necessary action to grant to Agent, on behalf of Lenders, a Lien on such property under the laws of Scotland acceptable to Agent.”

(b) Article 11 of the Original Credit Agreement is hereby amended by adding the following notice information for certain Guarantors:

If to Quotient Suisse SA:

Quotient Suisse

Pentlands Science Park, Bush Loan

Penicuik, Midlothian, EH26 0PL, United Kingdom

Attention: Roland Boyd

Fax: +44 131 445-6184

Email: roland.boyd@quotientbd.com

If to Quotient Biocampus Limited:

Quotient Biocampus Limited

Pentlands Science Park, Bush Loan

Penicuik, Midlothian, EH26 0PL, United Kingdom

Attention: Roland Boyd

Fax: +44 131 445-6184

Email: roland.boyd@quotientbd.com

(c) The definition of “Intellectual Property Security Agreement” in Section 16 of the Original Credit Agreement is hereby amended by replacing such definition in its entirety with the following:

““ Intellectual Property Security Agreement” means that certain Intellectual Property Security Agreement, dated as of the Original Closing Date, by and among Agent, Borrower, QBD (QSIP) Limited and Alba Bioscience Limited, as amended, restated, supplemented or otherwise modified from time to time.”

(d) The definition of “Permitted Indebtedness” in Section 16 of the Original Credit Agreement is hereby amended by adding a new clause (k) at the end thereof as follows:

“(k) Indebtedness consisting of obligations of Alba Bioscience Limited owed to Quotient Biocampus pursuant to the terms of the Scottish Intercompany Lease.”

(e) The definition of “Scottish Security Documents” in Section 16 of the Original Credit Agreement is hereby amended by replacing such definition in its entirety with the following:

““ Scottish Security Documents ” means (i) the bond and floating charge dated on or about the Original Closing Date by Alba Bioscience Limited in favor of the Agent, (ii) the bond and floating charge dated on or about the First Amendment Effective Date by Quotient Biocampus in favor of the Agent, (iii) the Standard Security Agreement, dated promptly after the First Amendment Effective Date, by Quotient Biocampus in favor of Agent with respect to the Scottish Ground Lease, (iv) the pledge of shares of Quotient Biocampus dated on or about the First Amendment Effective Date by Alba Bioscience Limited in favor of the Agent, (v) the pledge of shares of Alba Bioscience Limited dated on or about the date of the Original Credit Agreement by Quotient Limited in favor of the Agent, in each case, as amended, restated, supplemented or otherwise modified from time to time, and (vi) the Ranking Agreement, dated promptly after the First Amendment Effective Date, among Scottish Enterprise, Agent and Quotient Biocampus.”  

 

MidCap / Quotient – Amendment No. 1 and Joinder to Credit, Security and Guaranty Agreement


 

(f ) The definition of “Scottish Lease Documents” in Section 16 of the Original Credit Agreement is hereby amended by replacing such definition in its entirety with the following:

““ Scottish Lease Documents ” means (i) that certain Ground Lease to be entered into promptly following the First Amendment Effective Date between Scottish Enterprise and Quotient Biocampus, together with all annexes, schedules and exhibits thereto, all in a form substantially similar to, and with terms not materially less favorable to Credit Parties, Agent and Lenders than, the forms attached hereto as Exhibit E (the “ Scottish Ground Lease ”) (ii) that certain offer letter, to be issued promptly after the First Amendment Effective Date by Shepherd and Wedderburn LLP, as agents for Scottish Enterprise in favor of Quotient Biocampus, together with all annexes, schedules and exhibits thereto, all in a form substantially similar to, and with terms not materially less favorable to Credit Parties, Agent and Lenders than, the forms attached hereto as Exhibit F, (iii) that certain guarantee to be made promptly after the First Amendment Effective Date by Quotient Limited in favor of Scottish Enterprise, together with all annexes, schedules and exhibits thereto, all in a form substantially similar to, and with terms not materially less favorable to Credit Parties, Agent and Lenders than, the forms attached hereto as Exhibit G (the “ Scottish Lease Guarantee ”), and (iv) that certain standard security to be made promptly after the First Amendment Effective Date by Quotient Biocampus in favor of Scottish Enterprise, together with all annexes, schedules and exhibits thereto, all in a form substantially similar to, and with terms not materially less favorable to Credit Parties, Agent and Lenders than, the forms attached hereto as Exhibit H (the “ Scottish Lease Security Agreement ”).”

(g) The definitions of “First Amendment,” “First Amendment Effective Date”, “Scottish Enterprise”, “Scottish Intercompany Lease” and “Quotient Biocampus” are hereby added to Section 16 of the Original Credit Agreement in the appropriate alphabetical order therein:

““ First Amendment ” means that certain Amendment No. 1 and Joinder to Credit, Security and Guaranty Agreement, dated as of the First Amendment Effective Date, by and among the Borrower, the Agent and the Guarantors.”

““ First Amendment Effective Date ” means the effective date of the First Amendment.”

““ Quotient Biocampus ” means Quotient Biocampus Limited, a company incorporated in Scotland with registration number 514165.”

““ Scottish Enterprise ” means Scottish Enterprise, a company incorporated in Scotland.”

““ Scottish Intercompany Lease ” means that certain Lease Agreement, to be entered into after the First Amendment Effective Date, by and between Alba Bioscience Limited and Quotient Biocampus in form and substance reasonably satisfactory to Agent.”  

(h) Exhibits E , F , G and H to the Original Credit Agreement are hereby amended by replacing such Exhibits respectively with Exhibits E, F, G and H hereto.

4. Reserved .  

5. Representations and Warranties; Reaffirmation of Security Interest .  Each Credit Party represents and warrants to Agent and Lenders that, before and after giving effect to this Agreement:

(a) All representations and warranties of the Credit Parties contained in the Financing Documents were true and correct in all respects when made and, except to the extent that such representations and warranties relate expressly to an earlier date, continue to be true and correct in all respects on the date hereof;

(b) The execution and delivery by each Credit Party of this Agreement and the performance by it of the transactions herein contemplated (i) are and will be within its powers, (ii) have been authorized by all necessary action (corporate or otherwise), and (iii) are not and will not be in contravention of any order of any court or other agency of government, of law or any other indenture, agreement or undertaking to which such Credit Party is a party or by which the property of such Credit Party  is bound, or be in conflict with, result in a breach of, or constitute (with due notice and/or lapse of time) a default under any such indenture, agreement or undertaking or result in the imposition of any lien, charge or encumbrance of any nature on any of the properties of such Credit Party;

 

MidCap / Quotient – Amendment No. 1 and Joinder to Credit, Security and Guaranty Agreement


 

(c) This Agreement and any instruments, documents, and agreements executed and delivered in connection herewith, are and will be valid, binding, and enforceable against each Credit Party that is a party thereto in accorda nce with their respective terms; and   

(d) Each Credit Party confirms and agrees that all security interests and Liens granted to Agent continue in full force and effect, and all Collateral remains free and clear of any Liens, other than those granted to Agent and Permitted Liens.  Nothing herein is intended to impair or limit the validity, priority or extent of Agent’s security interests in and Liens on the Collateral.

6. Conditions to Effectiveness; Post Closing Conditions and Covenants.    This Agreement shall become effective as of the date on which each of the following conditions has been satisfied, each in form and substance satisfactory to Agent and each Lender:  

(a) the Credit Parties shall have delivered to Agent this Agreement, duly executed by an authorized officer of each Credit Party;

(b) the Credit Parties shall have delivered to Agent an updated Perfection Certificate, duly executed by an authorized officer of each Credit Party;

(c) the Credit Parties shall have delivered to Agent each Scottish Security Document to be entered into on the First Amendment Effective Date, duly executed by an authorized officer of each applicable Credit Party ;

(d) a duly executed legal opinion of Agent’s Scottish counsel;

(e) a certificate of the secretary or other officer of New Guarantor in charge of maintaining books and records of such New Guarantor certifying as to (A) the names and signatures of each officer of such New Guarantor authorized to execute and deliver any Financing Document, (B) the articles of association of New Guarantor attached to such certificate are complete and correct copies of such articles of association as in effect on the date of such certification; and (C) the resolutions of New Guarantor’s board of directors approving and authorizing the execution, delivery and performance of each Financing Document to which the New Guarantor is a party ;  

(f) a duly executed stock transfer form in respect of the shares held by Quotient Limited in the New Guarantor and a share certificate and updated register of members showing the Agent as the registered holder of the shares in New Guarantor;

(g) all representations and warranties of the Credit Parties contained herein shall be true and correct in all respects as of the First Amendment Effective Date (and such parties’ delivery of their respective signatures hereto shall be deemed to be their certification thereof);

(h) there are no Defaults or Events of Default that have not been waived or cured (and the Credit Parties’ delivery of their respective signatures hereto shall be deemed to be its certification that no Defaults or Events of Default currently exist);

(i) receipt by Agent from the Credit Parties all of the fees owing pursuant to this Agreement and Agent’s reasonable out-of-pocket legal fees and expenses; and

(j) the Credit Parties shall have delivered such further documents, information, certificates, records and filings, as Agent may reasonably request.

7. Grant of Security Interest in Collateral .  Notwithstanding the generality of Section 2 , as collateral security for the prompt and complete payment and performance when due (whether at stated maturity, by acceleration or otherwise) of the Obligations, New Guarantor hereby mortgages, pledges and hypothecates to the Agent for the benefit of the Lenders, and grants to the Agent for the benefit of the Lenders, a first priority Lien on and security interest in, all of its right, title and interest in, to and under the Collateral (excluding that part of the Collateral which is otherwise subject to the security interest granted in the Foreign Security Documents) of New Guarantor (subject only to Permitted Liens).

8 . Schedules .   Each Credit Party hereby agrees that the schedules to the Original Credit Agreement remain true and correct on and as of the date hereof .

9. Release.   Each Credit Party, voluntarily, knowingly, unconditionally and irrevocably, with specific and express intent, for and on behalf of itself and all of its respective parents, subsidiaries, affiliates, members, managers, predecessors, successors, and assigns, and each of their respective current and former directors, officers, shareholders, agents, and employees (collectively,

 

MidCap / Quotient – Amendment No. 1 and Joinder to Credit, Security and Guaranty Agreement


 

Releasing Parties ”), does hereby fully and completely release, acquit and forever discharge each Indemnitee of and from any and all actions, causes of action, suits, debts, disputes, damages, claims, obligations, liabilities, costs, expenses and demands of any kind whatsoever, at law or in equity, whether matured or unmatured, liquidated or unliquidated, vested or contingent, choate or inchoate, known or unknown that the Releasing Parties (or any of them) has against the Indemnitees (or any of them), whether directly or indirectly, arising on or before the date of this Agreement.  Each Credit Party acknowledges that the foregoing release is a material inducement to Agent’s and Lender’s decision to enter into this Agreement and to agree to the modifications contemplated hereunder.

10. No Waiver or Novation.   The execution, delivery and effectiveness of this Agreement shall not, except as expressly provided in this Agreement, operate as a waiver of any right, power or remedy of Agent or any Lender, nor constitute a waiver of any provision of the Credit Agreement, the Financing Documents or any other documents, instruments and agreements executed or delivered in connection with any of the foregoing.  Nothing herein is intended or shall be construed as a waiver of any existing Defaults or Events of Default under the Credit Agreement or other Financing Documents or any of Agent’s or any Lender’s rights and remedies in respect of such Defaults or Events of Default.  This Agreement (together with any other document executed in connection herewith) is not intended to be, nor shall it be construed as, a novation of the Credit Agreement.

11. Affirmation.   Except as specifically amended pursuant to the terms hereof, the Credit Agreement and all other Financing Documents (and all covenants, terms, conditions and agreements therein) shall remain in full force and effect, and are hereby ratified and confirmed in all respects by the Credit Parties.  Each Credit Party covenants and agrees to comply with all of the terms, covenants and conditions of the Credit Agreement (as amended hereby) and the Financing Documents, notwithstanding any prior course of conduct, waivers, releases or other actions or inactions on Agent’s or any Lender’s part which might otherwise constitute or be construed as a waiver of or amendment to such terms, covenants and conditions.

12. Costs and Fees .    The Credit Parties shall be responsible for the payment of all reasonable and documented out-of-pocket costs and fees of Agent’s counsel incurred in connection with the preparation of this Agreement and any related documents.  If Agent or any Lender uses in-house counsel for any of these purposes, the Credit Parties further agree that the Obligations include reasonable charges for such work commensurate with the fees that would otherwise be charged by outside legal counsel selected by Agent or such Lender for the work performed.

13. Further Assurances .   Borrower and the other Credit Parties hereby agree that at any time and from time to time, at the expense of the Credit Parties, they will promptly execute and deliver all further instruments and documents, and take all further action, that may be necessary or that Agent or Lenders may reasonably request, in connection with this Amendment, or to enable them to exercise and enforce their rights and remedies under this Amendment, the Credit Agreement and the other Financing Documents.

14. Miscellaneous.

(a) Reference to and Effect on the Credit Agreement. Upon the effectiveness of this Agreement, each reference in the Credit Agreement to “this Agreement,” “hereunder,” “hereof,” “herein,” or words of similar import shall mean and be a reference to the Credit Agreement, as amended by this Agreement.  Except as specifically amended pursuant hereto, the Credit Agreement, and all other Financing Documents (and all covenants, terms, conditions and agreements therein), shall remain in full force and effect, and are hereby ratified and confirmed in all respects by Borrower.  

(b) Incorporation of Credit Agreement Provisions.   The provisions contained in Section 12 (Choice of Law, Venue and Jury Trial Waiver), Section 13.2 (Indemnification) and Section 13.9 (Confidentiality) of the Credit Agreement are incorporated herein by reference to the same extent as if reproduced herein in their entirety.

(c) Headings.   Section headings in this Agreement are included for convenience of reference only and shall not constitute a part of this Agreement for any other purpose.

(d) Counterparts.   This Agreement may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument.  Signatures by facsimile or by electronic mail delivery of an electronic version (e.g., .pdf or .tif file) of an executed signature page shall be treated as delivery of an original and shall bind the parties hereto. This Agreement constitutes the entire agreement and understanding among the parties hereto and supersedes any and all prior agreements and understandings, oral or written, relating to the subject matter hereof.

[SIGNATURES APPEAR ON FOLLOWING PAGES]

 

 

 

 

MidCap / Quotient – Amendment No. 1 and Joinder to Credit, Security and Guaranty Agreement


 

IN WITNESS WHEREOF , intending to be legally bound, and intending that this Agreement constitute an agreement executed under seal, the undersigned have executed this Agreement as of the day and year first hereinabove set forth.

BORROWER:

Quotient Biodiagnostics, Inc.

 

By: /s/Paul Cowan___________________________(SEAL)

Name: DJPE Cowan__________________________

Title: Director_______________________________

 

 

MidCap / Quotient – Amendment No. 1 and Joinder to Credit, Security and Guaranty Agreement


 

GUARANTORS:

Quotient Limited

 

By: /s/Paul Cowan___________________________(SEAL)

Name: DJPE Cowan__________________________

Title: Director_______________________________

Alba Bioscience Limited

 

By: /s/Paul Cowan___________________________(SEAL)

Name: DJPE Cowan__________________________

Title: Director_______________________________

QBD (QSIP) Limited

 

By: /s/Paul Cowan___________________________(SEAL)

Name: DJPE Cowan__________________________

Title: Director_______________________________

Quotient Suisse SA

 

By: /s/Paul Cowan___________________________(SEAL)

Name: DJPE Cowan__________________________

Title: Director_______________________________

Quotient Biocampus limited

 

By: /s/Paul Cowan___________________________(SEAL)

Name: DJPE Cowan__________________________

Title: Director_______________________________

 

MidCap / Quotient – Amendment No. 1 and Joinder to Credit, Security and Guaranty Agreement


 

AGENT:

MIDCAP FINANCIAL TRUST

By:

Apollo Capital Management, L.P.,

its investment manager

By:

Apollo Capital Management GP, LLC,

its general partner

By:  /s/ Maurice Amsellem_________________(SEAL)

Name: Maurice Amsellem

Title: Authorized Signatory

 

MidCap / Quotient – Amendment No. 1 and Joinder to Credit, Security and Guaranty Agreement


 

LENDERS:

MIDCAP FUNDING V TRUST

 

By:

Apollo Capital Management, L.P.,

its investment manager

By:

Apollo Capital Management GP, LLC,

its general partner

By:  /s/ Maurice Amsellem_________________(SEAL)

Name: Maurice Amsellem

Title: Authorized Signatory

MIDCAP FUNDING XIII TRUST

 

By:

Apollo Capital Management, L.P.,

its investment manager

By:

Apollo Capital Management GP, LLC,

its general partner

By:  /s/ Maurice Amsellem_________________(SEAL)

Name: Maurice Amsellem

Title: Authorized Signatory

FLEXPOINT MCLS SPV LLC

 

By: /s/ Daniel Edelman____________________ (SEAL)

Name:  Daniel Edelman

Title:    Vice President

 

MidCap / Quotient – Amendment No. 1 and Joinder to Credit, Security and Guaranty Agreement


 

E XHIBIT E

SCOTTISH GROUND LEASE

(See attached)

 

 

 

 

MidCap / Quotient – Amendment No. 1 and Joinder to Credit, Security and Guaranty Agreement


 

 

GROUND LEASE

between

Scottish Enterprise

and

1. QUOTIENT BIOCAMPUS LIMITED

 

 

Subjects:  Site 3, Bio Campus, Roslin, Midlothian

 

 

 

Shepherd and Wedderburn LLP

191 West George Street

Glasgow

G2 2LB

DX GW409 Glasgow

T: +44 (0)141 566 9900

F: +44 (0)141 565 1222

www.shepwedd.co.uk

 

46649908-1


(1)

 

CONTENTS

 

Clause

 

 

 

Page No

1.

 

Definitions and Interpretations

 

2

2.

 

The Grant

 

4

3.

 

Rent/Interest/Payment of Net Premium

 

4

4.

 

Tenants' Monetary Obligations

 

4

5.

 

Tenants Non Monetary Obligations

 

5

6.

 

Landlords Warranty and Assurances

 

9

7.

 

Irritancy

 

9

8.

 

Acceptance of Rent/No Waiver/Rei Interitus

 

10

9.

 

Title Transfer

 

10

10.

 

Notices

 

10

11.

 

Registration

 

11

 

 

 

 

 

 

 

Schedule

 

12

 

 

Part 1 The Subjects

 

12

 

 

Part 2 Landlord's Reserved Rights

 

13

 

 

Part 3 Title Transfer Provisions

 

14

 

 

Part 4 Approved Plans and Specification

 

16

 

 

Part 5 Disposition

 

17

 

 

Part 6 Plan

 

18

 


(2)

 

LEASE

between

SCOTTISH ENTERPRISE , established under the Enterprise and New Towns (Scotland) Act 1990 and having their principal place of business at Atrium Court, 50 Waterloo Street, Glasgow (who and whose successors are hereinafter referred to as "the Landlords")

and

QUOTIENT BIOCAMPUS LIMITED , a company incorporated under the Companies Acts with registered number SC514165 and having its registered office at Douglas Building Pentlands Science Park, Bush Loan, Penicuik, Midlothian, EH26  (who and whose permitted successors and assignees are hereinafter referred to as "the Tenants").

1.

Definitions and Interpretations

1.1

In this Lease (including this sub-clause and the Schedule) the following words and expressions shall have the following meanings:-

 

"Advance Notice"

an advance notice as defined in section 56 of the 2012 Act;

 

 

"Architect"

means such suitably qualified firm of architects as may be employed or instructed by the Tenants to be the architect in connection with the Development Works;

 

 

"Approved Plans"

the detailed plans and specifications relating to the Development Works approved by the Landlords and contained in Part 4 of the Schedule subject to any permitted variations in terms of Clauses 5.4 and 5.5 of this Lease;

 

 

"Base Rate"

 

the Base Rate of the Bank of Scotland from time to time or in the case of the said Base Rate ceasing to exist such other equivalent rate as the Landlords (acting reasonably) may determine;

 

 

"Building Contract"

means the building contract relative to the execution of the Development Works entered into by the Tenants;

 

 

"Condam Regulations"

the Construction (Design and Management) Regulations 2015;

 

 

"Construction Expert"

a building surveyor practising in Scotland having not less than 10 years’ experience of substantial property development projects such as the Development Works, such surveyor to be jointly appointed by the parties to this Lease, or in the event of failure to agree upon the surveyor by the date falling 10 Working Days after the date of intimation by either party to the other of a dispute to be determined in terms of Clause 5.27 to be nominated by the President of the Scottish Branch of the RICS upon request by either party;

 

 

"Date of Practical Completion"

the date that a Certificate of Practical Completion is issued in terms of this Lease;

 

 

"Delay Event"

(a) any event or circumstance which would entitle the contractor under the JCT suite of standard form of building contracts or other form of industry standard building contracts as amended an extension of time (but excluding delays attributable to an act, default, omission or the financial circumstances of the Developer);  and (b) any act, default or omission of the Landlords, the Landlord's Representative or the Landlord's  agents, employees or contractors;

 

 

“Development Works”

means the construction by the Tenants on the Subjects of a facility as shown on the Approved Plans;

 

 

“Disposition”

means the disposition contained in Part 5 of the Schedule;

 

 

"Duration"

the period of 99 years from (and including) the [insert Date of Entry] to [          ] 2114;

 

 

"Lease"

this ground lease;

 

 

 


(3)

 

"Necessary Consents"

all planning consents required under the Planning Acts, building warrants and all other consents required from any statutory authority, person, property owner or body that are required to enable the Development Works to be commenced and completed;

 

 

"Net Premium"

the sum of NINE HUNDRED AND EIGHTY SIX THOUSAND, EIGHT HUNDRED POUNDS (£986,800) exclusive of VAT;

 

 

“Net Premium Interest Rate”

means 4%;

 

 

“Plan”

the plan of the Subjects contained in Part 6 of the Schedule;

 

 

“Planning Acts”

the Town & Country Planning (Scotland) Acts 1947 to 1997, the Planning (Listed Buildings and Conservation Areas) (Scotland) Act 1997, the Planning (Hazardous Substances) (Scotland) Act 1997, the Planning (Consequential Provisions) (Scotland) Act 1997, the Local Government and Planning (Scotland) Act 1982, the Town & Country Planning Act 1984, the Planning and Compensation Act 1991 and any other legislation from time to time in force relating to planning matters;

 

 

“Practical Completion”

means the date on which the Development Works are deemed practically complete in terms of the  Lease;

 

 

“Quarter Days”

means 28 February, 28 May, 28 August and 28 November in each year and the expressions “Quarter Day” and the relevant “Quarter Day” shall be construed accordingly;

 

 

"Reserved Rights"

the reserved rights in favour of the Landlords described in Part 2 of the Schedule;

 

 

"Schedule"

the schedule of six parts annexed and executed as relative hereto;

 

 

"SE Representative"

means such party appointed by the Landlords and notified to the Tenants in writing;

 

 

"Specified Rate"

the rate of 4 per centum per annum above the base rate of the Royal Bank of Scotland;

 

 

"Subjects"

the subjects described in Part 1 of the Schedule;

 

 

"Title Transfer Provisions"

the heritable title transfer provisions set out in Part 3 of the Schedule;

 

 

"Validly Executed"

executed in accordance with the requirements of Section 3 and 7 and Schedule 2 of the Requirements of Writing (Scotland) Act 1995;

 

 

"Working Day"

any day other than a Saturday, Sunday or Public Holiday in Glasgow, Edinburgh or London; and

 

 

"2012 Act"

the Land Registration etc (Scotland) Act 2012.

 

1.2

In this Lease:-

 

1.2.1

Words importing the singular shall include the plural and words importing the masculine gender shall include the feminine gender and vice versa .  Where there are two or more persons included in the expression "the Tenants", obligations expressed to be undertaken by the Tenants shall be deemed to be undertaken by such persons jointly and severally.  The word "person" shall mean an individual, partnership, company, public authority or any other body whatsoever.

 

1.2.2

If the Tenants consist of a firm or partnership the obligations of the Tenants shall be binding jointly and severally not only on all persons who are partners of the firm at the time that this Lease is executed but also on all persons who shall become partners of the firm at any time during the Duration and their respective executors and representatives whomsoever as well as on the firm and its whole assets and such obligations shall subsist notwithstanding any change or changes which may take place in the name of the firm or constitution of the partnership.  The retiral, death or outgoing of any individual partner shall not of itself discharge such a partner or his executors from such partner's joint and several liability in terms of this Lease but the Landlords’ consent will not be unreasonably withheld or delayed to the discharge of any retiring or outgoing partner or the estate of any deceased partner where the remaining partners are demonstrably capable of fulfilling the obligations of the Tenants under this

 


(4)

 

 

Lease If the Tenants comprise more than one person the Landlords shall be entitled to discharge any of the persons so comprised without in any way discharging any of the remaining persons so comprised in terms of this Lease.  

 

1.2.3

Any reference to a statute or subordinate legislation shall include any modification, extension or re-enactment thereof for the time being in force and shall include all instruments, orders and regulations for the time being made, issued or given thereunder or deriving validity therefrom.

 

1.2.4

Any obligation by the Tenants not to do an act or thing shall be deemed to include an obligation not to agree or suffer or permit such act or thing to be done by any agent, employee, invitee, contractor or other for whom the Tenants are responsible in law.

 

1.2.5

Any reference to any act, omission or default of the Tenants shall be deemed to include an act, omission or default of their sub-tenants, agents, employees, invitees, contractors, licensees and others for whom they are responsible in law and/or the Tenants or their sub-tenants' respective predecessors in title.

 

1.2.6

The clause, paragraph and schedule headings in this Lease are for reference only and shall not affect the construction or interpretation of this Lease.

2.

The Grant

2.1

In consideration of the payment of the Rent plus Value Added Tax due thereon, the Landlords hereby let to the Tenants the Subjects, but under reservation of the Reserved Rights and that for the Duration and on the terms and conditions contained in this Ground Lease.

3.

Rent/Interest/Payment of Net Premium

3.1

The Tenants shall pay to the Landlords rent at the rate of ONE POUND (£1) per annum (exclusive of VAT) payable annually in arrears on the 31 st day of January in each year throughout the Duration, only if asked;

3.2

The Tenants shall pay to the Landlords without deduction, retention or demand yearly interest on the Net Premium at the Net Premium Interest Rate by equal quarterly instalments in advance on the Quarter Days by Bankers Order or such other method as the Landlords may from time to time direct until the Net Premium is paid by the Tenants to the Landlords in accordance with Clause 3.3.  The first payment will fall due on the Date of Entry and being a proportionate payment calculated on a daily basis over a year for the period from (and including) the Date of Entry until (but excluding) the Quarter Day next following; and

3.3

The Tenants will pay to the Landlords without deduction, retention or demand the Net Premium (under deduction of the Deposit paid to the Landlords in terms of the Missives relating to this Lease) on the earlier of (i) Practical Completion; or (ii) the date falling two years after the Date of Entry.

4.

Tenants' Monetary Obligations

The Tenants bind and oblige themselves during the entire Duration:-

4.1

To pay the rent from time to time payable in terms of this Lease in accordance with the provisions of Clause 3.1;

4.2

To pay the interest payable on the Net Premium in accordance with the provisions of Clause 3.2;

4.3

To pay the Net Premium in accordance with the provisions of Clause 3.3;

4.4

To pay all existing and future rates, taxes, charges, assessments, impositions and outgoings whatsoever (whether payable by the owner or occupier) charged, assessed or imposed on or in respect of the Subjects;

 


(5)

 

4.5

To pay within 14 days of written demand all expenses, costs, charges and fees properly and reasonably incurred by the Landlords in connection with  

 

(i)

the enforcement of or procuring the remedy of any breach of any obligation on the Tenants in terms of this Lease; and

 

(ii)

in relation to every application for consent and approval made in terms of this Lease, whether such consent or approval is granted or refused in terms of the Lease save that the Tenants shall not be responsible for any expenses incurred by the Landlords in (a) the initial approval of the plans and specifications forming Part 4 of the Schedule (but not including expenses, costs, charges and fees relating to applications for consent and/or approval after the Date of Entry in terms of Clause 5.4 below and in terms of any other provision of this Lease); and (b)  in respect of any consent or approval that is withheld in breach of the terms of this Lease.

4.6

To pay to the Landlords or to such other party as the Landlords may direct within 14 days of written demand the proportion applicable to the Subjects in terms of the title deeds or by statute, common law or otherwise of the costs and expenses of repairing, maintaining, renewing, rebuilding, lighting and cleansing of all roads, pavements, sewers, drains, pipes, water courses, walls, fences and any other structure or facility owned or used in common by the Subjects and other adjoining, neighbouring or nearby properties;

4.7

To pay to the Landlords any Value Added Tax and/or any other tax or charge of a similar nature as shall be properly chargeable in respect of all monies (including rent) undertaken to be paid by the Tenants under this Lease all which monies are for the avoidance of doubt expressed exclusive of Value Added Tax or such other tax as aforesaid; and

4.8

To pay to the Landlords on demand all reasonable costs properly incurred by the Landlords in connection with the monitoring of the Development Works in terms of this Lease up to a maximum of £10,000 plus VAT; such costs are to be payable no later than (i) Practical Completion or (ii) the date falling two years after the Date of Entry upon receipt of properly vouched invoices;

4.9

Save as expressly otherwise specified in this Lease to pay to the Landlords on demand interest at the Specified Rate on all sums due to the Landlords under this Lease from the due date for payment thereof until the date of actual receipt of payment in full by the Landlords, such interest to be calculated on a daily basis on any balances outstanding.

5.

Tenants Non Monetary Obligations

The Tenants bind and oblige themselves throughout the entire duration as follows:-

5.1

The Tenants will commence and proceed diligently in a good and workmanlike manner with the Development Works in accordance with the Approved Plans and the Necessary Consents.  

5.2

The Tenants undertake to the Landlords to complete the Development Works within twenty four months of the Date of Entry.

5.3

The timescales specified in Clause 5.2 shall be extended in respect of the occurrence of any Delay Event by the period of time properly attributable to such Delay Event.

5.4

The Tenant shall not make any alterations to or deviations from the Approved Plans or use any materials in substitution for those specified therein without the prior written consent of the Landlords which consent shall not be unreasonably withheld or delayed for any internal or non-material external alterations or additions which do not materially alter the Development Works.  Upon such consent being given, all such amended drawings, specifications illustrating such alterations or deviations shall be deemed to be incorporated in the Approved Plans. For the avoidance of doubt, in the event of a dispute as to whether any such alteration to or deviation from the Approved Plans or use of materials in substitution as aforesaid materially alters the Development Works then either party may refer the matter to the Construction Expert for determination in terms of Clause 5.27.  

 


(6)

 

5.5

Notwithstanding the provisions of Clause 5.4 above, no consent shall be required in the case of the following alterations to the Approved Plans:-  

 

(i)

minor changes or variations of the sort normally instructed on a day to day basis under a building contract for works equivalent or similar to the Development Works ; and

 

(ii)

internal alterations (including fitting-out works), which are not fundamental to the structural integrity of the building to be constructed on the Subjects;

For the avoidance of doubt, in the event of a dispute as to whether consent is required or not as aforesaid then either party may refer the matter to the Construction Expert for determination in terms of Clause 5.27.  

5.6

The Tenants accept the Subjects as being in all respects fit for full occupation and use by the Tenants and to carry out any formal obligations otherwise incumbent upon the Landlords and/or the owner of the Subjects whether at common law or by statute or otherwise.

5.7

To comply at the Tenant's expense with the provisions and requirements of all European Union and United Kingdom statutes and subordinate legislation, regulations and directives and any notices and directions issued thereunder (including without prejudice to the foregoing generality, the Planning Acts, the Factories Act 1961, the Offices, Shops and Railway Premises Act 1963, the Fire (Scotland) Act 2005, the Health and Safety at Work Etc Act 1974, the Environmental Protection Act 1990, the Environment Act 1995, the Construction (Design and Management) Regulations 2015 and the Control of Asbestos Regulations 2012) and to comply likewise with all provisions contained in the title deeds relating to the Subjects and all requirements or regulations of any competent authority relating to the Subjects and their use and that whether the said provisions are imposed on the owner or occupier of the Subjects.

5.8

Not to use or permit or suffer the buildings constructed on the Subjects or any part thereof to be used otherwise than for use for the manufacture of biotechnology products and/or research into the production of biotechnology products and/or development of processes for the production of biotechnology products with ancillary offices and warehousing and without prejudice to the foregoing, not to:-

 

(i)

use the Subjects for a  noisy, offensive  or immoral trade or business or for any purpose which breaches any statutory provision or relevant regulations;

 

(ii)

bring on to the Subjects any hazardous, explosive, dangerous or combustible goods or materials without (i) complying with all necessary and applicable statutes and (ii) having due and reasonable regard to all health and safety considerations affecting all property and persons within the Subjects and beyond;

5.9

Not to knowingly pass or allow to pass into the pipes, drains, sewers or other serving the Subjects any polluting agent or noxious or deleterious effluvia or any substance that may cause any obstruction or injury to the said pipes and others or otherwise cause contamination, if necessary  to employ such plant for treating such effluent before it enters the drains as may be required by any local or public authority and make good and remedy any injury or contamination which occurs to the reasonable satisfaction of the Landlords, and not to permit any smoke, effluvia, vapour or grit to be emitted from the Subjects.

5.10

Not to knowingly do or permit anything on or in connection with the Subjects or any adjoining subjects which is likely to be an obstruction or cause of damage to the Landlords or to the owner or occupier of any adjoining or neighbouring property.  Without prejudice to the generality not to permit motor or other vehicles to obstruct  any roads leading to the Subjects.

5.11

Not to assign or sublet this Lease in whole or in part without the prior consent of the Landlords.  Declaring however that the Tenants shall be entitled to assign its interest in the Lease without the need for the Landlords’ consent to a Group Company of the Tenants at the relevant time as the term “Group Company” is defined in the Companies Acts 2006 or the Guarantor provided written notice of any such assignation is intimated to the Landlords in writing as soon as possible after the same occurs.

5.12

Not to grant any fixed security or floating charge over the Tenant's interest in this Lease without the consent of the Landlords which consent is not to be unreasonably withheld or delayed in respect of a bona fide security or floating charge granted to any established national or international financial institution or a Group Company as that term is defined in the Companies Acts 2006.  For the avoidance of doubt Landlords’ consent shall be deemed granted for any security granted in favour of the Landlords over the Tenants’ interest in the Lease.

 


(7)

 

5.13

Following Practical Completion of the Development Works to keep all buildings and other structures on the Subjects fully insured against loss or damage by fire, lightning, flooding, explosion, storm and tempest, impact, aircraft and such other risks as the Tenants may consider appropriate with a reputable insurance company for the full reinstatement value of such buildings and others (including site clearance and professional fees) and to produce to the Landlords on reasonable request evidence that the foregoing obligations have been complied with.  

5.14

Save where the Landlords are insured  to free, relieve and indemnify the Landlords from and against any liability in respect of any injury to or the death of any person, damage to any property, heritable or movable, any interdict or court action, the infringement, disturbance or destruction of any right, servitude or privilege or otherwise by reason of or arising directly or indirectly out of the repair, state of repair or condition of the Subjects or any buildings or other structures thereon or any alteration or addition or improvement to the same or the use of the Subjects or from any act, omission or default of the Tenants in the implementation and observance of the obligations contained in this Lease from all proper fees, penalties, charges proceedings costs, claims, expenses and demands of whatsoever nature in respect of any such liability or alleged liability or any such act, omission or default, provided the same does not arise through the fault of the Landlords or those for whom they are responsible in law.

5.15

The Tenants will procure the making good of any damage to footpaths, roads, pavements or adjoining property within the larger bio campus of which the subjects form part and any services therein to the extent that such damage arises directly out of or by reason of the carrying out of the Development Works or any part thereof, all to the reasonable satisfaction of the SE Representative.

5.16

The SE Representative shall be entitled at any reasonable time on reasonable prior written notice to enter on to the Subjects (but without impeding the progress of the Development Works and without giving any instructions in respect of the Development Works or otherwise and subject to the Landlords making good any damage caused thereby) to inspect the progress of the Development Works, to inspect materials and workmanship and generally to ensure that the Tenants are complying with its obligations under this Clause 5.

5.17

The SE Representative shall also be entitled to attend (as an observer only) the monthly design team meetings, and the Developer shall ensure that the SE Representative is given at least five working days’ prior written notice of and receives copies of the minutes of all such meetings.

5.18

The Tenants shall have due regard to any reasonable comments or representations made by the SE Representative in relation to the implementation of the Development Works in accordance with the terms of this Lease.

5.19

The Tenants shall in relation to the Development Works insure or cause to be insured the Subjects together with the Development Works from time to time from the date of commencement of the Development Works until the Practical Completion against all risks usually covered by a contractor's comprehensive "All Risks" policy.  The Tenants will when reasonably required produce to the Landlords evidence of such insurances.

5.20

In the event that any of the Development Works are destroyed or damaged by fire or other insured risks at any time before Practical Completion, then and as often as the same may happen, the Tenants shall procure that the monies paid by virtue of any insurance policy are applied forthwith towards carrying out and completing the Development Works and/or rebuilding, repairing or otherwise reinstating all damage to the Development Works in accordance with the provisions of this Lease.

5.21

In questions between the Tenants and the Landlords, the Tenants shall be "the client" for the purposes of the Condam Regulations and shall prior to the commencement of the Development Works make a declaration in writing to the Health & Safety Executive to the effect that it is the only client for the purposes of the Condam Regulations.  Copies of the declaration and any acknowledgement from the Health & Safety Executive shall be supplied to the Landlords upon reasonable request.

5.22

The Tenants shall procure that there is given to the SE Representative at least 10 Working Days’ notice of the anticipated date of Practical Completion and be given the opportunity to inspect the Development Works at or prior to the anticipated date of Practical Completion.

5.23

The Tenants shall deliver to the Landlords a copy of the Certificate of Practical Completion when issued (which may include a schedule of any works of an unfinished nature which would normally be the subject of a contractor’s snagging list (not including any items other than minor snagging items (“the snagging list”)).  In the event that the Landlords consider that notwithstanding the issue of Practical Completion, the Development Works have not been properly completed, then within a further 21 days (counting from the date of delivery of the Certificate of Practical Completion to the Landlords with reference to this clause of the Lease), the Landlords may refer the matter to the Construction Expert for determination in terms of

 


(8)

 

Clause 5.27.  In the event of such a referral, the Development Works shall not be deemed to be complete in terms of the Lease until the Construction Expert has issued his determination.  In the event the Construction Expert determines that the Development Works have not been properly completed, the Tenants shall be required to carry out all further works required to complete the Development Works as specified by the Construction Expert before the Development Works are deemed complete for the purposes of the Lease.  In the event of any dispute as to whether the further works have been completed, either party may refer the matter to the Construction Expert for determination in terms of Clause 5.27.  The provisions of this clause shall be repeated until the Development Works are deemed complete for the purposes of the Lease by the Expert (or agreed to be complete by the parties).  

5.24

If the Landlords do not make a reference to the Construction Expert within the 21 day period, then the Landlords shall be deemed to agree that the Development Works have been properly completed in accordance with the provisions of the Lease.

5.25

For the avoidance of doubt the Landlords shall not be permitted to make a reference to the Construction Expert because of the existence of the snagging list.

5.26

The Tenants shall exhibit to the Landlords within two months after the date of issue of the Certificate of Practical Completion an acceptance by the local authority of the issue of a Completion Certificate in respect of the Development Works.

5.27

 

5.27.1

All disputes, differences and questions between the Landlords and the Tenants, concerning, arising out of or connected with the execution or completion of the Development Works or any Delay Event shall be referred to the Construction Expert.

 

5.27.2

Any reference made under the provisions of Clause 5.27 may be made by the Landlords or the Tenants provided that they shall first have given the other party not less than 5 Working Days' written notice of their intention to make such reference.

 

5.27.3

The Construction Expert shall be entitled to call on the Landlords or the Tenants to provide such records or other information as they may consider necessary for the purposes of resolving the dispute in question and the Landlords and the Tenants undertake to provide all such information in their possession or under their control as quickly as reasonably practicable.

 

5.27.4

The Construction Expert appointed to resolve the dispute under this Agreement:-

 

(i)

shall fully consider all written representations made by or on behalf of the Landlords or the Tenants which are delivered to him within 10 Working Days of his appointment, and shall thereafter give each party a further period of 5 Working Days within which to make further written representations thereon;

 

(ii)

may call for such written evidence from the parties and seek such additional legal or expert assistance as they may reasonably require;

 

(iii)

shall not accept oral representations from any party without allowing the other party the opportunity to be present and to give evidence and cross-examine each other;

 

(iv)

shall have regard to all representations and evidence submitted when making his decision (which shall be in writing) and shall give reason for his decision;

 

(v)

shall use all reasonable endeavours to issue his decision (with reasons) within 20 Working Days of his appointment (or within such a longer period as may be agreed by the parties at the time of such appointment);

5.28

The decision of the Construction Expert in connection with any dispute shall be final and binding on the Landlords and the Tenants.

5.29

The fees and expenses and of the Construction Expert (including the fees of any party as to nominate such Expert) shall be payable by the Landlords and the Tenants in such proportions as the Construction Expert shall determine, or in default of such determination such be borne equally.

 


(9)

 

6.

Landlords Warranty and Assurances  

6.1

The Landlords warrant that the Tenants may, subject to the Reserved Rights, quietly enjoy the Subjects during the Duration.  Nothing contained in this Lease shall however be deemed to constitute any warranty by the Landlords that the Subjects or any part thereof are authorised for use under the Planning Acts or otherwise for any specific purpose or that the Subjects are fit for any of the Tenant's purposes under this Lease.

6.2

The Landlords shall not sell or dispose of or otherwise alienate their interest in the Subjects during the Duration, other than such a sale, disposal or alienation as aforesaid to a statutory successor of the Landlords, whom the Landlords shall specifically take bound (in self proving form addressed to the Tenants) to fulfil the Landlords’ obligations herein, including Clause 9 hereof.  

7.

Irritancy

7.1

If the Tenants shall fail to perform or observe any of the material obligations undertaken by them in this Lease or if the Tenants (being a corporation) shall go into liquidation, (whether compulsory or voluntary) (save for the purpose of amalgamation or reconstruction of a solvent company where such amalgamation or reconstruction has been approved in advance by the Landlords (the Landlords’ approval not to be unreasonably withheld or delayed)), or have a winding up order made against them or have a receiver or administrator appointed or if the Tenants (being a company with unlimited liability) apply to limit their liability or in the event that the Tenants or any of them enter into a composition for the benefit of creditors or shall make any arrangement with their creditors, or shall become insolvent or apparently insolvent or have a curator or judicial factor appointed then and in any of these events it shall be in the power of the Landlords by notice to bring this Lease to an end forthwith without any declarator or process of law to that effect and to remove the Tenants from possession of the Subjects, and repossess and enjoy the same as if this Lease had not been granted and that without prejudice to any other remedy of the Landlords in respect of any antecedent breach of any of the Tenants obligations hereunder, and under reservation of all rights and claims competent to the Landlords in terms of this Lease which irritancy is hereby deemed to be pactional and not penal and should not be purgeable at the bar.  Any such liquidation, receiver, administration, curator or judicial factor shall be referred to herein as a “Relevant Third Party”.

7.2

In the case of a material breach, non-observance or non-performance by the Tenants which is capable of being remedied, the Landlords shall not exercise any such option of forfeiture unless and until they shall first have given written notice to the Tenants and any other Relevant Third Party including every permitted creditor in any then existing standard security or floating charge affecting this Lease where such security has the consent of the Landlords as required under this Lease, specifying the breach, non-observance or non-performance and requiring the same to be remedied and intimating their intention to exercise their option of forfeiture and in the event of the said breach, non-observance or non-performance not being remedied within such period as may be stated in the notice (being such reasonable period of time as the Landlord shall stipulate in the notice which in the case of failure to pay monies due in terms of the Lease shall be a period of not less than twenty eight days and in the case of failure to comply with the Tenants’ development obligations under Clause 5.2 shall be a period of not less than six months from the date of service of the notice) and the Tenants or any Relevant Third Party shall fail to have remedied the same within the period specified in the notice.

7.3

In the case of the Tenants going into liquidation the Landlords shall allow the liquidator, receiver or administrator (as the case may be) and any such creditor as aforesaid a period of six months in which to dispose of the Tenants’ interest in this Lease and shall only be entitled to terminate this Lease if the liquidator, receiver, administrator or such creditor as the case may be shall have failed to dispose of the Tenants’ interest at the end of the said period provided always that the liquidator, receiver or administrator as the case may be or such creditor shall personally accept in written self proving form and implement full responsibility for payment of the rents (whether due in respect of a period occurring before, on or after the date of liquidation or administration or receivership as the case may be) and for the performance of all other obligations of the Tenants under this Lease from the date of liquidation or administration or receivership as the case may be to the date of disposal or termination of this Lease including settlement of any arrears of the rents and the performance of any outstanding obligations which may subsist at the date of liquidation, administration or receivership as the case may be and shall if reasonably requested by the Landlords find caution for such payment and performance in an amount acceptable to the Landlords.  And it is hereby declared that the Landlords shall deal with any request for consent to assign this Lease made by such liquidator, receiver, administrator or creditor as the case may be in the same manner as if the request had been made by the Tenants.

 


(10)

 

8.

Acceptance of Rent/No Waiver/Rei Interitus  

8.1

The demand for or acceptance of rent (or other sums) by the Landlords or their agents at any time shall not in any circumstances constitute nor be construed to be a waiver of any of the Tenants’ obligations under this Lease nor of the Landlords remedies for breach thereof.

8.2

Notwithstanding any rule of law to the contrary this Lease shall not come to an end and shall not be capable of being brought to an end by either the Landlords or the Tenants by reason of damage or destruction of the Subjects or the Development Works but shall continue in full force and effect according to its terms.

9.

Title Transfer

9.1

At any time following the date of completion of the Development Works in accordance with the terms of this Lease and provided all payments due under Clause 3.2 and Clause 3.3 of this Ground Lease have been made by the Tenants to the Landlords the Tenants may serve written notice on the Landlords requiring the Landlords to grant a disposition of the Subjects in accordance with the Title Transfer Provisions.

9.2

Notwithstanding the foregoing, the Landlords may at any time serve written notice on the Tenants requiring the Tenants to accept a disposition of the Subjects in accordance with the Title Transfer Provisions.

10.

Notices

10.1

All notices which require to be given in terms of this Lease shall be in writing and shall be deemed to be sufficiently given if sent by recorded delivery post addressed to :

 

(i)

in the case of the Tenants, to the Tenants (if a body corporate) at their Registered or Head Office and (if an individual) at his last known address in the United Kingdom and (if a partnership) to the partnership or any one or more of the partners thereof or at such other address as the Tenants may have notified in writing to the Landlords with reference to this Clause; and

 

(ii)

in the case of the Landlords, to the Head of Property, Scottish Enterprise, Atrium Court, 50 Waterloo Street, Glasgow, G2 6HQ and to Shepherd and Wedderburn LLP, 191 West George Street, Glasgow, G2 2LB (for the attention of GLM/MGH) or to such other address as the Landlords may have notified in writing to the Tenants with reference to this Clause.

10.2

Any such notice shall be deemed to be to have been served on the first Working Day after the date on which the same was posted.  In proving service, it shall be sufficient to prove that the envelope containing the notice was duly addressed to the Landlords or the Tenants, as the case may be, in accordance with this Clause and posted to the place to which it was so addressed.

 


(11)

 

11.

Registration  

11.1

The Landlords and Tenants consent to registration hereof for preservation and execution:-

IN WITNESS WHEREOF

 

Executed on behalf of Scottish Enterprise by

 

........................................................ (signature)

Full Name:........................................................

Director/Company Secretary/Authorised Signatory*

at......................................................................

on ....................................................................

* Please delete as applicable

 

In the presence of this witness:

Witness' Signature:

 

........................................................................

Full name of witness:

 

........................................................................

 

Address of witness:

........................................................................

........................................................................

........................................................................

 

 

 

Executed on behalf of QUOTIENT BIOCAMPUS LIMITED by

 

........................................................ (signature)

Full Name:........................................................

Director/Company Secretary/Authorised Signatory*

at......................................................................

on ....................................................................

* Please delete as applicable

 

In the presence of this witness:

Witness' Signature:

 

........................................................................

Full name of witness:

 

........................................................................

 

Address of witness:

........................................................................

........................................................................

........................................................................

 

 


(12)

 

This is Schedule referred to in the foregoing Lease between Scottish Enterprise and QUOTIENT BIOCAMPUS LIMITED relative to Site 3, Bio Campus, Roslin, Midlothian

Schedule

Part 1

The Subjects

ALL and WHOLE the subjects at Site 3, Bio Campus, Roslin, Midlothian, extending to 3.18 hectares or thereby as shown delineated in red on the Plan which subjects form part and portion of the subjects at Gowkley Moss Farm, Bush Loan, Milton Bridge, Penicuik, EH26 0NX, registered in the Land Register of Scotland under Title Number MID4540 together with (i) all rights which those Subjects benefit from as specified in the title to the Subjects and (ii) a right for construction traffic over the roads within the bio campus of which the Subjects form part.  [DWF:  the title only provides for vehicular traffic.  Construction traffic could be construed as increasing the burden]

 


(13)

 

Part 2

Landlord's Reserved Rights

1.There is reserved to the Landlords, their successors and to any persons to whom the Landlords may grant such rights (a) all necessary rights of access over the Subjects for the purposes of inspecting and monitoring the progress of the Development Works but only in accordance with the terms of this Lease; and (b) a servitude right of wayleave in respect of all existing and future service pipes, cables, wires and others (including without prejudice to the foregoing generality all electricity wires and cables) which now or in the future serve the Development or any part thereof and are situated within, over, through or under the Subjects by way of an existing route or routes or such other route or routes as the Landlords or their successors may reasonably require, such other route or routes to be subject to the prior written approval of the Tenants which approval shall not be unreasonably withheld or decision thereon unreasonably delayed (for the avoidance of doubt,  the Tenants shall not be unreasonably withholding  consent to any route or routes running through the buildings on the Subjects), together with all such necessary rights to lay, maintain, remove, repair or replace or renew the same  subject to the Landlords or their successors making good all damage caused by the exercise of such rights and exercising the rights in such a way to cause as little inconvenience as reasonably practicable to the occupiers of the Subjects.

 


(14)

 

Part 3

Title Transfer Provisions

1.

The Landlords shall grant the Validly Executed Disposition of the Subjects in favour of the Tenants or its nominees.

2.

The consideration for the grant of the Disposition shall be the sum of £1 only (exclusive of VAT).

3.

The date of entry in the Disposition shall be the twentieth Working Day after notice by either the Landlords or the Tenants in accordance with Clause 10 or such earlier date as may be agreed in writing

4.

The Landlords will apply to the Keeper for an Advance Notice for the Disposition, in the form adjusted with the Tenants, to be entered on the application record for the Subjects no earlier than 5 Working Days prior to the date of entry.  The cost of the Advance Notice for the Disposition will be met by the Landlords.

5.

The Landlords consent to the Tenants applying to the Keeper for Advance Notices for any deeds which the Tenants intend to grant in relation to the Subjects.  The cost of any Advance Notices which the Tenants apply for will be met by the Tenants.

6.

At the date of entry, the Landlord shall deliver to the Tenants (i) a Legal Report showing no entry adverse to the interest of the Landlords (ii) a Plans Report (Level 3) and (iii) Discharge of any Standard Security.  [DWF:  this is a transfer of part and a level 3 plan is required]

7.

The Disposition will contain the rights (if any) granted in favour of the Tenants in this Lease and the Reserved Rights in favour of the Landlords and the Landlords will deliver to the Tenants  a Land Register application form in respect of the same, as is necessary.

8.

The Tenants undertake to pay all Land and Buildings Transaction Tax payable on the disposition and register the disposition in the Land Register of Scotland within 21 days of the Date of Entry.

9.

Provided that the Disposition is presented for registration prior to the date of expiry of the Advance Notice registered in relation to the Disposition, the updated or newly created Title Sheet for the interest transferred by the Disposition will contain no exclusion or limitation of warranty in terms of Section 75 of the 2012 Act and disclose no entry, deed or diligence (including any charging order under the Buildings (Recovery of Expenses) (Scotland) Act 2014 or any notice of potential liability for costs registered under the Tenements (Scotland) Act 2004 or the Title Conditions (Scotland) Act 2003) prejudicial to the interest of the Tenants or its nominees other than such as are created by or against the Tenants or its nominees or have been disclosed to, and accepted in writing by, the Tenants or its nominees prior to the date of entry in the Disposition.

10.

The Landlords will deliver to the Tenants, on demand from time to time and at the Landlords' expense such documents and evidence as the Keeper may require to enable the Keeper to update or create (as the case may be) the Title Sheet of the Subjects to disclose the Tenants as the registered proprietors of the whole Subjects.

11.

The Landlords shall cooperate fully with the Tenants to procure that the Tenants’ applications for registration are dealt with by the Keeper as quickly as practicable.

12.

The minerals are included in the title transfer only to the extent to which the Landlords have any right to them.

 

12.1

Definitions

In Clause 12:

“Environment” means any and all organisms (including humans), ecosystems, natural or man-made buildings or structures, and the following media:

 

(a)

air (including air within buildings or structures, whether above or below ground)

 

(b)

water (including surface and ground water and water in wells, boreholes, pipes, sewers and drains); and

 

(c)

land (including surface land and sub-surface strata and any land under seabeds or rivers, wetlands or flood plains);

 


(15)

 

“Environmental Authority” means any person or legal entity (whether statutory or non-statutory or governmental or non-governmental) having regulatory authority under Environmental Law and/or any court of law or tribunal or any other judicial or quasi-judicial body;

“Environmental Law” means all laws, regulations, directives, statutes, subordinate legislation, rules of common law and generally all international, EU, national and local laws and all judgments, orders, instructions, decisions, guidance awards, codes of practice and other lawful statements of any Environmental Authority applying from time to time in relation to the Protective Strip in respect of pollution of or protection of the Environment or the production, processing, treatment, storage, transport or disposal of Hazardous Substances, in each case insofar as having the force of law;

“Hazardous Substances” means any natural or artificial substance (whether in solid or liquid form or in the form of a gas or vapour and whether alone or in combination with any other substance) capable of causing harm to the Environment and/or harm to the health of living organisms or other interference with the ecological systems of which they form part and/or harm to property and/or in the case of humans, offence caused to any sense;

 

12.2

Agreement as to Environmental Liabilities

The Landlords and the Tenants agree that:

 

12.2.1.

if any notice or requirement of any Environmental Authority made pursuant to Environmental Law is served on or made of either of them in respect of the Subjects or any Hazardous Substances attributable to the Subjects, then, as between the Landlords and the Tenants, the sole responsibility for complying with such notice or requirement is to rest with the Tenants to the exclusion of the Landlords; and

 

12.2.2

if any Environmental Authority wishes to recover costs incurred by it in carrying out any investigation, assessment, monitoring, removal, remedial or risk mitigation works under Environmental Law in respect of the Subjects or any Hazardous Substances attributable to the Subjects from either or both of the Landlords and the Tenants then, as between Landlords and the Tenants, the sole responsibility for the payment of such costs is to rest with the Tenants to the exclusion of the Landlords.

The agreements outlined under Clauses 12.2.1 and 12.2.2 are made with the intention that any Environmental Authority serving any notice or seeking to recover any costs should give effect to the agreements pursuant to the statutory guidance issued under Part IIA of the Environmental Protection Act 1990.  

The Landlords and the Tenants agree that the appropriate Environmental Authority may be notified in writing of the provisions of Clause 12 if required to give effect to the agreements outlined under Clauses 12.2.1 and 12.2.2.

 


(16)

 

Part 4

Approved Plans and Specification

[insert approved Development Works plans and specifications]

 


(17)

 

Part 5

Disposition

[insert agreed Disposition]

[DWF to send]

 


(18)

 

Part 6

Plan

[insert lease plan]

 

 

 

 


 

E XHIBIT F

OFFER LETTER

(See attached)

 


 

OUR REF   S2742.1572/GLM/MGH

YOUR REF  CJM/AF/M43117.36

[Date]

DWF LLP

Dalmore House

310 St Vincent Street

Glasgow

G2 5QR

Dear Sirs

Site 3, Bio Campus, Roslin, Midlothian

On behalf of and as instructed by our clients, the Landlords, we offer to lease to your clients, the Tenants, the Premises, and that on the following terms and conditions:

1.

Definitions and interpretation

1.1

In this Offer (including the foregoing preamble):

 

"2012 Act"

means the Land Registration etc (Scotland) Act 2012;

 

 

"Advance Notice"

means an advance notice as defined in Section 56 of the 2012 Act;

 

 

"Date of Entry"

means the date of conclusion of Missives or such other date as may be agreed in writing;

 

 

“Deposit”

means the sum of TWENTY THOUSAND POUNDS (£20,000) STERLING, exclusive of VAT which shall be payable in addition;

 

 

"duly executed"

means executed in accordance with the requirements of Sections 3 and 7 and Schedule 2 or sections 9(B) and 9(C) of the Requirements of Writing (Scotland) Act 1995, or in such other manner as is acceptable to the Landlords;

 

 

“Guarantee”

means the guarantee to be granted by the Guarantor in favour of the Landlords of the Tenants’ obligations under the Lease in terms of the draft Guarantee contained in Part 3 of the Schedule;

 

 

“Guarantor”

means Quotient Limited, a company incorporated under the laws of Jersey with registered number 109886 and having their registered office at Elizabeth House, 9 Castle Street, St Helier, Jersey JE4 2QP;

 

 

"HMRC"

means HM Revenue & Customs;

 

 

"Interest"

means interest on the sum in question at 4% per annum above the base rate from time to time of the Royal Bank of Scotland plc from the date that such sum is due for payment or, if there is no such date specified, the date of demand for such sum until such sum is paid;

 

 

"Landlords"

means Scottish Enterprise established under the Enterprise and New Towns (Scotland) Act 1990 and having their principal place of business at Atrium Court, 50 Waterloo Street, Glasgow;

 

 

"Landlords' Solicitors"

means Shepherd and Wedderburn LLP, 191 West George Street, Glasgow, G2 2LB (Ref S2742.1572/MGH/GLM);

 

 

"LBTT"

means Land and Buildings Transaction Tax under the Land and Buildings Transaction Tax (Scotland) Act 2013;

 

 

"Lease"

means the lease referred to in clause 4 of this Offer and set out in Part 1 of the Schedule;

 

 

"Missives"

means the binding contract constituted by this Offer and all formal letters following on it (subject always to clause 13.1 of this Offer);

 


 

 

 

"Offer"

means this offer;

 

 

" Premises "

means the subjects known as Site 3, Bio Campus, Midlothian all as more particularly described in the Lease;

 

 

"Premium"

means the sum of NINE HUNDRED AND EIGHTY SIX THOUSAND EIGHT HUNDRED POUNDS (£986,800) STERLING, exclusive of all, if any, VAT paid and less the Deposit in so far as already paid to the Landlords;

 

 

"Schedule"

means the schedule of four parts annexed to this Offer;

 

 

“Standard Security”

means the standard security by the Tenants in favour of the Landlords over the Tenants’ interest in the Ground Lease in terms of the draft Standard Security contained in Part 2 of the Schedule;

 

 

"Tenants"

means QUOTIENT BIOCAMPUS LIMITED , a company incorporated under the Companies Acts with registered number SC514165 and having its registered office at Douglas Building Pentlands Science Park, Bush Loan, Penicuik, Midlothian, EH26 0PL;

 

 

"Tenants' Solicitors"

means DWF LLP, Dalmore House, 310 St Vincent Street, Glasgow, G2 5QR (Ref CJM);

 

 

“Undertaking”

means the undertaking to be granted by the Tenants’ Solicitors to the Landlords undertaking to register the Standard Security simultaneously with the Ground Lease, in terms of the draft undertaking contained in Part 4 of the Schedule;

 

 

"Working Day"

means any day on which clearing banks in Edinburgh, Glasgow and London are open for normal business.

2.

Price

2.1

Payment

 

2.1.1

The Landlords and the Tenants agree that the Premium (but not any VAT payable thereon) shall be paid in terms of the Ground Lease.

 

2.1.2

The Deposit will be paid by the Tenants on the Date of Entry by instantaneous bank transfer of cleared funds from the Tenants’ Solicitors’ client account to the Landlords’ Solicitors’ client account.  The Landlord’s solicitor will provide details of their client account within 5 working days of conclusion of missives.  If the Tenants fail to pay any sums due at the time and in the manner stated in this Clause 2.1.2 (time being of the essence), t he Landlords shall be entitled to resile from the Missives, by written notice to that effect to the Tenants, provided the said notice is received prior to any subsequent payment of the Deposit in the foregoing manner. For the avoidance of doubt the Deposit shall be non-returnable.

 

2.1.3

Notwithstanding the foregoing the VAT due on the Premium and the Deposit will be paid by the Tenants on the Date of Entry by instantaneous bank transfer of cleared funds from the Tenants’ Solicitors’ client account to the Landlords’ Solicitors’ client account in exchange for a valid VAT invoice addressed to the Tenants.

 

2.1.4

A payment not made in accordance with Clause 2.1.2 and/or 2.1.3 may be refused.

2.2

Interest

If the VAT payable on the Premium and the Deposit or any part of it is not paid to the Landlords on the Date of Entry then notwithstanding consignation or that the Tenants have not taken entry, the Tenants will pay to the Landlords Interest on the outstanding money.

2.3

Cancellation of Sale/Lease

If the Tenants fail to pay the VAT payable on the Premium and the Deposit with Interest as set out in Clause 2.2 within 10 Working Days after the Date of Entry the Landlords will be entitled (but not bound) to rescind the Missives.  If the Landlords rescind the Missives as aforesaid or resile in terms of Clause 2.1.2 above, the Lease shall terminate contemporaneously with

 


 

the date of termination of the Missives and the parties to the Missives shall do all necessary things to document such termination where reasonably called upon to do so.

2.

Duration/Rent

3.1

The Lease will endure for the period from and including the Date of Entry until the date falling 99 years after the Date of Entry.

3.2

The annual rent payable under the Lease will be ONE POUND (£1) STERLING (exclusive of Value Added Tax) payable as provided for in the Lease.  

4.

The Lease

The Lease to be entered into between the Landlords and the Tenants will be in the form of the draft lease contained in Part 1 of the Schedule, which draft sets out the whole remaining terms and conditions of the Lease and will be deemed incorporated into this Offer mutatis mutandis , but incorporating such other additions and modifications as may be necessary to reflect the terms of this Offer and the Missives.

5.

Advance Notice

5.1

The Landlords will apply to the Keeper for an Advance Notice for the Lease, in the form adjusted with the Tenants, to be either (i) entered on the application record for the larger subjects of which the Premises form a part or (ii) recorded in the Register of Sasines, no earlier than 5 Working Days prior to the Date of Entry.  The cost of the Advance Notice for the Lease will be met by the Landlords.

5.2

The Landlords consent to the Tenants applying to the Keeper for Advance Notices for any deeds which the Tenants intend to grant in relation to the Premises.  The cost of any Advance Notices which the Tenants apply for will be met by the Tenants.

5.3

If the Landlords resile from the Missives in terms of Clause 2.1.2 or rescind the Missives in the circumstances set out in clause 2.3 the Tenants consent to the discharge of the Advance Notice for the Lease and the Tenants confirm that they will immediately discharge at their own cost any Advance Notice submitted by them if requested to do so by the Landlords.

5.4

If settlement is likely to occur after the Date of Entry, the Landlords, if requested to do so by the Tenants, will apply for a further Advance Notice for the Lease, in the form adjusted with the Tenants, and the cost of any additional Advance Notices will be met:

 

5.4.1

by the Landlords, if the delay in settlement is due to any failure or breach by or on behalf of the Landlords to implement their obligations under the Missives on time; or

 

5.4.2

by the Tenants, if the delay in settlement is due to any failure or breach by or on behalf of the Tenants to implement their obligations under the Missives on time.

5.5

The Landlords' Solicitors will not provide any letter of obligation or undertaking to clear the records of any deed, decree or diligence.

6.

Completion of Lease

6.1

The Landlords shall execute the Lease and deliver the same to the Tenants within 21 days of the Date of Entry.  The Tenants will ensure that the Lease is duly executed by the Tenants, and that a certified copy of the executed Lease is returned to the Landlords' Solicitors within 21 days after the date of delivery of the engrossment of the Lease, duly executed by the Landlords, to the Tenants' Solicitors, together with evidence of the valid execution of the Lease by the Tenants.

6.2

If the transaction contemplated by the Missives is notifiable for LBTT purposes, the Tenants will submit to Revenue Scotland an LBTT Return.

 


 

6.3

Within 7 days after receipt by the Tenants of the electronic submission receipt issued by Revenue Scotland, the Tenants will  

 

6.3.1

submit the Lease to the Books of Council and Session for registration for preservation and execution and will obtain 3 extracts of it, and will deliver 2 of the extracts to the Landlords' Solicitor for the use of the Landlords within 7 days of receipt of the extracts; and

 

6.3.2

be responsible for dealing with registration of the Lease in the Land Register and will deliver to the Landlords (i) a copy of the Keeper's acknowledgement of receipt showing the Title Number to be allocated to the Title Sheet for the Tenants' interest within 14 days of receipt of the same and (ii) within 7 days after receipt by the Tenants of a pdf of the Title Sheet in respect of that interest, a copy of the pdf of the Title Sheet, with a colour copy of the Title Plan(s).

6.4

The Tenants acknowledge that if they breach the terms of their obligations in clauses 6.2 and 6.3 inclusive, they will indemnify the Landlords in respect of loss suffered by the Landlords by virtue of such delay.  

7.

Tenants' obligations

Subject to the foregoing provisions of this Offer, if for any reason the Lease is not executed by the Date of Entry, the Landlords and the Tenants agree to be bound by the whole obligations and provisions specified in the Lease during the period from and after the Date of Entry.

8.

Title

By acceptance of this Offer, the Tenants are deemed to have satisfied themselves in all respects with the Landlords' title to the Premises both as to the extent and description of the Premises and the burdens and conditions affecting the Premises, and the Tenants will be bound to accept the title as it stands subject to Clause 10 and the exhibition of a legal report in terms of Clause 9.2.

9.

Settlement

On the Date of Entry the Landlords will deliver to the Tenants:

9.1

the Lease, duly executed by the Landlords;

9.2

a legal report brought down to a date as near as practicable to the Date of Entry which report will show:

 

(i)

no entries adverse to the Landlords’ interest in the Premises;

 

(ii)

the Advance Notice for the Lease; and

 

(iii)

no other Advance Notices other than those submitted by the Tenants and those disclosed to and accepted by the Tenants in writing prior to the Date of Entry;

9.3

a letter of consent to the grant of the Lease from any heritable creditor of the Landlords holding a heritable security over the Premises and/or if applicable, a letter of non-crystallisation from the holder of any floating charge affecting the Premises;

9.4

a valid VAT invoice addressed to the Tenants in respect of the VAT due on the Premium and on the Deposit;

9.5

all necessary signed Land Registration Forms for the registration of the Standard Security in the Land Register;

Simultaneously and in exchange for the above items the Tenants will deliver to the Landlords on the Date of Entry:-

9.6

the Guarantee, duly executed by the Guarantors plus Jersey legal opinion of Quotient Limited to be in agreed form by both parties acting reasonably;

9.7

a certified true copy of the Standard Security, duly executed by the Tenants; and

9.8

the duly executed Undertaking.

 


 

10.

Post completion  

10.1

Provided that the Lease is presented for registration prior to the date of expiry of the Advance Notice registered in relation to the Lease, the updated or newly created Title Sheet for the Lease will contain no exclusion or limitation of warranty in terms of Section 75 of the 2012 Act and will disclose no entry, deed or diligence (including any charging order under the Buildings (Recovery of Expenses) (Scotland) Act 2014 or any notice of potential liability for costs registered under the Tenements (Scotland) Act 2004 or the Title Conditions (Scotland) Act 2003) prejudicial to the interest of the Tenants other than such as are created by or against the Tenants or have been disclosed to, and accepted in writing by, the Tenants prior to the Date of Entry except for the Standard Security.

10.2

The Landlords will register the Guarantee in the Books of Council and Session and provide one extract to the Tenants, subject to the Tenants paying to the Landlords the costs of registration and obtaining two extracts.

11.

Frustration

Unless the parties otherwise agree in writing the Missives will remain in full force and effect notwithstanding any damage to or destruction of the Premises which may occur prior to the Date of Entry.

6.

Missives Personal

Quotient Biocampus Limited will not be entitled to assign, absolutely or in security, or otherwise part with or deal in any way with the rights conferred on them by the Missives other than as permitted in terms of the Lease.

7.

Prior communings

13.1

Any letter forming part of the Missives and any amendment to or variation of the Missives will require to be duly executed.

13.2

The Missives set out the entire agreement and understanding between the Landlords and the Tenants in relation to the Lease of the Premises and will supersede all previous proposals, agreements and other communications whether written, oral or otherwise relating to it.

14.

Time limit for acceptance

This Offer, unless previously withdrawn or amended, is open for written acceptance reaching us here not later than [          ].

Yours faithfully

 

…………………………………………..………….., a Member

For and on behalf of Shepherd and Wedderburn LLP,

as agents for Scottish Enterprise

 

………………………………………………………... (Witness)

of 191 West George Street, Glasgow

 


 

schedule

Part 1

The Lease

 


 

Part 2

Standard Security

 


 

Part 3

Guarantee

 


 

Part 4

Undertaking

[need draft from DWF]

 


 

Part 5

Opinion Letter

 


 

E XHIBIT G

SCOTTISH LEASE GUARANTEE

(See attached)

 

 

 

 


 

 

G UARANTEE

by

Quotient Limited

in favour of

Scottish Enterprise

Property: Site 3, Biocampus, Penicuik, Midlothian

 

 

 

Shepherd and Wedderburn LLP

191 West George Street

Glasgow

G2 2LB

DX GW409 Glasgow

T: +44 (0)141 566 9900

F: +44 (0)141 565 1222

www.shepwedd.co.uk


 

 

 

GUARANTEE

by

QUOTIENT LIMITED , , a company incorporated under the laws of Jersey with registered number 109886 and having their registered office at Elizabeth House, 9 Castle Street, St Helier, Jersey JE4 2QP  (" Guarantors ");

in favour of

SCOTTISH ENTERPRISE , established under the Enterprise and New Towns (Scotland) Act 1990 and having their principal place of business at Atrium Court, 50 Waterloo Street, Glasgow, and includes where the context so requires their successors as landlords under the Lease (" Landlords ");

WHEREAS:

(A)

The Landlords are in right of the landlord's part of the Lease.

(B)

The Tenants are in right of the tenant's part of the Lease.

(C)

The Guarantors have agreed to guarantee the obligations of the Tenants under the Lease;

IT IS AGREED as follows:

1.

Definitions and Interpretation

1.1

In this Guarantee:

 

" Guaranteed Obligations "

 

means all past, present, future and contingent obligations of the Tenants:

(a)      to pay all rents and other sums; and

(b)      to perform and fulfil all other obligations

which are now or may at any time in the future become due by the Tenants to the Landlords in terms of the Lease;

 

 

 

 

" Interest "

 

means interest on the sum in question at four per cent per annum above the base rate from time to time of the Royal Bank of Scotland plc from the date that such sum is due for payment or, if there is no such date specified, the date of demand for such sum until such sum is paid;

 

 

 

 

" Lease "

 

means the lease about to be entered into between the Landlords and the Tenants on or around the date hereof and about to be registered in the Books of Council and Session;

 

 

 

 

" Property "

 

means Site 3, Biocampus, Roslin, Midlothian being the subjects more particularly described in the Lease;

 

 

 

 

" Relevant Event "

 

 

means any of the following events or circumstances:

 

 

(i)

The Tenants going into liquidation including provisional liquidation or a petition being presented or resolution proposed or passed for their liquidation;  

 

 

(ii)

The Tenants having a receiver appointed in respect of any part of their undertaking or assets;

 

 

(iii)

The Tenants being dissolved, struck off or otherwise ceasing to exist;

 

 

(iv)

The Landlords serving notice on the Tenants that an event has occurred which entitles the Landlords to irritate the Lease;  

 

 

(v)

The Lease being terminated by reason of irritancy;

 

 

(vi)

The Tenants having an administrator appointed or a petition being presented for the appointment of an administrator or notice of intention to appoint an administrator being given;

 

 

(vii)

The Tenants instituting or giving notice of or indicating an intention to institute a voluntary arrangement or composition in respect of their debts or affairs; or

 

 

(viii)

The Tenants becoming unable to pay their debts within the meaning of section 123 of the Insolvency Act 1986;

 


 

 

 

 

 

 

 

" Tenants "

 

Means QUOTIENT BIOCAMPUS LIMITED , a company incorporated under the Companies Acts with registered number SC514165 and having its registered office at Douglas Building Pentlands Science Park, Bush Loan, Penicuik, Midlothian, EH26 0PL;

 

 

 

 

" Working Day "

 

means a day on which clearing banks in Edinburgh and Glasgow are open for normal business.

1.2

In this Guarantee, unless otherwise specified or the context otherwise requires:

 

1.2.1

any reference to one gender includes all other genders;

 

1.2.2

words in the singular only include the plural and vice versa;

 

1.2.3

any reference to the whole is to be treated as including reference to any part of the whole;

 

1.2.4

ny reference to a person includes a natural person, corporate or unincorporated body (whether or not having separate legal personality); words importing individuals include corporations and vice versa;

 

1.2.5

any references to this Guarantee or to the Lease or to any other document are references to this Guarantee, the Lease or to that other document as varied, supplemented, assigned, novated or replaced from time to time;

 

1.2.6

any reference to a Clause is to the relevant Clause of this Guarantee;

 

1.2.7

any reference to a statute or statutory provision includes any subordinate legislation which is in force from time to time under that statute or statutory provision;

 

1.2.8

any reference to any statute, statutory provision or subordinate legislation is a reference to it as it is in force from time to time taking account of any amendment or re-enactment;

 

1.2.9

any phrase introduced by the words "including", "include", "in particular" or any similar expression is to be construed as illustrative only and is not to be construed as limiting the generality of any preceding words;

 

1.2.10

references to writing or written do not include faxes or e-mail;

 

1.2.11

where at any one time there are two or more persons included in the expression "Guarantors" obligations contained in this Guarantee which are expressed to be made by the Guarantors are binding jointly and severally on them and their respective executors and representatives whomsoever without the necessity of discussing them in their order;

1.3

The headings in this Guarantee are included for convenience only and are to be ignored in construing this Guarantee.

1.4

Unless the context otherwise requires, words and expressions which are defined in the Lease will bear the same meanings for the purposes of this Guarantee.

2.

Guarantee

The Guarantors irrevocably and unconditionally guarantee to the Landlords full and punctual payment or performance by the Tenants of the Guaranteed Obligations as and when they fall due for payment or performance and failing such payment or performance by the Tenants the Guarantors will on demand by the Landlords make payment or effect performance of the Guaranteed Obligations in question together with:

all liabilities, losses, costs, damages and expenses incurred by the Landlords by reason of or in connection with any such failure together with Interest; and

all costs and expenses properly and reasonably incurred by the Landlords in connection with the enforcement of this Guarantee together with Interest.

 


 

 

 

3.

Primary Obligation  

The obligations of the Guarantors under this Guarantee will be independent primary obligations and not merely those of guarantor or cautioner and if any of the Guaranteed Obligations are not, or cease to be, valid and enforceable for any reason whatever (whether or not known to the Landlords) or for any reason are not recoverable from or capable of performance by the Guarantors under Clause 2 the Guarantors will still be liable to the Landlords in respect of such Guaranteed Obligations as if they were fully valid and enforceable and/or recoverable or capable of performance and the Guarantors were principal debtor in place of the Tenants.

4.

Indemnity

4.1

The Guarantors undertake to indemnify the Landlords on demand against all liabilities, losses, costs, damages and expenses which the Landlords may incur by reason of or in connection with any failure by the Tenants to make payment of or perform any of the Guaranteed Obligations as and when they fall due or as a result of any of the Guaranteed Obligations being or becoming void or unenforceable for any reason or the Guaranteed Obligations for any reason not being recoverable or capable of performance under Clause 2, together with Interest.

4.2

The Guarantors undertake to indemnify the Landlords on demand against all liabilities, losses, costs, damages and expenses which the Landlords may incur by reason of or in connection with the Tenants proposing or entering into any company voluntary arrangement or other scheme or arrangement having or purporting to have the effect of impairing, compromising or releasing any or all of the Guarantors' obligations under this Guarantee.

5.

Guarantors to take new lease

Without prejudice to any other provision of this Guarantee if a Relevant Event occurs, the Landlords may serve notice on the Guarantors within six months after the Relevant Event requiring the Guarantors to accept, as required by the Landlords, either:

5.1

a new lease of the Property for a period equal to the residue of the term of the Lease which would have remained if the Relevant Event had not occurred, at the same rent and on the same terms as the Lease commencing on the date of the Relevant Event, except that any works carried out by or on behalf of the Tenants (or their predecessors as tenants under the Lease) shall be treated by reference to the date of entry under the Lease and not the date of the Relevant Event; or

5.2

an assignation to the Guarantors of the Tenants' interest under the Lease, effective from the date of the Relevant Event.

6.

Duration

This Guarantee will be a continuing security notwithstanding any intermediate payment or performance and will remain in force so long as any liability (including any future or contingent liability):

6.1

on the part of the Tenants under the Lease, or

6.2

on the part of the Guarantors under this Guarantee

remains unfulfilled unless discharged by the Landlords in accordance with Clause 8.

7.

Non-impairment

This Guarantee will not be discharged or prejudiced by:

7.1

the Landlords holding, acquiring, failing to perfect, releasing or giving up any obligation, security or remedy (present or future) for the obligations of the Tenants under the Lease or any neglect, delay or forbearance on the part of the Landlords in enforcing such obligation, security or remedy;

7.2

the Landlords giving time or any other indulgence to the Tenants;

7.3

any variation, amendment, supplement or extension whether formal or informal, of the terms of the Lease or the implementation of any rent review provisions in the Lease;

 


 

 

 

7.4

the Landlords irritating the Lease;  

7.5

the Landlords releasing any person(s) comprised in the Tenants from liability under the Lease, or

7.6

any other act, omission or event whereby (but for this Clause) the Guarantors would be discharged in whole or in part from this Guarantee.

8.

Discharge

If the Tenants assign their interest under the Lease in accordance with the terms of the Lease, or the Landlords accept a renunciation of the Tenants' interest under the Lease, the Landlords will at the request and cost of the Guarantors grant a valid discharge of this Guarantee as at the date of valid intimation of such assignation or the effective date of such renunciation (as the case may be) provided that there are no outstanding claims under the Guarantee, or if there are any such claims, upon such claims being satisfied in full.

9.

Assignation

The Landlords have the right to assign or transfer this Guarantee to their successors as landlords under the Lease without the consent of the Guarantors.  

The Guarantors do not have the right to assign or transfer their rights or obligations under this Guarantee.

10.

Postponement of Claims by Guarantors

10.1

Until the Guaranteed Obligations have been fully and unconditionally paid or performed, the Guarantors will not be entitled to share any security held or money received by the Landlords on account of the Guaranteed Obligations.

10.2

Until the Guaranteed Obligations have been fully and unconditionally paid or performed, the Guarantors waive their rights of subrogation, reimbursement and indemnity against the Tenants and any other person and any other right they may have to stand in the place of the Landlords in respect of any security from or money payable by the Tenants or any other person.

10.3

Until the Guaranteed Obligations have been fully and unconditionally paid or performed, the Guarantors will have no recourse, nor be entitled to pursue any right or remedy, against the Tenants arising from the performance of any of the Guarantors’ obligations under this Guarantee.

10.4

In the event of the liquidation, receivership, administration, sequestration or other insolvency or dissolution of the Tenants the Guaranteed Obligations will be deemed to continue to be due and outstanding until fully and unconditionally paid or performed.  The Landlords will be entitled to claim in the liquidation, receivership, administration, sequestration or other insolvency of the Tenants for the full amount of the Guaranteed Obligations and to retain the whole of the dividends from such claim to the exclusion of any rights of the Guarantors as guarantor in competition with the Landlords until the Landlords' claim is satisfied in full.

11.

Exclusion of Set Off

11.1

All payments due by the Guarantors under this Guarantee will be made without any retention, deduction, set-off or counterclaim and free from any deduction or withholding for or on account of any taxes or other charges in the nature of taxes imposed by any competent authority.  If any such deduction or withholding shall be required by law the Guarantors will pay the Landlords such additional amount as may be necessary to ensure that the Landlords receive the full amount of the relevant payment as if such deduction or withholding had not been made.

11.2

The Guarantors will not be entitled to withhold or restrict performance of any obligation by them  under this Guarantee by reason of any purported right or claim of retention, set off or counterclaim or for any other reason.

12.

Certificate

A certificate signed by any authorised signatory on behalf of the Landlords will, except in the case of manifest error, conclusively constitute the amount of the Guaranteed Obligations or any sum due by the Guarantors under Clause 13 or any other provision of this Guarantee at the relevant time for all purposes of this Guarantee.

 


 

 

 

13 .

Costs  

13.1

The Guarantors will pay to the Landlords within five Working Days after written demand:

 

13.1.1

the costs of registering this Guarantee in the Books of Council and Session and of obtaining three extracts (one of which will be delivered to the Guarantors' solicitors);

 

13.1.2

the legal fees and expenses reasonably and properly incurred by the Landlords in connection with the preparation and completion of any new lease or assignation entered into under the terms of Clause 5 including the registration dues on such new lease or assignation and of obtaining three extracts (one of which will be delivered to the Guarantors' solicitors);

 

13.1.3

all Value Added Tax on any of the fees, costs and expenses set out above.

13.2

If any amount specified in Clause 13.1 is not paid within 14 days of demand the Guarantors will pay Interest on such amounts.

13.3

The Guarantors will be responsible for any Land and Buildings Transaction Tax chargeable on any such new lease or assignation.

14.

Notices

14.1

Any notice, demand, request or certificate required by this Guarantee will be in writing and may be delivered personally or sent by post to the relevant party using the relevant details specified in Clause 14.3.

14.2

Any notice, demand, request or certificate will be deemed to be received:

 

14.2.1

If delivered personally, (with proof of delivery) at the time of delivery;

 

14.2.2

if sent by recorded delivery post, 48 hours after the date of posting; and

 

14.2.3

in the case of fax, at the time when the sender’s fax machine confirms transmission;

Provided that if, in the case of personal delivery or transmission by fax, such delivery or transmission occurs outwith normal business hours on a Working Day or on a day which is not a Working Day, delivery will be deemed to occur on the next Working Day.

14.3

The details referred to in Clause 14.1 are:

Guarantors

Address: Quotient, Pentlands Science Park, Bush Loan, Penicuik, Midlothian EH26 0PL

For the attention of: Roland Boyd

Fax number:  0131 445 6184

Landlords

Address [                     ]

For the attention of [                     ]

or such other address or person as may be notified in writing from time to time by the relevant party to the other party for the purposes of this Clause.

15.

Applicable Law and Jurisdiction

This Guarantee is governed by and is to be construed in accordance with the law of Scotland and in so far as not already subject to it, the parties irrevocably submit to the non-exclusive jurisdiction of the Scottish Courts.

 


 

 

 

16.

Registration  

The Guarantors consent to the registration of this Guarantee and any certificate pursuant to this Guarantee for preservation and execution: IN WITNESS WHEREOF

 

Executed on behalf of Scottish Enterprise by

 

........................................................ (signature)

Full Name:........................................................

Director/Company Secretary/Authorised Signatory*

at......................................................................

on ....................................................................

* Please delete as applicable

In the presence of this witness:

Witness' Signature:

 

........................................................................

Full name of witness:

 

........................................................................

 

Address of witness:

........................................................................

........................................................................

........................................................................

 

 

Executed on behalf of Quotient Limited by

 

........................................................ (signature)

Full Name:........................................................

Director/Company Secretary/Authorised Signatory*

at......................................................................

on ....................................................................

* Please delete as applicable

In the presence of this witness:

Witness' Signature:

 

........................................................................

Full name of witness:

 

........................................................................

 

Address of witness:

........................................................................

........................................................................

........................................................................

 

 

 


 

 

 

EXHIBIT H

SCOTTISH LEASE SECURITY AGREEMENT

(See attached)

 

 

 

 


 

 

STANDARD SECURITY

by

Quotient Biocampus Limited

in favour of

Scottish Enterprise

 

 

Property:Site 3, Biocampus, Roslin, Midlothian

 

 

 

 

Shepherd and Wedderburn LLP

191 West George Street

Glasgow

G2 2LB

DX GW409 Glasgow

T: +44 (0)141 566 9900

F: +44 (0)141 565 1222

www.shepwedd.co.uk

 


1

 

WE , QUOTIENT BIOCAMPUS LIMITED , a company incorporated under the Companies Acts with registered number SC514165 and having its registered office at Douglas Building Pentlands Science Park, Bush Loan, Penicuik, Midlothian, EH26 0PL (hereinafter referred to as "the Proprietor") hereby IN SECURITY of all sums and obligations due and that may become due to SCOTTISH ENTERPRISE , established under the Enterprise and New Towns (Scotland) Act 1990 and having their principal place of business at Atrium Court, 50 Waterloo Street, Glasgow, and their successors and assignees (hereinafter referred to as "the Creditor") in terms of the Lease between the Creditor and the Proprietor dated [insert date] (the “Lease”) (hereinafter referred to as "the Borrower") or any variation or alteration thereof GRANT a Standard Security in favour of the Creditor over the tenants’ interest in the Lease of ALL and WHOLE [insert description and plan from Lease] ;   The Standard Conditions specified in Schedule 3 to the Conveyancing and Feudal Reform (Scotland) Act 1970, as amended, and any lawful variation thereof operative for the time being shall apply and we , the Borrower and the Proprietor, agree that Standard Condition 5(a) shall be varied to the effect that the sum for which the security subjects shall be insured in terms of said Condition 5(a) shall be reinstatement value and not market value;

 


2

 

And we grant warrandice:  IN WITNESS WHEREOF

 

Executed on behalf of Scottish Enterprise by

 

........................................................ (signature)

Full Name:........................................................

Director/Company Secretary/Authorised Signatory*

at......................................................................

on ....................................................................

* Please delete as applicable

In the presence of this witness:

Witness' Signature:

 

........................................................................

Full name of witness:

 

........................................................................

 

Address of witness:

........................................................................

........................................................................

........................................................................

 

 

Executed on behalf of Quotient Biocampus Limited by

 

........................................................ (signature)

Full Name:........................................................

Director/Company Secretary/Authorised Signatory*

at......................................................................

on ....................................................................

* Please delete as applicable

In the presence of this witness:

Witness' Signature:

 

........................................................................

Full name of witness:

 

........................................................................

 

Address of witness:

........................................................................

........................................................................

........................................................................

 

 

 

 

Exhibit 10.3

EXECUTION VERSION

AMENDMENT NO. 2 TO CREDIT, SECURITY AND GUARANTY AGREEMENT

This AMENDMENT NO. 2 TO CREDIT, SECURITY AND GUARANTY AGREEMENT (this “ Agreement ”) is made as of this 25th day of September, 2015 (the “ Effective Date ”), by and among quotient biodiagnostics, inc. , a Delaware corporation (the “ Borrower ”), the other Credit Parties listed on the signature pages hereof, MIDCAP FINANCIAL TRUST , a Delaware statutory trust, as administrative agent (together with its successors and assigns, the “ Agent ”), and the other financial institutions or other entities from time to time parties to the Credit Agreement referenced below, each as a Lender.

RECITALS

A. Pursuant to that certain Amended and Restated Credit, Security and Guaranty Agreement, dated as of August 3, 2015 (as amended and supplemented by that certain Amendment No. 1 and Joinder to Credit, Security and Guaranty Agreement, the “ Original Credit Agreement ” and as the same is amended hereby and as it may be hereafter amended, restated, supplemented or otherwise modified from time to time, the “ Credit Agreement ”), by and among the Borrower, Quotient Limited, a company incorporated under the laws of Jersey, Alba Bioscience Limited, a company incorporated in Scotland, Quotient Biocampus Limited, a company incorporated in Scotland, QBD (QS IP) Limited, a company incorporated under the laws of Jersey, Quotient Suisse SA, a company formed under the laws of Switzerland, each as a Guarantor, the Agent and the Lenders, the Lenders agreed to make available to Borrower term loans in an aggregate amount of $50,000,000.  Capitalized terms used but not otherwise defined in this Agreement, including in these Recitals, shall have the meanings set forth in the Credit Agreement.

B. Certain existing Lenders desire to assign certain of their Applicable Commitments and Credit Extensions to an Eligible Assignee pursuant to and in accordance with Section 13.1(a) of the Credit Agreement and each such Eligible Assignee set forth on the signature pages hereto, to the extent not already a Lender party to the Credit Agreement (a “ New Lender ” and, collectively with the other Lenders, the “ Lenders ”), wishes to become a Lender party to the Credit Agreement.

C. In connection with the assignment to the New Lender, the parties hereto have agreed to amend certain provisions of the Credit Agreement in accordance with the terms and conditions of this Agreement and the applicable requirements of the Credit Agreement as more fully set forth herein.

AGREEMENT

NOW, THEREFORE, in consideration of the foregoing, the terms and conditions set forth in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

1. Recitals.   This Agreement shall constitute a Financing Document and the Recitals set forth above shall be construed as part of this Agreement as if set forth fully in the body of this Agreement.

2. Amendments to Credit Agreement .

(a) The first sentence of Section 2.3(b) is hereby amended by replacing such sentence in its entirety with the following sentence:

“Principal payable on account of a Term Credit Facility shall be payable by Borrower to each Lender in accordance with each Lender’s respective Pro Rata Share of such Term Credit Facility immediately upon the earliest of (i) the date(s) set forth in the Amortization Schedule attached hereto for such Term Credit Facility (or if no such Amortization Schedule is attached, then upon Agent’s demand for payment), or (ii) the Maturity Date.”

(b) The first sentence of Section 2.6(c) is hereby amended by replacing such sentence in its entirety with the following two sentences:

“Except as otherwise provided in this Section 2.6(c), all payments in respect of the Obligations shall be made to Agent for the account of the applicable Lenders in accordance with their Pro Rata Share.  Payments of principal and interest in respect of any Credit Facility identified on the applicable Credit Facility Schedule as “Term” shall be made to each applicable Lender.”

Mid-Cap / Quotient – Amendment No. 2 to Credit, Security and Guaranty Agreement


 

(c) Section 3.1 of the Original Credit Agreement is hereby amended by replacing such Section in its entirety with the following:

“3.1 Conditions Precedent to Initial Credit Extension .  Each Lender’s obligation to make an advance in respect of a Credit Facility is subject to the condition precedent that Agent and each Lender shall consent to or shall have received, in form and substance satisfactory to Agent and each Lender, such documents, and completion of such other matters, as Agent and each Lender may reasonably deem necessary or appropriate, including, without limitation, all items listed on the Closing Deliveries Schedule attached hereto.”

(d) Sections 3.2(a), 3.2(b) and 3.2(e) of the Original Credit Agreement are each hereby amended by replacing adding the words “and each Lender” following the word “Agent” therein.

(e) Section 3.2(f) of the Original Credit Agreement is hereby amended by replacing such Section in its entirety with the following:

“(f) receipt by Agent and each Lender of such evidence as Agent and such Lender shall request to confirm that the deliveries made in Section 3.1 remain current, accurate and in full force and effect, or if not, updates thereto, each in form and substance satisfactory to Agent and such Lender; and”

(f) Section 3.2(g) of the Original Credit Agreement is hereby amended by replacing such Section in its entirety with the following:

“(g) as determined in such Lender’s reasonable discretion, there has not been any Material Adverse Change or any material adverse deviation by Borrower from the most recent business plan of Borrower presented to and accepted by Agent and such Lender.”

(g) The introductory sentence of Section 7 of the Original Credit Agreement is hereby amended by replacing such Section in its entirety with the following:

“No Credit Party shall do any of the following:”

(h) The definition of “Material Intellectual Property” in Section 8.1 of the Original Credit Agreement is hereby amended by adding the words “and each Lender” following the word “Agent” at the end of such definition.

(i) The definition of “Products” in Section 8.1 of the Original Credit Agreement is hereby amended by adding the words “and each Lender” following the word “Agent” in the forth in line thereof.

(j) Section 8.2(c) of the Original Credit Agreement is hereby amended by replacing such Section in its entirety with the following:

“(c) Borrower shall furnish to Agent and each Lender, together with the monthly financial reporting required of Borrower in this Agreement, a Compliance Certificate as evidence of Borrower’s compliance with the covenants in this Section.  The Compliance Certificate shall include, without limitation, (a) a statement and report, on a form approved by Agent and each Lender, detailing Borrower’s calculations, (b) if requested by Agent or any Lender, bank statements and (c) if requested by Agent or any Lender, back-up documentation (including, without limitation, invoices, receipts and other evidence of costs incurred during such quarter as Agent or any Lender shall reasonably require) evidencing the propriety of the calculations.”

(k) Section 10.1(n) of the Original Credit Agreement is hereby amended by replacing such Section in its entirety with the following:

“(n) Agent or any Lender determines, based on information available to it and in its reasonable judgment, that there is a reasonable likelihood that Credit Parties shall fail to comply with one or more financial covenants in this Agreement during the next succeeding financial reporting period.”

Mid-Cap / Quotient – Amendment No. 2 to Credit, Security and Guaranty Agreement


 

(l) Section 10.2(b) of the Original Credit Agreement is hereby amended by replacing the introductory paragraph to such Section in its entirety as follows:

“Without limiting the rights of Agent and Lenders set forth in Section 10.2(a) above, upon the occurrence and during the continuance of an Event of Default, Agent shall have the right, at the written direction of the Required Lenders, without notice or demand, to do any or all of the following:”

(m) The second sentence of Section 13.1(a) of the Original Credit Agreement is hereby amended by replacing such sentence in its entirety with the following:

“No Credit Party may assign this Agreement or any rights or obligations under it without Agent’s and each Lender’s prior written consent (which may be granted or withheld in Agent’s or such Lender’s discretion).”

(n) The definition of “Eligible Assignee” in Section 16 of the Original Credit Agreement is hereby amended by replacing such definition in its entirety with the following:

““ Eligible Assignee ” means (a) a Lender, (b) an Affiliate of a Lender, (c) an Approved Fund, and (d) any other Person (other than a natural person) approved by Agent and the Required Lenders; provided, however , that notwithstanding the foregoing, “Eligible Assignee” shall not include any Credit Party or any Subsidiary of a Credit Party.  Notwithstanding the foregoing, (x) in connection with assignments by a Lender due to a forced divestiture at the request of any regulatory agency, the restrictions set forth herein shall not apply and Eligible Assignee shall mean any Person or party becoming an assignee incident to such forced divestiture, and (y) in connection with a Lender’s own financing or securitization transactions, the restrictions set forth herein shall not apply and Eligible Assignee shall mean any Person or party providing such financing or formed to undertake such securitization transaction and any transferee of such Person or party upon the occurrence of a default, event of default or similar occurrence with respect to such financing or securitization transaction; provided that no such sale, transfer, pledge or assignment under this clause (y) shall release such Lender from any of its obligations hereunder or substitute any such Person or party for such Lender as a party hereto until Agent shall have received and accepted an effective Assignment Agreement from such Person or party executed, delivered and fully completed by the applicable parties thereto, and shall have received such other information regarding such Eligible Assignee as Agent reasonably shall require.”

(o) The definition of “Required Lenders” in Section 16 of the Original Credit Agreement is hereby amended by replacing such definition in its entirety with the following:

““ Required Lenders ” means, unless all of the Lenders and Agent agree otherwise in writing, Lenders having (a) more than sixty-seven percent (67%) of the Applicable Commitments of all Lenders, or (b) if such Applicable Commitments have expired or been terminated, more than sixty-seven percent (67%) of the aggregate outstanding principal amount of the Credit Extensions; provided, however, that so long as any of the Second Amendment Date Required Lenders do not assign any portion of its Applicable Commitment or Credit Extensions to any Person other than an Affiliate of such Lender, the term “Required Lenders” shall include such Lender (and any Affiliate to which it assigns its interests).  For purposes of this definition only, a Lender shall be deemed to include itself, and any Lender that is an Affiliate or Approved Fund of such Lender.”

(p) The definitions of “Second Amendment Date Required Lenders” is hereby added to Section 16 of the Original Credit Agreement in the appropriate alphabetical order therein:

““ Second Amendment Date Required Lenders ” means each of Oxford Finance LLC, MidCap Funding V Trust and MidCap Funding XIII Trust.”

(q) The table setting forth the Lenders’ Applicable Commitments for Credit Facility # 1 on the Credit Facility Schedule to the Original Credit Agreement is hereby amended by replacing such table in its entirety as follows:

 

Lender

Applicable Commitment

Midcap Funding V Trust

$3,000,000

MidCap Funding XIII Trust

$15,000,000

Oxford Finance LLC

$10,800,000

FlexPoint MCLS SPV LLC

$1,200,000

Total

$30,000,000

Mid-Cap / Quotient – Amendment No. 2 to Credit, Security and Guaranty Agreement


 

(r) The table setting forth the Lenders’ Applicable Commitments for Credit Facility # 2 on the Credit Facility Schedule to the Original Credit Agreement is hereby amended by replacing such table in its entirety as follows:

 

Lender

Applicable Commitment

Midcap Funding V Trust

$500,000

MidCap Funding XIII Trust

$2,500,000

Oxford Finance LLC

$1,800,000

FlexPoint MCLS SPV LLC

$200,000

Total

$5,000,000

(s) The table setting forth the Lenders’ Applicable Commitments for Credit Facility # 3 on the Credit Facility Schedule to the Original Credit Agreement is hereby amended by replacing such table in its entirety as follows:

 

Lender

Applicable Commitment

Midcap Funding V Trust

$1,500,000

MidCap Funding XIII Trust

$7,500,000

Oxford Finance LLC

$5,400,000

FlexPoint MCLS SPV LLC

$600,000

Total

$15,000,000

3. Representations and Warranties; Reaffirmation of Security Interest .  Each Credit Party represents and warrants to Agent and Lenders that, before and after giving effect to this Agreement:

(a) All representations and warranties of the Credit Parties contained in the Financing Documents were true and correct in all respects when made and, except to the extent that such representations and warranties relate expressly to an earlier date, continue to be true and correct in all respects on the date hereof;

(b) The execution and delivery by each Credit Party of this Agreement and the performance by it of the transactions herein contemplated (i) are and will be within its powers, (ii) have been authorized by all necessary action (corporate or otherwise), and (iii) are not and will not be in contravention of any order of any court or other agency of government, of law or any other indenture, agreement or undertaking to which such Credit Party is a party or by which the property of such Credit Party  is bound, or be in conflict with, result in a breach of, or constitute (with due notice and/or lapse of time) a default under any such indenture, agreement or undertaking or result in the imposition of any lien, charge or encumbrance of any nature on any of the properties of such Credit Party;

(c) This Agreement and any instruments, documents, and agreements executed and delivered in connection herewith, are and will be valid, binding, and enforceable against each Credit Party that is a party thereto in accordance with their respective terms; and  

(d) Each Credit Party confirms and agrees that all security interests and Liens granted to Agent continue in full force and effect, and all Collateral remains free and clear of any Liens, other than those granted to Agent and Permitted Liens.  Nothing herein is intended to impair or limit the validity, priority or extent of Agent’s security interests in and Liens on the Collateral.

4. Conditions to Effectiveness; Post Closing Conditions and Covenants.    This Agreement shall become effective as of the date on which each of the following conditions has been satisfied, each in form and substance satisfactory to Agent and each Lender:  

(a) the Credit Parties shall have delivered to Agent this Agreement, duly executed by an authorized officer of each Credit Party;

(b) Secured Promissory Notes, as requested by Agent or Lenders, duly executed by an authorized officer of Borrower;

(c) reissued First Tranche Warrants in favor of Lenders (or their Affiliates), as requested by Agent or Lenders, duly executed by an authorized officer of Quotient Limited;

(d) all representations and warranties of the Credit Parties contained herein shall be true and correct in all respects as of the Effective Date (and such parties’ delivery of their respective signatures hereto shall be deemed to be their certification thereof);

Mid-Cap / Quotient – Amendment No. 2 to Credit, Security and Guaranty Agreement


 

(e) there are no Defaults or Events of Default that have not been waived or cured (and the Credit Parties’ delivery of their respective signatures hereto shall be deemed to be its certification that no Defaults or Events of Default currently exist) ; and

(f) the Credit Parties shall have delivered such further documents, information, certificates, records and filings, as Agent may reasonably request.

5. New Lender.  

(a) New Lender (i) confirms that it has received documents and information as it has deemed appropriate to make its own credit analysis and decision to enter into this Agreement and become a party to the Credit Agreement as a Lender; (ii) agrees that it will, independently and without reliance upon Agent or any other Lender and based on such documents and information as it shall deem appropriate at the time, continue to make its own credit decisions in taking or not taking action under the Credit Agreement; (iii) appoints and authorizes Agent to take such action as Agent on its behalf and to exercise such powers under the Credit Agreement and the other Financing Documents as are delegated to Agent by the terms thereof, together with such powers as are reasonably incidental thereto; (iv) agrees that it will perform in accordance with their terms all obligations which by the terms of the Credit Agreement are required to be performed by it as a Lender; (v) represents that on the date of this Agreement it is not presently aware of any facts that would cause it to make a claim under the Credit Agreement; (vi) represents and warrants that New Lender is (or, upon receipt of any required consents hereto by Agent) an Eligible Assignee; and (vii) represents and warrants that it has experience and expertise in the making or the purchasing of loans such as the Credit Extensions and Applicable Commitments it is purchasing in connection with this Agreement, and that it has acquired the interests described herein for its own account and without any present intention of selling all or any portion of such interests.

(b) New Lender represents and warrants to the Agent and each other Lender that it has full power and authority to enter into this Agreement and to perform its obligations hereunder in accordance with the provisions hereof, that this Agreement has been duly authorized, executed and delivered by such party and that this  Agreement constitutes a legal, valid and binding obligation of such party, enforceable against such party in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting creditors’ rights generally and by general principles of equity.

(c) For the purposes hereof and for purposes of the Credit Agreement, the notice address of New Lender shall be as set forth its signature page hereto.  

(d) The Agent, the New Lender and each other Lender agree that with effect from the date of this Agreement, pro rata to its participation (i) becomes a party as a pledgee to the Share Pledge Agreement over the shares in Quotient Suisse SA (the “ Swiss Pledge Agreement ”) and is bound by all the terms and conditions thereof, (ii) assumes all rights and obligations of the a Lender under the Swiss Pledge Agreement and (iii) participates in the security granted pursuant to the Swiss Pledge Agreement

6. No Waiver or Novation.    The execution, delivery and effectiveness of this Agreement shall not, except as expressly provided in this Agreement, operate as a waiver of any right, power or remedy of Agent or any Lender , nor constitute a waiver of any provision of the Credit Agreement, the Financing Documents or any other documents, instruments and agreements executed or delivered in connection with any of the foregoing.  Nothing herein is intended or shall be construed as a waiver of any existing Defaults or Events of Default under the Credit Agreement or other Financing Documents or any of Agent’s or any Lender’s  rights and remedies in respect of such Defaults or Events of Default.  This Agreement (together with any other document executed in connection herewith) is not intended to be, nor shall it be construed as, a novation of the Credit Agreement.

7. Affirmation.   Except as specifically amended pursuant to the terms hereof, the Credit Agreement and all other Financing Documents (and all covenants, terms, conditions and agreements therein) shall remain in full force and effect, and are hereby ratified and confirmed in all respects by the Credit Parties.  Each Credit Party covenants and agrees to comply with all of the terms, covenants and conditions of the Credit Agreement (as amended hereby) and the Financing Documents, notwithstanding any prior course of conduct, waivers, releases or other actions or inactions on Agent’s or any Lender’s part which might otherwise constitute or be construed as a waiver of or amendment to such terms, covenants and conditions.

8. Costs and Fees .    Upon the request of Agent, the Credit Parties shall be responsible for the payment of all reasonable and documented out-of-pocket costs and fees of Agent’s counsel incurred in connection with the preparation of this Agreement and any related documents.  If Agent uses in-house counsel for any of these purposes, the Credit Parties further agree that the Obligations include reasonable charges for such work commensurate with the fees that would otherwise be charged by outside legal counsel selected by Agent for the work performed.

Mid-Cap / Quotient – Amendment No. 2 to Credit, Security and Guaranty Agreement


 

9. Further Assurances .   Borrower and the other Credit Parties hereby agree that at any time and from time to time, at the expense of the Credit Parties, they will promptly execute and deliver all further instruments and documents, and take all further action, that may be necessary or that Agent or Lenders may reasonably request, in connection with this Amendment, or to enable them to exercise and enforce their rights and remedies under this Amendment, the Credit Agreement and the other Financing Documents.

10. Miscellaneous.

(a) Reference to and Effect on the Credit Agreement. Upon the effectiveness of this Agreement, each reference in the Credit Agreement to “this Agreement,” “hereunder,” “hereof,” “herein,” or words of similar import shall mean and be a reference to the Credit Agreement, as amended by this Agreement.  Except as specifically amended pursuant hereto, the Credit Agreement, and all other Financing Documents (and all covenants, terms, conditions and agreements therein), shall remain in full force and effect, and are hereby ratified and confirmed in all respects by Borrower.  

(b) Incorporation of Credit Agreement Provisions.   The provisions contained in Section 12 (Choice of Law, Venue and Jury Trial Waiver), Section 13.2 (Indemnification) and Section 13.9 (Confidentiality) of the Credit Agreement are incorporated herein by reference to the same extent as if reproduced herein in their entirety.

(c) Headings.   Section headings in this Agreement are included for convenience of reference only and shall not constitute a part of this Agreement for any other purpose.

(d) Counterparts.   This Agreement may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument.  Signatures by facsimile or by electronic mail delivery of an electronic version (e.g., .pdf or .tif file) of an executed signature page shall be treated as delivery of an original and shall bind the parties hereto. This Agreement constitutes the entire agreement and understanding among the parties hereto and supersede any and all prior agreements and understandings, oral or written, relating to the subject matter hereof.

[SIGNATURES APPEAR ON FOLLOWING PAGES]

 

 

 

Mid-Cap / Quotient – Amendment No. 2 to Credit, Security and Guaranty Agreement


 

IN WITNESS WHEREOF , intending to be legally bound, and intending that this Agreement constitute an agreement executed under seal, the undersigned have executed this Agreement as of the day and year first hereinabove set forth.

BORROWER:

 

Quotient Biodiagnostics, Inc.

 

By:

 

/s/Paul Cowan_______________________(SEAL)

Name:

 

D.J.P.E. Cowan______________________

Title:

 

Director____________________________

 

Mid-Cap / Quotient – Amendment No. 2 to Credit, Security and Guaranty Agreement


 

GUARANTORS:

Quotient Limited

 

By:

 

/s/Paul Cowan_______________________(SEAL)

Name:

 

D.J.P.E. Cowan______________________

Title:

 

Director____________________________

Alba Bioscience Limited

 

By:

 

/s/Paul Cowan_______________________(SEAL)

Name:

 

D.J.P.E. Cowan______________________

Title:

 

Director____________________________

QBD (QSIP) Limited

 

By:

 

/s/Paul Cowan_______________________(SEAL)

Name:

 

D.J.P.E. Cowan______________________

Title:

 

Director____________________________

Quotient Suisse SA

 

By:

 

/s/Paul Cowan_______________________(SEAL)

Name:

 

D.J.P.E. Cowan______________________

Title:

 

Director____________________________

Quotient Biocampus limited

 

By:

 

/s/Paul Cowan_______________________(SEAL)

Name:

 

D.J.P.E. Cowan______________________

Title:

 

Director____________________________

Mid-Cap / Quotient – Amendment No. 2 to Credit, Security and Guaranty Agreement


 

AGENT:

 

MIDCAP FINANCIAL TRUST

 

By:

 

Apollo Capital Management, L.P.,

its investment manager

 

By:

 

Apollo Capital Management GP, LLC,

its general partner

 

By:

 

/s/ Maurice Amsellem_________________(SEAL)

Name:

 

Maurice Amsellem

Title:

 

Authorized Signatory

 

Mid-Cap / Quotient – Amendment No. 2 to Credit, Security and Guaranty Agreement


 

LENDERS:

MIDCAP FUNDING V TRUST

 

By:

 

Apollo Capital Management, L.P.,

its investment manager

 

By:

 

Apollo Capital Management GP, LLC,

its general partner

 

By:

 

/s/ Maurice Amsellem_________________(SEAL)

Name:

 

Maurice Amsellem

Title:

 

Authorized Signatory

MIDCAP FUNDING XIII TRUST

 

By:

 

Apollo Capital Management, L.P.,

its investment manager

 

By:

 

Apollo Capital Management GP, LLC,

its general partner

 

By:

 

/s/ Maurice Amsellem_________________(SEAL)

Name:

 

Maurice Amsellem

Title:

 

Authorized Signatory

FLEXPOINT MCLS SPV LLC

 

By:

 

/s/ Daniel Edelman___________________(SEAL)

Name:

 

Daniel Edelman

Title:

 

Vice President

 

Mid-Cap / Quotient – Amendment No. 2 to Credit, Security and Guaranty Agreement


 

NEW LENDER:

 

OXFORD FINANCE LLC

 

By:

 

/s/ Mark Davis

Name:

 

Mark Davis

 

Title:

 

Vice President – Finance, Secretary & Treasurer

Notice Information:

 

Oxford Finance LLC

133 North Fairfax Street

Alexandria, Virginia  22314

Attention:  Legal Department

Facsimile:  (703) 519-5225

Email: LegalDepartment@oxfordfinance.com

Mid-Cap / Quotient – Amendment No. 2 to Credit, Security and Guaranty Agreement

 

Exhibit 10.4

Second Amendment to the Development Agreement

Between

STRATEC Biomedical AG (“STRATEC”) Gewerbestr. 37, 75217 Birkenfeld, Germany

and

Quotient QS IP Ltd. (“QBD”), PO Box 1075,  Elizabeth House, 9 Castle Street, St Helier JE4 2QP, Jersey, Channel Islands

(hereinafter referred together as “Parties”)

WHEREAS on January, 7 st 2014 the Parties have signed a Development Agreement (“Development Agreement”) and on March 3 rd , 2014 the Parties have signed a First Amendment to the Development Agreement (“First Amendment”).

NOW, THEREFORE STRATEC and QBD hereby agree to amend the Development Agreement and the First Amendment in the following way:

2.2 a Payments by QUOTIENT:

The MILESTONE SCHEDULE and specifically the Milestones 6-8 shall be amended to read as follows:

 

MS

Development Milestone

Payment

1

Execution of Agreement

[***]

2

Completion of phase 1 and mutual sign-off of PDR, Reliability Program Plan, Acceptance criteria and Shipping criteria / breadboard testing

[***]

3

Approval of Hardware Design Specification Documents

[***]

4

Completion of phase 2 and delivery of first Prototypes for assay integration

[***]

5

Acceptance of Prototypes

[***]

6-1

Design Review with approval of build of Validation Instruments

[***]

6-2

Delivery of first Validation Instrument

[***]

6-3

Completion of Phase 3

[***]

7-1

Acceptance of Validation Instruments

[***]

7-2

Complete receiving of all ordered Validation Instruments

[***]

8-1

Delivery of first Series Units

[***]

8-2

Completion of Phase 4

[***]

All remaining terms and conditions set forth in the Agreement that are not amended hereby shall remain in full force and effect.

IN WITNESS WHEREOF, the Parties have executed this Amendment as of the Second Amendment Effective Date.

 

STRATEC Biomedical AG

 

Quotient QS IP Ltd

 

 

 

/s/ Marcus Wolfinger

 

/s/ Paul Cowan

Name: Marcus Wolfinger

 

Name: Paul Cowan

Title: CEO

 

Title: CEO

Date: August 24 th , 2015

 

Date: August 25 th , 2015

 

1

[***] CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION

Exhibit 31.1

CERTIFICATION

I, Paul Cowan, certify that:

1.

I have reviewed this Quarterly Report on Form 10-Q of Quotient Limited;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period for which this report is being prepared;

 

(b)

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 4, 2015

 

/s/ Paul Cowan 

 

 

Paul Cowan

 

 

Chief Executive Officer and Chairman of the Board of Directors

 

Exhibit 31.2

CERTIFICATION

I, Stephen Unger, certify that:

1.

I have reviewed this Quarterly Report on Form 10-Q of Quotient Limited;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period for which this report is being prepared;

 

(b)

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 4, 2015

 

/s/ Stephen Unger

 

 

Stephen Unger

 

 

Chief Financial Officer

 

Exhibit 32.1

CERTIFICATION

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of Quotient Limited, a company incorporated under the laws of Jersey, Channel Islands (the “Company”), does hereby certify, to such officer’s knowledge, that:

The Quarterly Report for the quarter ended September 30, 2015 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 4, 2015

 

/s/ Paul Cowan

 

 

Paul Cowan

 

 

Chief Executive Officer and Chairman of the Board of Directors

This certification is being furnished and not filed, and shall not be incorporated into any document for any purpose, under the Securities Exchange Act of 1934 or the Securities Act of 1933.

Exhibit 32.2

CERTIFICATION

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of Quotient Limited, a company incorporated under the laws of Jersey, Channel Islands (the “Company”), does hereby certify, to such officer’s knowledge, that:

The Quarterly Report for the quarter ended September 30, 2015 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 4, 2015

 

/s/ Stephen Unger

 

 

Stephen Unger

 

 

Chief Financial Officer

This certification is being furnished and not filed, and shall not be incorporated into any document for any purpose, under the Securities Exchange Act of 1934 or the Securities Act of 1933.